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Abstract 
 
In the evolving field of bone tissue engineering, bioactive glass-ceramic scaffolds continue to 
draw significant attention as they can provide a 3D template that promotes new bone formation. These 
scaffolds have proved that they can loosely mimic cancellous bone structure as well as exhibiting 
appropriate mechanical properties and bioactivity to support the growth of new bone tissue.  
This work concentrates on improving the functionality of 45S5 Bioglass® -derived scaffolds 
produced by the foam replication technique, by introducing silver and copper through molten salt ion 
exchange to provide an antibacterial function and through the use of gelatin coatings to improve 
compressional strength, whilst not impeding the original scaffold’s bioactivity. 
The results confirmed that the introduced modifications have enhanced the scaffolds 
functionality as well as improving existing properties of the scaffolds such as mechanical competence. 
Overall the compressive strength of the scaffolds was improved with the addition of copper and silver 
ions and by the presence of gelatin coatings. After immersion in SBF, the presence of the additives did 
not impede the formation of hydroxyapatite on the scaffolds and hence the bioactivity. The 
characterization of the doped and coated samples showed that they have similar behavior to those of 
the base scaffold or have improved them marginally in terms of wettability and surface topography. 
During cell culture studies, using HPLSC’s, rMSC’s and hMSC’s, the silver doped scaffolds 
caused a slight cytotoxic effect, whilst the copper and silver/copper samples caused a significant 
cytotoxic effect. Bacterial studies showed that the metal ion-doped materials produced an antibacterial 
effect against the E.coli, S.aureus and K.pneumoniae. The present study has contributed to the 
enhancement of the standard 45S5 Bioglass® -derived scaffolds and has provided a base for future in 
vitro and in vivo work involving these materials in bone regeneration strategies.  
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Chapter One 
1. Introduction 
 
The demand for transplantable tissue currently far out strips the supply of donor organs 
considering the increasing volume of tissue/organ transplants that are required due to an ageing 
population. The scientific community is devoting efforts to develop a range of strategies to produce 
alternative solutions to combat the increase in demand for transplantable tissue. One area that has 
rapidly expanded is the use of artificial materials to produce scaffolds for tissue regeneration. (1) In the 
field of bone regeneration the use of bioactive glass-ceramic scaffolds is gaining increasing interest for 
novel replacement/regeneration therapy, which is the research area in which this work has been carried 
out. 
Bioactive glass -derived glass-ceramic scaffolds have attracted in the last few years increased 
scientific interest. (2) They are highly suitable 3-D porous structures for bone tissue engineering (BTE) 
which provide mechanical support to the surrounding tissue whilst promoting new bone growth; in 
essence they fulfil the basic criteria set out for BTE. These base scaffolds not only exhibit a high degree 
of bioactivity and osteoconductivity but also suitable biodegradability. A family of scaffolds is based 
on the material Bioglass® (45% SiO2, 24.5% Na2O, 24.4% CaO and 6% P2O5 in wt %). (3) These 
Bioglass® -derived scaffolds (4) (5) developed for the first time in 2006 still need to be extensively 
improved for realistic consideration for clinical studies. 
Thus this work branches out from previous research carried out with 45S5 Bioglass® -derived 
glass-ceramic (BBG) scaffolds as the starting biomaterial. Produced using the foam replication 
technique, (4) (5) these scaffolds are attractive as starting structures for developing advanced 
multifunctional scaffolds with optimised properties for use in BTE. These BBG scaffolds have a pore 
structure that tried to mimic the trabecular bone porosity and they have an ability to induce the formation 
of hydroxyapatite (HA) on their surfaces in physiological conditions which by its nature encourages 
bone attachment and promotes bone regeneration. However these scaffolds exhibit certain drawbacks, 
for example in terms of their mechanical competence as they do not have the required compressive 
strength required for the safe handling and for load bearing applications. Moreover these scaffolds have 
not yet been fully tailored to further enhance their bone regeneration capabilities and the scaffolds 
structural integrity including their resistance to crack propagation (work of fracture) has not been 
optimised. Apart from the structural similarity to bone and the ability to form HA on their surfaces, 
BBG scaffolds have only recently been considered to incorporate other functions which are relevant for 
tissue engineering applications such as antibacterial effect or drug delivery ability. The ultimate aim of 
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this work is thus to develop multifunctional BBG based composite scaffolds suitable for BTE and 
exhibiting a range of properties (and combination of properties) focusing on antibacterial effect coupled 
with bioactivity and improved structural and mechanical integrity. A range of approaches were explored 
in this project in order to produce multifunctional scaffolds that achieve the projects aims, which are 
summarised in Figure 1. 
 
 
Figure 1:- Overview of the development of multifunctional BBG scaffolds within the frame-work of this project 
 
As shown in Figure 1  this work followed two paths to evolving the BBG scaffolds using molten 
salt ion exchange (MSIE) to introduce therapeutic metal ions, initially investigated by Di Nunzio et al 
(6) on other silicate systems and expanding on the use of polymer coatings, which has been previously 
researched, (7) by investigating the use of gelatin.  
Processing techniques such as foam replica technique to fabricate the BBG scaffolds, MSIE to 
introduce metal ions into the scaffolds structure and slurry dipping to obtain the novel polymer coatings 
have been utilized in this project. Simulated body fluid (SBF) studies were carried out to determine the 
bioactivity of the scaffolds. Along with mechanical testing of the scaffolds, characterisation techniques 
have ranged from scanning electron microscopy (SEM) to Fourier transform infra-red spectroscopy 
(FTIR), porosity studies, surface analysis and characterisation of the degradation behaviour. Combined 
with biological and bacterial testing, a comprehensive study about the modified scaffolds in comparison 
to the BBG scaffolds has been carried out. 
 Metal ions such as silver, zinc and copper have been shown to have some unique biological 
properties being, for example antibacterial and in some cases angiogenic. (8) (9) (10) (11) Considering 
the emerging field of using functional therapeutic ions in BTE (12) and the potential biological 
advantages provided by these ions and their controlled release, the present project is of relevance in the 
broader field of ion releasing scaffolds. In this project metal ions were incorporated into the surface 
structure of the scaffold, through MSIE, and the effect of ion incorporation on the structure and 
bioactive behaviour of the scaffolds was investigated.  
32 
 
This work also explored the use of polymer coatings to improve the mechanical properties of 
the base scaffold and to provide scaffolds with drug delivery ability, e.g. with the polymer coating acting 
as a possible drug carrier. An established synthetic polymer such as poly-DL-lactic acid (PDLLA) and 
the novel use of gelatin, comparing both gelatin type A and type B, were considered to explore gelatin’s 
suitability to coat BBG scaffolds, assessing how the polymer coatings can improve the scaffolds 
properties. 
The thesis is organised in the following manner. An extensive literature review is presented in 
chapter two, covering the current approaches and techniques which are relevant to this research field, 
in order to justify the materials and techniques used in this work. Chapter three presents the aims and 
objectives of this work and the strategies and experimental approaches employed to achieve these. 
Chapter four describes the materials and characterisation techniques used within this work. Chapter five 
presents the structural characterisation results and discussion of the different types of scaffold 
developed, whilst chapter six describes the results and discussion from the antibacterial studies and 
biological characterisation of the different types of scaffolds. Chapter seven contains the concluding 
remarks presenting a summary of the key results obtained in this work and finally chapter eight makes 
suggestions for future work in general as well as describing some of the developing work that has been 
started as immediate follow-up research activities originating from the presented work. 
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Chapter Two 
2. Literature review 
2.1 Introduction 
 
This chapter focuses on the key concepts which illustrate the science backbone of this work, 
including an overview of the current research surrounding tissue engineering concentrating in particular 
on BTE, the need for bioactive materials and current strategies for their use, the biology of bone and 
how this relates to BTE and a summary of the materials involved in the development of BTE scaffolds. 
This chapter will provide information behind the rationale for the choice of the materials and processes 
used throughout this work for the development of multifunctional scaffolds for BTE. 
 
2.2 Tissue engineering: the general principles  
 
Tissue engineering (TE) is an interdisciplinary research field which incorporates interaction 
between scientists of different backgrounds including biologists, engineers, material specialists, 
medical doctors and computer modelling experts since the mid 1980's. (13) (14) (15) This area of 
research can be described as a field that strives to produces techniques and tissue constructs by 
combining biomaterials, cells and signalling molecules that can be used in the repair or replacement of 
human tissue and organs. (16) (17) (18) TE utilizes thus principles from a variety of fields, such as cell 
biology, (19) material science, (20) biochemistry (21) and medicine (22) and it provides a different 
approach than more traditional therapeutic methods. (23) In orthopaedics, TE is important considering 
the increasing need for better therapeutic approaches, technologies and biomaterials to overcome the 
limitations of current orthopaedic implants. (24) (25)  
The TE field is split into several areas depending on the type of tissue that is being investigated; 
this work concentrates on bone tissue engineering (BTE). Other areas include cardiac tissue, (26) 
cartilage, (27) lung tissue, (28) liver tissue, (29) intestinal tissue, (30) nerve tissue (31) and dentistry. 
(32) In principle, the two strategies deployed fall under two general categories:- 
 The use of artificial matrices  
 The use of natural (decellularized) matrices (33)  
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The artificial matrices are manufactured from an appropriate biomaterial and then seeded with 
the appropriate cells (34) and this is the category that the work present here will fall under. Natural 
matrices are collagen-rich structures of animal origin (35) which are produced by chemical and 
mechanical manipulation of the tissue to remove the cellular components (decellularized scaffolds). 
(36) (37) (38)  
Tissues consists of three components: the cells, the extracellular matrix (ECM) and signalling 
systems and since the premise of TE is to mimic a specific tissue, any engineered tissue must have a 
similar triad of components. (15) (39) In this work, the ECM is the component that will be the main 
focus as this is the tissue component being mimicked by the scaffold. 
TE has enjoyed success in creating complex constructs that fulfil the criteria of tissue 
regeneration and repair. In recent years the research community has focused on tissues that have a 
predominately biomechanical function because of the challenges that these tissue types present and the 
extreme demand for them. (40) (41) (42)(24) This indicates that any developed material needs to not 
only assist the repair of the tissue but also needs to support the surrounding tissue by taking on the role 
of the host tissue. This requirement means that scaffolds have to be able to mimic the properties and 
structure of the host tissue in order to encourage and support the new tissue. (42) This set of principles 
is highly relevant for BTE as the biomechanical properties of bone are critical to their function in vivo. 
(42) If the scaffold is designed to follow these principles, other problems that can occur after 
implantation can be overcome, such as the possibility of implant rejection and of an inflammatory 
response. 
 
2.3 The need for tissue engineering 
 
At the present the demand for transplantable tissue far out strips the supply of donor organs due 
to the sheer volume of tissue/organ transplants that are currently needed. (43) (44) In the UK there were 
5532 patients on the organ transplant waiting list in March 2000, with 2311 transplants being completed. 
This rose to 7997 and 2645, on the waiting list and transplants being carried out respectively, a decade 
later, as shown in Figure 2. (45) (40) (41) Other types of surgeries that are in great demand are 
reconstruction/repair procedures, such as bone grafts and muscle grafts, for the repair of tissue due to 
significant trauma, infection or cancer. (46) 
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Figure 2:-Transplant waiting lists and the number of operations carried out over a ten year period for the UK
 (24)
 
 
 Suitable engineered tissues therefore are the logical way forward to reduce this difference 
between those patients waiting for transplants and those actually them. (47) (48) It is expected that the 
number of people dying whilst waiting for an organ transplant can be reduced by using engineered 
tissues as the replacement therapy. (49) (50) 
 
2.4 Bone tissue engineering 
 
The skeletal system is an integral part of the human body, acting not only as a scaffold but also 
as the storage reservoir for elements, including 99% of the body's calcium. (51) Bone is the main focus 
of this project. There are a number of reasons to focus the attention to bone regeneration approaches:- 
 Bone defects are extremely common (52) and can be highly debilitating for the patient (53) (54)  
 A shortage of viable material to use for bone grafts (55) (56) due to the increasing volume of 
bone defects, (57) ranging from shattered bones (58) to facial reconstruction, (55) that require 
surgical repair (59)  
 Simpler bone fractures can heal under conventional therapies and  do not require major surgery, 
(46) but the more problematic bone defects, caused by significant trauma, (60) infection (61) or 
cancer (46)  are difficult to repair surgically (62) and affect the quality of life of the patient due 
to loss of function of the bone. (63) 
To better understand the task in hand, the structure, composition, behaviour and the role of bone 
in the human body need to be explored. Indeed the whole concept of scaffolds for TE hinges on how 
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well the material mimics the structure and properties of the tissue it will be replacing, supporting and 
regenerating. (64) 
 A skeletal system has a range of functions that are categorised into mechanical, synthesis and 
metabolic. (65) Figure 3 shows the functions of bone in the human body and their grouping. The bones 
in the human skeletal system can be split into several regions with different structures; long bones which 
are generally concerned with movement, (66) (67) the tibia and femur for example, (62)  and flat bones 
which have more of a protection role, (68) (69) for example the bones of the skull and the rib cage. (65) 
 
 
Figure 3:- Schematic diagram showing the functions of bone in the human body (65) 
 
Bone is a complex composite matrix, which comprises of approximately 95% collagen I 
combined with HA (Ca10 (PO4)6(OH) 2) crystals. (70) Bone is formed of two layers, a dense outer layer 
called cortical bone and an inner spongy layer called trabecular bone. (71) (72) Approximately 80% of 
a human’s skeletal mass is made up by cortical bone and it is characterised by its smooth surface and 
closed cell network. (71) (72) Cortical bone is a dense structure with a porosity of about 10% (65) which 
is important as it acts as a protective layer to the trabecular bone. (73) Trabecular bone is made up of an 
open porous network allowing blood vessels, nutrients and cells to pass through the bone. (71) (72) 
Trabecular bone accounts for the remaining 20% of the total bone mass in the human skeletal system 
but has a surface area ten times that of cortical bone. (71) (72) This type of bone has porosity in the 
range of 50-90%. (65) (70) (74) (75) The compressive strength of cortical and trabecular bone ranges 
from 130 to 180MPa (76) and 0.8-11MPa (77), respectively. (33) The mechanical properties of the struts 
contained within both types of bone are very similar with a compressive strength of around 136MPa. 
(4) Figure 4 shows the structure of an adult human bone including the two layers discussed above. 
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Figure 4:-Schematic diagram of the cross section of an adult human bone showing the structure in detail (78) 
(75) 
 
Within bone there are four cell types present: osteoblasts, osteocytes, osteoclasts and bone 
lining cells each with their own unique purpose. (70) (74) Bone lining cells are believed to be inactive 
osteoblasts which cover every available surface of the bone structure, acting as a protective barrier 
against certain ions and are ready to become active when required. (70) Osteoblast cells are cuboid when 
mature, are responsible for synthesizing the bone matrix (the osteoid), contributing to bone 
mineralisation and they deposit the bone matrix at a rate of 1µm per day in an adult. (70) (75) Osteoclast 
cells are highly specialized and multinucleated cells whose sole purpose is the resorption of bone. (79) 
Osteoblast cells regulate the osteoclast cells activity, which can absorb as much as 200, 000 µm3 of 
bone per day, which is roughly the amount of bone that is formed by seven to ten generations of 
osteoblasts. (75) Osteocytes are derived from osteoblast cells and are buried in the bone matrix during 
bone formation. Osteocytes are the primary cells found in bone and these cells initiate the recruitment 
of osteoblasts and osteoclasts to a site which needs remodelling or repairing, acting as damage sensors. 
(70) (75)  
In order to understand how bone regenerates after a trauma, it is essential to understand how a 
bone remodels itself under normal conditions. This is a continuous process of bone resorption by the 
osteoclasts coupled with bone formation by the osteoblasts. This cycle of resorption and repair takes 
approximately three to six months to complete in an adult skeleton (75) and occurring at different rates 
depending on the type of bone (cortical or trabecular) and the location of the bone. (70) Around 1-3% 
of an adult’s skeletal system will be replaced each year up until the age of between 30-35 years old and 
this will ensure a constant density in the body’s bone. (65) The ratio between bone formation and bone 
38 
 
resorption will change in favour of the bone resorption after the age of approximately 35 years meaning 
the bone density will start to decrease. (65) This constant updating of the skeletal bone has evolved to 
help the skeleton to adapt when the mechanical conditions change whilst still maintaining the ability to 
participate in mineral regulation. (70) Normal bone remodelling cycle has five stages (65):- 
 Quiescence 
 Activation 
 Resorption 
 Formation  
 Mineralisation 
The remodelling cycle under normal conditions is depicted in Figure 5. 
Quiescence is the pre-remodelling state of the bone, with a layer of inactive bone lining cells 
on the upper most surface of the bone with a thin collagenous membrane underneath the cells which 
separates them from the mineralised bone. (65) (80) The activation phase starts with the removal of the 
membrane so the osteoclasts can start the process of bone resorption. Mononuclear cells travel to the 
cleared site, attach to the bone surface and then fuse together to become multinuclear osteoclasts. The 
mature osteoclasts begin the resorption of the mineralised bone matrix resulting in a cavity, this is the 
resorption stage. (81) (82) This process stops when the cavity reaches a depth of between 60-100µm. 
(81) In the formation phase, osteoblasts produce and deposit the components of ECM with the collagen 
fibres organising themselves into the lamellar structure of bone. (81) The initial rate of deposition is 
high at 2-3µm per day and is due to the high density of osteoblasts present at the start of this stage. (81) 
Once this un-mineralised osteoid reaches a width greater than 20µm the mineralisation phase can start. 
The mineralisation process starts at a rate of 1-2µm per day in order not to interrupt the formation 
process. The mineralisation continues, after the formation phase has ceased, until the boundary between 
the existing bone and new bone is removed. The remaining cells on the bone are then no longer required 
and they deposit themselves on to the surface of the bone, deactivate and become bone lining cells and 
returning the cycle to the quiescence phase. (65) 
This process is the body’s mechanism for bone remodelling, but is only part of the process of 
repair undertaken with a bone suffers a significant trauma. The four stages of the repair process are (82) 
: - 
 Inflammation 
 Soft callus formation 
 Hard callus formation 
 Remodelling 
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Figure 5:- Bone remodelling cycle under normal conditions (65) (81) 
 
 All of these stages need to be taken into consideration when designing a material/implant that 
is going to replace, support and help to rejuvenate or regenerate the bone. When there is no other option 
but to replace a large portion of bone several treatment options are currently available and these can be 
thought of as either synthetic or natural bone grafts. Figure 6 illustrates the different types of bone 
graft/implant that are currently being used in bone replacement therapy.  
 Natural bone grafts have been around since the mid-17th century (83) from work carried out by 
Anthonie van Leeuwenhock and Job van Meekeren (83) through the implantation of a piece of dog 
skulls into a soldiers skull and are more widely used than the synthetic bone grafts (84) which have only 
been around since the discovery of bioactive properties of certain ceramics (3) in particular bioactive 
glasses. (85) 
 
Figure 6:- Types of bone implants currently available as treatment options for significant bone trauma (84) 
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Autograft implants are considered the gold standard of bone implants (86) for a number of 
reasons, the main one being that this type of implant is taken from the patient who requires the bone 
graft. (86) This type of graft avoids the problem of the body rejecting the implant but as with all 
transplants there is still the risk of infection. (84) Autograft implants are usually gathered from the iliac 
crest of the patient. (87) Although this type of implant is the implant of choice it does have its problems 
including that there is only a very limited amount of bone that can be harvested to use as a graft and 
that the harvesting procedure is not only painful it comes with its own set of complications. (84)  
Allograft implants are harvested from a deceased human donor. (88) This type of implant has 
the advantage over Autograft implants that it doesn’t require a secondary surgical site as the implant is 
coming from another source. (89) However since this implant comes from another human it does suffer 
from the problem that the host body can reject the implant, (90) although the closest match in terms of 
blood type and antibodies is implanted. (91) This type of implant also suffers from the risk of infection 
due to the implantation of a foreign object into the patient; (92) this also induces an inflammatory 
response from the tissue surrounding the implant. (84) 
Xenograft implants are grafts that come from non-human sources and were first used back in 
the 16th century. (93) These types of grafts are not yet widely used in modern medicine as they normally 
induce an immune response from the host’s body and the graft doesn’t induce new bone growth. (84) 
However extensive research is being carried out in improving the decullularisation process to make this 
type of scaffold/implant a more realistic alturnative. 
Alloplastic implants can be inorganic, synthetic, organic or a combination of these and can be 
implanted as a treatment for bone trauma instead of the other natural grafts; (94) Table 1 shows the 
different types of alloplastic grafts. 
Table 1:- The different types of alloplastic graft (50) 
Group Type of Graft Examples References 
1 Biological - organic Decellularized bone matrix  (95) (96) 
    Calcium phosphates  (97) (98) 
2 Synthetic - inorganic HA  (99) (100) 
    Bioglass®  (101) (102) 
    Collagen  (103) (104) 
3 Synthetic - organic Poly-L-lactide   (105) (106) 
    Poly(D,L-lactide-co-glycolide)  (107) (108) 
4 Composites Composites of groups 1-3  (109) (110) 
 
This project is concentrating on alloplastic grafts from group four, Table 1, classed as composite 
materials.  
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2.5 Challenges faced in bone tissue engineering 
 
Some traumas to bone, such as open fractures, result in infection and contamination. (111) It is 
extremely difficult to control the resulting infection and treat the underlying bone defect with a graft at 
the same time. (112) This results in the patient’s treatment occurring in two parts, firstly controlling the 
infection and then once that has cleared up the bone graft surgery can go ahead. This is of course is 
expensive and results in an extended stay in the hospital for the patient. (112) This also needs to be 
taken into consideration during the design phase of the implant, such as introducing an antibacterial 
element into the scaffolds atomic matrix to reduce the likelihood of post-operative infections. (113) 
Another problem with implants is the body’s immune response after implantation which will 
lead to the body rejecting the implant. (114) Until recently it has been accepted by the medical 
community that the possibility of an implantation procedure occurring without the need for 
immunosuppressant drugs was impossible unless the bone graft was an autograft implant. (115)   
Unfortunately the problem of rejection can’t always be solved as the mechanism of the body 
rejecting the implant is the same as the body’s reaction to foreign organisms such as viruses and 
bacteria. (116)This is because the body’s immune system can’t distinguish between dangerous bacteria 
and a perfectly safe bone graft or implant. (117) (118) The need for implants to not be rejected is 
important because rejected implants require a longer stay in hospital increasing the cost to the hospital 
and increasing the discomfort for the patient. (119) The main solution to the immune response would 
be to produce an implant that is sufficiently inert not to produce an immune response but will fulfil the 
criteria for a TE implant that was set out in section 2.2. 
In recent years the developments of biomaterials, seeded with cells, have shown not to induce 
such a severe immunological response from the patient. (115) The implants that are produced in this 
way have not been rejected, with over 50,000 cases of this type of implant occurring and no rejections. 
(115) These implants are normally alloplastic and in order not to induce an immune response the 
implants should elicit a positive reaction at the interface with the surrounding tissue. (115) The BBG 
scaffolds that this work will be focusing on fall under this type of implant, e.g. Bioglass® is a bioactive 
material that induces new bone growth (3) without producing a severe immune response in the body. 
(120) These specific characteristics of bioactive glasses, more specifically Bioglass®, will be discussed 
section 2.7.2. 
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2.6 Properties for an ideal bone tissue engineering material  
 
In order for a material to be considered as a viable candidate for TE it needs to fulfil certain 
criteria. These are general criteria which not only apply to scaffolds for BTE but to other types of 
implants as well. These are split into two general areas (7) (121):- 
 Biological 
 Structural 
If a material exhibits suitable biological and structural properties and also tries to mimic the 
requirements of the tissue it is trying to replace then it represents a candidate for tissue engineering. 
 
2.6.1 Biological properties required  
 
 Before describing how the biomaterials are classified in terms of their interaction with the 
surrounding tissue, it must be highlighted that materials must be biocompatible. Biocompatible 
materials do not release elements in a concentration that is toxic and must not trigger an immune 
response from the host tissue which could lead to reactions such as inflammation and a septic rejection. 
(122) Whilst allowing the material to perform the desired function and generating the appropriate 
beneficial cellular response. (123) 
 How the material interacts with the surrounding tissue has a direct influence on how the material 
is used as an implant (or scaffold) or part of an implantable device and this interaction is classified into 
three types:- 
 Bioinert 
 Bioactive 
 Bioresorbable/Biodegradable 
Bioinert materials do not interact with or cause a response in the surrounding tissue. These 
materials do not release any toxic elements but they also do not have a positive influence on the host 
tissue making the materials biocompatible. (122) (123) Examples of bioinert materials used in 
orthopaedic and dental applications are alumina (Al2O3), (124) zirconia (ZrO2), (124) Ti-29Nb-13Ta-
4.6Zr titanium alloy (125) and Ti-6Al-4V titanium alloy. (125) Such bioinert materials are not usually 
applied to fabricate BTE scaffolds due to their lack of bioactivity, as discussed below. 
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Bioactivity in general is the materials ability to interact with the surrounding tissue to enhance 
the tissues response and the tissue/material bonding process (126) and specifically in the case of BTE 
materials the capacity to induce the formation of carbonated HA on its surface when exposed to 
simulated body fluid (SBF) or implanted in vivo is the is a well-documented process that is considered 
evidence of the bioactivity of a material used for BTE. (127) (128) (129) The process of HA formation 
on glass-ceramics can be described in a number of stages:- 
I). The exchange of cations, for example sodium, from the surface of the glass-ceramic with 
hydrogen ions from the physiological solution. (130) (128) (125) 
II). The loss of soluble silica in the form of Si(OH)4 from the glass-ceramic to the surrounding 
solution caused by the breaking of Si-O-Si bonds at the interface. (130) (125) 
III). Formation of silanol (Si-OH) groups on the surface of the glass-ceramic. (130) (125) (129) 
IV). Polycondensation of the silanol groups to form a SiO2 – rich layer on the surface of the glass-
ceramic. (130) (125) (129) 
V). Ca2+ and PO43- groups migrating to the surface of the glass-ceramic through the SiO2 – rich layer 
to form a CaO-P2O5-rich film on top of the SiO2-rich layer. (130) (128) (125) (129) 
VI). The amorphous Ca-O-P2O5 film crystallizes through the incorporation of OH-, CO32-, or F- 
anions. (130) (128) (125) (129) 
The final interaction class concerns whether a material is bioresorbable or biodegradable. 
Biodegradable materials breakdown due to structural and chemical degradation, dispersed in vivo and 
partially metabolised by the body. (131) (132) (133) Bioresorbable materials also breakdown due to 
structural and chemical degradation, are dispersed in vivo but are entirely removed from the body 
through metabolisation or through natural pathways. (131) (132) (133) Examples of these types of 
materials include calcium phosphates, (130) hydroxyapatite (130) (131) and polylactic-polyglycolic 
acid  (PLGA) copolymers. (131) (132) (133) It should be noted that materials that are both bioactive 
and biodegradable/bioresorbable and the materials of choice for fabricating BTE scaffolds. 
Ideally, once implanted the material must degrade at a suitable rate, a rate that matches the 
growth rate of the new tissue surrounding the implanted scaffold. (134)This means the rate of 
degradation should be controllable if the material is to be considered for a range of tissue engineering 
applications. (134) The degradation productions should be non-toxic and not cause an inflammatory 
response in the host tissue to keep the material biocompatible. (135) 
An ideal implanted material also needs to facilitate cell attachment, proliferation and 
differentiation. (136) (137) The material must not produce any toxic by-products or cause an 
inflammatory response once implanted into the host body. (136) (138) The chemical make-up of a 
material is therefore extremely important in order to determine if the material will behave in an 
appropriate manner when implanted. These statements only hold true for a single material and not a 
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whole implantable device as these will be made up of a number of components. (87) (139)Whilst these 
materials on their own might be biocompatible in a biological system once assembled into an implant 
device they whole ensemble might prove not to be biocompatible. (87) (139) The material ideally should 
provide a biocompatible surface that can act as a framework on which new bone growth can occur 
(Osteoconductive). (140) (141) (142) The material ideally should be capable of inducing the 
differentiation of stem cells into osteogenic bone forming cells, osteoblasts and osteocytes, 
(Osteoinductive). (140) (141) (142) The material should ideally be able to induce new bone growth by 
eliciting intracellular and extracellular responses at the interface between the material and the host tissue 
by inducing the integration between the host bone tissue and implant in the form of a continuous layer 
at the interface (Osteoproductive). (143) (144) (145) 
 
2.6.2 Structural properties required for an ideal bone tissue engineering material 
 
The mechanical properties of the material are important as the material has to provide support 
to the surrounding tissue during its regeneration. (146) (147) The material needs to have mechanical 
properties (elastic modulus, compression strength and fracture toughness) that closely mimic those of 
the tissue surrounding the implant. (148) (149) Bone repair involves interrelated chemical, biological 
and mechanical processes occurring simultaneously, with many of the chemical and biological 
processes being dependant on certain mechanical conditions. (150) (151) (152) Producing a material 
with mechanical properties that mimic those of bone with reduce the loss of the surrounding bone tissue 
due to stress-shielding. (153) (154) 
Other properties such as porosity, wettability and topography are more related to the type of 
implant produced, in this works case a scaffold, and will be discussed in the sections 2.3.7, 2.3.8 and 
2.3.9 respectively. 
 
2.7 The progression of materials in bone tissue engineering 
 
Since bone consists largely of crystalline hydroxyapatite (HA) and other related calcium 
phosphates (CaP), the logical step is to develop bone substitute materials and tissue engineering 
scaffolds from these materials. Both HA and CaP exhibit good biocompatibility due to the fact that they 
are chemically similar to bone. However, this similarity is also a hindrance as HA is stable within the 
body and in tissue engineering the scaffold should be biodegradable. (155) This fact leads researchers 
to investigate other materials that could be used in BTE such as silicate glasses and glass-ceramics, for 
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example Bioglass®, and other biomaterials based on a combination of bioceramics and biodegradable 
polymers, forming composites. 
 
2.7.1 Calcium phosphate and its derivatives 
 
Calcium phosphate ceramics (CPC’s) have been studied extensively for more than 40 years as 
bone substitute materials (156) due to their many desirable properties which match those of an ideal 
BTE material, as described in section 2.6, such as biocompatibility and bioactivity. (157) CPC’s can be 
split into four groups:- 
 Hydroxyapatite (HA) 
 Tricalcium phosphates (TCP’s) 
 Amorphous calcium phosphates (ACP’s) 
 Biphasic calcium phosphates (BCP’s) 
Modifications to the processing methods of CPC’s have given rise to a range of CPC’s with 
distinct differences in chemical and physical properties leading to a family of suitable materials for use 
in BTE. (157) 
 
2.7.1.1 Hydroxyapatite  
 
HA is a stable form of calcium phosphate in the form of Ca10(PO4)6(OH)2, as described in 
section 2.6.1, and is naturally found in both bones and teeth as a major component accounting for 
between 60% to 65% of the mineral content. (158) HA exhibits some of the desirable properties for 
scaffolds described in section 2.6, being thus a suitable candidate for BTE. (159) (160) As described in 
section 2.6 a key indicator in establishing a materials suitability for BTE is through its bioactivity which 
is determined by the formation of HA surface layer making HA scaffolds bioactive and exceptionally 
biocompatible. (159) (160) Although it should be noted that HA requires close proximity to the target 
area and bone cells in order to induce osteoconduction. (156) Two significant areas where HA has a 
disadvantage when it comes to its use as a BTE scaffold is its comparatively low mechanical strength 
and its long degradation period. (159) (160) (161) Due to its properties HA is also considered to coat 
implants, (161) (162) as a drug delivery vehicle (162) and combined with polymers or composite 
scaffolds. In fact HA coatings on implants for hip and knee joints have become the gold standard in 
joint replacement therapy (161) due to the imparted bioactivity achieving a faster healing process and 
a quicker recovery. (162) It should also be noted that on-going work to improve and change the 
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properties of HA through ionic substitutions, including substituting the carbonate with a phosphate to 
improve the solubility and bioactivity, (163) substituting the fluoride for hydroxide to increase the 
stability (163) and incorporating silicon ions to enhance osteoconduction. (163) 
 
2.7.1.2 Amorphous calcium phosphates  
 
 The vast majority of ACP’s are the first solid phase to appear when calcium and orthophosphate 
containing aqueous solutions are mixed. (164) (165) ACP’s have a wide range of compositions and 
therefore a range of applications including implant coating and injectable cements. (164) (165) They 
have many of the desirable properties listed in section 2.6 including a bioactive nature. In addition, 
ACP’s does not produce an immune or inflammatory response in the host tissue (166) and can be 
tailored to have the required degradation behaviour. However they are difficult to produce in any other 
form than a powder and is not mechanically strong. (164) (165) Most of the most recent work with 
ACP’s has concentrated on making composites to improve the mechanical properties whilst keeping 
the ACP’s desirable properties. (164) (165) 
 
2.7.1.3 Tricalcium phosphates  
 
 TCP’s come in two forms, alpha-TCP which is formed at high temperatures and beta-TCP. The 
high temperatures required to produce alpha-TCP has made it rather unattractive in the research 
community and this has led to the community to focus on the beta-TCP as a BTE material.  
TCP materials tend to be more soluble than the other CPC due to their composition and along 
with the other desirable properties such as bioactivity and biocompatibility makes this material suitable 
for BTE. In vitro and in vivo studies have shown that TCP’s exhibit suitable cell seeding capabilities 
(167) being biodegradable and comparable to the other CPC’s. (168) 
 
2.7.1.4 Biphasic calcium phosphates  
 
 BCP’s are composed of a layer of a stable CPC, normally HA to provide stability, and a more 
soluble phase such as a TCP. (157) This type of CPC has the advantage that it can be tailored to contain 
layers that will complement each other whilst enhancing the desirable properties of this class of 
materials such as bioactivity. (157) Introducing a more soluble CPC to HA gives the material a 
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controllable and tailorable resorption/solubility (157) Specific properties, including those discussed in 
section 2.6, depend on the individual phases used. (163) These layered materials have shown better 
osteogenic cell expansion and differentiation compared to TCP’s and HA on their own. (169) (170) 
 
2.7.2 Glass-ceramics in bone tissue engineering 
 
Glass-ceramics are formed by controlling the crystallisation of suitable silicate glass 
compositions by heat treatment. (171)  The resulting glass-ceramic has better mechanical properties 
than its parent glass and will exhibit other unique properties, meaning that glass-ceramics can find other 
applications than amorphous glasses. (171) There is currently a wide range of glass-ceramics used in 
the biomedical materials field, especially in bone regeneration, as the properties of glass-ceramics can 
be tailored for this purpose. (171) Among them, four key materials have been extensively researched; 
Apatite-wollastonite (A-W), Ceravital®, Bioverit® and 45S5 Bioglass® –derived glass-ceramics. These 
materials fulfil the requirements for improved bone substitute and tissue engineering scaffold materials. 
In this work the main material of interest is a glass-ceramic derived from thermal treatment (sintering) 
of 45S5 Bioglass®. 
 
2.7.2.1 Bioactive glasses 
 
A new class of materials, based on a silicate system, with high bioactivity and a remarkable 
ability to bond to both hard and soft connective tissue was discovered by Hench in 1969. (76)  These 
bioactive glasses have very specific compositions containing at least 55wt% SiO2 in the system of SiO2-
Na2O-CaO-P2O5. They are categorised as class A biomaterials as they are osteoconductive, osteogenic 
and osteoproductive compared with class B biomaterials (such as HA) which are just osteoconductive. 
(76) During reactions on the bioactive glasses surface, soluble ions of Si, Ca, P and Na are being 
released and they induce extracellular and intracellular responses (172) and form HA in physiological 
solutions. (127) (128) (129) The first developed bioactive glass composition, which is known as 45S5 
Bioglass®, contains (in weight %) 45% SiO2, 24.5% Na2O, 24.4% CaO and 6% P2O5 (3) and this is the 
composition that will be used as the base material in this work. 
Bioactive glasses have found niche application as bone fillers/cements (173) and small non-
load bearing implants (76) over the last forty years. It has taken this long to establish the materials 
credentials and carry out the necessary clinical trials required for its use in humans. (76)  The advantages 
of these materials have made them highly suitable for many biomedical applications, PerioGlas®, used 
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in the treatment of periodontal disease, and NovaBone® in bone fillers. (76) These materials have also 
been used in middle ear bone replacement implants and more recently they are being considered a 
promising scaffold material for BTE. (174)  
The main attribute of bioactive glass, including melt-derived and sol-gel glasses, is their 
bioactive behaviour and their ability to induce the formation of HA, as described previously. (76) (175) 
This ability to bond to bone once the material has been implanted is crucial as it will avoid loosening 
of the scaffold once implanted. (76) (175) 
Bioactive glasses have extra properties, compared to HA, which makes them more suitable for 
BTE. These include properties such as providing support for enzyme activity, (176) vascularisation and 
angiogenesis, (177) and osteoblast adhesion (178) (179) as well as cell differentiation. (180) (181) An 
observation is that as the bioactive glass structure biodegrades, the dissolution products influence the 
osteoblast cycle, the genes that control osteogenesis and the production of growth factors. (172) 
(182)Bone mineralization and gene activation are influenced by the released silicon and calcium ions 
from the glass (or glass-ceramic) in suitable concentrations. (172) 
Researchers have been working on the development of the ideal composition of bioactive glass 
in order to achieve the best trade-off between properties, since the bioactivity of the material is 
composition-dependant. (183) (184) With bioactive glasses being composition-dependant, the scientific 
community has studied a vast range of compositions by keeping the 6wt% P2O5 constant and changing 
the relative concentrations of the other components. (3) This approach is summarised by the ternary 
diagram shown in Figure 7. (3) (185) (186) (187) (122) 
By keeping the composition of the bioactive glass within the bone bonding area, in Figure 7, 
the best trade-off between mechanical properties, bioactivity and the rate of resorption/degradation can 
be achieved. (3) This composition diagram in Figure 7 also gives the option of tailoring the materials 
for particular criteria for applications in a specific area of BTE.  
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Figure 7:- Ternary diagram of SiO2 – Na2O - CaO which shows where the optimal compositions for bioactive 
behaviour lie (3) (185) (186) (187) (122) 
 
2.7.3 Other materials used in bone tissue engineering 
 
In addition to polymer/bioceramic composites mentioned above and discussed in the literature, 
(121) other materials that have come to the front of BTE scaffold research include zirconia, alumina 
and titanium oxide. Zirconia has been used in solid dental implants for some time and work is being 
carried out to develop zirconia porous scaffolds for BTE. Zirconia demonstrates good biocompatibility 
and there is evidence that the host bone responds positively to the material, however zirconia lacks the 
desirable resorption and bioactive properties that are required for BTE (188) and therefore it should be 
coated with a bioactive material. 
Titanium-based materials have been used in dental implants and exhibited some of the desirable 
properties described in section 2.6 with superior mechanical properties compared to the CPC’s and 
bioactive glasses described earlier. However titanium-based materials lack the crucial bioactivity which 
is key for BTE applications to encourage bone regeneration and the formation of HA. (189) Titanium-
based scaffolds have been also investigated, however as is the case with zirconia, to increase the 
bioactivity bioactive glass coatings maybe required. (190) 
Another possible candidate to be considered is mineralised collagen, which is also found in our 
skeletal system. It has been found to be more potent than TCP in terms of cell seeding efficacy, 
osteogenic marker generation, encouraging 3D cell alignment and cell infiltration. (191) Current efforts 
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concentrate on developing strategies to improve the mechanical properties (mainly compressive 
strength) of mineralised collagen, for example fabricating bioactive glass/collagen composites. (192) 
(193) 
 
2.8 Bioactive glass processing 
 
 There are two established techniques for producing bioactive glass powders that can then be 
turned into functional scaffolds; Melt quenching (5) and sol-gel processing. (2) Both are discussed in 
this section.  
  
2.8.1 Producing bioactive glasses by melt quenching 
 
 Melt quenching is the process of producing high quality bioactive glasses by essentially melting 
together the component materials (in the required quantities to achieve the desired composition), 
quenching the melt and grinding the melt into powder. (2) (194) (195) For 45S5 Bioglass® high purity 
analytical grade powders of SiO2, Na2CO3, CaCO3 and P2O5 are melted together in a platinum crucible 
at 1400oC for four hours then for a further five hours at 950oC to decarbonise the melt. (5) (194) (195) 
The melt is then either quenched in deionised water (for powder production) (5) (194) (195) or in 
graphite moulds for the production of rod or monoliths. (2) The melt quenched in deionised water, for 
powder production, is then milled with ethanol. (5) (194) (195) This quenching process, in either 
deionised water or graphite moulds, is quick enough to maintain the desired amorphous structure at this 
stage of scaffold production. (195) The final step is to anneal the powder at 480oC for eight hours to 
remove possible internal stress in the melted powder caused by the milling process. (195) Throughout 
this process the chemical composition is checked for impurities using inductively coupled plasma mass 
spectrometry. (194) (195) 
 This technique can be used to create bioactive glasses in a wide variety of compositions 
including SiO2-P2O5-CaO-Na2O-CaF2, (196) CaO-B2O3-P2O5 (197) and CaO-MgO-SrO-SiO2-P2O5-
CaF2. (198) 
The 45S5 Bioglass® powder used in this work, provided by Dr I Thompson (Kings College, 
London, UK), was produced using the melt quenching technique. 
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2.8.2 Producing bioactive glasses by sol-gel processing 
 
The second processing technique is a wet chemical low temperature approach called the sol-
gel method. This process allows the control of the materials homogeneity and final chemical 
composition. (175) (2) Generally a solution containing compositional precursors undergo polymer-type 
reactions at room temperature to form a gel, which is then dried, heated to form a glass before being 
milled into a powder. (2) Typical compositions produced using this technique have fewer components 
than those produced by melt quenching and include 58S (58wt% SiO2, 33wt% CaO and 9wt% P2O5), 
(199) 68S (68wt% SiO2, 23wt% CaO and 9wt% P2O5), (200) 77S (77wt% SiO2, 14wt% CaO and 9wt% 
P2O5) (199) and 91S (58wt% SiO2 and 9wt% P2O5). (200) 
This processing technique has only been recently applied to 45S5 Bioglass® compositions and 
other similar compositions containing Na2O, as the room temperature approach has little need for Na2O 
ability to reduce the melting point of the composition. (2) However due to the greater need for a material 
to be biodegradable, compositions including Na2O are now being processed using the sol-gel technique 
as the addition of Na2O increases the solubility of the composition. (2) 
The 45S5 Bioglass® is synthesised by a process of hydrolysis and polycondensation of an 
aqueous solution of tetraethyl orthosilicate (TEOS), triethyl phosphate (P(OEt)3), calcium nitrate 
tetrahydrate and sodium nitrate with HNO3 to hydrolyse the TEOL and P(OEt)3 to produce the sol. 
(201) The sol is cast into an air tight mould and a process of agglomeration and bonding of the nano-
particles continues until a gel is formed. (201) This gel is aged which allows the bonds within the gel 
to strengthen whilst it shrinks. The gel is dried and stabilized before being milled into a powder that can 
then be used in scaffold production. (201)  
Sol-gel processing does provide a great versatility in glass processing by simply changing the 
pH of the sol to produce powders, monoliths or nano-particles. (2) 
 
2.9 The need for scaffolds in bone tissue engineering and additional properties 
 
 The focus of this project is the development and characterisation of scaffolds for BTE and so 
far the discussion has centred on the materials that are currently used and not on the scaffolds 
themselves. Any scaffold suitable for BTE needs to have the properties already discussed in section 2.6 
but also requires other properties including 3D interconnected porosity, surface roughness and a wetting 
ability.  
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 Scaffolds provide structural support to cells and new tissue by acting as a temporary 
extracellular matrix compared to bulk materials. (202) Essentially, scaffolds allow for new bone to 
grown and to infiltrate them and to gradually replace the scaffold as it degrades whilst still providing 
mechanical/structural stability. (203) Scaffolds should accurately mimic the bones extracellular matrix 
allowing for almost seamless replacement during regeneration (204) (205) and they can be tailored in 
size and shape to fit into different bone defects. (206) (207) Surface properties have been empirically 
linked to cell attachment and proliferation for decades meaning that, for example surface chemistry and 
surface roughness are important for the biological compatibility of the scaffold. (208) 
 
2.9.1 Additional properties for a scaffold - Porosity 
 
Porosity is a key parameter for a scaffold as it determines the applicability of the scaffold in a 
given tissue engineering area. Figure 8 demonstrates the reasons why porosity is a parameter that is 
important in tissue engineering showing the different functions related to a porous structure. (209) 
Pore parameters such as orientation, interconnectivity and morphology have to be tailored to 
suit the needs of the tissue in question. Ideally a scaffold for BTE requires a pore size ranging from 
between 200 to 500µm and pores need to be interconnected. (207) This size range is required for cells 
and nutrients and other required elements to reach the target site and for waste material to be removed. 
(209) In addition, the scaffolds should be manufactured to maximise the porosity that should be 
achieved without compromising the mechanical properties of the scaffold. (210) (211) This pore size 
range (200-500µm) is required so that the cells and molecules involved in bone growth can infiltrate 
the scaffold. (210) (207) The porosity range of a human trabecular bone is between 50 and 90%, (65) 
(70) (74) (75) so any scaffold has to have porosity in this range in order to provide the seamless transition 
between implant and the surrounding tissue. (210) The porosity of a scaffold can be calculated using 
Equation 1.  
Equation 1:-Porosity of an uncoated scaffold 
 
Where ρscaffold and ρmaterial are the densities of the scaffold and the material that the scaffold is 
made of respectively, mscaffold is the mass of the scaffold and vscaffold is the total volume of the scaffold. 
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Figure 8:- Diagram showing the different functions that are directly related to the pore structure a scaffold. (209) 
 
As stated in section 2.6 the mechanical competence of a biomaterial needs to be comparable to 
that of the tissue it is replacing and this is clearly applicable to a scaffold. Thus the porous nature of the 
scaffold has to have mechanical properties similar to those of bone. In the context of BTE the scaffolds 
need to have compressive strengths in the range 0.8-11MPa in order to successfully mimic trabecular 
bone (77)(33) whilst maintaining a suitable porosity. (210) 
 
2.9.2 Additional properties for a scaffold – Wettability 
 
 Wetting is the ability of a liquid to maintain contact with a solid sample surface. The degree of 
wetting is determined by a force balance between adhesive and cohesive forces. (212) (213) This 
property is important in the field of biomaterials because it is significant to determine protein absorption 
and cell adhesion (214) when the materials come in contact with the biological environment. 
 An ideal contact angle for cell attachment should fall between 45 and 90 degrees which will 
imply that the material being tested has a hydrophilic surface as this is suitable for cell adhesion. (208) 
(214) Lower contact angles indicate a more hydrophilic nature compared to large contact angles which 
indicate that the surface has a more hydrophobic nature. (215) Figure 9 illustrates the relationship 
between the interfacial tensions acting on the sample surface and the liquid droplet as well as the 
relationship between the contact angle and the wetting capabilities of the sample’s surface. (212) (213) 
54 
 
 
Figure 9:-Illustration of the contact angle used to quantify the wettability of a sample along with the relationship 
of the wettability and the hydrophilic or hydrophobic nature of a sample (212) (213) (215) 
 
 Wetting plays an important role in cell adhesion, spreading and growth especially in the initial 
stages where the implant/scaffold is conditioned by proteins and the cells start to attach themselves to 
the scaffolds surface. (216) (217) (218) With a direct correlation between the contact angle and cell 
attachment it should also be noted that the cell attachment is also dependant on the stiffness of a 
substrate as cells required support to attach to a surface, for example rigid materials such as a glass-
ceramic compared to less rigid materials such as polymers. (208) This justifies the use of glass-ceramic 
as the base material for the scaffolds produced in this work as they provide a more suitable support 
system for the surrounding tissue. (208) 
 
2.9.3 Additional properties for a scaffold – Surface topography 
 
 The surface topography also has an effect on the suitability of a scaffold for use in BTE and it 
is directly related to the contact angle. (208) The change in surface roughness directly affects the contact 
angle and therefore the cell attachment of the surrounding tissue. (208) Osteoblasts are sensitive to the 
surface roughness and in some cases an increase in surface roughness has decreased healing times in 
vivo. (219) In the literature the general consensus is that the scaffolds surface needs to have a certain 
roughness in order to enhance cell adhesion and proliferation. (220) White light interferometry (221) 
can be used to investigate the surface topography of a material for BTE with two distinct values sets for 
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enhanced cell adhesion reported in the literature. (222) (223) (224) (225)  The first set of RMS (root 
mean square) values corresponds to the macro-topography in the range of 300nm to 800nm (222) (223) 
(224) (225)  and the second set of RMS values correspond to the micro-topography of the surface in the 
range of  1.1nm to 88nm (226) (227) (228) and both are important to enhance cell attachment and 
proliferation. In this work the focus is on the macro-topography of the surface of the scaffold as it is 
this roughness that supports the initial cell attachment. (222) (223) (224) (225)   
 
2.10 Current scaffolds in bone tissue engineering 
 
 This section charts the progress that has been made in fabricating scaffolds for BTE using 
materials described in section 2.7 with the properties described in sections 2.6 and 2.9.   
 
2.10.1 Glass-ceramic scaffolds for bone tissue engineering 
 
 As described in section 2.7, the logical step from the naturally occurring HA and calcium 
phosphates is to use synthetic glass-ceramic bioactive glasses which are then fabricated into three-
dimensional scaffold ready for implantation, however due to their disadvantages including their long 
degradation time (described in section 2.7) they aren’t being used in this work. Several key glass-
ceramics have come to the for front of the current development of glass-ceramic scaffolds for BTE 
including apatite-wollastonite (A-W), 13-93 bioactive glass and the original bioactive glass 45S5 
Bioglass® (BBG). 
 A-W derived glass-ceramic scaffolds have been manufactured using a variety of fabrication 
techniques including adding a plastic porosifer, (229) foam impregnation, (230) (231) wood powder 
burnt out during sintering, (232) three dimension printing (233) and laser sintering. (234) (235) All 
these scaffolds have produced evidence that A-W derived glass-ceramic scaffolds show the potential to 
be used in BTE showing suitable porosities, precipitation of HA after immersion in SBF, in vitro 
assessments have shown cell attachment and growth without cytotoxic effects and mechanical 
properties similar to those observed for trabecular bone. However these properties have not been found 
in one scaffold type making it difficult to identify the most suitable scaffold production method for A-
W glasses. Further research is required to improve this potentially important scaffold type before it can 
be considered for implantation in particular improving its resorption/degradation properties. (236) 
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 13-93 bioactive glass-ceramic scaffolds are a more recent addition to the BTE scaffold family, 
with a range of fabricated techniques being utilized to produce porous three dimensional constructs 
including laser sintering, (237) freeze extrusion fabrication (238) and foam replication. (239) Results 
for this scaffold material have showed promising results with growth and differentiation of osteoblasts, 
(240) suitable porosity, (239) suitable mechanical properties, (239) bioactivity (241) and variable 
degradation rates. (241) However more work is required on these scaffolds before they can be implanted 
as their affects in vitro, let alone in in vivo, have not been fully documented. 
 
2.10.2 45S5 Bioglass®- derived glass-ceramic scaffolds for bone tissue engineering 
 
One very important aspect of Bioglass® -derived glass-ceramics is its transformation from the 
Na2Ca2Si2O9 crystalline phase to an amorphous silicate matrix containing HA crystallites after 
immersion in simulated body fluid for 28 days. (121) The kinetic of HA formation can be tailored 
through the fabrication process by changing the sintering conditions. Fine crystals of Na2Ca2Si2O9 grow 
and nearly complete densification of the scaffolds struts occur when scaffolds are sintered at 
approximately 1000oC for a couple of hours. These conditions give the scaffold the reasonable 
compressive and flexural strength, (4) however further work must be carried out to further improve the 
structural integrity of these scaffolds, for which this project is expected to contribute. The ideal end 
point with any material that is being tailored for BTE is to provide in situ support, to the surrounding 
tissue, whilst remaining bioactive. Then in the later stages of the tissue regeneration process the 
materials can biodegrade at a set rate to provide continued support during this process. (242) To a certain 
extent this has been achieved with the BBG scaffolds (Chen et al (4)) and because of this they remain a 
very active research topic, considering the promising properties of these scaffolds in the scope of tissue 
engineering. There are a number of fabrication techniques including foam replication, (4) freeze casting, 
(243) sol-gel processing (244) and solid free form fabrication (which includes robocasting, (245) rapid 
prototyping (246) and 3D printing) and some of these will be discussed in section 2.11. 
 
2.10.3 Other bone tissue engineering scaffolds 
 
 Two of the most researched scaffold types are scaffolds made with HA and scaffolds made with 
calcium phosphates (CaP). HA scaffolds have been produced using a variety of techniques including 
freeze casting, (247) solid form fabrication, (248) foam replication (249) and sol-gel production. (250) 
These have produced scaffolds with properties which are sort after in the hunt for a perfect BTE 
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scaffold, including porosity, (251) mechanical strength, (252) cell attachment, (251) lack of a cytotoxic 
response (251) and bone growth. (248) However, as mentioned in section 2.6, the lack of a degradation 
of the scaffold does not make it suitable for regeneration therapy; (253) although work is being down 
to improve the degradation by combining it with more reactive materials to create a composite that is 
more suitable. (254) (255) 
 CaP scaffolds of various compositions (such as tricalcium phosphate (beta –TCP) (256) and 
biphasic calcium phosphate (257)) have been fabricated using a number of techniques such as foam 
replication, (258) sol-gel processing, (259) solid free-form fabrication (259) and freeze casting. (260)  
As with the HA scaffolds, described above, these scaffolds have the potential to be used in bone 
replacement/regeneration therapy as they are observed to have desirable properties such as porosity, 
(261) mechanical strength, (261) bioactivity (262) (263) and suitable surface topography, (264) lack of 
a cytotoxic effect (265)and encouraging cell attachment and differentiation. (263) However CaP 
scaffolds, as is the case with the HA scaffolds, are seen as a stepping stone to composite scaffolds with 
improved properties (266) (267) and a more suitable degradation/release rate. (253) 
 Current research has shown that composite scaffolds are the way forward for BTE by taking 
the materials with the most promise and combining to produce a scaffold which is closer to mimicking 
bone.  
  
2.11 Scaffold production 
 
 There are a variety of techniques being utilized to produce the required three dimensional 
porous scaffolds, but there are four main types have been identified in the literature as the techniques 
to use for BTE scaffolds:- 
 Foam replication 
 Sol-gel processing 
 Solid free-form fabrication 
 Freeze casting 
In this work the BBG scaffolds were produced using the foam replication technique as the BBG 
scaffold needs to a constant as other variables are being changed in this work and the foam replication 
technique, according to the literature (4) gives the most consistent scaffold form compared to the others 
method discussed in this section. 
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2.11.1 Foam Replication technique to produce scaffolds for bone tissue engineering 
 
 The foam replication technique, first described in Chen et al, (4) is a process of dipping a foam 
template, which range from a polyurethane foam (4) to wood or coral, (268) into a ceramic suspension 
containing the glass-ceramic, in this case melt-derived 45S5 Bioglass® powder, and a binding agent. (4) 
(268) The “green body” is then dried and sintered according to the method described in section 4.2.1. 
The replication technique produces highly porous three-dimensional scaffolds which are easily 
reproducible, easy to tailor the size and shape of the scaffold, with the added bonus of being 
mechanically stable, bioactive and biodegradable. (4) (268) When the sacrificial template used in the 
foam replication process is polyurethane (PU), as used in this work, this produces a highly 
interconnected pore network due to the nature of the PU foam. (269) (5) (270) In this work the PU foam 
has 45 pores per inch and a pore size of 350 to 800µm, which led to base 45S5 Bioglass® scaffolds with 
a pore size of approximately 500µm. (269) (5) (270) (271) The intrinsic permeability for these 45S5 
Bioglass® -derived scaffolds has been reported to be 1.96x10-9m2 which is in the range of the values 
reported for human trabecular bone. (270)  
However due to the extremely high porosity, upwards of 90% in some cases, the mechanical 
strength of the scaffolds is lower than observed for some of the other production methods but this can 
be improved through the use of polymer coatings. (4) (268) This is shown in Figure 10B) with data 
obtained from the literature, and shown in appendix A, it can be seen that majority of the scaffolds 
produced by this technique have a compressional strength similar to that observed for trabecular bone 
(between 2 and 10 MPa) with porosities of around 75%. It is also observed that the presence of a 
polymer coating improves the compressional strength whilst not compromising on the porosity. 
 
2.11.2 Sol-gel processing to produce scaffolds for bone tissue engineering  
 
 This fabrication technique typically involves the foaming of the gel, as described in section 
2.8.2, with the aid of a surfactant. (268) This is then followed by a condensation and gelation process 
with an ageing process, similar to the one described in section 2.8.2, to strengthen the structure. (268) 
Finally the liquid by products are removed allowing for the structure to be sintered. (268) This 
fabrication method produces scaffolds which are highly porous, with both macro-pores (10-500µm) and 
meso-pores (2-50nm) observed, (268) that are highly bioactive but these sol-gel derived scaffolds suffer 
from a low mechanical strength. (268) The low mechanical strength, which is also observed with the 
foam replicated scaffolds and shown in Figure 10C), can be improved through the use of polymer 
coatings and by producing composite scaffolds. Foam replication is preferred over sol-gel processing 
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because of the composition of the base 45S5 Bioglass® that is used in this work, , which contains Na2O 
and compositions with Na2O have only recently been used to form scaffolds using sol-gel processing, 
as described in section 2.8.2. (2)  
 
 
Figure 10:-Evaluation of compressive strength against porosity for scaffolds fabricated using A) Freeze casting, 
B) Foam replication, C) Sol-gel and D) solid free-form fabrication with data for glass-ceramics only, scaffolds 
coated in a polymer and MSIE samples. Data is shown in appendix A 
 
2.11.3 Freeze drying to produce scaffolds for bone tissue engineering 
 
 Freeze casting fabrication (or freeze drying) involves a colloidally stable suspension containing 
the glass-ceramic which is then rapidly frozen in a mould. (268) The sublimation of the suspensions 
solvent, at freezing temperatures in a vacuum, leaves behind a porous construct, which after drying is 
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sintered to leave a porous scaffold with improved mechanical strength. (268) However this technique 
does not produce scaffolds, using 45S5 Bioglass®, which are porous enough to allow cell proliferation 
and attachment at the present time. However, as shown in Figure 10C), some scaffolds fabricated in 
this manner have both a suitable porosity (above 75%) and a compressional strength similar to that 
observed for trabecular bone.  Progress is being made, through the use of different suspension solvents, 
to increase the porosity without losing the increased mechanical strength. (268) This is a technique that 
once it has established a protocol for 45S5 Bioglass® which balances compressional strength and 
porosity can be used to produce scaffolds for BTE in the future. 
 
2.11.4 Solid free-form fabricated scaffolds for bone tissue engineering  
 
 Solid free-forming fabrication is an umbrella term used for a number of processing techniques 
including 3D printing, (233) robocasting, (245) fused deposition modelling, (272) ink jet printing, (273) 
stereolithography, (274) selective laser sintering (234) (235) and rapid prototyping. (246) This 
technique broadly involves producing scaffolds layer by layer through the use of a paste containing the 
glass-ceramic. The design of the scaffold, including its shape, size, surface topography, pore structure 
and pore orientation is controlled by computer aided design rather than traditional moulds (as in sol-gel 
processing) and foams (as in foam replication). In this way the design of the scaffold is modelled 
extensively using all the current knowledge of the most suitable and desirable properties before being 
produced. 
 This fabrication technique is promising in producing scaffolds that have a desirable balance 
between porosity and compressional strength, as shown in Figure 10D) but as it is in the early stages of 
being explored, scaffolds produced using this group of techniques using 45S5 Bioglass® have only just 
produced the first generation of scaffolds. (275) (276) Since this work is looking at varying the 
composition through MSIE and polymer coatings an established fabrication technique is required so the 
scaffolds structure is constant throughout the work. It should be noted that this branch of scaffold 
fabrication has a lot of potential as these would be easy to reproduce on a large scale because the 
fabrication is completed by machine rather than by hand, as in the case of foam replication, and the 
scaffolds can easily be tailored to any size and shape. 
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2.12 Multifunctional scaffolds for bone tissue engineering 
 
The BBG scaffolds, used in this work, have been developed/manufactured for BTE to have a 
clear set of functions, which have been described in the previous sections, to encourage and support 
new bone growth. This scaffold type needs to be developed further incorporating additional functions 
in order to be a viable option in bone tissue replacement/regeneration therapies. The approach taken in 
this work is to improve the BBG scaffolds by improving the weak points of this scaffold type, for 
example the mechanical strength, without disrupting the desirable ones such as the high bioactivity 
through the use of functional additives which will give the scaffold additional properties, such as 
antibacterial or angiogenic properties whilst improving pre-existing properties. 
One issue with BBG scaffolds is that their mechanical properties, in particular compression 
strength, does not completely match those of bone making them unsuitable for implantation, as 
demonstrated for the four main fabrication techniques in Figure 10. One route that researchers have 
been exploring to improve these mechanical properties is introducing polymers into the scaffold either 
as a coating or incorporating the polymer into scaffold structure. (121)  Researchers have found that 
these polymer/bioceramic composite scaffolds have improved the scaffolds mechanical properties (7) 
(121) without compromising on properties such as porosity or biological surface reactivity of the 
scaffold. Figure 10 shows that the incorporation of polymers into the scaffolds construction improves 
the compressional strength whilst maintaining the desirable high porosity. The difference in mechanical 
properties between bone, BBG scaffolds and these polymer/Bioglass® composite scaffolds is illustrated 
in both Figure 10 and Figure 11. (121) In this project, a number of polymer/Bioglass® composite 
scaffolds will be investigated to improve the mechanical competence of the scaffolds. From the point 
of view of making the scaffold have a variety of functions the addition of a polymer coating is 
advantageous as these polymer coatings have the potential to act as drug delivery vehicles for a range 
of additives such as antibacterial ions (113)and antibiotics, (224) angiogenic elements, (277) growth 
factors (278) (279) and vitamins. (280) 
With post-operative infections and implant rejection a concern, the ideal scaffold implant would 
be one that incorporated an antibacterial element to help to prevent these issues and thus reducing the 
post-operative care and improve the patient’s recovery time. One of the main reasons behind 
complications in the recovery of a patient after having an implant is bacterial infection. (281) In order 
to reduce the likelihood of infection an antibacterial element needs to be introduced into the implant 
and this is one of the main objectives of this work. 
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Figure 11:- Comparison of elastic modulus against compressive strength for a variety of biomaterials 
including composites, polymers, bone and bio-ceramics (121) 
 
2.13 Antibacterial scaffolds 
 
 One method to reduce the risk of post-operative infection is to incorporate an anti-bacterial 
element into the implants construction during fabrication rather than over use antibiotics after 
implantation. In this work the aim is to incorporate an antibacterial element into the scaffold in an effort 
to produce a scaffold that will help prevent and combat post-operative infection. 
As previously stated it is imperative to avoid surgical site infection (SSI) in the tissue after the 
scaffold has been implanted as infections can be incredibly persistent and difficult to treat without 
eventually removing the implant. (282) The most common cause of bacterial infection in bone 
replacement therapy is Staphylococcus aureus (S.aureus) (283) which can be treated with a number of 
antibiotics including gentamicin (284) and vancomycin. (283) The issue that has arisen in recent years, 
due to the overuse of antibiotics, is that bacteria have become resistant. (285) With methicillin-resistant 
S. aureus strains (MRSA) (286) and vancomycin-resistant S. aureus (VRSA) (287) becoming more 
problematic an alternative therapy is required. 
The idea and exploration of metal ions as antibacterial agents has been around for some time 
with many metals showing promise including silver, (288) (113) copper (289) and zinc. (290) This work 
is concentrating on incorporating silver and copper into the BBG scaffold in order to produce an 
antibacterial effect that will reduce the need to use antibiotics after implantation. The release rate of the 
therapeutic metal ion needs to be such that it is released over a long period (not in a burst) to provide 
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antibacterial coverage that prevents SSI, allows the implant to settle into the implantation site and 
prevents any other infections developing near the implantation site which ranges between ten to thirty 
days. (291) 
Also it should be noted that the advantage of developing these antibacterial scaffolds would be 
that they would provide a better localised targeted antibacterial coverage compared to antibiotics 
delivered by traditional means, such as oral and intravenous. This will allow infections/bacteria to be 
swiftly dealt with at the source and keeps the surrounding area bacteria/infection free.  
 
2.13.1 Antibacterial properties of 45S5 Bioglass® -derived glass-ceramic scaffolds 
 
 Although 45S5 Bioglass® was developed in the late 1960’s, (76) more enthansis was placed on 
the materials bioactivity and other desirable properties. Now with SSI’s and resistant bacteria becoming 
more of an issue in bone replacement/regeneration therapy the antibacterial properties are just as 
important as its other desirable properties. 
 It has been shown that 45S5 Bioglass® has an antibacterial effect against a wide range of 
bacteria including both gram-negative and gram-positive bacteria. With 45S5 Bioglass® causing a 
higher antibacterial effect on gram-negative bacteria, such as E.coli at concentrations between 10 and 
50mg/ml. (292) Concentrations above 50mg/ml showed an equal antibacterial performace for both 
gram-negative and gram-positive bacteria. The difference in antibacterial effect, for the lower 
concentrations, can be attributed to the difference in the bacteria’s surface properties (the difference in 
the make up of the bacteria’s cell wall), which are discussed in section 2.18. (292) (293) 
 A solid theory as to the antibacterial mechanism against bacteria (of either class) has yet to be 
established. Although there are a number of factors that are being considered as possible contributors 
to the antibacterial effect of 45S5 Bioglass® including the antibacterial effect of the pH increase casued 
by the ion exchange at the surface of the 45S5 Bioglass® once it is immersed in a physiological fluid, 
such as SBF or cell culture media. (292) Another factor to consider that the cell walls are 
destroyed/damaged by the formation of crystalline structures during the precipatation of HA on the 
surface of the 45S5 Bioglass® which would lead to cell death. (292) 
 It should also be noted that due to advances in sterilisation techniques and procedures used in 
the implantation surgery the antibacterial effect required at the point of implantation will be lower than 
the effect required after 24 hours for example or in most of the in vitro models used in the literature 
currently. (294) 
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2.13.2 Antibacterial properties of silver 
 
 Silver has been on the radar of scientists for a long time as an antibacterial element (6) (295) 
and it has been shown to be a good candidate for the treatment of bone infections (288)with an increase 
in the research being carried out using silver as an antibacterial element. (288) (113)  
 Previous research on the exposure of bacteria to silver has been carried out and the following 
has been observed:- 
 The cytoplasm membrane surrounding the cell wall shrinks or detaches (296) (297) 
 Electron-light region appears in the centre of the bacteria containing the DNA in a condensed 
form (296) 
 Electron-dense region around the electron-light region which contains deposited proteins and 
silver ions (296) 
 Disrupts ATP production (297) (295) 
 If the concentration is high enough the cell wall collapses causing bacteria death (296) (295) 
 Prevents DNA replication meaning that the bacteria cant replicate (296) (297) (295) 
There are many theories as to the mechanism of how the silver ions cause an antibacterial effect 
including attributing it to their small size and therefore their high surface to volume ratio. (295) This 
allows the metal ions to interact closely with the cytoplasm membranes of the bacteria causing the 
inactivation of proteins through interactions with thiol groups. (295) (296) This close interaction causes 
the silver ions to be incorporated into the bacteria’s cell membrane causing the intercellular substances 
to leak out of the cell leading to cells death. (295)  By passing through into the bacteria’s interior the 
silver disrupts ATP production and DNA replication leading to a bacteriostatic effect as the bacteria 
can no longer replicate. (296) (297) (295) The concentration of silver used needs to be carefully 
controlled as high levels of silver causes human cell toxicity. (298) (297) (299) This toxic effect also 
occurs at a high release rate of silver ions, (300) (301) so when incorporating silver into the scaffold 
construct the release rate and the concentration both need to be considered. (6) (113) 
 
2.13.3 Copper ions as an antibacterial agent 
 
Copper is also considered to be an antibacterial element, (295) but it also has other properties 
which are of interest in BTE, such as causing an angiogenic effect, (10) (277) making the addition of 
copper an ideal choice for a multifunctional BTE scaffold. 
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 Copper ions cause their antibacterial effect in a similar way that silver ions do, in that the 
positive copper ions are attracted to the negatively charged cell wall, punching holes in the cell wall 
causing the intercellular substances to leak out leading to cell death. (302) As with the mechanism 
theorised for the antibacterial effect of silver, more research is required to ascertain a solid theory as to 
how the copper ions are causing this antibacterial effect. (295) (302) From research carried out with 
copper ions, extrapolated from work with silver ions, it is clear that the antibacterial effect is dependent 
on the concentration of metal ions released from the implant and the rate of release and in turn the effect 
is dependent on the surface concentration of the therapeutic metal ions. It has been found that the higher 
the surface concentration of the metal ions the greater the antibacterial effect. (6) (281) However the 
higher the concentration the more likely the surrounding cells are going to succumb to cell death or 
changes due to toxicity as a result of the presence of the metal ions. (302)  
 
2.14 Angiogenic scaffolds 
 
 Another function that could be imparted into the BBG scaffold is the ability to help the 
surrounding tissue to spontaneously form blood vessels in otherwise to make the scaffolds angiogenic 
as this would be an appropriate function for a BTE scaffold to have. 
 In order to facilitate bone regeneration a good vascular network (303) (304) is required to 
transport the cells (303) and growth factors (305) (306) to the implantation site and to carry away waste 
away from the implantation site. (307) (308) Angiogenesis is essential in bone regeneration/formation 
as it regulates bone remodelling, prevents osteoblast cell death, and stimulates blood vessel 
development and osteogenesis. (277) Bone remodelling and blood vessel development can be triggered 
by growth factors, such as bone morphogenetic proteins (BMP) for bone remodelling and for 
angiogenesis vascular endothelial growth factors (VEGF) and fibroblast growth factor-2 (FGF-2). (277) 
If a material/implant can encourage the vascular network to form faster by being angiogenic whilst 
maintaining other desirable properties, such as bioactivity, this would produce a suitable implant for 
BTE. Producing angiogenic scaffolds for BTE is an emerging topic in this field and this project will 
contribute to producing an angiogenic glass-ceramic scaffold. 
 The research that has been carried out on the mechanisms that stimulate angiogenesis have 
found two distinct branches being mechanical stimulation (309) (310) and chemical stimulation. The 
mechanical stimulation shows that mechanical stress on existent capillaries causes an angiogenic effect. 
The chemical stimulation of angiogenesis is performed by a number of angiogenic proteins/growth 
factors such as VEGF, (311) FGF, (312) Ang1, (313) Ang2, (313) TGF-beta (314) and endoglin. (315) 
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This work, through the use of copper, will be looking to stimulate these growth factors in order to speed 
up the angiogenesis process. 
 
2.14.1 Angiogenic properties of 45S5 Bioglass® 
 
 It has become apparent recently that 45S5 Bioglass® -derived glass-ceramic without any 
additives exhibits angiogenic properties. It has been observed that 45S5 Bioglass® increases the 
secretion of VEGF and FGF in vitro (316) (317)as well as increasing the proliferation of micro-vascular 
endothelial cells which form the base for the new blood vessels in vitro (316) (317) and for formation 
of endothelial tubules in vitro. (317) It has been shown in vivo that bloods are infiltrating the 45S5 
Bioglass® -derived glass-ceramic scaffold to form a fully functional vascular network just three weeks 
after implantation. (318) Investigation into the angiogenic effects of BBG scaffolds are still in the early 
stages but are showing promise and in combination with other angiogenic additives, composite scaffolds 
containing 45S5 Bioglass® would increase the angiogenesis process. (317) 
 
2.14.2 Copper ions as an angiogenic agent 
 
One of the other interesting desirable properties that copper ions have, for tissue engineering 
applications, is the ability to enhance angiogenesis. (10) (277) As stated previously, growth factors are 
required to trigger angiogenesis, however incorporating growth factors into a scaffold for use in BTE 
is problematic as they are require large concentrations to be effective and the bioactivity period that 
these growth factors is relatively short as they can be unstable. (319) (320) (321)Researchers trying to 
overcome these problems have stabilised the growth factors in a number of ways such as combing them 
with polymers, embedding them in microspheres and incorporating them directly into a scaffold. (277) 
None of these methods are ideal as high doses of the growth factors are required which is not cost 
effective, safe and there is the problem that they have to be properly preserved until needed.  
Researchers are searching for alternative angiogenic agents and this is where copper ions has 
excelled as they are easier to use as they are less expensive, they do not lose their bioactivity, are stable 
and they are easier to manipulate. (277) Instead of using the Bioglass® scaffolds as vessels for growth 
factors, they can be used to delivery copper ions which then go on to stimulate the production of 
angiogenic growth factors such as VEGF, (9) (289) bFBF (322) and angiogenin (322) and the 
production of transcription factors important in activating the growth factors such as HIF-1 (289) (322) 
and NF-kB. (322) 
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Research has shown that the presence of copper stimulates both the proliferation and migration 
of essential endothelial cells. (323) (324) (322) It has also been shown to enhance the infiltration of a 
vascular network into an implanted scaffold. (325) (322) Certain bio-molecules such as heparin, glycl-
histidyl-lysine (GHK) and ceruloplasmin that when bound to copper were found to enhance the 
formation of blood vessels. (322) Initial research which combined CaP scaffolds with copper has shown 
that in vivo, micro-vessels where formed propagating along the pores of the scaffold. (277) 
The challenge that faces researchers, and indeed this work, is controlling the release rate of the 
copper into the human body as it is cytotoxic at high prolonged or burst doses (326) but if this can be 
controlled then the addition of copper to a BTE scaffold would produce a composite scaffold capable 
of inducing angiogenesis. Another issue that has come to light, which has been investigated in terms of 
intrauterine devices (IUDs), is the problem of a burst release of the copper causing abnormal bleeding 
and pain in the surrounding tissue. (327) 
 
2.15 Molten salt ion exchange (MSIE) 
 
 MSIE is a technique used to introduce metal ions into the crystalline structure of glasses and 
glass-ceramics. It is a technique that has been used for decades in optics to introduce metal ions such 
as Rb+, (328) K+, (329) Ag+ (329) (330) and Cu+ (330) into a range of glass optical devices such as 
wave guides (328) and optical splitters. (329) MSIE has been used to change the refractive index, (331) 
to chemically strengthen glass (332) and to increase the electrical conductivity of the material. (333) 
Research has shown that the change in the properties of the material due to MSIE is due to the glass 
undergoing local re-structuring at the surface at temperatures which are far lower than the glass 
transition temperature. (334) 
The MSIE technique is an established method used to chemically strengthen glass by 
exchanging a smaller ion within the glass with a larger ion from the molten salt bath. (332) (335) A 
common example is the exchange of sodium from a soda lime glass with potassium in a potassium 
nitrate molten salt bath, as demonstrated in Figure 12. (336) (337) 
In the present work, the main purpose of the MSIE process was to incorporate specific ions, 
e.g. silver and copper, into bioactive glass, for enhanced functionality, e.g. antibacterial effect. It is also 
possible that the MSIE process could contribute to increasing the mechanical properties of the structure 
(strengthening effect) but this was not the main goal of the MSIE process in this research. 
Essentially strengthening by the use of ion exchange works by the larger ion from the salt bath, 
silver and copper ions in this work, exchanging with the smaller ion from the glass, the sodium ion in 
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this case, and the larger ions force themselves into the space left behind by the smaller ions, essentially 
“stuffing” the rigid structure at surface of the glass. (332) (335) (336) (337) This stuffing effect leads 
to a high compression on the surface of the glass and a corresponding balancing tension in the interior 
of the glass. (332) (335) (336) (337) 
 
 
Figure 12:- Schematic representation of the chemical strengthening of glass through molten salt ion exchange 
showing the exchange process between potassium in the melt and sodium in the glass 
 
In the scope of this work a technique is sort to introduce the chosen therapeutic metal ions into 
the surface of the BBG scaffolds where they will be released soon after implantation. Evidence has 
shown that MSIE introduces the metal ions only into the surface of the glass if the immersion period is 
restricted. (330) 
 Using MSIE to introduce both silver and copper into these optical devices is extremely common 
and the process is well documented and characterised. (329) (330) (338)However using MSIE to 
introduce functional therapeutic metal ions (in this work copper and silver have been selected, as 
discussed in sections 2.13 and 2.14) has not been extensively investigated. (6) (113) With Di Nunzio et 
al (6) introducing silver into a silicate glass for antibacterial applications and Lopes et al (339) 
introducing additional calcium into 45S5 Bioglass® -derived glass-ceramic structures to modulate the 
desirable properties of the 45S5 Bioglass®.  
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2.15.1 Incorporating Silver ions into 45S5 Bioglass® -derived glass-ceramic scaffolds using molten 
salt ion exchange 
 
Work has already been carried out using MSIE to introduce silver into silica based glass-
ceramics (340) and phosphate based glass-ceramics (341) through the sol-gel technique which was 
described in section 2.8.2. There are several ways of introducing metal ions into the scaffold, including 
the traditional melt quenching technique, sol-gel processing and molten salt ion-exchange. Both the sol-
gel method and the melt quenching methods are useful if the silver is required throughout the whole 
structure of the scaffold, (340) however the idea with these scaffolds is that the silver acts as an initial 
antibacterial element whilst the risk of infection is at its highest. This approach requires that silver ions 
are only present on the surface of the scaffold; the obvious choice would be to use the molten salt ion-
exchange technique. (6)  
MSIE has been investigated in the past for use in introducing melt ions into glass waveguides 
for optical applications. (342) (329)  Di Nunzio et al (6) shows that using the MSIE method silver ions 
can be introduced into bioactive glasses, specifically SiO2-CaO-Na2O. MSIE allows the fabrication of 
silver-doped scaffolds that can easily be reproduced, with constant diffusion profiles and silver content. 
This method offers a simple and low cost way to introduce silver into a pre-fabricated scaffold after 
they have been sintered. (6) The mechanism of silver MSIE, represented in the Equation 2, from Di 
Nunzio et al (6) was between sodium ions in the glass and silver ions in the salt bath. (6) 
Equation 2:- Mechanism of silver-sodium molten salt ion exchange in a glass 
 
 Since this project used BBG scaffolds with a composition of SiO2-Na2O-CaO-P2O5, (3) a 
similar MSIE technique, like those described by Di Nunzio et al, (6) can be used. The molten salt bath 
needs to contain both silver nitrate and sodium nitrate salts, with the sodium nitrate salt being used to 
regulate the amount of silver being exchanged into the material; this exchange process is described by 
Equation 3.  
Equation 3:- Molten salt ion exchange process to introduce silver into a pre-fabricated BBG scaffold 
 
This technique is described in more detail, with specific details pertaining to using MSIE to 
introduce silver into pre-fabricated BBG scaffolds, in the methodology section (section 4.2). This 
process was also described in Newby et al for pre-fabricated BBG scaffolds for BTE. (113) 
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2.15.2 Incorporating Copper ions into 45S5 Bioglass® -derived glass-ceramic scaffolds using 
molten salt ion exchange 
 
As with the silver ions described in section 2.15.1, copper can be introduced into the pre-
fabricated scaffolds via the molten salt ion-exchange method and this has been used to introduce copper 
into waveguides for the past 20 to 30 years. (342) No work has been done, so far, to introduce copper 
ions into 45S5 Bioglass® scaffolds using the MSIE technique, making the work with copper in this 
project novel. Oven et al (342) describes the process of copper/sodium MSIE in soda lime glass for 
wave guides and combined with the silver MSIE processes described in Di Nunzio et al (6)  and Newby 
et al (113) the following exchange equations have been deduced, shown in Equation 4 and Equation 5.  
Equation 4 shows that the MSIE process occurs between the copper in the salt bath and the sodium in 
the scaffold and Equation 5 shows the chemical exchange occurring in the salt bath once the BBG 
scaffold is immersed in the salt bath. 
Equation 4:- Mechanism of copper-sodium molten salt ion exchange in a glass 
 
Equation 5:- Molten salt ion exchange process to introduce copper into a pre-fabricated BBG scaffold 
 
The technique is described in the methodology section (section 4.2), with specific details 
pertaining to the use of MSIE to introduce copper into pre-fabricated BBG scaffolds. The sodium nitrate 
in the salt bath acts as a regulator to control the amount of copper infiltrating the BBG scaffold’s 
structure. Controlling the amount of copper that is infiltrating the scaffold is paramount as toxicity 
issues need to be avoided. Burst release can be avoided if the copper is loaded into the scaffold in small 
but effective dose or loaded into a polymer carrier. (327)  
 
2.15.3 Dual ion incorporation into 45S5 Bioglass® -derived glass-ceramic scaffolds using molten 
salt ion exchange 
 
 The previous section, sections 2.15.1 and 2.15.2, have described the process behind 
silver/sodium and copper/sodium MSIE. The last ion-doped scaffold type that is being investigated in 
this work is to introduce both copper and silver through MSIE. This is a novel application of the MSIE 
technique especially its use in biomaterials. 
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Equation 6 shows that the MSIE process occurs between the silver/copper in the salt bath and 
the sodium in the scaffold and Equation 7 shows the chemical exchange occurring in the salt bath once 
the 45S5 Bioglass® -derived scaffold is immersed in the salt bath.  
Equation 6:- Mechanism of copper/silver-sodium molten salt ion exchange in a glass 
 
Equation 7:- Molten salt ion exchange process to introduce copper and silver into a pre-fabricated BBG scaffold 
 
This technique is described in more detail, with specific details pertaining to using MSIE to 
introduce silver into pre-fabricated BBG scaffolds, in the methodology section (section 4.2). The 
sodium nitrate in the molten salt bath acts as a regulator to control the amount of copper/silver 
infiltrating the BBG scaffold’s structure. As described in previous sections the release mechanism of 
the silver and copper needs to be controlled in order to prevent a cytotoxic effect occurring once the 
ion-doped scaffold is introduced to cells. 
 
2.16 Polymer coated scaffolds for bone tissue engineering 
  
 As described in section 2.12, one solution to the problem of lack of mechanical strength of the 
BBG scaffolds is to introduce a polymer into the structure by either coating the scaffold or infiltrating 
the polymer into the materials structure. (7) (343) Figure 10 shows that previous research has shown 
regardless of which fabrication method was used to produce the bio-ceramic scaffolds the addition of a 
polymer into the scaffolds structure improved the compressional competence of the scaffolds. Complete 
polymer infiltration is not relevant in this work as one of the aims of this study is to produce a highly 
porous scaffold that should be infiltrated by cells during the regeneration process. This work will 
investigate the use of polymers to cover the surface of the scaffold struts forming a homogenous layer, 
but not blocking the macropores. 
 The fracture toughness of a material is an expression of a materials behaviour, whilst cracked 
to resist fracturing and crack propagation. (344) Ceramics and glass-ceramics have a low fracture 
toughness as they are brittle materials and cracks will extend when more force is applied but in their 
bulk form have a high compressive strength and stiffness. (344) Polymers, however, have a higher 
fracture toughness due to their elastic nature, ductility and plasticity but have a low compressive 
strength. (344) By combining the two in a composite structure by coating the highly porous glass-
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ceramic scaffold with a polymer it is hoped that the fracture toughness will improve due to the polymer 
coating whilst maintaining a suitable compressive strength. (344) (345) 
It is hypothesised that by coating a structure with a polymer it will fill micro-cracks, bridge 
cracks and forms a polymer-ceramic network, behaving in a way similar to collagen fibres and HA 
crystals in bone. (65) (77) (344) (346) Collagen fibres help to bridge cracks in bone to increase the 
fracture strength and toughness. (7) (344) (346) 
The polymer acts as a toughening mechanism for the composite in the following ways:- 
 Crack bridging 
 Crack deflection 
 Crack tip shielding 
 Pulling out 
The polymer acts as a bridge across any micro-cracks in the surface of the scaffold and acts to 
closure stress to counter act the applied force. (345) Crack deflection occurs when the path of the crack 
is deflected by the polymer resulting in in more energy being dissipated for a reduced crack propagation. 
(345) Crack tip shielding occurs at the leading point of a crack and in this case the polymer prevents 
further propagation of the crack tip. (345)  Pulling out occurs when the polymer is pulled out over a 
crack or defect. (345) All of these mechanisms in combination would protect the glass-ceramic scaffold 
underneath the polymer coating whilst preventing further propagation of the micro-cracks formed 
during the sintering process. (345) 
 
 
Figure 13:- Fracture toughening mechanisms observed for polymer coated ceramics in the literature showing A) 
crack bridging, B) crack deflection, C) crack tip shielding and D) pull-out. (345) 
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In selecting a suitable polymer to use as a coating material, the way in which the polymer covers 
the scaffold and infiltrates the micro-cracks is important as it is this infiltration that improves the 
mechanical competence of the scaffold. (7) (110) This will be more affective in employing the 
toughening mechanisms described above compared to if the polymer just forms a layer on top of the 
scaffold. (344) (345) 
Ideally any polymer that is used in this work should infiltrate into the micro-cracks, produced 
in the sintering process, so the polymer can have a dual purpose, one to improve the mechanical 
properties of the scaffold and another to act as a drug delivery vehicle, leading thus to multifunctional 
scaffolds. In the following sections two polymers used in tissue engineering will be discussed in terms 
of their use in BTE scaffolds as a coating material. The polymers discussed and used in this work are 
Poly(D,L-lactic acid) (PDLLA) and gelatin. 
 
2.16.1 Poly (D, L-lactic acid) coated scaffolds 
 
A commonly used synthetic polymer group used in tissue engineering are polyesters since the 
esterification process used to form these polymers is reversible making these polymers easily 
metabolised by the body making them ideal candidates for use as polymer coatings. (347) Poly(D, L-
lactic acid) (PDLLA), structure shown in Figure 14, is one of four isotopes of poly(lactic acid) (PLA) 
due to its chiral nature with the L and D acid monomer units spread along the polymeric chain which 
results in a completely amorphous polymer due to its irregular structure. (348) (347) (349) PDLLA has 
the lowest degradation rate of the four PLA isotopes and for this reason has appealed to researchers in 
tissue engineering. (348) (347) (349) 
 
 
Figure 14:- Structure of PDLLA (350) 
 
Recently researchers have used PDLLA to coat bioactive glass scaffolds in order to improve 
the mechanical properties of the glass-ceramic scaffolds without compromising the desirable properties 
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of the glass-ceramic scaffolds. Various researchers have combined BBG scaffolds and have showed 
that the addition of the PDLLA coating increases the compressional strength of the scaffold, infiltrates 
the micro-cracks and overall improves the mechanical competence and stability of the glass-ceramic 
scaffolds. (110) (351) (352) (353) 
It was observed despite the presence of the PDLLA coating the BBG scaffolds maintained the 
bioactivity. Moreover the PDLLA/Bioglass® scaffold also maintained its mechanical integrity during 
the immersion period in SBF. (110) In the polymer coated scaffolds the PDLLA retards the 
transformation of the crystalline phase (Na2Ca2Si3O9) to the amorphous calcium phosphate phase and 
this ensures mechanical stability of the scaffold over a longer period of time in SBF. (110) 
The use of PDLLA as a biodegradable drug delivery vehicle has started to be explored with 
research into its use to transport antibiotics such as gentamicin (354) (355) and growth factors such as 
insulin-like growth factor-1 (IGF-1) and transforming growth factor-β1 (TGF-β1). (356) However this 
falls outside the scope of this work and will not be investigated in this work. 
PDLLA coated BBG scaffolds represents the control polymer coated scaffold for this work, as 
it is already been proven to be a viable coating material for BTE. 
 
2.16.2 Gelatin as a potential coating agent 
 
Gelatin is a natural, biocompatible polymer which is completely dissolvable in vivo and is 
obtained through the physical/chemical degradation or thermal denaturation of collagen which breaks 
the triple helix structure. (357) (358) Gelatin contains a mixture of single and multi-stranded 
polypeptides each with extended left-handed proline helix with a typical structure shown in Figure 15 
which contains a number of compounds such as glycine, proline and 4-hydroxyproline. (357) (358) 
Since gelatin is a natural polymer, derived from collagen, it is naturally biocompatible and 
doesn’t induce cell toxicity which can be an issue with synthetic polymers. (359) (360) It comes in two 
type’s dependant on the preparation of the collagen; type A and type B. (361) (362) Type A gelatin is 
prepared using an acid pre-treatment and is derived mainly from pig skin and is also known as porcine 
gelatin. (362) Type B gelatin is prepared using an alkaline pre-treatment and is derived mainly from 
cow skin and bones and is also known as bovine gelatin. (362) As they are processed in different ways 
they have slightly different properties. (361) (362) 
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Figure 15:- Structure of gelatin (357) (358) 
 
The gelatin coating process described by Liu et al (357) is similar to the process to be used in 
this work and is fully described in the methodology sections (sections 4.2.3.II). Liu et al (357) showed 
that the presence of gelatin coating on a porous calcium phosphate scaffold improved the compressive 
strength by a factor of 5 and the elastic modulus by a factor of 3, (357) making gelatin an ideal candidate 
to improve the mechanical properties of a BBG scaffold. Metze et al (363) which is based on the 
preliminary studies produced in this work, presented in the results section, showed that coating a highly 
porous BBG scaffold with gelatin improved the compressional strength without retarding the desirable 
properties of the BBG scaffold. (363) It has been used in composite materials as a coating agent with 
HA (364) and CaP, (357) (365) but has only recently been used to coat BBG scaffolds fabricated by the 
foam replication technique. (363) 
 Tabata et al (366) discussed the combination of bFGF growth factor with gelatin in a form of a 
hydrogel. (366) The bFGF is released, caused by the gelatin degrading, and the growth factor goes on 
to induce angiogenesis. (366) Patel et al (367) describes how gelatin is combined with the growth factor 
BMP-2 to form a growth factor release system. This work found that the gelatin degraded linearly for 
up to 28 days and this demonstrated that the release of the growth factor can be controlled by 
incorporating it into a polymer. (367) This indicates that gelatin is an ideal candidate for being used as 
a drug delivery system. However there has been no research on incorporating copper or silver with 
gelatin, so this will also be investigated during the course of this work. 
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2.17 In vitro cell culture studies to test the behaviour of bone tissue engineering 
scaffolds 
 
 As previously touched upon, in vitro testing of glass-ceramic scaffolds is important to ascertain 
how the cells interact with the scaffolds. This type of in vitro testing investigates issues with 
biocompatibility and toxicity that could arise once the scaffold has been implanted. This work subjects 
the multifunctional scaffolds to three types of cells and how they are used is described in the 
methodology section:- 
 Human periodontal ligamental stromal cells (HPLSC’s) 
 Rat bone marrow stem cells (rMSC’s) 
 Human bone marrow stem cells (hMSC’s) 
There is limited literature assessing the behaviour of HPLSC’s exposed to BBG scaffolds. 
However the literature has shown that 45S5 Bioglass® supported the proliferation and attachment of 
these cells without any toxicity issues. (113) (368) (369) Studies have indicated that the BBG scaffolds 
have osteogenic potential due to enhanced expression of collagen type I, osteocalcin and alkaline 
phosphatise. (369) (370) The BBG also showed improvements in stimulation in mineralisation and 
production of the extracellular matrix and calcium nodules. (370) (371) It should also be noted that 
when exposed to either rMSC’s or hMSC’s 45S5 Bioglass® was found to support cell proliferation and 
differentiation and cell survival. (372) (373)In particular induction of the genes responsible for cell 
adhesion and differentiation have been observed. (374) 
When exposed to low levels of silver, HPLSC’s are found to behave normally; there is no 
difference in their proliferation or attachment compared to the BBG scaffolds and there is no cytotoxic 
effect observed. (113) Increased exposure to high concentrations of silver has a detrimental effect of 
the cells due to a cytotoxic effect eventually leading to cell death. (375) Silver has shown dose-
dependent cytotoxicity when exposed to both hMSC’s (376) and rMSC’s. (377) The concentration of 
silver needs to be kept low enough not to have a detrimental effect on the human cells whilst being high 
enough to have the desired effect on the bacteria.  
Similar observations have been made for copper when exposed to HPLSC’s that the HPLSC’s 
are relatively resistant to the copper (378) although it has been observed that copper does cause a toxic 
effect on oral cancer cells. (378) It should also be noted that copper released from gold alloys used in 
dental implants have been observed to damage oral fibroblasts due to the copper elevating the reaction 
oxygen species. (379) Copper is also observed to have a dose dependant cytotoxic effect on both the 
rMSC’s (380) and hMSC’s (381) with a detrimental effect at higher concentrations. The concentration 
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of copper also needs to be kept low enough not to have a detrimental effect on the human cells whilst 
being high enough to have the desired antibacterial and angiogenic effect.  
 
2.18 Bacterial testing on bone tissue engineering scaffolds 
 
 As one of the main additional functions that it is hoped that is imparted to the scaffolds is an 
antibacterial capability this needs to be established in vitro through exposing the multifunctional 
scaffold to bacteria. This type of in vitro testing investigates whether the scaffold will cause a 
bacteriostatic or bactericidal effect on the bacteria. A bacteriostatic effect would occur if the bacteria 
are inhibited but not necessarily killing the bacteria. (382) (383) A bacteriostatic agent merely prevents 
the growth and/or reproduction of the bacteria whereas a bactericidal agent kills the bacteria. (382) 
(383) In order to define the antibacterial effect of a material the minimum inhibitory concentration 
(MIB) and the minimum bactericidal concentration (MBC) need to be determined. These values give 
the minimum concentration of the material that is required to cause a bacteriostatic or a bactericidal 
effect, respectively. (382) (383) 
This work subjects the multifunctional scaffolds to three different bacteria and how they are 
used is described in the methodology section:- 
 Escherichia coli (E.coli) 
 Staphylococcus aureus (S.aureus) 
 Klebsiella pneumoniae (K.pneumoniae) 
Bacterial can be split into two classes and depending on which class they belong determines a 
general behaviour with respect to antibiotics and antibacterial agents. Bacteria are either classed as 
gram-negative or gram-positive. Gram-negative bacteria do not retain the crystal violet dye when 
subjected to the gram staining protocol whereas gram-positive bacteria do. (384) Along with the cell 
shape and structure of the cell wall, this gram staining is the main difference between the two bacterial 
classes. (384) E.coli and K.pneumoniae are gram-negative rod shaped bacteria whereas S.aureus is a 
spherical gram-positive bacterium. 
A distinct difference between these classes is the structure and thickness of the cell wall, with 
the cell walls being between 15-80nm for a gram-positive bacteria and only 2nm for a gram-negative 
bacteria. (385) A gram-positive bacterium has a basic cell wall which is predominately made up of 
peptidoglycans (386) which makes this bacteria class more mechanically stable than the gram-negative 
bacteria. (387) Gram-negative bacteria have a complex cell wall made up predominantly of 
phospholipids, lipopolysaccharides, proteins and a thick layer of peptidoglycans. (386) The thickness 
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of the peptidoglycan layer determines how susceptible the bacterium is to antibacterial agents. (296) 
(388) 
The mechanism of the antibacterial potential of silver and copper was discussed in sections 
2.13.2 and 2.13.3 respectively. The literature shows that these metal ions should be more effective, i.e. 
require a lower concentration of the metal ions to achieve the MIC and the MBC, against the gram-
negative bacteria compared to the gram-positive bacteria due to difference in the cell wall structure. 
(296) (388) (387) (386) (385) 
E.coli is a common bacteria which is inexpensive and easy to grow and work with, making it 
the standard gram-negative bacteria used to ascertain a materials antibacterial potential. S.aureus is the 
most common cause of post-operative infections and any antibacterial implant material needs to be 
tested against this bacterium to establish its potential. As S.aureus is a gram-positive bacteria which is 
causing a lot of problems when it becomes resistant to established antibiotic treatments (MRSA) it is 
standard for antibacterial testing as if a material has a suitable antibacterial effect on this bacteria it is 
likely to show an antibacterial effect for other resistant bacteria. K.pneumoniae has also come to notice 
as a cause of nosocomial infections (hospital-acquired infections) so it is prudent to test an implant 
material against it to establish the materials antibacterial potential. An antibacterial agent needs to be 
tested against a range of bacteria as its effect and the MIC and MBC will differ. 
 
2.19 Summary of the literature review 
 
With more people suffering from significant bone trauma which requires extensive 
reconstructive surgery, the field of BTE has had more of a role to play in the last few decades in 
becoming a realistic alternative for current bone replacement therapies and treating bone diseases. A 
large range of materials have been investigated for BTE scaffolds and many of them have been 
discarded as they do not fulfil the requirements set out by the mandate of BTE, as described in sections 
2.6 and 2.9. More recently bioactive glass-ceramics and polymer/bioceramic composites have come to 
the forefront of the research effort as they can be designed /fabricated to have the desirable properties 
and structure which are comparable to those exhibited by bone tissue.  
In this work BBG scaffolds combined with polymers and/or MSIE to introduce therapeutic 
metal ions represent a move forward to develop multifunctional scaffolds with enhanced compatibility 
for bone regeneration. The literature has shown that silver and copper will add additional functionality 
to the BBG scaffold and can be introduced into the structure of the pre-fabricated scaffold through 
MSIE. It is hypothesised that the additional copper and silver will improve the base scaffolds 
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antibacterial and angiogenic properties whilst maintaining the desirable properties. However, there is 
limited literature available on the use of MSIE to introduce therapeutic metal ions into BBG scaffolds. 
 Biocompatible polymers, such as gelatin and PDLLA, can be used as coatings on BBG 
scaffolds to improve the mechanical competence by filling up the micro-cracks that occur after the 
scaffold sinters but to act also as a delivery vehicle for bioactive molecules/therapeutic drugs to 
introduce an extra function to the scaffold. Combining BBG scaffolds coated with biopolymers is an 
emerging research area which is slowly expanding and this work will add to the current knowledge by 
considering gelatin as a suitable biopolymer coating. There is currently no literature on the combination 
of gelatin coating and metal ion doping as technologies to impart extra functionality to the bioactive 
glass scaffolds, meaning this work will be the first to produce such ion-exchanged scaffolds coated with 
gelatin.  
This literature review has revealed that the systems selected to this project, including MSIE 
BBG scaffolds, gelatin coated BBG scaffolds and gelatin coated ion-doped BBG scaffolds are novel 
and represent a great potential for development of advanced, multifunctional scaffolds for BTE. 
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Chapter Three 
3. Aims and objectives of the project 
3.1 Aims 
 
As indicated in chapter 1, the overall aim of this work is to produce a new family of 
multifunctional Bioglass® based composite scaffolds for BTE. The goal is thus to improve the existing 
first generation 45S5 Bioglass® scaffolds whilst maintaining the properties that make these scaffolds 
attractive for BTE, such as high bioactivity, and to incorporate other functions for improved 
performance. A number of approaches and experimental methods have been attempted during the 
course of this work including introducing therapeutic metal ions (copper and silver ions) through a 
MSIE process and coating the base scaffolds with a polymer (gelatin and PDLLA) to improve the 
structural integrity of the scaffolds. 
 
3.2 Objectives 
 
To achieve the overall aim of this work, stated above, the following tasks were considered:- 
 To carry out structural characterisation on the BBG scaffolds using a standard set of 
characterisation techniques.  
Bioactivity will be assessed through immersion in simulated body fluid (SBF) and the 
mechanical competence will be tested though compression strength testing.  Further 
characterisation will be carried out through scanning electron microscopy (SEM), energy 
dispersive x-ray analysis (EDX), x-ray diffraction (XRD) analysis and Fourier transform infra-
red spectroscopy (FTIR). The surface topography of the scaffolds will be investigated using 
white light interferometry (WLI) and the wetting behaviour will be determined by contact angle 
measurements. The base scaffold will act as a control for the rest of the modified scaffolds.  
 To carry out a series of cell culture studies on the BBG scaffold.  
To assess the biocompatibility of the samples using relevant cells investigating cell behaviour 
when in contact with these scaffolds. 
 To introduce silver ions and copper ions into the BBG scaffold using the MSIE technique.  
To optimise the MSIE technique, for the first time here applied to incorporate silver and copper 
into BBG  scaffolds, including control of the concentrations used and, for the combination work 
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(MSIE introducing simultaneously both silver and copper ions) the ratio between the 
concentrations of silver and copper ions. 
 To structurally characterise the MSIE scaffolds.  
These scaffolds will then be characterised using SBF immersion tests to detect bioactivity, 
involving a large series of characterisation techniques which includes:- SEM, EDX, FTIR, 
XRD, mechanical testing, degradation studies, WLI, contact angle studies to measure 
wettability and depth EDX.  
 To biologically characterise the MSIE scaffolds. 
Using different cells to study the biocompatibility and possible toxicity of the MSIE scaffolds to 
compare their behaviour with that of base scaffolds. 
 To carry out a range of bacterial studies using the MSIE scaffolds. 
Using a range of bacteria to study the anti-bacterial properties of the MSIE scaffolds compared 
to the base scaffolds 
 To coat the BBG scaffold with PDLLA and both types of gelatin, using PDLLA as a control 
polymer.  
To optimise the coating conditions including weight percentage of gelatin in solution used and 
immersion period used. To compare the two types of gelatin against each other and against the 
base scaffold coated in PDLLA, including homogeneity of the coating, effect on the scaffolds 
porosity and mechanical properties 
 To structurally characterise the polymer coated scaffolds. 
Using the standard set of structural characterisation techniques, mentioned above, polymer 
coated base scaffolds are tested and compared to assess the effect of the presence of the polymer 
coating on scaffold behaviour for BTE. 
 To coat MSIE scaffolds with gelatin. 
To optimise the coating conditions for theses scaffolds, including weight percentage of gelatin 
and type of gelatin used. 
 To structurally characterise the polymer coated MSIE scaffolds.  
Using the standard range of characterisation techniques the polymer coated MSIE scaffolds 
are tested and compared against each other. 
 To evaluate all results and draw pertinent conclusions regarding knowledge generated from the 
research and to indicate and suggest avenues for related future research activities. 
 
To facilitate the reading of this thesis Figure 16 gives an illustration of the experimental 
program indicating how these tasks have been carried out during the course of this work from the 
starting material, e.g. BBG samples, up to the experimental techniques used to characterise the different 
scaffold systems developed. 
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Figure 16:- Overview of tasks and experiments carried out in the framework of the present project 
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Chapter Four 
4. Materials, Methodology and Characterisation techniques 
 
4.1 Materials  
 
The following sections provide the details for the materials used in this work including where 
they were obtained from and in what capacity they were used in this project.  
 
4.1.1 45S5 Bioglass® 
 
 This work utilises the most common and commercially available bioactive glass called 45S5 
Bioglass® developed by Hench et al (76) in the 1960’s, as described in chapter two. This bioactive glass 
has a composition of 45 wt% SiO2, 24.5 wt% Na2O, 24.5 wt% CaO and 6 wt% P2O5. (3) The 45S5 
Bioglass® powder was provided as a gift by Dr I Thompson of King’s College London, UK. The 45S5 
Bioglass® powder was fabricated by the melt quenching as described in section 2.8.1. The size of the 
Bioglass® particles used in this project range from 10 to 20µm. The Bioglass® powder has a density of 
2.70gcm-3. (389) 
 
4.1.2 Foam replication technique materials 
 
This project utilises the foam replication technique, described in Chen et al (4) and detailed in 
section 2.11.1, to produce the standard BBG scaffolds which will then be modified and characterised. 
The foam that is used as the template is polyurethane foam (PU foam) brought from Recticel, Corby 
(UK) which has 45 pores per inch (ppi). This template should lead to a trabecular pore structure of the 
scaffolds with a pore size and interconnectivity suitable for the objectives of this project. (269) (5) (270) 
(271) The binding agent used is polyvinyl alcohol (PVA) which was obtained from Sigma Aldrich 
(UK). The foam can be cut to the size and shape required by the characterisation test but the standard 
size used was 10x10x10mm3. 
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4.1.3 Molten salt ion exchange techniques 
 
For the silver MSIE process, silver nitrate (AgNO3) (at 0.05mol/l) and sodium nitrate (NaNO3) 
from VWR (UK) and Sigma Aldrich (UK), respectively, were used. For the copper MSIE process, the 
same sodium nitrate was used and also copper (II) nitrate (Cu(NO3)2) was used, both from Sigma 
Aldrich (UK). 
 
4.1.4 Biopolymers for scaffold coating 
 
 Gelatin was the biopolymer chosen to coat the scaffolds. The two types of gelatin used in this 
work are Type A and type B gelatin, with the difference between then described in chapter two. These 
were both obtained from Sigma Aldrich (UK). Type A gelatin has a pH between four and six, a bloom 
in the range 240-270 and a density of 0.777gcm-3. (390) Type B gelatin has a bloom of approximately 
225, a pH between five and seven and a density of 0.812gcm-3. (391) For this project the two types of 
gelatin were dissolved in deionised water to produce coatings on the scaffolds. The degradation period 
depends on the content of the water added which is a measure of the extent of the cross-linking. The 
higher the water content the faster the gelatin will degrade in vitro. (362) 
 The other polymer used in this work is poly (D, L lactic acid) (PDLLA) and this has been 
obtained from PURAC Biomaterials, Holland. PDLLA has a degradation rate of between 12 and 16 
months in SBF (211) (205) and a density of 1.26gcm-3. (392) This polymer is dissolved in 
dimethylcarbonate (DMC) in order to prepare coatings on scaffolds. The DMC was bought from Sigma 
Aldrich (UK). 
 
4.1.5 Other materials used 
 
 The chemicals used in the production of simulated body fluid (SBF), shown in Table 6, were 
all purchased from Sigma Aldrich (UK). The potassium bromide (KBr) used in the Fourier transform 
infra-red spectroscopy (FTIR) characterisation was purchased from VWR. 70% Ethanol was used in 
the sample preparation to fix the samples for X-ray diffraction (XRD) characterisation and this was 
obtained from VWR (UK). Phosphate buffer solution purchased from Sigma Aldrich (UK) was used in 
the inductively coupled plasma mass spectroscopy characterisation (MS-ICP). The 70% Ethanol used 
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to remove the excess salt residue after the molten salt processes was purchased from VWR. Sodium 
dodecylsulfate (SDS) and Extran powder were obtained from Sigma Aldrich (UK). 
 
4.1.6 Materials for the human periodontal ligamental stromal cell study 
 
 This part of the research was carried out at the Leeds Dental Institute, UK in collaboration with 
Dr R El-Gendy. 
 Teeth used to extract the human periodontal ligamental stromal cells (HPLSC’s) from were 
obtained with permission from the patients as donations to the Leeds Dental Institute Research Tissue 
Bank (LREC 07/H1306/93). The alpha modified minimum essential medium (α-MEM) and the foetal 
bovine serum (FBS) where procured from Lonza (USA), with the L-glutamine and the 
penicillin/streptomycin from Sigma Aldrich (UK) and Gibco (UK) respectively. The PBS used was 
obtained Lonza (UK) and was mainly used as a washing agent during this work. 
 The enzyme Collagense P used to remove the cells from the tooth pulp was provided by Roach 
(UK) and the 0.25% Trypsin Ethlenediaminetetraacetic acid (EDTA) used to de-attach the cells in the 
passage process where brought from Sigma Aldrich (UK). The two stains used in the cell viability study, 
Cell TrackerTM Green CMFDA and Ethidium homodimer-1 (Eh1), were purchased from Invitrogen 
(UK). 
 
4.1.7 Materials for the rat bone-marrow stromal cell and human bone-marrow stromal cell 
studies 
 
 This part of the research was carried out at the University of Erlangen Medical Centre, Germany 
in collaboration with Dr L Strobel. 
 The rat bone-marrow stromal cells (rMSC’s) were obtained from Syngeneic male lewis rats 
from the Charles River Laboratory, Sulzfeld, Germany with the study approved by the animal care 
committee of the University of Erlangen-Nuremberg and the government of Mittelfranken, Germany. 
The human bone-marrow stromal cells (hMSC’s) were obtained from PromoCell Heidelberg, Germany 
(catalogue number C-12975). 
The cell culture medium (CCM) used in this section of the cell biology work was a pre-mixed 
cell culture medium with Dulbecco’s modified eagle medium (DMEM) and Ham’s F-12 nutrient 
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mixture (Ham’s F-12)(DMEM/F-12), which was bought from Biochrome AG (Germany) with 10% 
Foetal bovine serum (FBS) from InVitrogen (Germany), 1% L-glutamine from Sigma Aldrich 
(Germany) and 1% penicillin/streptomycin from Biochrome AG (Germany). Later on 1% Bufferall 
from Sigma Aldrich (Germany) was added to the CCM. The PBS used in this work was bought from 
Sigma Aldrich (Germany). Alamar blue (AB) was bought from InVitrogen (Germany) and was used in 
a 10% solution. The trypsin-EDTA used to detach the cells in the passage stages was brought from PAA 
(Germany) and the trypin blue used to stain the cells in order to count them was brought from InVitrogen 
(Germany). 
 
4.1.8 Bacterial study materials 
 
This part of the research was carried out at the Friedrich-Alexander University of Erlangen-
Nuremberg, Germany in collaboration with Mrs A Antmann. 
  The Escherichia coli, Staphylococcus aureus and Klebsiella pneumonia have ATCC (American 
type culture collection) identifies, which are the internationally recognised strain numbers for the 
bacteria, of ATCC 23716, ATCC 6538 and ATCC 4352 respectively. The industry standard medium 
for bacterial work and used in this work was Muller Hinton broth (MHB) and was provided by CARL 
ROTH (Germany). The other media is based on the one used for the cell biology work described in 
sections 4.4.4 onwards, with DMEM/F-12 from Biochrome AG (Germany) as the base with 10% FBS 
from InVitrogen (Germany) and with 1% L-glutamine and 1% Bufferall Sigma Aldrich (Germany). The 
materials used to produce the Standard Agar I plates used throughout the bacterial work, as described 
in appendix B.6, were all brought from CARL ROTH (Germany) except for the peptin which was 
purchased from MERCK (Germany). The metal salts used in determining the minimum inhibitory 
concentration of the metal salts, CuCl2, AgNO3 and Cu(NO3)2, where all provided by Sigma Aldrich 
(Germany). Finally the inoculation solutions used in the final bacteria study, described in section 4.4.13, 
(NaCl and Tween 80) were both brought from CARL ROTH (Germany). 
 
4.2 Methodology 
 
The following sections describe the various methods and processing techniques used in this 
work, including the foam replication technique to make the scaffolds, the MSIE process and the 
technique developed to coat scaffolds with the chosen biopolymers. 
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4.2.1 Foam replication technique 
 
 The scaffolds that form the back bone of this research were produced by the foam replication 
technique first described by Chen et al (4) and explored further in section 2.11.1. This involves 
producing a bioactive glass slurry mixture, dipping the sacrificial (PU foam) template, drying, burning 
out the PU foam template and finally sintering to densify the struts. 
The slurry was prepared by mixing 6wt% of PVA and 40wt% of 45S5 Bioglass® powder. This 
slurry composition has been developed over time to be the optimal by members of Boccaccini’s research 
group at Imperial College to give suitable “green bodies” (Bioglass® coated PU foams) for scaffold 
production. In the present study, the following steps were followed. The PVA is dissolved in distilled 
water at 80oC, being constantly stirred on a magnetic heating stirrer. After the PVA granules have 
dissolved, after at least an hour, the powered 45S5 Bioglass® is added and left to be stirred, for a 
minimum of one hour, with the heating element switched off. Once the glass powder has been 
thoroughly mixed in, has cooled sufficiently that it can be handled, the dipping process to produce the 
“green bodies” can occur. 
The PU foam is cut into a shape and size that is suitable for the characterisation technique that 
it will be subjected to. The standard size of the template foam was 20x20x20mm3 to produce scaffolds 
of 10x10x10mm3, considering that due to shrinkage during sintering the template foams need to be 
double of the size required, as a volumetric shrinkage of approximately 50% is anticipated. (4) Once 
the foam scaffolds are shaped and cut, they then can be dipped into the now cooled slurry mixture, 
making sure that the foam is thoroughly coated in the slurry mixture but also making sure that excess 
slurry is removed from the green bodies. Usually the dipping process takes approximately an hour for 
50ml of slurry, which would produce between 15-20 20x20x20mm3 green bodies. The green bodies are 
then dried by either being left in a fume cupboard for 24 hours or in a furnace for 12 hours at 60oC. 
Once dry, the green bodies are then sintered according to pre-set conditions which have been 
investigated and optimised by Bretcanu et al (269) and the sintering profile is shown in Figure 17. 
The PVA/PU foam template is burnt out first at 550oC before densification (and crystallisation) 
can take place at 1100oC.  Once the scaffolds have cooled down to room temperature they can be 
removed from the furnace and used for the rest of the work described in future chapters.  
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Figure 17:- Sintering profile for the fabrication of BBG scaffolds by the foam replication technique described in 
Chen at al. (4) 
 
4.2.2 Molten salt ion exchange processing 
 
This technique, as described in section 2.15, has been adapted for use in biomaterials from 
processing glasses for other purposes such as wave guides (328) (336) (337) and optical splitters (329) 
(336) (337)  and is based on the method which was originally described by Di Nunzio et al (6) for glass-
ceramic scaffolds. This technique has been modified, for the first time in this project to work with 45S5 
Bioglass® powder to incorporate silver and copper separately and in combination.  
 
I  Silver molten salt ion exchange process 
 
As shown in section 2.15.2 the use of MSIE to modify the chemistry of a glass has been applied 
before in both biomaterials and other applications. Based on the work carried out by Di Nunzio et al (6) 
silver ions can be introduced into the silicate matrix of a prefabricated scaffold using MSIE. This is 
possible by using sodium nitrate as a controlling agent in the salt bath. The aim is for a proportion of 
the sodium in the scaffolds glassy matrix to exchange with the silver in the molten salt bath, as shown 
by Equation 2 and Equation 3. 
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The melting points of NaNO3 and AgNO3 are 310oC and 210oC, respectively. The molten salt 
bath temperature will need to be higher than that to ensure that the salt bath is fully molten before the 
scaffolds are immersed into the salt mixture. In this work the temperature of the furnace was set to 
400oC throughout the silver MSIE process. Preliminary testing was carried out using the NaNO3 to 
AgNO3 ratios suggested by Di Nunzio et al (6) and shown in Table 2. 
Table 2:- Concentrations, ratios and quantities of sodium nitrate and silver nitrate used in the preliminary study 
of the silver MSIE process 
Concentration Ratio of NaNO3 Mass of Mass of 
 to AgNO3 NaNO3 (g) AgNO3 (ml) 
High 20 to 1 4.25 50 
Medium 200 to 1 42.5 50 
Low 2000 to 1 42.5 5 
 
The MSIE process used in this work, as described in Newby et al, (113) involves dipping the 
sintered BBG scaffolds into the molten salt bath for a set immersion period, which for the preliminary 
study was 15 minutes, removing the scaffold and once cooled washing the scaffold in distilled water 
before subjecting the silver MSIE scaffolds to a battery of characterisation tests, as out-lined in Figure 
18. 
 
 
Figure 18:- Flow diagram of the MSIE process applied to incorporate silver into Bioglass® - based scaffolds 
 
 Based on the preliminary study results, a main MSIE study was carried out. For the main silver 
MSIE study a number of changes were introduced to the process as the method described previously 
needed optimising due to several issues identified during the preliminary study. For example, it was 
found that due to thermal shock the scaffolds could be fractured in the salt bath or in the washing stage 
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or were mechanically failing during handling after cooling and during the washing process. This effect 
was negated by having the scaffolds in the furnace whilst the salt bath was melting and controlling the 
rate of temperature increase to 5oC per minute. The heated scaffolds were then dipped into the molten 
salt bath, left for the required immersion period, removed from the salt bath and placed back into the 
furnace and cooled at 5oC per minute. 
 The concentrations used in the preliminary study, listed in Table 2, were only proof of concept 
concentrations and, as stated also by Di Nunzio et al, (6) the high and medium concentrations from 
Table 2 were too high and would likely lead to a cytotoxic effect. The silver nitrate concentrations for 
the main study were then selected from the lowest concentration stated in Table 2 up towards the 
medium concentration from Table 2, as shown in Table 3.  
Table 3:- Concentrations, ratios and quantities of sodium nitrate and silver nitrate used in the main study of the 
silver MSIE 
Concentration Ratio of NaNO3 Mass of Mass of 
 to AgNO3 NaNO3 (g) 
AgNO3 
(ml) 
High 800 to 1 42.5 12.5 
Medium 1400 to 1 42.5 7.14 
Low 2000 to 1 42.5 5 
 
 In the preliminary study the only immersion period investigated was 15 minutes, however it 
was shown that for the lowest concentration at this immersion period it was difficult to detect the 
presence of silver in the scaffold. Longer immersion periods were required for the lower silver nitrate 
concentrations to allow the silver ions to exchange into the scaffold. Therefore, immersion periods of 
15, 30, 45 and 60 minutes were investigated to improve the chances of the MSIE occurring.  
 The last alteration from the method used in the preliminary study was related to the washing 
stage after the MSIE process. It was found that a large amount of salt residue was still present on the 
scaffolds surface despite the scaffolds being washed in distilled water. In this investigation (see also the 
published study; Newby et al (113)) it was found that introducing an ethanol washing step should help 
to reduce or even eliminate the salt residue on the surface of the scaffold. The new washing procedure 
starts with an initial washing step in warm distilled water (at approximately 40oC) for 10 minutes, 
followed by 10 minutes in 70% ethanol at room temperature and for a further 10 minutes in warm 
distilled water. Finally the scaffolds are left to dry either in a fume cupboard for 24 hours or for 12 
hours at 60oC in a furnace.  
 This revised process is summarised in Figure 19 and it was used in the main silver MSIE study. 
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Figure 19:- Flow diagram of the optimised MSIE process for the incorporation of therapeutic ions into Bioglass® 
-based scaffolds 
 
II Copper molten salt ion exchange process 
 
The copper MSIE process itself followed the same procedure described above for the main 
silver MSIE study, as shown in Figure 19, with differences in the chemicals used. Once again sodium 
nitrate is used in the salt melt to act as a controlling mechanism for the MSIE process, as described in 
chapter two, along with copper(II) nitrate (Cu(NO3)2). The MSIE process is described by Equation 4 
and Equation 5 in section 2.15.3. 
The melting point of Cu(NO3)2 is 256oC and as previously stated the melting point of NaNO3 
is 310oC making the furnace temperature requirement to be above these values. The furnace temperature 
was set at 400oC. Table 4 shows the concentrations, quantities and ratios of Cu(NO3)2 and NaNO3 used 
for this work. The copper MSIE process follows the protocol set out in Figure 19 with a limited 
immersion period of 15 minutes. 
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Table 4:- Concentrations, ratios and quantities of sodium nitrate and copper nitrate used in the study of the copper 
MSIE 
Concentration Ratio of NaNO3 Mass of Mass of 
 to Cu(NO3)2 NaNO3 (g) Cu(NO3)2 (g) 
High 800 to 1 200 0.25 
Medium 1400 to 1 175 0.125 
Low 2000 to 1 200 0.1 
 
III Silver and copper combined molten salt ion exchange process 
 
 The final MSIE process involves having both copper nitrate and silver nitrate in the salt bath 
along with sodium nitrate to control the MSIE process. This has been described by Equation 6 and 
Equation 7 shown in section 2.15.4. As stated in sections 4.2.2.I and 4.2.2.II the furnace temperature 
was set to 400oC to ensure that the salt bath is fully molten when the scaffolds are dipped into the salt 
bath. The quantities of Cu(NO3)2, AgNO3 and NaNO3 used in this work were 0.25g, 1.56ml and 350g 
respectively, giving a metal salt ratio of 1:1:1400 in the salt bath. This combination MSIE follows the 
protocol shown in Figure 19 with immersion periods of 15, 30, 45 and 60 minutes. 
 
4.2.3 Biopolymer coating 
 
The coating of BBG scaffolds by biodegradable polymers to produce scaffolds with enhanced 
mechanical properties and with additional functions was carried out, as described in section 2.16. In the 
following sections details of the coating procedure employed for PDLLA and gelatin are provided. 
 
I  Poly (D, L-lactic acid) coating 
 
PDLLA coating of BBG scaffolds has been carried out previously; including the work depicted 
by Chen et al (110) and Bretcanu et al. (352) In the present work, a 5wt% PDLLA solution in an organic 
solvent (DMC) was required to produce suitable coatings by dipping in solutions. The technique uses 
one gram of PDLLA to 20ml in DMC to form a solution which is stirred constantly for two hours at 
room temperature. A simple dipping method was employed to coat the BBG scaffolds with PDLLA, as 
depicted in Figure 20. The scaffold samples are slowly dipped into the PDLLA solution, left to immerse 
for five minutes and then scaffolds are left to dry at room temperature in a fume cupboard for 24 hours 
to undergo further characterisation once they are dry. 
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Figure 20:- Flow diagram of the coating process used to coat the BBG scaffolds with PDLLA 
 
II Gelatin coating 
 
This coating process was carried out with the two types of gelatin (type A and B), both 
described in the literature review in section 2.16.3, and the results were compared to determine which 
gelatin type is more suitable for this particular application. The gelatin solution, for both type A and 
type B gelatin, is made by adding the gelatin powder (or pellets) to distilled water heated to 50oC stirring 
continuously until the entire amount of the solid gelatin has dissolved, this took approximately 30 
minutes. The solution is then cooled to 40oC for the dipping process to allow the viscous nature of the 
gelatin to appear and so the scaffolds can be handled during the dipping process. The scaffolds are then 
slowly immersed into the gelatin solution and left for the required immersion period. The scaffolds are 
then removed, shaken gently and patted with tissue paper to remove excess gelatin, and left to dry in a 
fume cupboard for 24 hours in preparation for characterisation. This process is represented in Figure 
21. 
 
94 
 
 
Figure 21:- Flow diagram representing the process used to coat BBG scaffold samples with gelatin in this work 
 
 With very little literature or previous work to give a starting point in terms of which gelatin 
type, gelatin solution concentration, immersion period in the gelatin solution and the number of coats 
to use, the first set of studies was designed to determine the concentration of the gelatin solution to be 
used in the main study. In Liu et al (357) and Bellucci et al (393) a 5wt% gelatin solution was used to 
coat porous bio-ceramics with gelatin and this was the starting point for the present study. These initial 
concentrations for both gelatin types are shown in Table 5 with concentrations of 5-15wt% used for 
type B and 5-10wt% used for type A. To determine which of these concentrations should be considered 
for optimal results the porosity of the coated scaffold shall be assessed, which was determined using 
Equation 8. For the preliminary study, immersion periods of one, five, ten and fifteen minutes were 
used in conjunction with the concentrations stated in Table 5. 
 As stated in section 5.6.1, the first half of the preliminary study showed that gelatin solutions 
with concentrations of 5 and 6 wt% combined with an immersion period of one minute gave results that 
presented the best compromise between the required high porosity and the coating thickness. These 
concentrations and immersion period were then used to produce multi-layered coated scaffolds, still 
following the flow chart shown in Figure 21, but repeating the coating process once and twice to 
produce scaffolds with two and three coats of gelatin, respectively. 
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Table 5:- Concentrations and quantities of gelatin used in the preliminary studies 
Concentration of gelatin Mass of gelatin Mass of distilled water 
in solution (wt%) (g) (ml) 
5 5 95 
6 6 94 
7 7 93 
8 8 92 
9 9 91 
10 10 90 
11 11 89 
12 12 88 
13 13 87 
14 14 86 
15 15 85 
 
 Since the preliminary studies have shown that a single coat of 5 or 6 wt% gelatin using an 
immersion period of one minute produces the best compromise between samples porosity and coating 
thickness, these samples, produced following the procedure outlined in Figure 21, were subjected to a 
full batch of characterisation techniques, as described in section 4.3, to determine their suitability as 
scaffolds for BTE. 
 
4.2.4 Combination scaffolds 
 
 This set of samples was developed to combine the MSIE process shown in section 4.2.2 with 
the gelatin coating method described in section 4.2.3. Copper and combination MSIE scaffolds were 
prepared as described in sections 4.2.2.II and 4.2.2.III, respectively. Only the lowest concentration 
samples for the copper MSIE and only using samples that are immersed in the molten salt bath for 15 
minutes for the combination MSIE scaffolds were considered. After these MSIE scaffolds have been 
left to dry for 24 hours, as shown in Figure 19, they were coated in gelatin as described in section 4.2.3, 
following Figure 21, using gelatin solution concentrations of 5 and 6 wt% and an immersion period of 
one minute for both types of gelatin. Once these coated MSIE scaffolds were dry were submitted to 
characterisation studies as described in section 4.3. 
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4.3 Structural Characterisation techniques 
 
The following sections describe the relevant techniques used to characterise the samples. The 
basic principles behind each of the techniques will be briefly described with any relevant additional 
information included in the appendices. 
 
4.3.1 Porosity studies 
 
For un-coated scaffolds the porosity is determined by means of Equation 1 shown in section 
2.9.1. Only the overall porosity of the scaffolds has been established during this work as the other 
porosity related characteristics such as pore size and interconnectivity are directly related to this 
measurement and they have been already established for the base scaffold in previous work. (269) (5) 
(270) (271) This required the dimensions of the scaffold to be measured (height, width and length) to 
obtain the volume of the scaffold and the mass of each scaffold is needed in order to calculate the 
porosity by geometrical methods. For the BBG scaffolds this will produce an accurate measure of the 
porosity of the scaffold as the density of 45S5 Bioglass® can be used in the calculation. However as the 
density of the modified glass-ceramic was not determined in this work, the density of 45S5 Bioglass® 
powder was used, assuming it to be close to the density of the crystallised 45S5 Bioglass® material. 
This means that the porosity values for the MSIE scaffolds will only be estimation of the porosity and 
given an appropriate error of 5% on top of the experimental errors. These values will still give a 
meaningful estimation of the porosity as theoretically the density of the MSIE modified 45S5 Bioglass® 
powder should not be vastly different from that of the 45S5 Bioglass® powder.  
 For polymer coated scaffolds a slightly different method is needed in order to work out the 
coated scaffold porosity. Karageorgiou et al (210) described the equation that is required in order to 
calculate the porosity of a coated scaffold; this is Equation 8 shown below. 
Equation 8:- Porosity of polymer coated scaffolds (210) 
 
The difference between the porosity of uncoated and coated scaffolds will give useful 
information as to how much the coating is infiltrating into the scaffolds porous structure. With the ideal 
porosity for BTE scaffold being above 70% (394) and the foam technique producing scaffolds with a 
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porosity of over 90%, (244) the polymer coatings should not be too thick as to significantly decrease 
the overall porosity of the scaffold. 
 
4.3.2 Simulated body fluid studies 
 
Immersion in simulate body fluid (SBF) is the standard technique currently used to test the 
acellular bioactivity of biomaterials, as described in chapter two, with the precipitation of HA on the 
surface being the marker of bioactivity. SBF is prepared according to the standard procedure written by 
Kokubo et al. (395) (396) It is prepared by dissolving a range of chemicals, shown in Table 6, in 750ml 
of deionised water at 37oC being stirred constantly. The chemicals are added one at a time in the order 
shown in and then the solution is then buffered at pH 7.4 using HCL (listed at number 10 in Table 6). 
Once this pH adjustment has been completed the SBF needs to cool for two to three hours and then it 
needs to be topped up to one litre using deionised water and stored in a refrigerator until needed.  
In a typical experiment, the samples are placed in centrifuge tubes, immersed in 45ml of SBF, 
placed in an incubator at a constant 37oC for the required immersion period of the study refreshing the 
SBF every three to four days, as described in Chen et al. (4) The samples are left immersed in the SBF 
solution for different immersion periods ranging from 24 hours to four weeks. After immersion, the 
samples are gently washed in deionised water and left to dry in a fume cupboard for 24 hours and then 
characterised. 
Table 6:- Chemicals used for the production of simulated body fluid (SBF) 
Order  Chemical Quantity 
number     
1 NaCl 7.996g 
2 NaHCO3 0.350g 
3 KCL 0.224g 
4 K2HPO4 . 3H2O 0.228g 
5 MgCl2 . 6H2O 0.305g 
6 HCL 40cm3 with a concentration of 1kmol/m3 
7 CaCl2 0.278g 
8 NaSO4 0.071g 
9 (CH2OH)CNH2 6.057g 
10 HCL as much as is required to change the pH 
     with a concentration of 1kmol/m3 
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4.3.3 Scanning electron microscopy 
 
Scanning electron microscopy (SEM) is a technique which makes use of a high energy beam 
of electrons to interact with the atoms on the surface of a sample. Energy signals that result from these 
interactions are then detected and converted into high resolution images of the sample’s surface. The 
images have a 3D appearance because of the large depth of field that the images have, this is useful as 
it gives a better insight into the structure of the material. (397) For this work the variable pressure JEOL 
JSM 5610LV instrument has been used. This SEM is fitted with a secondary electron detector as well 
as a backscattered electron detector and has a magnification range from x50 to x90000. Samples 
prepared for SEM characterisation have to be dry, mounted on sample stubs using carbon tape and then 
gold coated (approximately 15nm thick). All MSIE samples were washed in accordance with the 
washing protocol described in section 4.2.2.I before imaging. 
 
4.3.4 Energy dispersive X-ray spectroscopy 
 
Energy dispersive X-ray spectroscopy (EDX) is a characterisation technique used to determine 
the elemental composition of a sample. This technique relies on the interaction between a beam of high 
energy radiation (such as x-rays) and the sample. (398) The elemental composition of a sample can then 
be identified as each element will give a specific energy signal. (398) 
This technique was primarily used to detect the elements present in the tested samples, in 
particular it was used to determine if silver and copper are present after the MSIE processes, and to 
examine the change in composition of the scaffold surfaces after the samples were immersed in SBF, 
as described in section 4.3.2. All MSIE samples were washed in accordance with the washing protocol 
described in section 4.2.2.I before characterisation. The EDX instrument is an attachment to the JEOL 
JSM 5610LV SEM described in section 4.3.3. Spot analysis of the sample was carried out at a range of 
magnifications, between x1000 and x10,000, at a number of sites across the sample to ascertain the 
elemental composition and that it was consistent across the sample. 
 
4.3.5 X-ray diffraction analysis 
 
X-ray diffraction (XRD) was used to determine the crystalline composition of samples. (399) 
A Phillips PW 1700 Series automated powder diffractometer was used employing Cu Kα radiation and 
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scanning over an angle range of 5-80o. Pellet samples were analysed straight after they had been 
produced and modified and subjected to the washing protocol described in 4.2.2.I. Scaffold samples 
had to first be prepared, modified, washed and then crushed and ground into a fine powder before XRD 
characterisation. 
 
4.3.6 Fourier transform infra-red spectroscopy 
 
Infrared spectroscopy represents a finger print of a sample with specific peaks (absorption or 
transmission depending on the equipment) which corresponds to the frequency of vibrations in the 
sample, related to its bonds and atoms. (400) Since each material has a unique set of atoms and bonds 
it means that no two materials will produce the same infrared spectrum. (400) This technique is very 
fast, with one sample being characterised in approximately one minute, and is non-destructive. This 
technique was used to identify specific bond combinations within the samples which were then used to 
identify the presence of the modified additions to the BBG construct. This project used a Bruker Vector 
22 TGA-IR instrument using the transmission attachment, making all the spectra transmission spectra. 
The samples were prepared by grinding the washed scaffolds into a fine powder, mixing them with 
potassium bromide (KBr) and then formed into pellets by using a pellet press, as described in appendix 
B.1.  
 
4.3.7 White light interferometery 
 
 The surface topography of the materials, as described in section 2.9.3, was assessed by white 
light interferometry using a Zygo® white light interferometer and using MetroPro® 8.1.5 software to 
analyse the data. Pellets of the different samples types, described in sections 4.2.1, 4.2.2 and 4.2.3, and 
were prepared as described in appendix B.1 and washed in accordance with the washing protocol 
described in section 4.2.2.I. The changes in surface topography caused by the MSIE process or the 
addition of a polymer coating or both (sections 4.2.2, 4.2.3 and 4.2.4 respectively) need to be assessed 
as well as the surface changes caused by the immersion in SBF for 1, 3, 7, 14, 21 and 28 days as 
described in section 4.3.2. The use of sintered pellets instead of the sintered scaffolds is because this 
technique measures the surface topography of a flat substrate (224) and can not be carried out on the 
scaffolds that have been produced in this work. The substitution of a pellet instead of the scaffold has 
been used in previous studies. (224) The pellets are sintered and modified in the same manner as the 
scaffolds meaning that changes to the surface due to the sintering process, MSIE and polymer coating 
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can be extrapolated from the pellet measurements. For future work in order to produce pellets that are 
closer to the base scaffold, both chemical and physically, the pellets could be produced from a slurry, 
as described in 4.2.1 for the scaffolds, which when dried is used to make the pellets. 
The three quantities that are used to compare different surface topography characteristics are 
the RMS, the Ra and the PV. RMS is the root-mean-square deviation from the centre line which is 
selected by the MetroPro® software. (401) RMS is calculated by Equation 9 and is illustrated by Figure 
22. (401) 
Equation 9:- RMS of a sample being characterised using white light interferometry (401) 
 
 
Ra is the mathematical average deviation from a central line that is determined by the 
MetroPro® software and is given by Equation 10, illustrated in Figure 22 and Ra is larger the RMS. 
(401)  PV is the peak to valley distance measured between the lowest and highest points on a sample 
cross-section. The PV is the maximum roughness height for a sample and it compares the two extremes 
found on a sample surface as demonstrated in Figure 22. (401) 
Equation 10:- Ra of a sample being characterised using white light interferometry (401) 
 
 
 
Figure 22:- Definitions of RMS, Ra and PV when applied to the roughness of a sample (401) 
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RMS and Ra give deviations away from the given central line that the software deems the best 
fit for that particular cross-section of the sample and the PV gives the distance between the tallest peak 
and the lowest valley. (401) 
 All three quantities give an overall picture of the surface topography of a sample. Images are 
also obtained when carrying out this technique and can be used to gain a qualitative assessment of the 
sample’s topography including a 2D black and white intensity plot, 2D solid colour plot, 3D oblique 
plot, cross-sections showing the surface profile and 2D coloured surface map. Both the qualitative and 
the quantitative results will be used to assess the changes in the surface topography due to the different 
surface modification processes and the immersion in SBF to assess the samples bioactivity. 
 
4.3.8 Wettability 
 
 To evaluate the wettability of a sample, as described in section 2.9.2, static contact angle 
measurements were carried out in collaboration with researchers at the University of Erlangen-
Nuremberg, Germany. Pellets were produced as described in appendix B.1 and washed in accordance 
with the washing protocol described in section 4.2.2.I. As described in section 4.3.7, pellets were used 
as their surface correlates to a suitable extent to the surface observed for the scaffolds, after sintering 
and modification. As indicated in appendix B.1, the pellets are sintered and modified in the same manner 
as the scaffolds meaning that the changes to the surface due to the sintering process, MSIE and polymer 
coating can be extrapolated from the pellet measurements. It is however understood that this will not 
be 100% correct due to the slight pressure applied to make the pellets, which is not applied in the 
scaffold fabrication, which could have an effect on the densification process. Nevertheless such surfaces 
of sintered pellets can closely resemble the topography and wettability of the porous scaffold. 
A 3µl drop of distilled water is placed onto the surface of the sample and the contact angle is 
measured using a Krüss DSA30 instrument. This was repeated five times and the average was taken for 
each sample type using a DSA4 program. Wettability information is important because it indicates how 
well the cells will attach to the surface of the materials after the modifications have been made. In this 
case an advancing angle was recorded to give contact angle results and as long as the surface of the 
sample is not significantly very rough, this value will give an accurate contact angle for the sample. In 
order to get the best measured value for the contact angle both the advancing and the receding angles 
need to be measured and averaged as the measured contact angle falls between the two angles. This 
especially needs to be carried out if a significant difference between both contact angles is expected 
when the sample surface is very rough, which was not the case of the present pellets. 
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4.3.9 Inductively coupled plasma mass spectrometry 
 
 Inductively coupled plasma mass spectrometry (ICP-MS) is a mass spectroscopy technique 
capable of detecting metal ions at very low concentrations within a liquid sample. This is done by 
ionizing the sample with high temperature plasma and then using a mass spectrometer to separate and 
quantify those ions.  ICP-MS allows the detection of elements within the range of lithium and uranium. 
ICP-MS can detect a number of elements simultaneously or it can be set to only detect the user required 
elements. This is done by calibrating the instrument first with control samples of deionised water with 
the ions that are of interest. In this case control samples of deionised water with copper and silver ions 
were used to calibrate the instrument as these were of interest. Only changes in the quantity of silver 
and/or copper ions were detected so the release rate of these ions could be assessed. The sample is 
vaporised first (before ionisation occurs) and the sample passes through a super-heated plasma (ICP). 
The ions are separated according to their specific mass to charge ratios by passing the ions through an 
electromagnetic field. The ions are detected and the signals given off are processed into spectra which 
is characteristic for the sample. 
 The washed MSIE samples, prepared as described in sections 4.2.1, 4.2.2 and 4.2.3, were 
immersed in PBS for immersion periods of 1, 3, 7 and 28 days. The supernatant was removed, with a 
minimum quantity of 3ml being required, and tested for silver and/or copper using an Optima 7300 DV 
MS-ICP instrument. The change in the quantity of silver and copper detected in the supernatant was 
plotted over time to indicate the release rate of silver and the copper from the samples. This release rate 
was compared between the two immersion media to confirm it is consistent. 
 
4.3.10 Mechanical properties 
 
 The mechanical competence of the samples was quantitatively asses by measuring the 
compressional strength using a Zwick/Roell Z010 instrument with a cross-head speed of 0.5mm per 
minute and a load of 1kN. The load was applied until the compressive strain (%) reaches 70% and the 
maximum compressive strength was recorded. 
 The prismatic sample scaffolds, prepared and washed in accordance with the methods described 
in sections 4.2.1, 4.2.2 and 4.2.3, have nominal dimensions of 10x10x15mm3 with the load being 
applied on one of the 10x10mm2 sides. To prevent the sample slipping whilst under the load a 0.05mm 
Teflon® film was placed onto the plates holding the scaffold. The scaffolds should be visually checked 
to ensure that the sample has parallel sides to ensure the compressional force being applied will be 
applied homogenously. The compressional testing was carried out on samples before and after 
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immersion in SBF to investigate the degradation of the sample and the effect of this on the mechanical 
competence of the sample. Both coated and uncoated samples were tested along with the MSIE samples. 
 
4.3.11 EDX depth studies 
 
 Sample pellets for a variety of sample types, including the BBG and the MSIE samples as 
described in sections 4.2.1 and 4.2.2, were prepared and washed as described in appendix B.1. As 
described in previous sections, pellets were used as their surface correlates to the surface observed for 
a scaffold considering that the pellets were sintered and modified in the same manner as the scaffolds 
and therefore changes to the surface due to the sintering process, MSIE and polymer coating can be 
directly extrapolated from the pellet measurements. 
 To ascertain how far the MSIE ions (silver and copper in this work) are penetrating the silicate 
matrix, the pellets need to be fixed in a resin and polished down to reveal the cross section of the pellet, 
as shown in Figure 23. The fixing and polishing methods used in this work are described in detail in 
appendix B.2.  EDX, as described in section 4.3.4, was carried out at a number of points across the 
exposed cross-section, as shown in Figure 23. This gives an indication of the depth of penetration of 
the ions into the glass matrix. 
 
 
Figure 23:-Schematic diagram illustrating the fixing, polishing and preparation of samples ready for the EDX 
depth analysis 
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4.4 Biological Characterisation techniques 
 
This section covers the techniques used to carry out the cell biology and bacterial studies 
reported in this work. the work detailed in the following sections was carried out in collaboration with 
the Leeds Dental Institute, UK, for the in vitro studies using human periodontal ligamental stromal cells 
(HPLSC’s) (sections 4.4.1 to 4.4.3), the Department of Plastic and Hand surgery at the University of 
Erlangen Medical Centre, Germany, for the in vitro studies using rat bone-marrow stromal cells 
(rMSC’s) and human bone-marrow stromal cells (hMSC’s) (sections 4.4.4 to 4.4.7). The Institute of 
Bioprocess Engineering at the Friedrich-Alexander University of Erlangen-Nuremberg, Germany, 
carried out the bacterial work carried out using Escherichia coli (E.coli) (sections 4.4.8 to 4.4.12.I) and 
the Institute of Hygiene and Biotechnology at Hohenstein Institute in Bönnigheim, Germany 
collaborated with the bacterial work carried out using Staphylococcus aureus (S. aureus) and Klebsiella 
pneumoniae (K. pneumoniae) (sections 4.4.12.II and 4.4.13).  All the studies used the BBG scaffold as 
the control sample to give a comparison. 
 
4.4.1 Cell preparation and extraction for human periodontal ligamental stromal cells 
 
 The human periodontal ligamental stromal cells (HPLSC’s) have to be extracted from the 
external tooth surface of adult wisdom teeth using sterile scalpel as described in Somerman et al. (402) 
Collagense P suspended in PBS, with a ratio of 5mg:1ml, was used to extract the cells from the 
periodontal ligament tissue that is obtained from extracted wisdom teeth. The extraction of the tooth 
periodontal ligament is described in appendix B.3 and in Somerman et al. (402) The enzyme, collagense 
P, digests the collagen matrix which holds the cells together and the enzyme required 15 to 45 minutes 
at 37oC at 5%CO2 in order to complete this process. 
 The resulting cells are a mixture of cell types, and they are not purified into one cell type, as a 
mixture of cells is more accurate biologically and will give more relevant results as a variety of relevant 
molecular signals remains. 
 The HPLSC’s are transferred to a cell culture medium of α-MEM with 20% FBS, 2nm of L-
glutamine and 100 units/ml of penicillin/streptomycin; this is the standard cell culture medium (CCM) 
used in this study. (113) This fluid is then centrifuged at 1000 rpm for ten minutes and the excess CCM 
is removed leaving a cell pellet. Afterwards 5ml of fresh CCM was added to the cell pellet and stirred 
together. The cell suspension was then passed through a 70µm nylon mesh cell strainer (Falcon) to 
leave a single cell suspension ready for the cell cultivation. 
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 The single cell suspension was placed into a cell culture flask in an incubator at 5% CO2 and 
37oC. After 24 hours the cells will have been firmly attached to the bottom of the flask and will have 
started to elongate. This behaviour can be observed under a light microscope confirming that the cells 
are alive and in suitable growing conditions with no toxicity issues. 
 When the cells have almost covered the bottom of the cell culture flask (80-90% confluence) 
the cells need to be detached using trypsin/EDTA and the resulting cells should be split between two 
fresh flasks after adding fresh CCM to re-suspend the cells. This process of removing the cells, re-
suspending them and splitting them between two new flasks is called passage. More than four passages 
will cause the cells to differentiate and lose their original character and that is why cells are used as this 
point in the cell culture studies. This process of obtaining the cell suspension is described by Somerman 
et al (402) in general and specifically in terms of a study carried out on BBG scaffolds in the work of 
Newby et al. (113) 
 
4.4.2 In vitro cell seeding using human periodontal ligamental stromal cells 
 
 BBG scaffolds prepared by the foam replication technique, as described in section 4.2.1, and 
silver MSIE scaffolds, as described in section 4.2.2.I, of all three main study concentrations immersed 
for the four time periods (in total 13 different sample types) with dimensions of 2x2x2mm3 were 
sterilized using ultra violet radiation at 725nm for 45 minutes. 
 The sterilized samples were then placed into sample tubes with the lids, which have a hole in 
the top in order to pipette in 1 ml of the HPLSC’s suspension and top them up with another ml of CCM, 
which was described in section 4.4.1. This amount equates to approximately 2x105 cells from passage 
four which equates to a cell density of 500,000 cells. The hole in the tube’s lid is then sealed with 
breathable film and placed into a rig (developed in-house in the department of Oral Biology, University 
of Leeds) that will rotate the tubes to keep a constant flow of cell suspension moving over and through 
the samples; this is known as dynamic cell seeding. This rotating rig was then placed in an incubator at 
5%CO2 and 37oC for three days. The dynamically seeded scaffolds were then removed from the rotating 
rig and were statically cultured for a further seven days in 24well well plates in an incubator at 5%CO2 
and 37oC with fresh CCM.  
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4.4.3 Biological characterisation using human periodontal ligamental stromal cells  
 
 To ascertain the cells viability, after seven days, the seeded scaffolds were stained with cell 
tracker green and Eh1. The cells were incubated for 45 minutes in plain CCM containing 5µl:5ml of 
CMFDA 2.5µl:5ml. The seeded scaffolds are washed off for 45 minutes in plain CCM before viewing 
the samples using a confocal laser microscope (CLSM).  
Cell viability assays are classified into four categories:- 
 Cytolysis or membrane leaking assays (403) (404) 
 Mitochondrial activity or caspase assays (405) 
 Functional assays (406) 
 Genomic and proteomic assays (407) 
The cell tracker green stains the living cells green and is a functional assay aimed at showing 
the proliferation of the target cells and Eh1 stains the dead cells red by binding to the DNA in dead or 
dying cells through holes in the cell membrane making it a cytolysis assay. Eh1 was chosen as it detects 
all dead cells and not just those that have undergone programmed cell death. By complementing it with 
a dye that stains only living cells it gives a complete picture of which cells are living and dying. This is 
shown in the results is stacked up images with a penetration depth ranging between 1.06mm to 1.55mm. 
 
4.4.4 Cell preparation and extraction for rat bone-marrow stromal cells and human bone-marrow 
stromal cells 
 
 The cells are prepared and extracted in a similar way to the HPLSC’s described in section 4.4.1 
with some exceptions and differences. The CCM used for this cell biology work is DMEM/F-12 with 
10% FBS, 1% L-glutamine and 1% penicillin/streptomycin unless otherwise stated. 
The rat bone-marrow stromal cells (rMSC’s) and the human bone-marrow stromal cells 
(hMSC’s) where extracted and prepared as described in appendix B.4 and B.5, respectively, and 
cultivated up to the fourth passage, as described in section 4.4.1 for the HPLSC’s. 
 The cells are cultivated in the same manner as described in section 4.4.1 in an incubator with 
5%CO2 at 37oC until at least 90% confluence is achieved. Cells are then ready to be used in the 
experiments described in sections 4.4.5 and 4.4.6 after cells have been counted. Cells are counted to 
make sure that an equal number of cells are present in each well at the start of each study to achieve an 
accurate comparison between samples. 
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 A digital cell counting device was used to count the cells in suspension. For this study, cells 
were centrifuged at 1000rpm for five minutes to create a cell pellet. The old CCM was removed and 
5ml of fresh CCM is added to the cell pellet and mixed thoroughly to “un-make” the pellet. Then 10µl 
of this cell suspension was pipetted along with 10µl trypin blue (cell stain) into an epidoth tube and the 
suspension mixed thoroughly. 10µl of this stain cell suspension were pipette into the counting device 
which will give the quantity of cells in cells per ml of CCM. From this result, the amount of cell 
suspension per well can be calculated and the required amount can be transferred into each well 
depending on the study being carried out. In this work the base line of approximately one hundred 
thousand cells were suspended in 200µl cell suspension.  
 
4.4.5 2D cell cultures using rat bone-marrow stromal cells and human bone-marrow stromal cells 
 
 The cells, either rMSC’s or hMSC’s, need to be seeded onto the bottom of wells of 12well well 
plates before being put in contact with the scaffolds. To give 20 thousand cells per well 40µl of the 
relevant cell suspension needs to be transferred into each well. This is then topped up with 2ml of CCM. 
The well plate is then inspected under a light microscope to check the cell suspension and then placed 
in an incubator with 5%CO2 at 37oC for 24 hours to allow the cells to form a monolayer at the bottom 
of each well. 
 The BBG scaffolds produced and modified using MSIE, as described in sections 4.2.1 and 
4.2.2, were subjected to cell biology tests using rMSC’s and hMSC’s. Including the BBG scaffold, four 
different sample types were investigated in this part of the work. The dimensions of the scaffolds were 
between 5x5x5mm3 and 3x3x3mm3. Scaffolds were conditioned using the washing protocol outlined in 
Table 7. The first four steps, are established in section 4.2.2, were required to remove excess salt residue 
from the MSIE process and the rest of the steps were required to prepare the scaffolds for the cell 
biology work.  
The scaffolds were then autoclaved at 120oC for ten minutes in H2O steam for sterilization 
purposes, immersed in DMEM/F-12 with no additives for an hour, dried in a fume hood for an hour and 
then used in the preliminary 2D culture study. 
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Table 7:- Washing protocol used for the cell biology work using rMSC’s and hMSC’s 
Washing Solution type/drying period Immersion period Quantity used 
step type (minutes) (ml) 
1 Distilled water 15 50 
2 70% Ethanol 10 50 
3 Distilled water 10 50 
4 Drying in a fume cupboard at least 24 hours n/a 
5 2.5% SDS 5 25 
6 Millipore distilled water 1 50 
7 5% Extran 5 25 
8 Millipore distilled water 1 50 
9 Millipore distilled water on a shaker 15 50 
10 Drying in a fume cupboard at least 12 hours n/a 
 
For cell culture, the CCM from the incubated well plate needs to be removed with a pipette and 
the wells with the monolayer of cells in the bottom are gently washed with PBS before 2ml of fresh 
CCM is added. A well insert is placed into each well that will contain a sample, with three of each of 
the four sample types and one well free to act as a well insert control, leaving at least two wells free to 
act as a media and cell suspension control, respectively. One scaffold was placed into each well before 
the wells are topped up with another 1ml of CCM. This is depicted in Figure 24. 
The whole well plate ensemble was placed in an incubator with 5%CO2 at 37oC for the duration 
of the study, replacing the CCM every 24 hours. When fresh CCM is required, the old CCM is pipetted 
out of the well, the well insert is removed and placed into another sterile well plate for holding, whilst 
the cell well plate is gently washed in PBS and 2ml of fresh CCM is added. The well inserts were then 
replaced into the cell well plate and each well was topped up with another 1ml of CCM before being 
placed back into the incubator at 37oC with 5%CO2. 
 
Figure 24:- Preparation of the 2D culture, showing the placement of the well insert and the sample scaffold 
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 After that fresh CCM was added to the well plate, but before the well inserts are replaced the 
monolayer of cells, as shown in Figure 24, can be observed under a light microscope to gauge how the 
cells are behaving and to assess the cell response to the presences of the scaffolds in the well inserts. 
The well inserts can then be replaced and the whole ensemble is returned to the incubator, as described 
in the previous paragraphs. This preliminary 2D culture method is depicted by the flow diagram shown 
in Figure 25. 
 
 
Figure 25:- Flow chart showing the initial protocol used for the 2D culture study 
 
 The method described in the beginning of this section, shown in Figure 25, was modified after 
the preliminary study was completed due to the high cell death due to the pH increase caused by the 
presence of the scaffolds in the well inserts. The pH increase in the area surrounding a BBG sample has 
frequently been reported in the literature. (182) (408) As described in section 6.3.2, the following 
changes were made to the protocol to tackle this issue, as outlined in Figure 25:- 
 Removal of washing protocol steps 5 to 10 in Table 7 as these steps were considered to hinder 
the reduction of the pH in the CCM when the scaffolds were added 
 1% Bufferall was added to the CCM and for the rest of the study to help to buffer the pH to a 
more suitable level 
 Reducing the scaffold size to between 2x2x2mm3 and 3x3x3mm3 
 Increasing the pre-culture stage after autoclaving the scaffolds from an hour in DMEM/F-12 to 
four days in DMEM/F-12 with the first 24 hours spent being agitated 
The final version of the 2D cell culture process is shown in Figure 26. 
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Figure 26:- Flow chart showing the optimised protocol used for the 2D cell culture study 
 
At certain time points AB assays were done to ascertain the change in the number of living cells 
present in the well. This is done when fresh CCM is due to be added as the well inserts have to be 
removed in order to carry out the protocol outlined for AB assays in section 4.4.7. The AB assays were 
completed at 1, 7, 14 and 21 days into the study. 
 
4.4.6 3D cell cultures using rat bone-marrow stromal cells 
 
 This 3D cell culture protocol involves statically seeding the rMSC’s directly onto a 3D scaffold 
meaning the cells will be in direct contact with the scaffold for this study. This protocol follows the 
work done in the previous 2D culture study and therefore uses the revised conditions, such as the new 
scaffold dimensions (between 2x2x2mm3 and 3x3x3mm3) and the addition of 1% Bufferall to the CCM. 
In this part of the study, BBG scaffolds produced and modified using MSIE, described in 
sections 4.2.1 and 4.2.2 were subjected to cell biology tests using rMSC’s. Including the BBG scaffold, 
four different sample types were investigated in this section of the work. The dimensions of the scaffolds 
were between 3x3x3mm3 and 2x2x2mm3. Scaffolds were conditioned using the washing protocol 
outlined in the washing and pre-culturing parts of Figure 26.  
The cells were prepared as stated in section 4.4.4 and approximately 7.5x104 cells were seeded 
onto each scaffold. Three of each scaffold type (12 scaffolds in total) were placed into a 12well well 
plate with one scaffold per well. 2ml of the cell suspension was slowly pipetted onto each scaffold to 
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give the cells the best chance of infiltrating the scaffold and attaching themselves to the inside network 
of pores of the scaffolds. The well was then topped up with an additional 1ml of the CCM. 
The whole ensemble was then placed into the incubator with 5%CO2 at 37oC for 24 hours. The 
cells settled and started to attach themselves to the well and the scaffold after three hours so fresh CCM 
was added after 24 hours and subsequent 24 hours were considered until the end of the study without 
disturbing the cells. 
AB assays, as described in section 4.4.7, are required at set time points in order to assess the 
changes in the number of living cells present in the well including 1,7 and 14 days. These assays were 
completed when the CCM was replaced as described in section 4.4.5. 
The protocol for the 3D cell culture is summarised in the flow chart shown in Figure 27. 
 
 
Figure 27:- Flow chart for the 3D cell culture study 
 
 
4.4.7 Biological characterisation using rat bone-marrow stromal cells and human bone-marrow 
stromal cells 
 
 In this part of the study the main characterisation technique, other than observations under a 
light microscope, was the assessment using an Alamar Blue (AB) assay. 
 For this study, the CCM in the well plate was removed and the samples were gently washed in 
PBS before 1ml of a 10% AB solution was added to each well. Two controls were prepared in the same 
well plate with one containing just 1ml of the 10% AB solution and the other having 1ml of the 10% 
AB solution and 1ml of the CCM. 
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 The well plate was then covered in foil, as the AB solution is light sensitive, and incubated for 
two to three hours at 37oC and 5%CO2. By the end of this incubation period the solution in the sample 
wells will have changed from dark blue to a dark pink purple colour. 
 After the incubation period three 100µl samples of the AB solution were removed from each 
sample well and the two control wells and they are pipetted into a 96well well plate for the resulting 
measurements. The sample well plate had fresh CCM media added to the sample wells and it was placed 
back into the incubator at 37oC and 5%CO2 for the rest of the study. The result well plate was wrapped 
in foil to prevent fluorescent interference from adjacent wells. 
 The relevant measurement is the absorption of the stained cell suspension from each well at 
570nm and 600nm which is measured using a spectromax 190 instrument with the measured absorption 
results being used in Equation 11 and Equation 12 to give the percentage reduction of the AB. 
The number of living cells present in the wells is related to the percentage reduction of the AB. 
The higher the percentage reduction the more living cells are present in the sample well. Thus this test 
is only indicative of the number of living cells present at the time of the measurement. The AB assay 
can be used to assess how the cell population is changing over time, with respect to the sample type and 
it can give an indication if there are any toxicity issues with the sample. 
 
Equation 11:- AB reduction equation 
 
Equation 12:- Correction factor for the AB reduction equation 
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4.4.8 Bacterial preparation, counting and growth curves  
 
 Standard I Agar plates (agar plates) need to be prepared first to give a surface for the bacteria 
to grow on. The preparation of these plates is described in appendix B.6. 
 A stock bacteria plate needs to be cultivated to provide the bacteria for the later studies. The 
bacteria, listed in section 4.1.9, are removed from the freezer and placed in a sterile fume hood which 
is dedicated to bacterial studies. 100µl of the bacteria are removed once the stock has become liquid, 
the stock bacteria is then replaced back in the freezer. After that this stock bacteria is pipetted on to an 
agar plate before using a platinum loop to spread the bacteria around the agar plate. The plate is then 
labelled, sealed with Parafilm® and placed in an incubator at 37oC for a minimum of 48 hours to 
cultivate. 
 The wavelength at which the absorbance is measured needs to be established for the two types 
of media being used in the bacterial work. The two media that the bacteria will be suspended in:- 
 An industry standard, Muller Hinton broth (MHB) 
 A modified version of the CCM used in the cell biology studies described in sections 4.4.4 
onwards containing DMEM/Ham’s F-12 with 10% FBS, 1% L-glutamine and 1% Bufferall 
(DMEM/F-12). 
 The absorbance of MHB, DMEM/F-12, pure distilled water and the McFarland standard over 
a range of 350-800nm was measured using a Perkin Elmer Enspire 2300 multiwave reader coupled with 
Enspire management software. This will provide spectra of absorbance against wavelength to establish 
the wavelength that future absorbance values should be measured at. From this result, shown in section 
6.4.1, future absorbance values were measured at 650nm to give an expected absorbance for both media 
types of approximately 0.1. 
 For the experiments, a pre-culture stock solution is created by adding three to five colony 
forming units (CFU’s), from the stock bacteria plate to 10ml of media (either MHB or DMEM/F-12). 
Once the bacteria is added to the media the pre-culture stock is incubated with 5% CO2 at 37oC on a 
shaker for one hour for MBH pre-culture solutions and two hours for DMEM/F-12 pre-culture solutions. 
The absorbance of the pre-culture suspension and the media is measured at using a Specord 205 
photometer at 650nm. The difference in absorption at 650nm before and after the bacteria were added 
to the media, Δabs, is used to calculate the amount of the pre-culture stock that should be added to the 
stock solution, using Equation 13. Throughout the studies it will be stated what absorbance difference 
is used for that particular study. In general the required absorbance difference will either be 0.01 or 
0.001. 
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Equation 13:- Calculation of the amount of pre-culture stock solution which is required to be transferred to the 
stock solution 
 
 Subsequently, the required pre-culture stock solution is added to the stock solution and 
incubated with 5%CO2 at 37oC until it is needed. 
 Growth curves of E.coli have to be established to predict the bacteria’s behaviour in DMEM/F-
12 compared to the industry standard MHB. 
 The change in absorption at 650nm from media to the stock suspension is measured at a number 
of time points to establish the growth of the bacteria. This will provide a graph of the change in 
absorption against time but won’t provide the number of bacteria per ml. This value is evaluated by 
removing the stock suspension at specific time points, diluting it with NaCl and plating 100µl of these 
dilutions onto agar plates and transferring into an incubator at 37oC for 24 hours to cultivate. 
 The dilutions used depend on the number of bacteria found in the bacteria suspension at the 
time of the absorbance measurement. Using the bacteria counting protocol, outlined in appendix B.7, 
the number of bacteria in the pre-culture suspension was found to range between 1x108 and 3x108 
bacteria per ml. Equation 14 is used to calculate an approximate number of bacteria per ml at the given 
time point and the number of dilutions needed to produce a plate on which bacteria’s CFU’s can be 
counted is calculated. 
Equation 14:- Number of bacteria per ml to work out dilutions for plating the bacteria 
 
A typical dilution set is shown in Table 8 and gives approximate values that are predicted to be 
obtained based on the values calculated from Equation 14 and will give the maximum dilution values 
that are expected to be encountered during these studies. Only the last four dilutions of any dilution set 
should be plated. The last four dilutions of any sample should be in the magnitude range of 101, 102, 
103 and 104 as shown by Table 8 and illustrated in Figure 28. 
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Table 8:- Working dilution table of the dilutions required to get the required number of CFU’s on an agar plate 
Dilution  Number of CFU's wanted Predicted magnitude of CFU's Predicted dilution factor 
number on the agar plate on the agar plate per 100µl 
D8 Below 10 (*) 101 10-7 
D7 Between 10 and 100 (*) 102 10-6 
D6 Between 100 and 1000 (*) 103 10-5 
D5 Between 1000 and 10000 (*) 104 10-4 
D4 Not plated 105 10-3 
D3 Not plated 106 10-2 
D2 Not plated 107 10-1 
D1 Not plated 108 100 
* 100µl of this dilution is plated, incubated for 24 hours and the results CFU's are counted 
 
 
Figure 28:- Colony forming units (CFU's) of E.coli showing the process of diluting the E.coli suspension, plating 
it and then counting the CFU’s after incubation 
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After 24 hours the cultivated plates are removed from the incubator and the CFU’s are counted 
as shown in Figure 28. Using Equation 15 the number of bacteria per ml present in each plate can be 
calculated. This can be plotted against time to give another growth curve that can be used to determine 
the best growing conditions for the bacteria. 
Equation 15:- Number of bacteria per mL from counting CFU’s 
 
 
4.4.9 Minimum inhibitory concentration testing using metal salts against Escherichia Coli 
 
 To calculate the minimum concentration of metal salts required to cause either a bacteriostatic 
or bactericidal effect a stock solution needs to be prepared as well as agar plates as described in section 
4.4.8 and appendix B.6, respectively. 
 Dilutions of several metal salts were prepared using distilled water to a 10mM concentration 
before using either MBH or DMEM/F-12 (depending on the study), to bring the dilutions to their final 
concentrations. Table 9 shows the concentrations that were investigated in this work using the protocol 
outlined in this section. These concentrations were chosen based on previous work in the literature, in 
particular the work reported in Heidenau et al. (409) The metal salt dilutions will be further diluted 
when they are added to the bacteria suspension and this was taken into account when making the metal 
salt dilutions, as shown in Table 9. 
Several studies were carried out using the method to be outlined including investigating if 
Cu(NO3)2 can be used in the main inhibition study instead of the more commonly used CuCl2, as used 
in Heidenau et al (409) and investigating the minimum inhibitory concentration (MIC) of AgNO3, 
Cu(NO3)2 and a 1:1 ratio of both salts to represent the three different MSIE scaffolds produced in this 
work and described in section 4.2.2. This investigation will act as a comparison to the study described 
in section 4.4.11 where the supernatants from immersed MSIE scaffolds were tested to determine their 
anti-bacterial potential. 
 The metal salt dilutions (1ml) were added to 1ml of the stock solution, as described in section 
4.4.8, and left to cultivate in an incubator with 5%CO2 at 37oC. At certain time points some of the 
suspension was removed, diluted with NaCl, plated on agar plates and incubated, as described in section 
4.4.8. After incubation the CFU’s can be counted and the bacteriostatic effects of the metal salts can be 
determined for each concentration tested. 
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Table 9:- Metal salts concentrations used in the minimum inhibition study 
Metal salt Wanted concentration Working concentration 
  (mM) (mM) 
  0.05 0.1 
  0.1 0.2 
CuCl2 0.5 1 
  1 2 
  0.005 0.01 
  0.01 0.02 
  0.02 0.04 
  0.05 0.1 
  0.1 0.2 
Cu(NO3)2 0.2 0.4 
  0.5 1 
  1 2 
  2 4 
  5 10 
  0.005 0.01 
  0.01 0.02 
  0.02 0.04 
AgNO3 0.05 0.1 
  0.1 0.2 
  0.2 0.4 
  0.5 1 
  0.01 0.02 
Combination of  0.05 0.1 
AgNO3 and 0.1 0.2 
Cu(NO3)2 0.5 1 
  1 2 
 
The MIC will be the lowest concentration that produces a bacteriostatic or bactericidal effect 
on the bacteria. The method described in this section can determine the MIC to cause a bacteriostatic 
effect on the bacteria as it is not possible to know if the metal salts are killing the bacteria (bactericidal 
effect) or simply “switching off” the bacteria (bacteriostatic effect) by looking and counting CFU’s. 
The MIC for a bactericidal effect is described in section 4.4.10. 
 This study gives thus a narrower focus for the rest of the work by giving a range of 
concentrations that the metal salts work against the bacteria and the results will be relevant in later 
studies when the supernatants taken from immersed MSIE scaffolds will be tested, described in section 
4.4.11, to confirm if they fall within the minimum inhibitory scale. 
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4.4.10 Testing the bacteriostatic or bactericidal capabilities of metal salts 
 
 To test the bacteriostatic/bactericidal capabilities of the concentrations determined through the 
studies described in section 4.4.9 the following changes to that protocol need to be made. The method 
used in section 4.4.9 changes at the step where the solutions are due to be plated onto agar plates. The 
solutions are still diluted and plated as described in section 4.4.9 to produce the series of agar plates 
used to determine the number of bacteria per ml through counting CFU’s. However an additional plate 
is made by mixing 10µl of the sample suspension with 100µl sodium thiosulfate in an epidoth tube and 
transferring this to an agar plate and incubating as normal. Sodium thiosulfate, as used and described 
by Heidenau et al, (409) deactivates the silver and the copper in the suspensions. This is added to 
determine if the observed effect on the bacteria is bacteriostatic or bactericidal when compared to the 
metal salt/bacteria suspensions that did not have sodium thiosulfate added. 
 If the concentration of the metal salt is bactericidal both the CFU agar plates and the sodium 
thiosulfate plate will show no bacteria activity. If the concentration of the metal salt is bacteriostatic the 
CFU plate will show little or no bacteria growth in the form of CFU’s and the sodium thiosulfate plate 
will show normal bacteria growth coverage as seen in control plates. If the concentration of the metal 
salts has no effect on the bacteria at all, both the CFU plates and the sodium thiosulfate plate will show 
normal bacterial growth as seen on a control plate with no metal salts in suspension. 
 
4.4.11 Growth inhibition using supernatants against Escherichia coli 
 
 The stock solution used was prepared as described in section 4.4.8 along with the agar plates 
described in appendix B.6. 
 This study involves immersing sample scaffolds as described in sections 4.2.1 and 4.2.2 in 
DMEM/F-12 for 1, 3, 7 and 28 days in an incubator with 5%CO2 at 37oC. The samples studied were 
the BBG scaffold, and the three MSIE scaffold types at the lowest concentrations immersed for 15 
minutes. These samples were chosen as they are the same as the ones studied in the cell biology studies, 
described in sections 4.4.5 and 4.4.6. There were two scaffolds immersed for each sample type meaning 
that ten samples were tested including two control runs. 
 After the scaffolds have been immersed for the given time periods 1ml of the supernatant is 
removed, decanted into fresh tubes, 1 ml of the stock suspension is added and then the tubes are placed 
into an incubator with 9.5%CO2 at 37oC on a shaker for 24 hours. 
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 After 24 hours the samples are removed and prepared for dilution and plating, as described in 
section 4.4.8, to give a CFU count which will give an indication of the bacteriostatic nature of the 
samples. Sodium thiosulfate plates are also required to ascertain if any changes in the CFU plates for 
these supernatant samples is due to scaffold supernatant being bacteriostatic or bactericidal as described 
in section 4.4.9. 
 
4.4.12 Agar diffusion to show growth inhibition of Staphylococcus aureus and Escherichia coli 
  
 This section covers the two methods used to determine the growth inhibition of the scaffolds 
produced (as described in sections 4.2.1 and 4.2.2) to both S.aureus and E.coli through agar diffusion. 
 
I Growth inhibition demonstrated through agar diffusion on Escherichia coli 
 
 Agar plates with an E.coli “lawn” need to be prepared in order to test the antibacterial properties 
of the samples. This is done by preparing the pre-culture stock suspension as described in section 4.4.8, 
transferring 500µl of this pre-culture stock onto an agar plate as described in appendix B.6. Once this 
inoculum is on the agar plate it is spread evenly on the surface using a sterile drygalski spatula making 
sure to distribute the inoculum crosswise in at least three different directions across the plate. These 
plates are then left to dry in a sterile bacteria specific fume hood for 10 to 15 minute before application 
of the testing disks. 
 After the plates have started to dry, sterile testing disks made of filter paper are gently pressed 
into the surface of the plate using a pair of sterile tweezers, making sure there is plenty of room between 
each of the disks, meaning there is a maximum of five testing disks per agar plate. 
 20µl of the sample solution was pipetted onto each disk, taking care to get the inoculum only 
on the disk, and the plates were then incubated for 24 hours at 37oC. After the incubation period the 
plates were observed looking for a halo effect around the testing disks. If the samples are having an 
effect on the bacteria, whether it is bacteriostatic or bactericidal, then there should be a clear E.coli free 
zone around the testing disk. 
 The following sample types were tested in this way to ascertain if they were having an anti-
bacterial effect on the E.coli. The supernatants taken from the immersed scaffolds described in section 
4.4.11 were tested along with a range of concentrations of metal salt dilutions as described in 4.4.9 for 
comparison purposes. 
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II Growth inhibition demonstrated through agar diffusion on Staphylococcus aureus 
 
 As described in section 4.4.12.I, a bacteria lawn needs to be created first on an agar plate. For 
this agar diffusion study the bacteria lawn was created by growing S.aureus instead of E.coli. 
 Once the bacteria lawn had been created and allowed to dry small scaffold pieces were gently 
pressed into the agar plate. The four samples tested in this study were a BBG scaffold along with the 
lowest concentration (immersed for 15 minutes) MSIE samples, as described in sections 4.2.1 and 4.2.2, 
respectively, and in line with the previous bacterial work using the supernatants (section 4.4.9) and the 
cell biology work (sections 4.4.5 and 4.4.6). The S.aureus lawn plates with the scaffold samples are 
then incubated for 24 hours at 37oC before the observations of the anti-bacterial effect of the samples 
on the S.aureus lawn are made. As in section 4.4.12.I a halo around the scaffold is the desired 
observation as this would indicate that the sample is having an anti-bacterial effect on the S.aureus. 
 
4.4.13 Growth inhibition on 3D scaffolds using Klebsiella pneumoniae 
 
 For this part of the study, a 50µl suspension of K.pneumoniae in 0.9%NaCl + 0.05% Tween 80 
was pipetted into each sample scaffold. The four samples tested in this study were a BBG scaffold along 
with the lowest concentration (immersed for 15 minutes) MSIE samples as described in sections 4.2.1 
and 4.2.2  respectively and in line with the previous bacterial work using the supernatants (section 4.4.9) 
and the cell biology work (sections 4.4.5 and 4.4.6). The inoculated scaffolds were then incubated for 
18 hours at 37oC. 
 The scaffolds were eluted using 20ml of a mixture of 0.9%NaCl + 0.20% Tween 80 and the 
extracted solution was diluted and plated in the same manner as described in section 4.4.8. After these 
agar plates were incubated for 24 hours at 37oC, the CFU’s were counted and compared to a control 
sample of a sterile standard textile disk (PES). The number of bacterial cells was determined and 
compared to the number of bacteria added before the incubation period on the sample. If this number 
decreases then there has been some anti-bacterial effect caused by the scaffold and if the number of 
bacteria increases then the presence of the scaffold has had no anti-bacterial effect. 
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4.5 Statistical Analysis 
 
Statistical analysis has been carried out on the collected data where appropriate using Excel. 
The statistical methods are shown in Appendix E which includes all of the relevant equations used.  
All data is expressed as the mean ± standard error, as described in appendix E, and unless otherwise 
stated the number of samples used to determine these values is greater than or equal to five. 
To determine if the statistical relevance of the data, analysis of variance (ANOVA) statistical 
analysis, using Excel, was carried out where p ≤ 0.05 is regarded as a statistically significant result. 
The method is described in detail in appendix E.   
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Chapter Five 
5. Structural results and discussion 
 
5.1 General remarks 
 
This chapter covers the structural characterisation studies carried out on the modified BBG 
scaffolds developed in this study, namely the MSIE scaffolds, polymer coated scaffolds and BBG 
samples. This chapter covers the use of a number of techniques which have been introduced in chapter 
four, which enable the complete structural characterisation of the novel scaffolds developed in this 
work. 
This chapter is split into a number of sub-sections dealing with specific scaffold types and 
reports the development of the novel scaffold types from conception to fine tuning.  
 
5.2 45S5 Bioglass®- derived glass-ceramic scaffolds 
 
 The comprehensive structural characterisation of the BBG scaffold is required as this material 
will act as a control for the modified samples that have been developed during the course of this work. 
This section presents the structural characterisation of these samples using the materials and techniques 
described in chapter four. 
 Sintered BBG scaffolds produced using the foam replication technique, as described in chapter 
4.2.1, gave an average porosity of 92±3% which is consistent with the results found in the literature (4) 
(410) and as calculated using Equation 1. The un-sintered green body scaffolds were found to have an 
average porosity of 93±2% indicating that during the binder burn out phase and the subsequent sintering 
phase the samples are not losing pore volume (within the accuracy of the measurement), through the 
shrinkage of the scaffold. 
 From examining the BBG scaffolds using a scanning electron microscope (SEM), as described 
in chapter 4.3.3, a number of observations can be made. Figure 29 shows a range of SEM images taken 
of BBG scaffolds showing that the pores of the sintered scaffold range from approximately 200 to 600 
microns (Figure 29A) which is consistent with results presented in the literature on this type of scaffolds. 
(411) (4) (410) (269) (5) (270) (271) Figure 29B shows that the cross sections of the sintered struts are 
hollow after the PU foam and binder have been burnt out and that the struts have transactional dimension 
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in the range of 25 to 75 microns which is in line with current research. (411) (4) (410) Figure 29 C and 
D show that the surface topography of the scaffold is not smooth and this rough micro-topography is 
considered important as it should encourage cell attachment (222) (223) (214) and accelerate the 
reactions occurring at the surface of the scaffold, (223) which has also been reported in the literature. 
(222) (223) 
 
 
Figure 29:- SEM images of BBG scaffolds produced using the foam replication technique at magnifications of A) 
x50, B) x300, C) x1400 and D) x10000 
 
 As described in chapter 4.3.10, the mechanical competence of the BBG scaffolds can be 
measured by compressive strength testing and this has given rise to a compressive strength of 
0.53±0.08MPa which falls into line with results from the literature. (113) (4)  
 The wettability of BBG samples was determined by measuring the static contact angle on 
pellets, as described in section 4.3.8. A value of 28±4° was measured, which is in agreement with 
literature results. (412)  
White light interferometry was used to examine the surface roughness of the sintered 45S5 
Bioglass® using pellets fabricated using the same process used to make the scaffolds. The measurements 
were carried out as described in section 4.3.7. The white light interferometry results can be split into 
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quantitative and qualitative results with the qualitative results shown in Figure 30. Figure 30 shows a 
range of different plots obtained from this technique that can be used to ascertain the topography of the 
sample. Figure 30a) shows the white light microscopy intensity plot which gives an indication of areas 
of interest on the samples surface. For the BBG samples little can be seen from this plot and the surface 
appears fairly smooth but once the settings are changed to show a solid colour plot of the sample area 
(shown in Figure 30b), the contours of the sample are now highlighted with the peaks and valleys shown 
in yellow and black, respectively. This image shows that whilst the surface of the pellet appears to be 
smooth to the naked eye it does actually contain a rough topography, as shown also in both SEM images 
in Figure 29. 
Figure 30c) shows a 3D representation of the surface of the sample showing the change in the 
surface topography through the use of colour. This data is in agreement with the topography shown in 
Figure 30b) and in Figure 29. Figure 30d) shows a cross-section of the sample giving an idea of the 
extent of the surface peaks and valleys which gives rise to the sample PV value. Finally Figure 30e) 
shows a 2D colour surface map of the sample which shows the peaks and valleys of the sample in terms 
of a colour scale. Overall Figure 30 shows that a number of different plot types can represent the 
topography of the sample and in this case it can be seen that apart from one significant peaked area the 
surface of the pellet appears to have a micro-roughness which is one of the features that is desired for 
an ideal scaffold for BTE. (222) (223) 
From this qualitative data shown in Figure 30 the quantitative results were derived and the 
average values of the RMS, Ra and PV parameters were found to be 3±1µm, 2.6±0.9µm and 19±9µm, 
respectively, which is consistent with current data available in the literature on similar bioactive glass-
derived scaffolds. (224) (225)  
As stated in chapter four, this characterisation technique was carried out on pellets rather than 
on the foam replicated scaffolds as the measurement can not easily be carried out on a curved surface 
such as the strut of a scaffold. As an approximation, the pellets can be used as a direct substitute to 
investigate the surface topography at the micro level because the pellets are prepared and sintered in the 
same way as the foam replicated scaffolds and thus a similar surface topography is expected. 
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Figure 30:-White light interferometry results for a sintered BBG pellet showing A) a 2D white light microscopy 
intensity plot, B) a 2D solid plot coloured version of the white light microscopy intensity plot shown in A), C) a 
3D oblique plot showing the surface roughness of the sample in terms of colour, D) a sample cross section across 
the pellet showing the surface profile and E) a 2D coloured surface map of a BBG pellet showing the peaks and 
valleys in terms of different colours 
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 The next set of characterisation techniques investigate the chemical composition and crystalline 
structure of the BBG samples using EDX, XRD and FTIR as described in sections 4.3.4, 4.3.5 and 4.3.6, 
respectively. Figure 31 shows the FTIR spectrum of sintered BBG exhibiting the characteristic bond 
peaks of this material which have been shown in the literature. (413) (414) (415) Relevant peaks include 
a pair of asymmetric stretching Si-O-Si bonds at 1097 – 1100cm-1 and 1037 – 1050cm-1, a peak showing 
a stretching Si-O bond at 920 and 940cm-1 which is indicative of a non-bridging oxygen bond, a pair of 
P-O bending bonds at 720 – 650cm-1 and 625 – 580cm-1 and finally a pair of Si-O-Si bending bonds at 
528 – 536cm-1 and 455 – 457cm-1. These four sets of bond peaks should always be present as these are 
the characteristic peaks for sintered BBG, which is the base material in the present research and the 
results are supported by previous related studies in the literature. (413) (414) (415) 
 
 
Figure 31:- FTIR analysis of sintered BBG scaffold including the associated characteristic bond peaks (413) (414) 
(415) 
 
From the SEM images shown in Figure 29C and D small crystalline grains can be identified 
which have a diameter of approximately 0.5µm, leading to the conclusion that the sintering process 
leads to partial crystallisation of the scaffold. This is confirmed by the XRD characterisation shown in 
Figure 32. Figure 32 confirms the crystalline nature of the sintered BBG samples, the XRD pattern 
exhibits the characteristic peaks previously recorded for Na2Ca2Si3O9, which in the literature has been 
shown to be the main crystalline phase of sintered 45S5 Bioglass® after heat treatment at over 100oC. 
(4) (5) (389) (416) 
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Figure 32:- XRD spectrum of sintered BBG scaffold (at 1100oC for two hours) confirming the crystalline nature 
of the material (4) (5) (389) (416) 
 
EDX analysis of the BBG scaffold (Figure 33) showed the presence of silicon, sodium, calcium, 
phosphorus and gold, (the presence of gold is due to the coating applied for SEM observations as 
described in section 4.3.4). The other elements detected are from the BBG scaffold and are consistent 
with the literature. (394) (417) (5) 
 
 
Figure 33:- EDX analysis of a BBG scaffold to determine the elemental composition of the sample 
 
 The next stage of the characterisation of the BBG scaffolds is to assess their bioactivity in order 
to determine if the scaffolds exhibit the expected behaviour in SBF, characterised by the formation of 
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HA on their surface after a short immersion period in SBF. Bioactivity of a material, in the context of 
bone substituting materials, is assessed by immersing the samples in SBF, as described in section 4.3.2 
and by Kokubo et al, (396) for a set time frame. Once removed, the samples are characterised using the 
same techniques that were used for sample characterisation before immersion.  Immersion in SBF for 
1, 3, 7, 14, 21 and 28 days is considered to track the development of HA on the surface of the samples, 
as this is the marker of bioactivity and it is required to promote bone cell attachment as discussed in 
chapter 2. 
 Figure 34 shows through SEM images the progression of HA formation on the surface of the 
BBG scaffold. All six immersion periods show the characteristic HA knobbles on the surface of the 
scaffold and the increased frequency and density of these knobbles as the immersion period in SBF 
increases, which is as expected and consistent with the literature. (4) (5) With the presence of 
characteristic HA formation on the surface of the scaffold it can be determined that the scaffold is in 
principle suitable for use in BTE. Figure 34 also showed that the samples have a micro-roughness, due 
to surface reactions leading to the formation of HA, which is one of the desirable features for an ideal 
scaffold for BTE. (222) (223) 
 The porosity of the BBG scaffolds, as determined by using Equation 1, declined the longer the 
scaffolds were immersed in SBF. Decreasing from an average pre-immersion porosity of 93±2% to an 
average post-immersion porosity of 92.0±0.8%, 91±1%, 89±2%, 84±2%, 80±3% and 79±2% for 
immersion periods of 1, 3, 7, 14, 21 and 28 days, respectively, which is in line with observations 
reported in the literature. (241) 
 The compressive strength of the immersed scaffolds was observed to decrease with increased 
immersion period, as displayed in Table 10. This is to be expected as the scaffolds will start reacting 
(ion release) as soon as they are immersed in SBF and the precipitated HA does not provide mechanical 
reinforcement. (352) (418) The slight reduction in porosity does not counteract the effect of scaffold 
degradation. 
 The surface wettability of the BBG pellets was assessed after 14 days of immersion in SBF 
using the method described in section 4.3.8 and the contact angle was found to be 23±2 degrees, being 
consistent with available results in the literature. (419)  This contact angle is important as hydrophilicity 
has an effect on the attachment of cells. Contact angles obtained before and after immersion in SBF 
should be suitable for cell attachment as ideally the contact angle should fall between 48 and 62 degrees 
in order for the surface to be exhibit the desirable moderately wettable behaviour. (419)  
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Figure 34:- SEM images of BBG scaffolds after immersion in SBF for A) one day (magnification x600), B) three 
days (magnification of x1500), C) seven days (magnification of x1500), D) 14 days (magnification of x1500), E) 
21 days (magnification of x1500) and F) 28 days (magnification of x170) (arrows indicating HA) 
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Table 10:- Average compressive strength of BBG scaffolds after immersion in SBF. * Indicates a statistically 
significant change due to the immersion period (p≤0.05) using ANOVA analysis.  
Immersion Period Compressive Strength 
(Days) (MPa) 
1 0.52±0.06    * 
3 0.50±0.04    * 
7 0.47±0.05    * 
14 0.43±0.05    * 
21 0.35±0.08    * 
28 0.24±0.03    * 
 
White light interferometry has again been used to examine the surface roughness of the sintered 
BBG pellets after immersion in SBF for 1, 3, 7, 14, 21 and 28 days. Table 11 shows the RMS, Ra and 
PV values for the different SBF immersion periods. It is shown that as the immersion period increases 
so does the RMS, Ra and PV values which is consistent with the current literature. (224) This increase 
in the roughness values can be attributed to the precipitation of HA onto the surface of the sample, as 
seen in the SEM images in Figure 34 for the scaffolds. 
Table 11:- White light interferometry results for the surface roughness of BBG pellets after immersion in SBF for 
a number of days. * Indicates a statistically significant change due to the change in immersion period (p≤0.05) 
using ANOVA analysis.  
Immersion period RMS Ra PV 
(days) (µm) (µm) (µm) 
1 4±1  * 3±2  * 20±5  * 
3 4±1  * 3±1  * 22±4  * 
7 6±2  * 5±1  * 24±7  * 
14 6±1  * 6±1  * 26±9  * 
21 7±2  * 6±1  * 27±8  * 
28 7±1  * 7±2  * 29±5  * 
 
 The chemical composition at the scaffolds surface after immersion in SBF has been examined 
using EDX and the resulting spectra are shown in Figure 35. Compared with Figure 33, Figure 35 shows 
the lack of sodium, found at approximately 1keV in Figure 33. Increased levels of both calcium and 
phosphorous are seen in all immersion periods culminating and levelling out after 7 days of immersion 
in SBF and this indicates the precipitation of HA from as early as 1 day as seen  in Figure 35A).  
As stated in chapter two the Ca/P ratio can be considered to determine if HA is present on a 
sample as this ratio for stoichiometric HA should be approximately 1.67 for stoichiometric HA. (420) 
The Ca/P ratio can be seen to increase in Figure 35, which indicates that HA is formed. The changes to 
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the elemental composition, detected by EDX, are consistent with results in the literature. (421) (422) 
(420) 
 
 
Figure 35:- EDX analysis of a BBG scaffolds which have been immersed in SBF for A) 1 day, B) 3 days, C) 7 
days, D) 14 days, E) 21 days and F) 28 days showing high levels of Ca and P which confirms the formation of HA 
 
Figure 36 shows the FTIR analysis for BBG scaffolds which have been immersed in SBF for 
1, 3, 7, 14, 21 and 28 days. The change in the FTIR spectra, shown in Figure 31 (before SBF immersion), 
compared to those shown in Figure 36 (after SBF immersion) indicates the exchange of ions from the 
surface of the scaffold into the SBF and the precipitation of HA onto the scaffolds surface. (423) This 
continuous exchange of Na, Ca, P and Si leads to the bonds rearranging themselves leading to changes 
in the FTIR spectra, shown in Figure 31, as the immersion period in SBF increases. (423) 
 The four important peaks, as indicated in Figure 31, are present in Figure 36 and they still 
dominate with the Si-O-Si and P-O bonds but a change is observed due to the formation of HA. (423) 
(424) The asymmetric stretching Si-O-Si bonds are still present between 1100cm-1 and 1037cm-1 but 
they decrease in intensity over the SBF immersion period due to Si leaching out of the scaffold. (424) 
(222) The stretching Si-O (the non-bridging oxygen) bond has shifted from 940cm-1- 920cm-1 to 980cm-
1 – 940cm-1and decreases in intensity during the immersion period. This is due to the Si-O bond 
changing to a bending Si-O-Si bond as the HA forms. This is one of the changes that is indicative of 
HA formation on the surface of the scaffold and therefore its bioactive capabilities. (423) (424) (222) 
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Moreover a new peak is formed during SBF immersion between 880cm-1 and 900cm-1, which is 
indicative of an out of plane C-O bending bond which is part of a carbonate group. The presence of this 
new peak, in Figure 36, suggests the presence of a carbonate apatite on the surface of the scaffold, which 
is another indicator of the materials bioactivity. (425) 
 
 
Figure 36:-FTIR analysis of BBG scaffolds immersed in SBF for 1, 3, 7, 14, 21 and 28 days 
   
 The P-O bending bonds between 875cm-1 to 825cm-1, 760cm-1 to 650cm-1 and 625cm-1 to 
575cm-1, show in Figure 31, are all still present in Figure 36. However the bonds, at 875cm-1 to 825cm-
1, increase in size during the immersion period which indicates the presence of a precipitated HA layer. 
(423) (424) (222) Moreover peaks indicating a dual P-O bond, between 760cm-1 to 650cm-1, are seen to 
merge to form one peak which suggests the crystallisation of the precipitated HA. (424) Finally the P-
O bond shown between 625cm-1 to 575cm-1 remains constant in its intensity and position in the spectra 
and is indicative of BBG. The bending Si-O-Si bonds between 536cm-1 and 457cm-1 are still present, in 
Figure 36 , and they increase in intensity with the immersion period. (423) (424) (222) All of the changes 
described above are indicative of the precipitation of HA onto the surface of the BBG scaffold after 
immersion in SBF for a prolonged period and are consistent with previous behaviour reported in the 
literature. (423) (424) (222) The presence of these surface changes thus confirm the bioactivity of the 
BBG scaffold and it measures the bioactivity of the modified BBG scaffold produced for this work. 
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 Figure 37 shows the XRD analysis for BBG scaffolds after immersion in SBF for 1,3,7,14,21 
and 28 days. It can be seen that as the immersion period increases the crystalline structure indicative of 
BBG, shown in Figure 32, is changing and the characteristic peaks for HA can be seen appearing after 
1 day in SBF. However the change in the spectra is most apparent after 14 days of immersion in SBF 
as the crystalline structure has disappeared to such a point that only HA peaks are observed which is 
consistent with previous work reported in the literature. (5) (4) (426)  
 
Figure 37:- XRD analysis of BBG scaffolds which have been immersed in SBF for 1, 3, 7, 14, 21 and 28 days 
 
The pH of SBF and the cell culture media (CCM) used in some of the in vitro cell biology work 
(DMEM/F-12) was measured to investigate the change in pH due to the presence of the BBG scaffold 
over time. Figure 38 shows that the pH of the SBF and the CCM increased statistically significantly 
once the scaffold was introduced. This observation agrees with the literature (244) (408) and is caused 
by the release of ions (for example sodium and calcium) from the surface of the scaffold as soon as the 
scaffold is immersed. (408)  There is some advantage to a slight increase in the pH as it has been found 
to enhance glycolysis and hence cellular ATP production. (182) (427) However the increases in pH to 
over 9 will cause a cytotoxic effect when the scaffolds are introduced to cells. (408) Ways to reduce the 
pH through a specific pre-condition of the scaffolds and its effects are discussed in the in vitro results 
(Chapter six). 
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Figure 38:- pH changes in supernatants due to the presence of BBG scaffolds with A) pH changes in SBF and B) 
pH changes in cell culture media (DMEM/F-12). * Indicates a statistically significant change between the SBF 
and CCM (p≤0.05) using ANOVA analysis.  
 
 This section gives an overview of the characteristics of the BBG scaffold that acts as a control 
for the characterisation of the novel and modified scaffolds developed in this work. 
 
5.3 Silver molten salt ion exchanged scaffolds 
 
This part of the chapter presents the results obtained when the MSIE technique was used to 
introduce silver ions into the structure of the pre-fabricated BBG scaffolds. The “proof of concept” 
work is shown in section 5.3.1 which is followed by the more extensive structural characterisation of 
these novel samples shown in section 5.3.2.  
 
5.3.1 Preliminary processing of silver molten salt ion exchange scaffolds 
 
 This “proof of concept” study was designed on the basis of the three concentrations originally 
proposed by Di Nunzio et al (6) but using sintered BBG constructs in place of the glass-ceramic system 
investigated by Di Nunzio et al. (6) MSIE was used to incorporate silver ions into sintered BBG pellets, 
as described in section 4.2.2.I. This preliminary study investigated whether MSIE is a suitable method 
to introduce therapeutic metal ions into the silicate matrix of pre-fabricated BBG scaffolds. Using XRD 
and EDX techniques, preliminary information about of the success of the technique was acquired. 
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Figure 39 shows a typical EDX spectra obtained for the preliminary study about the use of 
MSIE to introduce silver ions into BBG pellets. Figure 39A) shows the characteristic peaks for BBG 
but no peaks indicating the presence of silver. Silver was detected on the surface of the pellets, as shown 
in Figure 39B) and C). These results show that the EDX analysis did not pick up the presence of silver 
in the lowest concentration samples, indicating that silver in samples immersed in this extremely low 
concentration won’t be detected by the equipment. Since the experiments of the two higher 
concentrations have produced EDX spectra with silver peaks, it could be extrapolated that the lowest 
silver concentration was also successful in incorporating silver into the structure but the equipment was 
not sensitive enough to detect this.  
 
 
Figure 39:- EDX spectra for silver doped BBG scaffolds with concentrations of silver nitrate in the salt bath; A) 
low concentration of silver nitrate, B) medium concentration of silver nitrate and C) high concentration of silver 
nitrate as shown in section 4.2.2.I 
 
To confirm that the silver introduced during the MSIE process is incorporated into the glass 
structure, and not just forming a residual salt layer on the surface, XRD characterisation has been carried 
out. Figure 40 shows the XRD patterns for all three concentrations of silver used. 
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Figure 40:- XRD analysis of silver doped scaffolds obtained from different silver concentrations in the molten salt 
bath showing the peaks indicative of sintered/crystallised 45S5 Bioglass® (Na2Ca2Si3O9), silver and silver 
phosphate 
 
Comparing the XRD spectra of the silver MSIE samples and that of an unaltered scaffold, 
shown in Figure 40 and Figure 32 respectively, it can be seen that the Na2Ca2Si3O9 peaks are still present 
in the spectrum of the MSIE samples. Figure 40 shows the presence of metallic silver and silver 
phosphate peaks in all three samples. The XRD characterisation thus confirms the presence of silver in 
the structure of the BBG samples after the MSIE process. Since the XRD analysis confirmed the 
presence of silver in the lowest concentration samples, unlike the EDX analysis in Figure 39, it can be 
conclusively stated that the low concentration MSIE was also effective.  
Based on these preliminary results, it was confirmed that the silver MSIE process was 
successful, indicating that a further more extensive study should be carried out. The conclusions of Di 
Nunzio et al (6) stated that the most suitable molten salt bath concentration out of the three tested was 
the lowest, as this still imparted the silver ions into the glass-ceramic structure whilst not having a 
detrimental effect on the HA formation on the material and not having a toxic effect on cells. This proof 
of concept study showed therefore that all three molten salt bath concentrations of silver investigated 
here imparted silver ions into the glass-ceramic structure.  
As in Di Nunzio et al paper, (6) this proof of concept study has shown the lowest salt bath 
concentration has led to the successful incorporation of silver ions into the structure of the pre-fabricated 
scaffold and the next stage would be to optimize this process including investigating a range of 
immersion periods (15, 30, 45 and 60 minutes) and other concentrations of salt bath. These new 
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concentrations fall between the lowest and medium concentrations from the proof of concept study, 
shown in Table 3. 
 
5.3.2 Structural characterisation of silver molten salt ion exchange scaffolds 
 
 Based on the results presented in the preliminary study, shown in section 5.3.1, a new set of 
concentrations of silver nitrate in the salt bath was chosen as shown in Table 3 from section 4.2.2.I. 
These concentrations were chosen as the best trade-off between being toxic when the scaffolds are in 
contact with cells and having enough silver in the melt to actually diffuse into the silicate matrix. A 
range of longer immersion periods in the salt melt were used to enable silver at the low concentrations 
in the salt bath to diffuse into the structure of the scaffold. This means that there are 12 sample types 
investigated in this main study, the three concentrations (low, medium and high) over four immersion 
periods (15, 30, 45,60 minutes). 
 One of the changes in the production of the silver MSIE samples was the introduction of an 
updated washing protocol as it was observed that the surface of the scaffold was still covered in a layer 
of salt residue even after the scaffolds were washed in distilled water, as shown in Figure 41. The new 
washing protocol, as described in section 4.2.2.I, involved washing the MSIE samples in distilled water, 
ethanol and distilled water and it was observed that this treatment reduced the salt residue issue as 
shown in Figure 43. All the MSIE samples, unless stated, in this section have under gone the washing 
protocol before characterisation. 
 The other change to the production method shown in Figure 18 was to introduce a controlled 
rate of heating/cooling to prevent the scaffolds mechanical failure due to thermal shock. This was 
achieved by heating the scaffolds alongside the salt bath at a rate of 5o/min and after the MSIE process 
letting them to cool at 5o/min. The optimized production method is described in Figure 19. 
 The porosity of the silver-doped BBG scaffolds was measured, before MSIE, after MSIE, after 
being subjected to the updated washing protocol and after immersion in SBF for 14 days, using Equation 
1 and results are collectively shown in Figure 42. The results clearly show that the new washing protocol 
was required as the porosity was reduced from 93±2% for the BBG scaffold to as low as 55±12% which 
was unacceptable. As explained in the literature review section, an ideal scaffold should have porosity 
of over 70% in order for the bone regeneration process to occur. After implementing the updated 
washing protocol the porosity of the silver-doped scaffolds rose to between 74±6% and 81±6% which 
is a suitable porosity for a BTE scaffold. 
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Figure 41:- BBG scaffolds immersed in a low silver concentration molten salt bath for A) 15 minutes, B) 30 
minutes, C) 45 minutes and D) 60 minutes showing the presence of non-desired salt residue from the salt bath 
(arrows indicating the salt residue) 
 
 
Figure 42:- Porosity of sintered BBG scaffolds before being doped with silver through MSIE, after MSIE but 
before being subjected to the washing protocol and after MSIE and after being subjected to the washing protocol 
* Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis.  
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 It was observed using SEM that there was no apparent physical difference between silver doped 
scaffolds for the three concentrations used and there was no perceptible difference between the four 
immersion periods. The results are shown in Figure 43 with the SEM images for the other concentrations 
shown in appendix C1. These images also show that the silver-doped scaffolds exhibit the same 
characteristics observed with the BBG scaffolds, shown in Figure 29, in terms of pore size, pore 
interconnectivity and strut dimensions. The only observed difference is in the surface topography, the 
silver –doped scaffolds have rougher surface compared to the BBG scaffolds, which is in agreement 
with observations made by other researchers. (113) 
 
 
Figure 43:- BBG scaffolds immersed in a low silver concentration molten salt bath for A) 15 minutes, B) 30 
minutes, C) 45 minutes and D) 60 minutes  
 
 The silver-doped scaffolds were subjected to the same series of structural characterisation 
techniques applied on the BBG scaffolds so that a direct comparison can be made, therefore the BBG 
scaffolds can act as a control throughout this work. XRD, FTIR and EDX and depth EDX techniques 
were carried out on silver-doped scaffolds to assess the possible chemical changes to the structure due 
to the MSIE process. Figure 44 shows the XRD characterisation for the all three concentrations of silver 
nitrate in the salt bath after a 15 minute immersion period, the spectra for the other three immersion 
periods are shown in appendix C1. 
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Figure 44:- XRD characterisation of BBG scaffold after introducing silver through MSIE. Spectra for the three 
concentrations with an immersion period of 15 minutes are shown 
 
 Figure 44 indicates that all the peaks indicative of sintered/crystallised 45S5 Bioglass® are 
present, as shown in Figure 32. (4) (5) (389) (416) Some peaks indicate the presence of silver in the 
crystal structure of the silver-doped samples, as seen in the preliminary study in Figure 40. The silver 
peaks were present in all of the spectra for all three concentrations over all four immersion periods. 
 The FTIR spectra presented in Figure 45, along with the two spectra for the other two 
concentrations shown in appendix C1 show the peaks indicative of BBG including the pair of P-O 
bending bonds at 720 – 650cm-1 and 625 – 580cm-1 and the pair of Si-O-Si bending bonds at 528 – 
536cm-1 and 455 – 457cm-1 as shown in Figure 31. (413) (414) (415) The difference between the spectra 
shown in Figure 31 and in Figure 45 is the presence of a NO-3 bond at 1387cm-1 indicating the presence 
of a nitrate and the amalgamation of the stretching Si-O bond at 920 and 940cm-1 as well as the pair of 
asymmetric stretching Si-O-Si bonds at 1097 – 1100cm-1 and 1037 – 1050cm-1 to a single peak at 950-
1000cm-1 which shows the bonds are shifting to lower wavenumbers due to the presence of the silver, 
with  similar observations reported in the literature. (428) (429) (430) The presence of another shifted 
Si-O peak was detected at 670-680cm-1 which indicates that the structure of the sample is re-arranging 
itself to accommodate the additional silver present in its structure. (428) (429) (430) These two peaks 
are considered to be indicative of the inclusion of silver in the structure of a silica based material (428) 
141 
 
(429) (430) and are present in all spectra corresponding to all concentrations of the salt bath and for all 
immersion periods. 
 
 
Figure 45:- FTIR spectra showing medium concentration of silver MSIE scaffolds with immersion periods of 15, 
30, 45 and 60 minutes  
 
 Figure 46 shows the EDX analysis of the all the different silver-doped samples, as with Figure 
39, there is little indication of the presence of silver at approximately 3keV, (113) (431) for the lowest 
concentration samples after 15 and 30 minutes (Figure 46A) and B)), but there is a silver peak present 
for the lowest concentration sample after 45 and 60 minutes MSIE (Figure 46C) and D)). The medium 
concentration samples at 15 minutes also showed no silver peak but it was found to be present for the 
three remaining immersion periods. For the highest concentration samples the silver peak at ~3keV was 
seen at all four immersion periods. (113) (431)  
 Depth EDX analysis was carried out in accordance with the method described in section 4.3.11 
and is shown in Figure 47. This analysis showed that the silver MSIE had a maximum penetration depth 
ranging between 6±1µm and 30±1µm, which is in agreement with the literature. (432) (433) (434) (435) 
The maximum intensity count increased with increasing concentration of silver nitrate in the salt bath 
and the maximum penetration depth increased with both the concentration and the immersion period. 
This analysis reflects the concentration of silver as a function of the distance from the surface. 
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Figure 46:- EDX analysis of silver doped BBG scaffolds showing low concentrations samples with an immersion 
periods of A) 15 minutes, B) 30 minutes, C) 45 minutes and D) 60 minutes, medium concentration samples 
immersed in the salt bath for E) 15 minutes, F) 30 minutes, G) 45 minutes  and H) 60 minutes and high 
concentration samples immersed in the salt bath for I) 15 minutes, J) 30 minutes,  K) 45 minutes and L) 60 minutes 
 
 
Figure 47:- Depth EDX analysis of silver doped BBG pellets covering all concentrations of silver nitrate in the 
molten salt bath and all immersion periods investigated. * Indicates a significant change between the sample 
types (p≤0.05) using ANOVA analysis. 
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 The compressive strength of the silver-doped scaffolds is shown in Table 12. Compared to the 
compressive strength of the BBG scaffold, 0.53±0.08MPa, (113) (4) a slight but significant increase is 
observed for silver-doped scaffolds. There are difference plausible explanations as to why the ion 
exchange process increases the mechanical strength of a glass-ceramic and the relevant theories are 
presented here. The main theory, explained in chapter two, is that the glass-ceramic is strengthened by 
the mere fact that the ionic radius of the in-bound ion (in this case the silver ion) is larger than the ion 
that is leaving the glass (in this case the sodium ion), (335) this mechanism is called induced residual 
stress build up or the stuffing effect. (436) (437) As the larger ions plug the gaps in the atomic structure 
a high surface compression is introduced as well as a balancing interior tension. (336) (437) This is 
somewhat supported by the slight change in mass observed in the scaffolds after the ion exchange 
process. This effect however does not give us the whole picture as to why the ion exchange process 
increases the compressional strength. A complementary theory that could occur as well as the stuffing 
effect is that as the BBG scaffolds have a silicate network that contains calcium and sodium as network 
modifiers, (113) (438) the phosphate is incorporated into the structure as a orthophosphate which is 
charged, and it is balanced by the calcium in the structure. (113) (438) When silver is exchanged, ions 
are ionically bonded to non-bridging oxygen’s but the silver also interacts with nearby bridging 
oxygen’s forming a 2-coordinate system. (113) (438) This interaction is supported by the amalgamation 
of the Si-O bond at 920 and 940cm-1 and the pair Si-O-Si bonds at 1097 – 1100cm-1 and 1037 – 1050cm-
1 as seen in the FTIR results shown in Figure 45 and appendix C1. (428) (429) The extra interaction 
between the silver and the bridging oxygen’s depends on how easily silver can shed its outer electron 
and it is this extra structural interaction that could explain the increased compressive strength due to the 
silver MSIE. (113) (438) Further research is required to obtain the complete knowledge and to answer 
the question why the compressional strength of the scaffold is increased by the introduction of the silver 
ions into the scaffold through the use of MSIE. 
Table 12:- Compressive strength of silver MSIE BBG scaffolds. (113) * Indicates a significant change between 
the sample types (p≤0.05) using ANOVA analysis. 
Immersion period Compressive strength in MPa for a range of concentrations 
(minutes) Low concentration Medium concentration High concentration 
15 0.62 ± 0.04  * 0.65 ± 0.07  * 0.68 ± 0.06  * 
30 0.64 ± 0.03  * 0.66 ± 0.07  *  0.69 ± 0.09  * 
45 0.65 ± 0.06  * 0.68 ± 0.04  * 0.72 ± 0.05  * 
60 0.67 ± 0.06  * 0.70 ± 0.08  * 0.73 ± 0.04  * 
 
 Table 13 shows the RMS, Ra and PV values for the silver-doped samples. It can be seen that 
these values do not increase with increasing concentration of silver in the salt bath but instead they 
increase as the immersion period increases. They are however lower than the values seen for the BBG 
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pellets (3±1µm, 2.6±0.9µm and 19±9µm for RMS, Ra and PV, respectively), (224) (225) which 
indicates that the topography at the surface of the silver-doped pellets is smoother than that of the BBG 
pellets, which is a result of the MSIE process. Whether this change to the surface topography, compared 
to the BBG scaffold, will have an effect on the cell behaviour in the cell culture studies will be shown 
in chapter six. 
Table 13:- White light interferometry results for the surface roughness of silver doped 45S5 Bioglass® –derived 
glass-ceramic pellets * Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Concentration of  Immersion period RMS Ra PV 
silver in the salt bath (minutes) (µm) (µm) (µm) 
Low concentration 15 0.6±0.2  * 0.4±0.1  * 4±1  * 
Low concentration 30 0.7±0.1  * 0.5±0.1  * 5±1  * 
Low concentration 45 0.8±0.1  * 0.6±0.1  * 5±1  * 
Low concentration 60 1.6±0.6  * 1.2±0.4  * 8±1  * 
Medium concentration 15 0.6±0.1  * 0.5±0.1  * 4±1  * 
Medium concentration 30 0.7±0.2  * 0.5±0.1  * 6±1  * 
Medium concentration 45 0.8±0.2  * 0.7±0.2  * 6± 1  * 
Medium concentration 60 1.6±0.5  * 1.3±0.3  * 9±1  * 
High concentration 15 0.6±0.1  * 0.5±0.1  * 4±1  * 
High concentration 30 0.7±0.1  * 0.6±0.1  * 6±1  *   
High concentration 45 0.9±0.1  * 0.7±0.1  * 6±1  * 
High concentration 60 1.7±0.2  * 1.3±0.6  * 10±1  * 
 
The next stage is to test the bioactivity of the silver-doped scaffolds by immersing them in SBF 
for 14 days and characterising them again. An immersion period in SBF of 14 days was chosen as this 
allows the precipitation of HA, as seen for the BBG scaffold, but will also allow any delay in the H A 
formation caused by the MSIE process to be observed. The SEM images shown in Figure 48 and the 
corresponding SEM images in appendix C1 for the other two concentrations all show the characteristic 
HA knobbles which is consistent with the SEM images in Figure 34 and with results in the literature. 
(4) (5) These observations indicate that the presence of silver in the structure does not have a detrimental 
effect on the samples bioactivity. (113) Figure 48 also shows the surface topography has changed from 
that shown in Figure 43, with a micro-roughness present, as seen in Figure 34, which is due to the MSIE 
process and the formation of a HA surface layer after immersion in SBF and in this case the release of 
silver ions. (222) (223) (113) 
The porosity of the silver-doped scaffolds, as shown in Figure 42, is seen to decrease by on 
average 10% after 14 days in SBF which is in line with the porosity decrease seen in the BBG scaffolds 
as reported in section 5.2. (241) 
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Figure 48:- BBG scaffolds immersed in a medium concentration molten salt bath for A) 15 minutes, B) 30 minutes, 
C) 45 minutes and D) 60 minutes and then immersed in SBF for 14 days. Images have a magnification of x1500 
(arrows indicating HA) 
  
The XRD analysis shown in Figure 49 and appendix C1 show the characteristic peaks for a 
BBG scaffold that has undergone SBF immersion, as seen in Figure 37, with the presence of key HA 
peaks in the crystal structure which is consistent with the literature. (5) (4) (426) The indicative peaks 
for silver, seen in Figure 32 and Figure 44, are also present indicating that silver is still present in the 
structure of the silver-doped scaffolds after immersion in SBF for 14 days. (113) 
The FTIR analysis shown in Figure 50 and appendix C1 show the results of silver-doped 
scaffolds after immersion in SBF for 14 days. They show the changes that spectra undergo after 
immersion in SBF for 14 days, as seen in Figure 36, with the development of the C-O bond at 880cm-1 
and 900cm-1 which indicates the presence of carbonate apatite. (425) In addition, the P-O bond at 875cm-
1 to 825cm-1, which increases in size, indicates the presence of a precipitated HA layer, (423) (424) (222) 
and the dual P-O bond at 760cm-1 to 650cm-1, which indicates the crystallisation of the precipitated HA. 
(424) Thus, introduction of silver into the crystal structure does not have a detrimental effect on the 
bioactivity of the BBG scaffold and the formation of HA after 14 days of immersion in SBF is 
confirmed. The FTIR analysis also showed a reduced NO-3 bond at 1387cm-1 and a reduced Si-O bond 
at 950-1000cm-1. (428) (429) (430) The second Si-O peak detected at 670-680cm-1 in has been reduced 
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to such an extent that it is almost undetectable suggesting that this is bond that breaks first when silver 
diffuses out of the silicate structure during immersion in SBF. 
 
 
Figure 49:- XRD characterisation of BBG after introducing silver through MSIE. Spectra for the three 
concentrations investigated with an immersion period of 15 minutes after immersion in SBF for 14 days are shown
  
 
 
Figure 50:- FTIR spectra showing low concentration silver MSIE scaffolds with immersion periods of 15, 30, 45 
and 60 minutes after immersion in SBF for 14 days 
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 The EDX analysis of the silver-doped samples after SBF immersion is shown in Figure 51 and 
appendix C1 showed that the silver peak at ~3keV, as seen in Figure 46, was non-existent in the spectra. 
(113) (431) However the changes in the calcium and phosphorus peaks, as seen in Figure 35 and 
discussed in chapter two, which indicate the presence of HA are seen in Figure 51. (421) (422) (420) 
This result supports the premise that the addition of silver in the crystal structure does not have a 
detrimental effect on the bioactivity of the sample. 
 
 
Figure 51:-EDX analysis showing the elemental composition of the silver doped samples over the three 
concentrations with an immersion period of 60 minutes with A) low concentration of silver in the salt bath, B) 
medium concentration in the salt bath and C) high concentration of silver in the salt bath 
 
The Depth EDX analysis is shown in Figure 52 and is in agreement with the results shown in 
Figure 47, in that the maximum penetration depth of silver is between 6±1µm and 30±1µm. (432) (433) 
(434) (435) Due to the diffusion of some of the silver out of the structure the maximum intensity of the 
silver decreased. The highest value of relative intensity shown in Figure 47 was at the surface after 
MSIE as expected, but the highest value of relative intensity shown in Figure 52 after immersion in 
SBF ranged from 2µm to 10µm. Indicating that during immersion in SBF silver diffused from the 
surface first, leaving a higher concentration silver below the surface behind. This indicates that 
incorporation of silver through MSIE gives the scaffold a controlled release mechanism rather than 
inducing the release of all incorporated silver in one burst. From this result it cannot be ascertained how 
the formation of HA on the surface of the silver-doped BBG scaffold, but when the ICP-MS results are 
discussed this should be considered. 
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Figure 52:- Depth EDX analysis of silver doped BBG pellets covering all concentrations of silver nitrate in the 
salt bath and all immersion periods in the salt bath after 14 days in SBF. * Indicates a significant change between 
the sample types (p≤0.05) using ANOVA analysis. 
 
 As with the BBG scaffolds, the compressive strength of the silver-doped scaffolds decreased 
after immersion in SBF for 14 days, as shown in Table 14. This result is supported by data in the 
literature as the combination of ion loss and HA precipitation seems to have a detrimental effect on the 
mechanical competence of the scaffold. (352) (418) The compressive strength values are still all higher 
than the corresponding value of 0.43±0.05MPa for the BBG scaffold. As discussed previously, this 
increase in the mechanical competence can be attributed to the stuffing effect (395) (436) (437)(397) of 
the silver ions and the extra interaction in the silicate network to form a 2-coordinate system. (113) (438)  
Table 14-: Compressive strength of silver MSIE BBG scaffolds after immersion in SBF for 14 days. (113) * 
Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Immersion period Compressive strength in MPa for a range of concentrations 
(minutes) Low concentration Medium concentration High concentration 
15 0.50 ± 0.04  * 0.51 ± 0.06  *  0.55 ± 0.05  * 
30 0.50 ± 0.05  * 0.53 ± 0.05  *  0.56 ± 0.04  * 
45 0.51 ± 0.06  * 0.52 ± 0.06  *  0.55 ± 0.06  * 
60 0.49 ± 0.03  * 0.53 ± 0.08  *  0.58 ± 0.07  * 
 
 The surface topography, shown in Figure 48, was observed to be marginally changed in 
comparison to the topography observed in Figure 43 and this is supported by the white light 
interferometry results shown in Table 15. The RMS, Ra and PV values are marginally higher than those 
obtained for the BBG pellet after immersion in SBF for 14 days but still fall in the range that is 
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considered suitable for cell attachment. (224) The overall increase in surface roughness can be attributed 
to the precipitation of HA as is seen in Figure 48. Again whether the change in roughness due to the 
precipitation of HA on the modified scaffolds surface has an effect on the cell behaviour observed will 
be discussed in chapter six. 
Table 15:- White light interferometry results for the surface roughness of silver doped BBG pellets after immersion 
in SBF for 14 days. * Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Concentration of  Immersion period RMS Ra PV 
silver in the salt bath (minutes) (µm) (µm) (µm) 
Low concentration 15 6±1  * 5±1  * 23±7  * 
Low concentration 30 6±1  * 5±1  * 23±4  * 
Low concentration 45 7±2  * 5±1  * 23±7  * 
Low concentration 60 7±2  * 5±1  * 24±6  * 
Medium concentration 15 7±2  * 6±1  * 24±7  * 
Medium concentration 30 7±2  * 6±2  * 24±5  * 
Medium concentration 45 7±2  * 6±2  * 24± 6  * 
Medium concentration 60 7±2  * 6±2  * 24±7  * 
High concentration 15 7±2  * 6±2  * 25±7  * 
High concentration 30 7±2  * 6±1  * 25±8  * 
High concentration 45 7±2  * 6±2  * 25±4  * 
High concentration 60 7±2  * 6±2  * 25±9  * 
 
The wettability of the silver-doped samples was obtained in accordance with the method 
described in section 4.3.8. Results are shown in Figure 53 for samples before immersion in SBF and 
after immersion in SBF for 14 days. The BBG pellet before immersion in SBF had a contact angle of 
28±4o which decreased to 23±2o after SBF immersion. (419)  The values for silver-doped samples, 
shown in Figure 53, are all lower than the corresponding BBG pellet values and they fall outside the 
lower limit of the range of contact angles, which is considered suitable for cell attachment (between 48 
and 62 degrees). (419) As with the white light interferometry results, whether the change in topography 
has an observable effect on the cells will be shown and discussed in chapter six. 
ICP-MS analysis was carried out on the supernatant taken from PBS soaked silver-doped 
scaffolds and the results are shown in Figure 54. It can be seen that as silver concentration in the salt 
bath increased so did the released ion concentration and a similar relation was seen for the immersion 
period, i.e. as the immersion period in the molten salt bath increased so did the released ion 
concentration. This result indicates release rates of between 27.7±0.05mg per litre per day and 
2.43±0.05mg per litre per day. To put that into perspective the release rates extrapolate down to between 
0.00115mg per ml per hour and 0.000101mg per ml per hour, which is an extremely small release rate 
and similar to data reported in the literature. (439) (440) 
150 
 
 
Figure 53:- Wettability data for silver doped BBG scaffolds showing results for pre and post immersion in SBF 
for 14 days (Data shown are mean values and standard deviation of at least 3 measurements). * Indicates a 
significant change between the sample types (p≤0.05) using ANOVA analysis. 
  
 
Figure 54:-ICP-MS data for silver MSIE scaffolds for all concentrations of silver in the molten salt bath and over 
all immersion periods. * Indicates a significant change between the scaffold types (p≤0.05) using ANOVA 
analysis. 
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5.4 Copper molten salt ion exchanged scaffolds 
 
 This study investigated copper-doped scaffolds which were produced following the procedure 
described in section 4.2.2.II and depicted in Figure 19. The investigation focused on three 
concentrations of copper nitrate in the molten salt bath, shown in Table 4, with a single immersion 
period of 15 minutes. 
 The porosity of the copper-doped BBG scaffold was measured after MSIE and after the washing 
protocol had been implemented using Equation 1. The porosities were found to be 72±6%, 73±7% and 
72±7% for the low, medium and high concentration doped samples, respectively. These values are all 
lower than the porosity of 93±2% for the BBG scaffolds, but are still above the ideal porosity threshold 
of 70% suggested in the literature. (210) 
 SEM micrographs, shown in Figure 55, compared with those seen in Figure 29, show that there 
is marked difference in the surface topography of the copper-doped scaffold compared to the BBG 
scaffolds. This change in topography is due to the MSIE process and was observed to a lesser extent for 
the silver-doped scaffolds as discussed in section 5.3.2. However the copper-doped samples still all 
show the key characteristics that are desirable for a BTE scaffold in terms of pore size, pore 
interconnectivity and strut placement and dimensions, just with an increase in the surface roughness of 
the surface. 
XRD, FTIR, EDX and depth EDX analysis were carried out to determine the changes to the 
microstructure, chemistry and crystal structure of the BBG samples that occurred when the samples 
were subjected to copper MSIE.  XRD results, shown in Figure 56, show the characteristic peaks that 
are associated with sintered/crystallised 45S5 Bioglass®, as seen in Figure 32. (4) (5) (389) (416) There 
are additional peaks observed in the spectra that are indicative of the possible presence of copper oxide, 
copper and copper phosphate (441) (442) (443) in the structure and this result indicates that the copper 
MSIE process was successful in introducing copper into the silicate structure. There were three phases 
of copper observed, over many samples, and it can not be determined, from the XRD analysis alone, 
which phase is represented as the indicative peaks for Cu, CuO and CuPO4 overlap each other or are 
not present in some of the samples. This is in fact a complex glass-ceramic system, but relevant peaks 
were properly identified, as shown in Figure 56. 
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Figure 55:- BBG scaffolds immersed a variety of different concentrations of copper nitrate molten salt bath for 
15 minutes with A) low concentration salt bath (magnification of x150), B) low concentration salt bath 
(magnification of x1000), C) medium concentration salt bath (magnification of x150) and D) high concentration 
salt bath (magnification of x150)  
 
 
Figure 56:- Offset XRD spectra of the three concentrations of copper doped BBG scaffolds  
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 The FTIR analysis for the copper-doped samples, shown in Figure 57, indicates the presence 
of peaks that are associated with BBG scaffolds including the pair of P-O bending bonds at 720 – 
650cm-1 and 625 – 580cm-1 and the pair of Si-O-Si bending bonds at 528 – 536cm-1 and 455 – 457cm-1 
as shown in Figure 31. (413) (414) (415) As with the silver-doped samples, the difference in the spectra 
is the presence of a NO-3 bond at 1387cm-1 indicating the presence of a nitrate and the amalgamation of 
the stretching Si-O bond at 920 and 940cm-1 and the pair of asymmetric stretching Si-O-Si bonds at 
1097 – 1100cm-1 and 1037 – 1050cm-1 to a single peak at 950-1000cm-1, which indicates that the 
wavenumber bands are shifting lower showing that the copper is having a depolymerisation effect on 
the silicate-phosphate framework. (444) (445) (446) A second shifted Si-O peak was detected at 670-
680cm-1 which indicates that the structure accommodates the additional copper present as the CuO is 
replacing the Na2O. (444) (445) (446) These two shifts in the Si-O peaks are considered to be indicative 
of the inclusion of copper into the structure of a silica based material (444) (445) (446) 
 
 
Figure 57:- FTIR spectra of copper doped BBG scaffolds of all concentrations after immersion in the molten salt 
bath for 15 minutes 
 
Figure 58 shows the EDX analysis for the copper-doped samples and shows the presence of 
copper at 0.5keV and 8keV which is consistent with the literature. (447) A slight increase in the intensity 
of the peaks is observed as the concentration of copper in the salt bath increased. 
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Figure 58:- EDX analysis of copper doped BBG scaffolds for all three concentrations of copper in the salt melts 
with A) low concentration, B) medium concentration and C) high concentration 
 
 The depth EDX analysis, shown in Figure 59 , showed that the maximum penetration depth 
ranged between 9±1µm and 10±1µm which agrees with the literature. (448) (434) The maximum 
penetration depth increased marginally with increasing copper concentration but the relative intensity 
measured was observed to increase rapidly with increasing copper concentration. 
 
 
Figure 59:- Depth EDX analysis of copper doped BBG pellets. * Indicates a significant change between the 
change in concentration (p≤0.05) using ANOVA analysis. 
 
The compressive strength of the copper-doped scaffolds is shown in Table 16. An increase in 
the compressive strength of the samples is observed, compared to the value of the BBG scaffolds, (113) 
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(4) which is in agreement with the literature. (449) (450) As discussed earlier for the silver-doped 
scaffolds, the main mechanism for the increased compressional strength can be attributed to the stuffing 
effect, (335) (436) (437)(397) as discussed in section 5.3.2. It can also be hypothesized that, in a similar 
way to the behaviour of the silver ions in the BBG structure, (113) (438) the copper could behave 
ionically bonded to a non-bridging oxygen’s,  but also interacts with other near-by bridging oxygen’s 
forming a 2-coordinate system which may lead to the increased compressional strength observed. This 
result is supported by the FTIR analysis, shown in Figure 57, with the amalgamation of the Si-O bond 
at 920 and 940cm-1 and the pair Si-O-Si bonds at 1097 – 1100cm-1 and 1037 – 1050cm-1. 
Table 16:- Compressive strength of copper MSIE BBG scaffolds (samples prepared by MSIE for 15 minutes). * 
Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Copper nitrate  Compressive strength of  
concentration  (MPa) 
Low 0.59 ± 0.05  * 
Medium 0.60 ± 0.04  * 
High 0.62 ± 0.04  * 
 
 The white light interferometry analysis results are shown in Table 17 for the copper-doped 
samples and it can be seen that the RMS, Ra and PV values have increased with the increasing copper 
concentration in the salt bath. These values are higher than those observed for the BBG pellets (3±1µm, 
2.6±0.9µm and 19±9µm for RMS, Ra and PV, respectively) (224) (225) which indicate that the 
topography at the surface of the copper-doped pellets is rougher than that of the BBG pellets, which is 
likely due to the MSIE process. This result is supported by the observations on SEM images of the 
copper-doped scaffolds compared to the BBG scaffold, seen in Figure 55 and Figure 29, respectively. 
Whether this increase in roughness compared to the BBG scaffold and the silver-doped scaffolds has 
an effect on the cell behaviour in the cell culture studies is shown in chapter six. 
Table 17:- White light interferometry results for the surface roughness of copper doped BBG pellets. * Indicates 
a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Concentration of  RMS Ra PV 
copper in the salt bath (µm) (µm) (µm) 
High concentration 4.1±0.3  * 2.9±0.2  * 22±3  * 
Medium concentration 4.4±1.0  * 3.1±0.9  * 23±5  * 
Low concentration 5.1±1.1  * 3.8±0.9  * 26±5  * 
  
 As with the previous studies, the bioactivity of the copper-doped samples was assessed by 
immersion in SBF for 14 days. Figure 60 shows the SEM images of the copper-doped scaffolds after 
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immersion in SBF for 14 days. These images show the presence of the characteristic HA knobbles on 
the surface of the copper-doped scaffolds, which is consistent with the SEM images in Figure 34 and 
with results in the literature (4) (5) and indicates that the presence of the copper does not have a 
detrimental effect on the samples bioactivity. Figure 60 also shows that the topography of the scaffolds 
has changed due to the presence of the precipitated HA. 
 
 
Figure 60:- BBG scaffolds immersed in a variety of different concentrations of copper nitrate molten salt bath for 
15 minutes with A) low concentration salt bath, B) medium concentration salt bath and C) high concentration salt 
bath after immersion in SBF for 14days. All images have a magnification of x300  
  
The porosity of the copper-doped scaffolds was measured at 63±7%, 64±6% and 62±7% for 
the low, medium and high concentration of copper in the salt bath, respectively. The porosity has 
decreased by on average 10% after 14 days in SBF which is in line with the porosity decrease seen by 
the BBG scaffolds, discussed in section 5.2. (241) 
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The XRD spectra, shown in Figure 61, exhibit the characteristic peaks for a BBG scaffold that 
has undergone SBF immersion, as seen in Figure 37, with the presence of HA peaks consistent with the 
literature. (5) (4) (426) The indicative peaks for the possibility of the presence of copper, seen in Figure 
56, are also present in the XRD spectra in Figure 61, indicating that there is still copper present in the 
structure of the copper-doped scaffolds after immersion in SBF for 14 days. (441) (442) (443) As was 
observed in Figure 56, copper maybe present in three phases, but it can not be determined with certainty 
(based only on these results) which phase is predominant as the indicative peaks observed for Cu, CuO 
and CuPO4 overlap each other or were not always present in all observed spectra shown in Figure 61. 
It is also seen that the presence of copper does not have a detrimental effect on the precipitation of HA 
on the surface of the copper-doped samples. 
 
 
Figure 61:- Offset XRD spectra of the three concentrations of copper doped BBG scaffolds after immersion in 
SBF for 14 days 
 
The FTIR spectra of the copper-doped scaffolds after immersion in SBF for 14 days are shown 
in Figure 62. They all show the typical changes that spectra undergo after BBG scaffolds are immersed 
in SBF for 14 days, as seen in Figure 36, with the development of the C-O bond at 880cm-1 and 900cm-
1, (425) the P-O bond at 875cm-1 to 825cm-1, which increases in size indicating the presence of a 
precipitated HA layer, (423) (424) (222) the dual P-O bond at 760cm-1 to 650cm-1, which by merging 
indicates the crystallisation of the precipitated HA. (424) These changes in the spectra show that the 
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introduction of copper does not have a detrimental effect on the bioactivity of the BBG as anticipated 
by the XRD results shown in Figure 61. Figure 62 also shows a reduced NO-3 bond at 1387cm-1 and a 
reduced Si-O bond at 950-1000cm-1. (444) (445) (446) The second shifted Si-O peak detected at 670-
680cm-1 has been reduced to such an extent that it is almost undetectable suggesting that this is the bond 
that breaks first when the copper diffuses out of the crystal structure during the immersion period in 
SBF. 
 
 
Figure 62:- FTIR spectra for all concentrations of copper doped scaffolds after 15 minutes in the molten salt bath 
and after immersion in SBF for 14 days 
 
The EDX analysis of the copper-doped samples after SBF immersion shown in Figure 63 
confirms the presence of copper at 0.5keV and 8keV which is consistent with the literature (447) but 
the peaks are reduced compared to the peaks seen in Figure 58. However the change in the calcium and 
phosphorus peaks, as seen in Figure 35, indicates the presence of precipitated HA, as seen in Figure 63. 
(421) (422) (420) This result supports the premise that the addition of copper does not have a detrimental 
effect on the bioactivity of the sample, at least considering the first 14 days of immersion in SBF. 
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Figure 63:- EDX analysis of copper doped BBG scaffolds for all three concentrations of copper in the salt melts 
with A) low concentration, B) medium concentration and C) high concentration after immersion in SBF for 14 
days 
The Depth EDX analysis is shown in Figure 64 and it supports the results obtained for the 
copper-doped scaffolds before immersion in SBF shown in Figure 59, in that the maximum penetration 
depth ranges between 9±1µm and 10±1µm. (448) (434) Due to the diffusion of some of the copper out 
of the samples, the maximum intensity of the copper peak decreased. The highest value of relative 
intensity shown in Figure 59 was recorded at the surface after MSIE, but the highest value of relative 
intensity shown in Figure 64 after immersion in SBF was at 5µm. This result indicates that during 
immersion in SBF copper diffused from this region first, leaving some copper behind. This result 
suggests that incorporation of copper through MSIE into the glass-ceramic matrix of the BBG scaffolds 
gives the scaffold a controlled release mechanism rather than releasing all of the incorporated copper 
in one burst. This effect will have implications for the application of the scaffolds as an ion releasing 
scaffold for antibacterial properties. 
The compressive strength of the copper-doped scaffolds decreased after immersion in SBF for 
14 days, as was observed with the BBG scaffolds and shown in Table 18. This result is supported by 
the literature as the combination of ion leaching and HA precipitation usually has a detrimental effect 
on the mechanical competence of the scaffold. (352) (418) The compressive strength values are still all 
higher than the corresponding value of 0.43±0.05MPa for the BBG scaffold, indicating that although 
some of the copper has diffused out of the structure it is still having a positive effect on the scaffold 
compressive strength. The increased compressional strength can be attributed to the stuffing effect (335) 
(436) (437)(397) and extra interaction in the silicate network to form a 2-coordinate system, (113) (438) 
as discussed in previous sections. 
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Figure 64:- Depth EDX analysis of copper doped BBG pellets after immersion in SBF for 14days. * Indicates a 
significant change between the sample types (p≤0.05) using ANOVA analysis. 
 
Table 18:- Compressive strength of copper MSIE BBG scaffolds after immersion in SBF for 14 days (samples 
prepared by MSIE for 15 minutes). * Indicates a significant change between the sample types (p≤0.05) using 
ANOVA analysis. 
Copper nitrate  Compressive strength 
concentration (MPa) 
Low 0.50 ± 0.04  * 
Medium 0.49 ± 0.06  * 
High 0.51 ± 0.06  * 
 
The white light interferometry results, shown in Table 19, support the observations taken from 
the SEM images in Figure 60, in that the surface topography has changed due to the presence of the 
precipitated HA. The RMS, Ra and PV values are higher than those obtained for the BBG pellet after 
immersion in SBF for 14 days but still fall in the range that are considered suitable for cell attachment. 
(224) The overall increase in surface roughness can be attributed to the precipitation of HA, as seen in 
Figure 60. The discussion on if this increase in topography will affect the cells used in the cell biology 
will be discussed in chapter six. 
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Table 19:- White light interferometry results for the surface roughness of copper doped BBG pellets after 
immersion in SBF for 14 days. * Indicates a significant change between the sample types (p≤0.05) using ANOVA 
analysis. 
Concentration of  RMS Ra PV 
copper in the salt bath (µm) (µm) (µm) 
High concentration 8.0±0.8  * 7.4±0.3  * 23±5  * 
Medium concentration 9±1  * 7.7±0.8  * 23±5  * 
Low concentration 9±1  * 8.0±1.0  * 23±5  * 
 
The wettability of the copper-doped samples is shown in Figure 65 for samples before and after 
immersion in SBF for 14 days. The BBG pellet before immersion in SBF had a contact angle of 28±4o 
which was reduced to 23±2o after SBF immersion. (419)  The contact angle values of samples with the 
highest concentration of copper were in the same range as the ones measured for the BBG pellet, but 
the contact angles for both the medium and low concentration samples were high both before and after 
immersion in SBF. These results indicate that when the concentration of copper increased so did the 
measured contact angle. The contact angles for the lowest copper concentration are high enough to fall 
within the range considered to be suitable for cell attachment, which is between 48o and 62o. (419) 
Whether the change in topography due to the copper doping process has an effect on the cell behaviour 
compared to the BBG scaffolds will be shown in chapter six. 
  
 
Figure 65:- Wettability data for copper doped BBG scaffolds showing results for samples before and after 
immersion in SBF for 14 days (Data shown are mean values and standard deviation of at least 3 measurements). 
* Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
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ICP-MS analyses were carried out to obtain the amount of copper being released from the 
copper doped samples after immersion periods in PBS. Results are shown in Figure 66, indicating that 
as the concentration of copper in the sample increased so did the released amount of copper and the 
release rate. This data gives release rates of 38.90±0.05mg per litre per day, 118.13±0.05mg per litre 
per day and 137.67±0.05mg per litre per day for the low, medium and high concentrations of copper in 
the salt bath, respectively. To put that into perspective the release rates extrapolate down to between 
0.0016mg per ml per hour and 0.00571mg per ml per hour, which is an extremely small release rate. 
(451) 
 
 
Figure 66:- ICP-MS analysis of copper ion release from copper doped BBG scaffolds immersed in PBS for the 
three different concentrations of copper nitrate salt used in the MSIE study. * Indicates a significant change 
between the sample types (p≤0.05) using ANOVA analysis. 
 
5.5 Combination molten salt ion exchanged scaffolds 
 
 This part of the study investigated silver/copper-doped scaffolds which were produced 
following the procedure described in section 4.2.2.III and depicted in Figure 19. This study concentrated 
on a single concentration of silver and copper in the molten salt bath over four immersion periods of 
15, 30, 45 and 60 minutes. 
 The porosity of the silver/copper-doped BBG scaffolds was measured using Equation 1 after 
MSIE and after the washing protocol had been implemented. The porosities were found to be 72±7%, 
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73±7%, 71±7%, and 73±6% for the immersion periods of 15, 30, 45 and 60 minute samples, 
respectively. These values are all lower than the porosity of 93±2% for the BBG scaffolds, but are still 
above the ideal porosity threshold of 70% as described in the literature. (210) 
 From SEM observations of the silver/copper-doped scaffolds, shown in Figure 67, the surface 
of the samples appears to be rougher than that of the BBG scaffolds shown in Figure 29, but still having 
a convenient pore size, strut dimensions and pore interconnectivity. 
 
 
Figure 67:- SEM images of BBG scaffolds immersed in the combination silver nitrate, copper nitrate and sodium 
nitrate salt bath for A) 15 minutes (magnification of x400), B) 30 minutes (magnification of x400), C) 45 minutes 
(magnification of x400) and D) 60 minutes (magnification of x150) 
 
XRD analysis, shown in Figure 68, shows the characteristic peaks that are associated with 
sintered/crystallised BBG, as seen in Figure 32. (4) (5) (389) (416) There are additional peaks observed 
in the spectra, which are indicative of the possible presence of copper, (441) (442) (443) as seen in 
Figure 56, and silver, as seen in Figure 44. As stated in section 5.4 the presence of copper can not be 
easily attributed to a unique phase due to the fact that in some samples not all the phases were present 
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or overlapping of peaks occurred. This result indicates that the silver/copper MSIE process was 
successful in introducing both silver and copper into the crystal structure of the BBG. 
 
 
Figure 68:- XRD patterns of BBG after MSIE introducing both silver and copper for immersion periods of 15, 30, 
45 and 60 minutes 
 
 The FTIR analysis results, shown in Figure 74, show the indicative peaks associated with the 
BBG scaffold as seen in Figure 31 including the pair of P-O bending bonds at 720 – 650cm-1 and 625 
– 580cm-1 and the pair of Si-O-Si bending bonds at 528 – 536cm-1 and 455 – 457cm-1. (413) (414) (415)  
The difference appears in the form of a NO-3 bond at 1387cm-1 indicating the presence of a nitrate and 
in the form of the merger of the stretching Si-O bond at 920 and 940cm-1 and the pair of asymmetric 
stretching Si-O-Si bonds at 1097 – 1100cm-1 and 1037 – 1050cm-1 to a single peak at 950-1000cm-1 
which suggest the transformation and shift of the Si-O between 920-940cm-1 to accommodate the 
presence of the additional copper and silver in the silicate-phosphate framework which has been 
reported in the literature. (428) (429) (444) (445) (430) (446) With the available results, it is not possible 
to determine which of the two bonds is present as these bonds occur at the same wavenumber. The 
presence a second shifted Si-O band was detected at 670-680cm-1 which also indicates that the structure 
of the sample rearranges to accommodate the additional silver and copper present. (428) (429) (444) 
(445) (430) (446) The shifting of these two peaks is considered to be indicative of the inclusion of both 
silver and copper into the structure of a silica based material. (428) (429) (444) (445) (430) (446) 
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Figure 69:- FTIR spectra for silver/copper doped BBG scaffolds obtained by MSIE with different salt bath 
immersion periods 
 
Figure 70 shows the EDX analysis for the silver/copper-doped samples confirming the presence 
of silver (at approximately 3keV) and copper (at 0.5keV and 8keV) which is consistent with the results 
reported above (Figure 46 and Figure 58) and with the literature. (447) (113) (431) 
 
 
Figure 70:- EDX analysis of the silver/copper doped BBG scaffolds with immersion periods in the salt bath of A) 
15 minutes, B) 30 minutes, C) 45 minutes and D) 60 minutes 
 
 The depth EDX analysis, presented in Figure 71, shows that the maximum penetration depth 
ranged between 6±1µm and 21±1µm for the silver ions and between 11±1µm and 21±1µm for the 
copper ions which is consistent with results in the literature. (432) (433) (448) (434) (435) The relative 
amount of silver diffusing into the BBG scaffold is over half that of the copper. This result also shows 
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that the longer the immersion period for the MSIE process, the greater the penetration depth for both 
silver and copper ions. This analysis would also indicate that copper was favoured in the MSIE process 
as more copper was detected in the silver/copper-doped scaffolds compared to silver while the ratio of 
copper to silver in the molten salt bath was equal. 
 
 
Figure 71:- Depth EDX analysis of silver/copper doped BBG pellets after immersion in salt bath for 15, 30, 45 
and 60 minutes. * Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
 
The compressive strength of the silver/copper-doped scaffolds, shown in Table 20 shows a 
moderate increase compared to the value (0.53±0.08MPa) of the BBG scaffolds, (113) (4) which is in 
line with the literature. (449) (450) (113) (4) It can also be postulated that silver and copper ions affect 
the mechanical strength of the scaffolds as discussed previously. Namely the increase in the 
compressive strength can be attributed to the stuffing effect (335) (436) (437)(397) caused by the ion 
exchange process and to the fact that the ions ionically bond to a non-bridging oxygen’s, replacing a 
sodium and they also interact with other near-by bridging oxygen’s forming a 2-coordinate system 
which leads to the increased compressive strength observed. This assumption is supported by the FTIR 
analysis, shown in Figure 69, with the amalgamation of the Si-O bond at 920 and 940cm-1 and the pair 
Si-O-Si bonds at 1097 – 1100cm-1 and 1037 – 1050cm-1. (428) (429) (438) 
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Table 20:- Compressive strength of silver/copper-doped MSIE BBG scaffolds obtained by immersion in lower 
concentration salt bath for the given time periods. * Indicates a significant change between the sample types 
(p≤0.05) using ANOVA analysis. 
Immersion period Compressive strength  
(minutes)  (MPa) 
15 0.61 ± 0.05  * 
30 0.62 ± 0.04  * 
45 0.64 ± 0.03  * 
60 0.65 ± 0.06  * 
  
Table 21 shows the RMS, Ra and PV values for the silver/copper-doped scaffolds indicating 
that these values have increased compared to the values (3±1µm, 2.6±0.9µm and 19±9µm) for RMS, 
Ra and PV, respectively for the BBG pellet. (224) (225) This result confirms, the SEM observations in 
Figure 67 in that the surface of the scaffold is much rougher than that of the BBG scaffold shown in 
Figure 29. Whether or not the increase in topography observed for the combination ion-doped scaffolds 
has an effect on the cells is shown and discussed in the cell biology study shown in chapter six. 
Table 21:- White light interferometry results for the surface roughness of combination ion doped BBG pellets. * 
Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Immersion period RMS Ra PV 
(minutes) (µm) (µm) (µm) 
15 4.1±0.2  * 2.7±0.1  * 20±4  * 
30 4.1±0.6  * 2.9±0.3  * 19±4  * 
45 4.2±0.6  * 3.3±0.5  * 21±4  * 
60 4.2±0.7  * 3.2±0.6  * 19±2  * 
 
 The silver/copper-doped scaffolds bioactivity was investigated by immersing them in SBF for 
14 days and repeating the characterisation tests mentioned previously. The porosity values of the 
silver/copper-doped scaffolds after immersion in SBF for 14 days were measured as 63±6%, 62±7%, 
63±6% and 64±7% for immersion periods of 15, 30, 45 and 60 minutes, respectively. This is on average 
20% lower than the values of the BBG scaffold after the same immersion period and on average 10% 
lower than the porosity of the doped samples before being immersed in SBF. These decreases of 
porosity are in line with the observations made for the porosity of the silver-doped and copper-doped 
samples. Moreover, the decrease in porosity observed after SBF immersion is consistent with the 
porosity decrease seen by the BBG scaffolds reported in section 5.2. (241) 
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 Figure 72 shows SEM images of the silver/copper-doped BBG samples after SBF immersion. 
The images show characteristic HA knobbles on the surface, consistent with the SEM images in Figure 
34 and with reports in the literature, (4) (5) indicating that the presence of either silver or copper ions 
does not have a detrimental effect on the samples bioactivity, as was reported in the previous sections 
(sections 5.3.2 and 5.4). Figure 72  also shows that the topography of the scaffolds has changed due to 
the presence of the precipitated HA. 
 
 
Figure 72:- BBG scaffolds immersed in the combination silver nitrate, copper nitrate and sodium nitrate salt bath 
for A) 15 minutes (magnification of x1000), B) 30 minutes (magnification of x1000), C) 45 minutes (magnification 
of x1000) and D) 60 minutes (magnification of x1500) after immersion in SBF for 14days 
 
 The XRD patterns, shown in Figure 73, exhibit the characteristic peaks of a BBG scaffold that 
has undergone SBF immersion, as seen in Figure 37, with the presence of key HA peaks. (5) (4) (426) 
The indicative peaks of both silver and copper (Ag and AgPO4 and possible Cu, CuO and CuPO4 phases 
for silver and copper, respectively), shown in Figure 68, are still present indicating that silver and copper 
persist in the structure of the sample. (113) (441) (442) (443) As stated in section 5.4 the presence of 
copper can not be easily attributed to an unique phase due to the fact that in some samples not all the 
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phases were present or overlapping of peaks occurred The presence of both the silver and the copper 
along with the characteristic HA peaks indicates that the silver and copper ions have not had a 
detrimental effect on the bioactivity of the sample. 
 
 
Figure 73:- XRD analysis of BBG scaffolds after MSIE processing introducing silver and copper for immersion 
periods of 15, 30, 45 and 60 minutes after immersion in SBF for 14 days 
 
Figure 74 shows the results of the FTIR analysis for the silver/copper doped samples after 14 
days in SBF. They all show changes in their spectra that are indicative of the changes in the structure 
of the BBG sample undergoing SBF immersion. The presence of the C-O bond at 880cm-1 and 900cm-
1, (425) the P-O bond at 875cm-1 to 825cm-1 increasing in size indicate the presence of a precipitated 
HA layer, (423) (424) (222)  and the dual P-O bond at 760cm-1 to 650cm-1 merging suggests the 
crystallisation of the precipitated HA. (424) Such peaks support the premise that the presence of silver 
and copper ions has no detrimental effect on the bioactivity of the sample. The NO-3 bond at 1387cm-1 
is present but it is smaller after SBF immersion, which is consistent with the single ion doped samples, 
along with the shifted bond at 950-1000cm-1. (428) (429) (430) (444) (445) (446)The second shifted Si-
O peak detected at 670-680cm-1 has been reduced to such an extent that it is almost undetectable 
suggesting that this is the bond that breaks first when copper and/or silver diffuses out of the structure 
when the sample is immersed in SBF. 
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Figure 74:- FTIR spectra for silver/copper doped BBG scaffolds with different salt bath immersion periods after 
immersion in SBF for 14 days 
 
Figure 75 shows the EDX analysis of the post SBF immersion silver/copper samples, the 
presence of copper and silver  is detected by the at 0.5keV and 8keV and ~3keV, respectively, which is 
consistent with Figure 75 and the literature. (113) (447) (431) The intensity of the peaks is reduced 
compared to those observed in Figure 70. The changes in the phosphate and calcium peaks for the BBG 
scaffold which indicated the formation of HA, as seen in Figure 35, are also observed in Figure 75. 
(421) (422) (420) This result supports the premise that the addition of copper and silver does not have 
a detrimental effect on the bioactivity of the sample. 
 
 
Figure 75:- EDX analysis of the silver/copper doped BBG scaffolds with immersion periods in the salt bath of A) 
15 minutes, B) 30 minutes, C) 45 minutes and D) 60 minutes after immersion in SBF for 14 days 
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The Depth EDX analysis is shown in Figure 76 and supports the results shown in Figure 71, in 
that maximum penetration depth ranges between 6±1µm and 21±1µm for silver and between 11±1µm 
and 21±1µm for copper. (432) (433) (434) (435) (448) Due to the diffusion of some of the copper and 
silver ions, the maximum intensity of the copper and silver peaks has decreased. The highest value of 
relative intensity shown in Figure 71 was at the surface after MSIE, but the highest value of relative 
intensity shown in Figure 76 after immersion in SBF was between 7 to 11µm for copper and 2 to 7µm 
for silver. These results suggest that during immersion in SBF copper and silver ions diffused from this 
region first, leaving some copper and silver behind. This indicates that incorporation of copper and 
silver through MSIE into the glass-ceramic matrix of the BBG scaffolds could give the scaffold a 
controlled release mechanism, rather than releasing all of the incorporated copper and silver in one 
burst. This analysis shows that copper was favoured in the MSIE process as more copper was detected 
in the silver/copper-doped scaffolds, however copper also diffused out faster than silver ion. 
 
 
Figure 76:- Depth EDX analysis for silver/copper doped BBG pellets after immersion in the salt bath for 15, 30, 
45 and 60 minutes followed by immersion in SBF for 14 days. * Indicates a significant change between the sample 
types (p≤0.05) using ANOVA analysis. 
 
As with the BBG scaffolds, the compressive strength of the silver/copper-doped scaffolds 
decreased after immersion in SBF for 14 days, as shown in Table 22, indicating that the combination 
of ion loss and HA precipitation has a detrimental effect on the mechanical competence of the scaffold. 
(352) (418) The compressive strength values are still all higher than the corresponding value of 
0.43±0.05MPa for the BBG scaffold. 
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Table 22:- Compressive strength of combination MSIE BBG scaffolds after immersion in SBF for 14 days. 
Samples were produced by MSIE, immersing them in the lowest concentration salt bath for the given periods of 
time. * Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Immersion period in Compressive strength  
 salt bath (minutes)  (MPa) 
15 0.51 ± 0.06  * 
30 0.50 ± 0.06  * 
45 0.52 ± 0.05  * 
60 0.51 ± 0.05  * 
 
The surface topography, shown in Figure 72, was observed to be marginally rough in 
comparison to the topography observed in Figure 67 for the BBG scaffold and this result is supported 
by the white light interferometry results shown in Table 23. The RMS, Ra and PV values are marginally 
higher than those obtained for the BBG pellet after immersion in SBF for 14 days but still fall in the 
range that is considered convenient for cell attachment. (224) The overall increase in the surface 
roughness can be attributed to the precipitation of HA, as is seen in Figure 72. The question of whether 
the silver/copper MSIE modification has a direct effect on the behaviour of the cells it is exposed to is 
discussed in chapter six. 
Table 23:- White light interferometry results for the surface roughness of combination ion BBG pellets after 
immersion in SBF for 14 days. * Indicates a significant change between the sample types (p≤0.05) using ANOVA 
analysis. 
Immersion period 
in salt bath RMS Ra PV 
(minutes) (µm) (µm) (µm) 
15 4.9±0.2  * 4.0±0.1  * 20±6  * 
30 4.9±0.6  * 4.0±0.3  * 21±6  * 
45 5.1±0.6  * 4.1±0.5  * 22±6  * 
60 5.0±0.7  * 4.0±0.6  * 21±7  * 
 
The wettability of the silver/copper-doped samples is shown in Figure 77 for the states before 
immersion and after immersion in SBF for 14 days. The BBG pellet before immersion in SBF had a 
contact angle of 28±4o, which changes to 23±2o after SBF immersion. (419)  All contact angles 
measured were above 35 degrees for the silver/copper-doped scaffolds. The contact angle generally 
increased as the immersion period in the salt bath increased but it did not fall in the range that is deemed 
most suitable for cell attachment of between 48 and 62 degrees. (419) As with the white light 
interferometry data for the silver/copper scaffold, the change of topography shown by the wettability 
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results will likely have an effect on the behaviour of the cells that are seeded onto it and this is discussed 
in chapter six. 
  
 
Figure 77:- Wettability data for the combination ion doped BBG scaffolds showing spectra for samples before 
and after immersion in SBF for 14 days (Data shown are mean values and standard deviation of at least 3 
measurements). * Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
 
ICP-MS analysis was carried out on the silver/copper-doped samples to obtain the amount of 
copper and silver that is being released from the doped scaffolds during immersion in PBS, shown in 
Figure 78. This shows that as the concentration of copper and silver in the sample increased so did the 
released amount of the ions and the release rate. This result indicates far more copper was being released 
from the samples compared to silver, which supports the depth EDX data shown in Figure 71 and Figure 
76. This analysis also showed that the release rate for the silver compared to copper was significantly 
slower. Silver was released at a rate of approximately 27.11mg per litre per day while copper was being 
released at a rate between 35.47±0.05mg per litre per day and 52.48±0.05mg per litre per day. To put 
that into perspective the release rates extrapolate down to approximately 0.0011mg per ml per hour for 
silver and between 0.0015mg per ml per hour and 0.0022mg per ml per hour for copper. 
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Figure 78:- ICP-MS data for the silver/copper doped samples obtained by different immersion periods in the salt 
bath, A) showing the release of silver from the samples and B) showing the release of copper from the samples. * 
Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
 
5.6 Polymer coated 45S5 Bioglass®- derived glass-ceramic scaffolds 
 
This section presents the results obtained when gelatin was used to coat pre-fabricated BBG 
scaffolds. The “proof of concept” work is shown in section 5.6.1 which is followed by the more 
extensive structural characterisation of these novel composite samples shown in section 5.6.2 with 
PDLLA coated scaffold acting as a control sample.  
 
5.6.1 Preliminary processing of gelatin coated 45S5 Bioglass®- derived glass-ceramic scaffolds 
 
This study involved coating BBG scaffolds with the two types of gelatin at different 
concentrations to determine the best concentration leading to uniform coatings without reducing the 
porosity of the scaffold detrimentally, as described in section 4.2.3II. The concentrations of gelatin used 
for this preliminary study are listed in Table 5. Four scaffold coating immersion periods were 
investigated: one, five, ten and 15 minutes. The porosity of the coated scaffolds was calculated using 
Equation 8, with the density of gelatin being 0.777gcm-3 and 0.812gcm-3 for type A and B, respectively. 
(390) (391)  The porosity results for the coated scaffolds are shown in Table 24 and Table 25 for BBG 
scaffolds coated in type A gelatin and type B gelatin, respectively.  
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Table 24:- Porosity data for gelatin type A coated BBG scaffolds for a range of polymer immersion periods. * 
Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
 Immersion period in the gelatin suspension 
Gelatin  1 minute 5 minutes 10 minutes 15 minutes 
amount Porosity (%) 
% wt before after before after before after before after 
5 94±2  * 93±3  * 88±2  * 87±3  * 95±2  * 93±1  * 92±3  * 90±1  * 
6 90±2  * 87±1  * 90±1  * 87±1  * 92±1  * 88±2  * 83±1  * 79±3  * 
7 93±2  * 87±2  * 92±1  * 84±1  * 88±2  * 81±2  * 91±1  * 85±3  * 
8 93±1  * 85±1  * 92±2  * 82±2  * 89±2  * 77±1  * 84±3  * 76±2  * 
9 89±1  * 77±3  * 93±2  * 78±1  * 93±2  * 70±2  * 93±2  * 70±1  * 
10 94±3  * 79±3  * 90±1  * 70±1  * 88±2  * 66±3  * 90±2  * 70±1  * 
11 95±3  * 84±2  * 93±2  * 79±2  * 79±2  * 69±2  * 92±2  * 76±2  * 
12 96±1  * 87±1  * 92±2  * 78±3  * 96±3  * 87±1  * 91±2  * 71±1  * 
13 90±1  * 71±2  * 93±1  * 74±3  * 91±3  * 72±2  * 90±1  * 65±1  * 
14 88±1  * 80±2  * 88±1  * 70±2  * 90±1  * 70±1  * 92±2  * 71±2  * 
15 90±2  * 75±2  * 86±1  * 69±2  * 86±1  * 69±1  * 87±2  * 72±2  * 
 
Table 25:- Porosity data for gelatin type B coated BBG scaffolds for a range of polymer immersion periods. * 
Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
 Immersion period in gelatin suspension 
Gelatin  1 minute 5 minutes 10 minutes 15 minutes 
amount Porosity (%) 
% wt before after before after before after before after 
5 90±1  * 90±2  * 84±1  * 84±3  * 90±2  * 88±2  * 87±1  * 85±1  * 
6 90±1  * 89±1  * 88±2  * 86±2  * 85±1  * 84±2  * 90±2  * 88±2  * 
7 85±1  * 84±2  * 87±2  * 87±1  * 85±2  * 83±2  * 85±2  * 83±1  * 
8 92±2  * 88±1  * 87±2  * 86±1  * 92±1  * 90±1  * 89±1  * 86±1  * 
9 94±2  * 89±2  * 94±2  * 90±2  * 94±2  * 91±2  * 91±2  * 84±2  * 
10 91±2  * 86±2  * 94±1  * 87±1  * 88±2  * 82±2  * 89±1  * 87±2  * 
 
Table 24 indicates that concentrations of 5wt% and 6wt% of type A gelatin with a scaffold 
immersion period of one minute gave the best trade-off between a desirable scaffold porosity of above 
70% and forming a homogeneous coating on the surface of the scaffold. Table 25 also indicates that 
with an immersion period of one minute concentrations of 5wt% and 6wt% of type B gelatin gave the 
best trade-off between porosity and formation of a homogeneous layer on the surface of the scaffold. 
Porosity above 70% is desirable for bone tissue scaffolds and when, in a later study (section 5.7), 
copper-doped and silver/copper-doped scaffolds are coated in gelatin the overall porosity should still 
be above this threshold. Since it has been seen, in sections 5.4 and 5.5, that the MSIE process reduces 
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the porosity up to 20% compared to the BBG scaffolds porosity (93±2%) it is important that the addition 
of a polymer coat does not further significantly reduce the porosity of the modified scaffold. 
Figure 79 shows SEM images of 5wt% and 6wt% coated scaffolds with a one minute coating 
period for both types of gelatin. Compared to the SEM images for the BBG scaffolds, shown in Figure 
29, it is observed that gelatin formed a smooth homogeneous layer over the surface whilst not blocking 
the pore structure. It should be noted that occasionally the polymer (in this work PDLLA and gelatin) 
will block some of the pores (as seen in Figure 79A)), however it is generally minimal and does not 
affect the overall porosity to a significant level. 
 
 
Figure 79:- BBG scaffolds coated with gelatin with A) a single coating of 5wt% type A gelatin (magnification of 
x50), B) a single coating of 6wt% type A gelatin (magnification of x850), C) a single coating of 5wt% type B 
gelatin (magnification of x550) and D) a single coating of 6wt% type B gelatin (magnification of x2500) with a 
coating immersion time of one minute (arrows indicate the gelatin coating) 
 
Multiple immersions in the gelatin solution to form a multi-layer coat was investigated for the 
two types of gelatin using concentrations of 5wt% and 6wt% with an immersion period of one minute, 
as described in 4.3.II and Figure 21. The measured porosity for these multi-layer gelatin coated 45S5 
Bioglass® -derived scaffolds is shown in Table 26. The results show that introducing multiple layers of 
gelatin reduced the porosity but not by a significant amount with all coated samples remaining above 
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the desirable 70% threshold. (4) It should be noted however, that the double and triple layered samples 
were more difficult to handle and required a longer drying period in order for the coating to be stable 
and ready for characterisation.  
Table 26:- Porosity data for multiple coats of gelatin on BBG scaffolds. * Indicates a significant change between 
the sample types (p≤0.05) using ANOVA analysis. 
Coating Original porosity 1st coat porosity 2nd coat porosity 3rd coat porosity 
type (%) (%) (%) (%) 
5% type A 90±1  * 90±2  * 89±3  * 88±3  * 
6% type A 91±1  * 88±1  * 87±3  * 86±2  * 
5% type B 94±1  * 92±1  * 91±1  * 90±1  * 
6% type B 93±1  * 90±2  * 89±2  * 89±2  * 
 
 SEM images of multiple gelatin layer coated BBG scaffolds for both gelatin types with 
concentrations of 5wt% and 6wt% are shown in Figure 80 and Figure 81, respectively. They both show 
the smooth and homogeneous coatings similar to that observed for the single coated samples, in Figure 
79. In particular, Figure 80B) shows the formation of two separate layers and not the merging into one 
single layer during the coating process. 
 
 
Figure 80:- BBG scaffolds coated with gelatin type A with A) two coats of 5wt% type A gelatin (magnification of 
x350), B) three coats of 5wt% type A gelatin (magnification of x350), C) two coats of 6wt% type A gelatin 
(magnification of x450) and D) three coats of 6wt% type A gelatin (magnification of x450) with a coating 
immersion time of one minute for each coat (arrows indicate the gelatin coating) 
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From this preliminary study it can concluded that the most suitable concentration of gelatin in 
the coating process are 5wt% and 6wt% for both gelatin types with a single immersion cycle for one 
minute. These parameters gave the best trade-off between a desirable porosity and a single 
homogeneous coating layer. A single coat was preferred because of the favourable crack propagation 
observed in the SEM images in Figure 79, Figure 80 and Figure 81. In Figure 79D) fraying at the edges 
of the gelatin coating is observed which indicates that as the crack occurred and the gelatin stretches to 
keep the two sides of the break together which can contribute to the toughness of the scaffold by a crack 
bridging mechanism. (452) (453) (454) This behaviour is not present in the multi-layer scaffolds shown 
in Figure 80 and Figure 81. 
 
 
Figure 81:- BBG scaffolds coated with gelatin type B with A) two coats of 5wt% type B gelatin (magnification of 
x700), B) three coats of 5wt% type B gelatin (magnification of x400), C) two coats of 6wt% type B gelatin 
(magnification of x900) and D) three coats of 6wt% type B gelatin (magnification of x350) with a coating 
immersion time of one minute (arrows indicate the gelatin coating) 
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5.6.2 Structural characterisation of polymer coated 45S5 Bioglass®- derived glass-ceramic 
scaffolds 
 
 As described in the previous section the parameters used for this study are concentrations of 
gelatin (both types) in the coating procedure (5wt% and 6wt%) with an immersion period of one minute. 
In this study the gelatin samples were characterised alongside a 5wt% PDLLA coated BBG scaffold for 
comparison, given that PDLLA coating on similar bioactive scaffolds has already been investigated. 
(110) (352) 
 As shown in the previous section, the porosities of the gelatin coated samples were found to be 
93±3% and 90±2% for 5wt% and 6wt% type A gelatin coated samples, respectively, and 90 ±2% and 
89±1% for 5wt% and 6wt% type B gelatin coated samples, respectively, and 90±3% for the 5wt% 
PDLLA coated scaffolds. (110) (352) These results show that the gelatin coated scaffolds have a similar 
porosity to that obtained when using PDLLA as a coating agent. (110) (352) 
 Figure 82 shows PDLLA coated scaffolds, similarly to the gelatin coated scaffolds (of all 
types), shown in Figure 79, the addition of the polymer coating has reduced the surface roughness 
compared to the uncoated BBG scaffolds, shown in Figure 29, whilst not negatively affecting the pore 
interconnectivity and size. Although Figure 82A) does show that the PDLLA coating can occasionally 
block the pores of the scaffold but this was found not to have a significant detrimental effect on the 
coated scaffolds porosity. 
The XRD spectra of the polymer coated samples, shown in Figure 83, exhibit the characteristic 
peaks for the BBG scaffolds seen in Figure 32, with the exception of the halo between 5o and 17o which 
corresponds to the presence of the gelatin and PDLLA coatings. (110) (352) 
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Figure 82:- BBG scaffolds coated with PDLLA with A) a 5wt% coating (magnification of x50), B) a 5wt% coating 
(magnification of x430), C) a 5wt% coating (magnification of x250) and D) a 5wt% coating (magnification of 
x1000) (arrows indicate the PDLLA coating) 
 
 
Figure 83:- XRD spectra for gelatin and PDLLA coated BBG scaffolds 
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 FTIR analysis was carried out on all four gelatin coated samples and on the PDLLA coated 
sample and results are presented in Figure 84 and Figure 85, respectively. Figure 84 shows the FTIR 
spectra for the 5wt% PDLLA coated scaffolds showing the characteristic peaks of certain groups found 
within PDLLA according to the literature. (455) These include a –OH group at 3502cm-1, a CH3 and –
CH group between 2995cm-1 and 2847cm-1 and a carbonyl group at 1756cm-1, which are consistent with  
literature results. (455) An expanded view of the peaks attributed to PDLLA, from 3750cm-1 to 1500cm-
1, in the spectra shown in Figure 84 can be found in appendix C as some of the peaks are difficult to see 
when observing the full spectrum to include the peaks attributed to the BBG. Between 1200cm-1 and 
455cm-1 the peaks indicative of the BBG scaffold are observed which is consistent with the FTIR spectra 
in Figure 31 and with literature results. (413) (414) (415)  
 
 
Figure 84:- FTIR spectra for PDLLA coated BBG scaffolds before and after immersion in SBF for 14 days with 
A) showing both spectra indicating the peaks corresponding to PDLLA and B) depicting the distinctive peaks 
characteristic of BBG scaffolds 
 
Figure 85 shows the results of the FTIR analysis for the gelatin coated scaffolds. Spectra exhibit 
indicative peaks for the BBG scaffold between 1200cm-1 and 455cm-1 consistent with results shown in 
Figure 31 and with the literature. (413) (414) (415) Peaks that, according to the literature, indicate the 
presence of gelatin are also observed including an amide A group between 3625cm-1 and 2750cm-1, 
water at between 2500cm-1 and 2250cm-1 and amide I, II, III between 1700cm-1 and 1100cm-1. (456) 
(457) An expanded view of the peaks attributed to the gelatin, from 3750cm-1 to 1200cm-1, in the spectra 
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shown in Figure 85 can be found in appendix C as some of the peaks are difficult to see when observing 
the full spectrum to include the peaks attributed to the BBG. 
 
 
Figure 85:- FTIR spectra for gelatin coated BBG scaffolds 
  
 The EDX analysis of the polymer coated samples is shown in Figure 86, characteristic peaks 
that are indicative of the BBG scaffolds are observed, as shown also in Figure 33. 
 
 
Figure 86:- EDX analysis of polymer coated BBG scaffolds including A) Type A 5wt% gelatin coated scaffold, B) 
Type A 6wt% gelatin coated scaffold, C) Type B 5wt% gelatin coated scaffold, D) Type B 6wt% gelatin coated 
scaffold and E) PDLLA coated scaffold. 
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 The compressive strength of the coated scaffolds was measured and results are presented in 
Table 27. The values are significantly higher than those measured for the BBG scaffolds at 
0.53±0.08MPa. This is due to the presence of the polymer coating confirming that gelatin coatings 
improved the mechanical competence of the BBG scaffolds to a higher extent than PDLLA. 
Table 27:- Compressive strength of polymer coated BBG scaffolds. * Indicates a significant change between the 
sample types (p≤0.05) using ANOVA analysis. 
Polymer type Compressive strength  
and wt% (MPa) 
Gelatin type A 5wt% 1.4 ± 0.1  * 
Gelatin type A 6wt% 1.4 ± 0.1  * 
Gelatin type B 5wt% 1.4 ± 0.1  * 
Gelatin type B 6wt% 1.4 ± 0.1  * 
PDLLA 5wt% 0.7 ± 0.1  * 
 
 The white light interferometry analysis of the gelatin and PDLLA coated samples is shown in 
Table 28. These RMS, Ra and PV values are all significantly lower than those recorded for the BBG 
samples at 3±1µm, 2.6±0.9µm and 19±9µm, respectively. This result suggests that the addition of the 
polymer coating reduces the surface roughness which is supported by the SEM images shown in Figure 
79 and Figure 82 .  
Table 28:- White light interferometry results for the surface roughness of polymer coated BBG pellets. * Indicates 
a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Polymer type RMS Ra PV 
and wt% (µm)  (µm)  (µm)  
Gelatin type A 5wt% 0.5±0.1  * 0.4±0.1  * 4±1  *   
Gelatin type A 6wt% 0.5±0.1  * 0.4±0.1  * 4±1  * 
Gelatin type B 5wt% 0.5±0.2  * 0.4±0.1  * 4±1  * 
Gelatin type B 6wt% 0.5±0.1  * 0.4±0.1  * 4±1  * 
PDLLA 5wt% 0.5±0.1  * 0.3±0.1  * 4.0±0.9  * 
 
 The samples bioactivity was assessed by immersing the polymer coated samples in SBF for 14 
days and re-characterising them. The porosity of the SBF immersed gelatin coated scaffolds was 
measured at 72±1% and 71±3% for 5wt% and 6wt% type A gelatin coated samples, respectively and at 
70±2% and 69±1for 5wt% and 6wt% type B gelatin coated samples, respectively. The porosity of the 
PDLLA coated scaffolds was measured to be 71±2%. Compared to the porosity of the BBG scaffold 
after the same period of immersion in SBF (84±2%), these porosities are lower but they are in line with 
the reduction in porosity recorded after immersion in SBF for the BBG scaffolds. Whether this 
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topography has an effect on a cells ability to attach itself to the scaffold and proliferate has not been 
explored in this work but for future studies this needs to be addressed and this will be discussed in detail 
later in this chapter. 
 SEM images of gelatin coated scaffolds after immersion in SBF for 14 days are shown in Figure 
87 and Figure 88. Figure 87 shows the SBF immersed type A (5wt% and 6wt%) gelatin coated BBG 
scaffolds and Figure 88 shows the SBF immersed type B (5wt% and 6wt%) gelatin coated BBG 
scaffolds. As with the BBG scaffolds, shown in Figure 34, after immersion in SBF the presence of the 
characteristic HA knobbles is detected on the surface of the gelatin coated scaffolds which indicates 
that the presence of the gelatin coating does not have a detrimental effect on HA precipitation on the 
surface of the scaffold struts. The presence of the observed HA is observed both on top of the gelatin 
coating and in areas where the coating has degraded. It’s likely that HA formation has started in an area 
of the struts not completely covered by gelatin, especially considering the irregular and rough 
topography of the BBG scaffolds. In the literature, ion diffusion through gelatin has been observed 
which would explain the presence of HA on top of the gelatin coating as ions released from the scaffold 
can diffuse through the gelatin coating and interact with the SBF solution to form HA. (458) (459) (460) 
The time taken for ions to diffuse through the gelatin coating would explain the retarded level of HA 
present on the gelatin coated samples compared to that on the BBG scaffolds (observed in Figure 34). 
Figure 87 and Figure 88 both show the gelatin coatings starting to disintegrate after 14 days 
immersed in SBF and both show HA formation on top of the gelatin coating and in regions where the 
coating has lifted up or has degraded HA knobbles are present.  Figure 89 shows SEM images of the 
PDLLA coated scaffolds after immersion in SBF for 14 days. These images also show the presence of 
the characteristic HA knobbles indicating the samples bioactivity, as seen in the base BBG scaffolds in 
Figure 34. 
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Figure 87:- BBG scaffolds coated with gelatin type A with A) a 5wt% coating (magnification of x750), B) a 5wt% 
coating (magnification of x900), C) a 6wt% coating (magnification of x1900) and D) a 6wt% coating 
(magnification of x900) after immersion in SBF for 14 days (Black arrows indicating the gelatin and white arrows 
indicating the HA) 
 
Figure 88:- BBG scaffolds coated with gelatin type B with A) a 5wt% coating (magnification of x550), B) a 5wt% 
coating (magnification of x100), C) a 6wt% coating (magnification of x600) and D) a 6wt% coating 
(magnification of x450) after immersion in SBF for 14 days (Black arrows indicating the gelatin and white arrows 
indicating the HA) 
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Figure 89:- BBG scaffolds coated with PDLLA with A) a 5wt% coating (magnification of x50) and B) a 5wt% 
coating (magnification of x1700) after immersion in SBF for 14 days (Black arrows indicating the PDLLA and 
white arrows indicating the HA) 
 
 These SEM images for the polymer coated scaffolds (Figure 87, Figure 88 and Figure 89) 
suggest the presence of the characteristic HA knobbles. However, compared to the BBG scaffold after 
the same immersion period in SBF (shown in Figure 34), the quantity of HA as judged by SEM 
observation seems to be less on the polymer coated scaffolds, especially for the PDLLA coated samples. 
It can be hypothesised that the direct contact of the bioactive glass-ceramic surface with SBF, which is 
required to start the HA formation process is being impaired by the presence of the polymer coating, 
especially in the case of the PDLLA samples. Only in areas of incomplete coating or as the polymers 
begin degrade a direct contact between the SBF and the BBG surface occurs leading to HA formation. 
In the case of gelatin ion diffusion through the coating layer should facilitate the formation of HA on 
top of the gelatin coating. 
 XRD analysis of the polymer coated samples after SBF immersion is shown in Figure 90. The 
presence of a halo between 2ϐ 5 and 17 degrees indicates the presence of the gelatin and PDLLA. (110) 
(352) The XRD spectra also show the presence of the peak indicative of the formation of HA, as 
previously shown for the BBG scaffold after SBF immersion (shown in Figure 37). This result indicates 
that the polymer coated scaffolds are bioactive. 
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Figure 90:- XRD spectra for gelatin coated BBG scaffolds and PDLLA coated 45S5 Bioglass® -derived scaffolds 
after immersion in SBF for 14 days. 
 
The FTIR analysis carried out on the gelatin coated samples is shown in Figure 91. The 
indicative gelatin peaks are present, as shown in Figure 85 , including an amide A group between 
3625cm-1 and 2750cm-1, water at between 2500cm-1 and 2250cm-1 and an amide I, II, III between 
1700cm-1 and 1100cm-1. (456) (457) The indicative peaks for the BBG scaffold are present between 
1200cm-1 and 455cm-1 consistent with Figure 36 and the literature. (423) (424) The changes in the 
spectra recorded before and after SBF immersion are consistent with the precipitation of HA on the 
surface of the sample (shown from Figure 31 and Figure 36). Including the decrease in intensity of the 
Si-O-Si bonds at 1100cm-1 and 1037cm-1, (424) (222) the shift and reduction of  the Si-O (the non-
bridging oxygen) bond from 940cm-1- 920cm-1 to 980cm-1 – 940cm-1 (423) (424) (222) and the formation 
of the C-O bond between 880cm-1 and 900cm-1. (425) An expanded view of the peaks attributed to 
gelatin, from 3750cm-1 to 1200cm-1, in the spectra shown in Figure 91 can be found in appendix C as 
some of the peaks are difficult to see when observing the full spectrum to include the peaks attributed 
to the BBG. 
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Figure 91:- FTIR spectra for gelatin coated BBG samples after immersion in SBF for 14days showing A) the full 
spectra and B) the area of the spectra showing the peaks indicative of the BBG 
 
The FTIR spectra for the PDLLA coated samples after immersion in SBF are shown in Figure 
84. The peaks indicative of PDLLA are shown, including a –OH group at 3502cm-1, a CH3 and –CH 
group between 2995cm-1 and 2847cm-1 and a carbonyl group at 1756cm-1 consistent with the literature. 
(455) The FTIR spectra also shows between 1200cm-1 and 455cm-1, the peaks indicative of the BBG 
scaffold after immersion in SBF. (423) (424) (222) (425) The spectra indicate the intensity decrease of 
the Si-O-Si bonds at 1100cm-1 and 1037cm-1, (424) (222) the movement and reduction of  the Si-O (the 
non-bridging oxygen) bond from 940cm-1- 920cm-1 to 980cm-1 – 940cm-1 (423) (424) (222) and the 
formation of the C-O bond between 880cm-1 and 900cm-1. (425) 
The EDX analysis, shown in Figure 92, was carried out to confirm the possible change in the 
elemental composition which would indicate the presence of HA in the sample. This is seen as a change 
in the ratio between calcium and phosphorous peaks to approximately 1.67, as shown also in Figure 35. 
This result confirms that the polymer coating does not have a significant detrimental effect on the 
bioactivity of the BBG scaffold. 
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Figure 92:- EDX analysis of polymer coated BBG scaffolds including A) Type A 5wt% gelatin coated scaffold, B) 
Type A 6wt% gelatin coated scaffold, C) Type B 5wt% gelatin coated scaffold, D) Type B 6wt% gelatin coated 
scaffold and E) PDLLA coated scaffold after immersion in SBF for 14 days 
 
 The compressive strength values of the polymer coated scaffolds after 14 days of immersion in 
SBF are shown in Table 29. A vast improvement on the BBG scaffolds (at 0.43±0.05MPa) is recorded. 
The gelatin coated samples outperformed the PDLLA samples but there was no difference between the 
two types of gelatin or the different concentrations used. 
Table 29:- Compressive strength of polymer coated BBG scaffolds after immersion in SBF for 14 days. * Indicates 
a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Polymer type Compressive strength  
and wt% (MPa) 
Gelatin type A 5wt% 1 ± 0.1  * 
Gelatin type A 6wt% 1 ± 0.1  * 
Gelatin type B 5wt% 1 ± 0.1  * 
Gelatin type B 6wt% 1 ± 0.1  * 
PDLLA 5wt% 0.4 ± 0.1  * 
 
 The white light interferometry results for RMS, Ra and PV after the polymer coated scaffolds 
were immersed in SBF for 14 days are shown in Table 28. These values are lower than those observed 
for the BBG samples after the sample immersion period in SBF, shown in Table 11. This is due to the 
presence of the polymer coating starting to degrade and the precipitation of HA on the samples surface. 
If the modification to the surface topography has an effect on the modified scaffolds ability to encourage 
cell attachment and other desirable cell behaviour is not observed for this type of scaffold but it is 
something that needs to be researched in the future and will be discussed in comparison to the BBG 
scaffolds in the summary of this chapter. 
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Table 30:- White light interferometry results for the surface roughness of polymer coated 45S5 Bioglass® –derived 
glass-ceramic pellets after immersion in SBF for 14 days. * Indicates a significant change between the sample 
types (p≤0.05) using ANOVA analysis. 
Polymer type RMS Ra PV 
and wt%  (µm) (µm)  (µm)  
Gelatin type A 5wt% 5.0±0.1  * 3.2±0.1  * 16±4  * 
Gelatin type A 6wt% 5.5±0.2  * 4.0±0.1  * 16±4  * 
Gelatin type B 5wt% 4.7±0.1  * 3.6±0.1  * 17±6  * 
Gelatin type B 6wt% 5.1±0.1  * 4.0±0.1  * 17±6  * 
PDLLA 5wt% 6.0±0.2  * 4.9±0.2  * 20±5  * 
 
The wettability values for the polymer coated samples before and after immersion in SBF is 
shown in Figure 93. Significantly the 5wt% samples of both types of gelatin exhibited lower contact 
angles compared to those observed for the 6wt% gelatin coated samples and the PDLLA coated samples 
and are outside the ideal contact angle range of 48 to 65 degrees. (419) The values were similar to those 
observed for the uncoated scaffolds of 28±4 degrees and 23±2 degrees, before and after SBF immersion, 
respectively. However the 6wt% gelatin coated samples and the PDLLA coated samples both fall within 
in the ideal contact angle range pre and post SBF immersion. As with the white light interferometry 
data for this work, whether the changes in topography and contact angle will have an effect on the 
scaffolds ability to interact with cells in a positive manner has not been determined for these scaffolds 
but it is something that needs to be addressed and will be discussed at the end of the chapter. 
 
 
Figure 93:- Wettability data for the gelatin coated BBG samples showing spectra from before and after immersion 
in SBF for 14 days (Data shown are mean values and standard deviation of at least 3 measurements). * Indicates 
a significant change between the sample types (p≤0.05) using ANOVA analysis. 
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5.7 Polymer coated molten salt ion exchanged 45S5 Bioglass®- derived glass-
ceramic scaffolds 
 
This section presents the results obtained when the MSIE technique was used to produce 
copper-doped and silver/copper-doped BBG scaffolds, which were then coated in gelatin. The copper-
doped and gelatin coated BBG scaffold results are presented in section 5.71 and the results for the 
silver/copper-doped gelatin coated BBG scaffolds are shown in section 5.7.2. 
 
5.7.1 Structural characterisation of polymer coated copper molten salt ion exchanged scaffolds 
 
 This study investigated copper-doped scaffolds, as described in section 4.2.2.II and depicted in 
Figure 19, which were then coated in gelatin. The lowest concentration of copper in the molten salt bath 
was used with an immersion period of 15 minutes. The MSIE scaffolds were then coated in one of the 
four variations of gelatin coating from 5wt% type A, 6wt% type A, 5wt% type B and 6wt% type B. 
 The porosity values of the gelatin coated copper-doped scaffolds were 70±7%, 70±7%, 69±7% 
and 68±7% for 5wt% type A, 6wt% type A, 5wt% type B and 6wt% type B, respectively. These are 
lower than porosities observed for the copper-doped scaffolds (72±6%) and the gelatin coated scaffolds 
(93±3% and 90±2% for 5wt% and 6wt% type A gelatin coated samples, respectively, and 90 ±2% and 
89±1% for 5wt% and 6wt% type B gelatin coated samples, respectively). This reduction of the porosity 
compared to the BBG scaffolds porosity (93±2%) is mainly due to the MSIE process rather than the 
polymer coating. These recorded porosities are still above the ideal porosity threshold of 70%, described 
in the literature review. (210) 
 SEM images of the four samples types, shown in Figure 94, indicate that the surface of the 
scaffold has the peaks and troughs typical of BBG scaffolds and copper-doped scaffolds, shown in 
Figure 29 and Figure 55, respectively, but the surface exhibits the overall smoothness and homogenous 
structure of the gelatin coated scaffolds, shown previously in Figure 80 and Figure 81. The pore size 
and dimensions as well as the pore interconnectivity that are desirable for scaffolds for BTE are 
maintained. 
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Figure 94:- 45S5 Bioglass® –derived glass-ceramic scaffolds doped with copper and then coated with gelatin with 
A) a 5wt% coating of type A gelatin (magnification of x550), B) a 6wt% coating of type A gelatin (magnification 
of x250), C) a 5wt% coating of type B gelatin (magnification of x700) and D) a 6wt% coating of type B gelatin 
(magnification of x900) (arrows indicate the gelatin coating) 
 
The XRD analysis of the copper-doped gelatin coated scaffolds is shown in Figure 95. The 
characteristic peaks observed for the BBG scaffolds (shown in Figure 32) are observed. (4) (5) (389) 
(416) The characteristic peaks that were observed in the copper-doped scaffolds (shown in Figure 56) 
(441) (442) (443) and the peak between 5 and 17 degrees indicating the presence of the amorphous 
gelatin coating are also present. (110) (352) As stated in section 5.4 the presence of copper can not be 
easily attributed to a unique crystalline phase due to the fact that in some samples not all the phases 
where present or overlapping peaks occurred. 
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Figure 95:- XRD analysis of gelatin coated copper-doped 45S5 Bioglass® -derived scaffolds 
 
The results of the FTIR analysis of the copper-doped gelatin coated samples is presented in 
Figure 96 showing the indicative peaks for copper-doped BBG scaffolds, as seen in Figure 57 between 
1400cm-1 and 455cm-1. The NO-3 bond at 1387cm-1 indicates the presence of a nitrate, a shifted Si-O 
bond at 950-1000cm-1, (444) (445) a pair of P-O bending bonds at 720 – 650cm-1 and 625 – 580cm-1, 
the second shifted Si-O peak was detected at 670-680cm-1 (444) (445) (446) and the pair of Si-O-Si 
bending bonds at 528 – 536cm-1 and 455 – 457cm-1. Figure 96 also shows the peaks indicative of the 
presence of gelatin, as seen in Figure 85, with an amide A group between 3625cm-1 and 2750cm-1, water 
at between 2500cm-1 and 2250cm-1 and an amide I, II, III between 1700cm-1 and 1100cm-1. (456) (457) 
An expanded view of the peaks attributed to the gelatin, from 3750cm-1 to 1200cm-1, in the spectra 
shown in Figure 96 can be found in appendix C as some of the peaks are difficult to see when observing 
the full spectrum to include the peaks attributed to the BBG. 
Figure 97 shows the EDX analysis for the copper-doped gelatin coated samples. The presence 
of copper peak at 0.5keV and 8keV is confirmed which is consistent with the copper-doped only 
samples shown in Figure 58 and the literature. (447) The spectrum also shows peaks indicative of the 
elements that make up the BBG scaffold as seen in Figure 33. 
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Figure 96:- FTIR analysis of gelatin coated copper doped BBG scaffolds showing A) the full spectrum and B) the 
part of the spectrum exhibiting the peaks indicative of the copper-doped scaffold 
 
 
Figure 97:- EDX analysis of polymer coated copper-doped BBG scaffolds including A) Type A 5wt% gelatin 
coated scaffold, B) Type A 6wt% gelatin coated scaffold, C) Type B 5wt% gelatin coated scaffold and D) Type B 
6wt% gelatin coated scaffold  
 
 The compressive strength of the copper-doped gelatin coated scaffolds is shown in Table 31. 
The values indicate an increase in the compressive strength of the samples compared to the value 
(0.53±0.08MPa) of the BBG scaffolds. (113) (4) These values are higher than those of the copper-doped 
scaffolds, shown in Table 16, and the values measured for the gelatin coated scaffolds shown in Table 
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27. This result indicates that the increased compressive strength observed from the copper-doped gelatin 
coated scaffolds compared to the BBG scaffolds is mainly due to the introduction of the polymer coating 
but a fraction of it is likely the result of the MSIE process. 
Table 31:- Compressive strength of copper doped gelatin coated BBG scaffolds. * Indicates a significant change 
between the sample types (p≤0.05) using ANOVA analysis. 
Polymer type Compressive strength  
and wt%  (MPa) 
Gelatin type A 5wt% 1.5 ± 0.1  * 
Gelatin type A 6wt% 1.5 ± 0.1  * 
Gelatin type B 5wt% 1.5 ± 0.1  * 
Gelatin type B 6wt% 1.5 ± 0.1  * 
 
 The white light interferometry analysis for the copper-doped gelatin coated scaffolds is shown 
in Table 32. The RMS, Ra and PV values are all significantly lower than those recorded for the BBG 
samples at 3±1µm, 2.6±0.9µm and 19±9µm, respectively, and for the copper-doped samples at 5±1µm, 
3.8±0.9µm and 26±5µm, respectively. However these values are in line with those observed for the 
gelatin coated scaffolds shown in Table 28, indicating that the topography of the scaffold was altered 
by the addition of the polymer coating, as expected. How this change to the topography affects the 
scaffolds interaction with cells has not been investigated in this work, however it has been discussed in 
relation to the other types of modified scaffolds later in this chapter. 
Table 32:- White light interferometry results for the surface roughness of gelatin coated copper doped BBG 
pellets. * Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Polymer type RMS Ra PV 
and wt% (µm) (µm) (µm) 
Gelatin type A 5wt% 0.5±0.1  * 0.4±0.1  * 4±1  * 
Gelatin type A 6wt% 0.5±0.1  * 0.4±0.1  * 4±1  * 
Gelatin type B 5wt% 0.5±0.1  * 0.4±0.1  * 4±1  * 
Gelatin type B 6wt% 0.5±0.1  * 0.4±0.1  * 4±1  * 
 
 The copper-doped gelatin coated scaffolds bioactivity was determined through characterisation 
of the samples after immersion in SBF for 14 days. The porosities of the copper-doped gelatin coated 
scaffolds were measured as 65±7%, 66±7%, 66±6% and 66±7% for type A 5wt%, type A 6wt%, type 
B 5wt% and type B 6wt% gelatin coated copper-doped scaffolds. The porosity of the samples was 
observed to fall in line with the decrease in porosity measured for the BBG scaffolds (approximately 
10%). 
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 SEM images of copper-doped gelatin coated scaffolds are shown in Figure 98. There is limited 
indication of the presence of the gelatin coating (observed in Figure 94) but the presence of the 
characteristic HA knobbles is confirmed, which is consistent with the SEM images in Figure 34 and in 
the literature, (4) (5) indicating that the presence of the copper or gelatin coating does not have a 
detrimental effect on the samples bioactivity, as seen in section 5.4 and 5.6 for copper-doped scaffolds 
and gelatin coated scaffolds, respectively. SEM images show an increase in the surface roughness of 
the struts which can be attributed to the presence of HA crystals precipitated onto the samples surface. 
 
 
Figure 98:- BBG scaffolds doped with copper and then coated with gelatin with A) 5wt% coating of type A gelatin 
(magnification of x300), B) 6wt% coating of type A gelatin (magnification of x500), C) 5wt% coating of type B 
gelatin (magnification of x170) and D) 6wt% coating of type B gelatin (magnification of x250) after immersion in 
SBF for 14days (Black arrows indicating the gelatin and white arrows indicating the HA) 
 
The XRD analysis of the copper-doped gelatin coated scaffolds is shown in Figure 99. The 
spectra exhibits the characteristic peaks observed for the BBG scaffold that has undergone SBF 
immersion, shown in Figure 37. (5) (4) (426) The spectra also show the reduced characteristic peaks that 
were observed for copper containing phases in the copper-doped scaffolds (shown in Figure 61) (441) 
(442) (443) and the peak between 5 and 17 degrees indicating the presence of the amorphous gelatin 
coating (shown in Figure 90). (110) (352) As stated in section 5.4 the presence of copper can not be 
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easily attributed to a unique phase due to the fact that in some samples not all the phases were present 
or peak overlapping occurred.  
 
 
Figure 99:- XRD analysis of gelatin coated and copper-doped BBG scaffolds after immersion in SBF for 14 days 
 
The FTIR analysis of the gelatin coated copper-doped scaffolds after immersion in SBF for 14 
days is shown in Figure 100. The spectra shows all the characteristic gelatin peaks, as seen also in 
Figure 85, including an amide A group between 3625cm-1 and 2750cm-1, water at between 2500cm-1 
and 2250cm-1 and an amide I, II, III between 1700cm-1 and 1100cm-1. (456) (457) The indicative peaks 
of a copper-doped scaffold are also present between 1400cm-1 and 455cm-1, as seen in Figure 57. An 
expanded view of the peaks attributed to the gelatin, from 3750cm-1 to 1200cm-1, in the spectra shown 
in Figure 100 can be found in appendix C as some of the peaks are difficult to see when observing the 
full spectrum to include the peaks attributed to the BBG.  
The peaks characterising the bioactivity in BBG scaffolds are present in the form of the C-O 
bond between 880cm-1 and 900cm-1, (425) the P-O bond at 875cm-1 to 825cm-1 increasing in size (423) 
(424) (222) and the dual P-O bond at 760cm-1 to 650cm-1 merging. (424) The peaks associated with a 
copper-doped sample after SBF immersion include a reduced NO-3 bond at 1387cm-1, a reduced shifted 
Si-O bond at 950-1000cm-1 (444) (445) (446) and the second shifted Si-O peak detected at 670-680cm-
1 which has been reduced to such an extent that it is almost undetectable indicating that this bond breaks 
first when the copper diffuses out of the crystal structure during immersion in SBF. 
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Figure 100:- FTIR analysis of gelatin coated copper doped BBG scaffolds after immersion in SBF for 14 days 
showing A) the full spectrum and B) the part of the spectrum that presents the peaks indicative of the doped 
scaffold 
 
 The EDX analysis for the copper-doped gelatin coated samples is shown in Figure 101. The 
change in the composition is observed, which is indicative of HA precipitation with the ratio between 
the phosphorous and calcium changing to approximately 1.67 (as seen in Figure 35). The presence of 
copper is also detected at 0.5keV and 8keV, which is consistent with the results shown in section 5.4 
and in the literature. (447) This result supports the premise that the addition of copper and coating in 
gelatin do not have a detrimental effect on the bioactivity of the sample. 
 
 
Figure 101:- EDX analysis of polymer coated copper-doped BBG scaffolds including A) Type A 5wt% gelatin 
coated scaffold, B) Type A 6wt% gelatin coated scaffold, C) Type B 5wt% gelatin coated scaffold and D) Type B 
6wt% gelatin coated scaffold after immersion in SBF for 14 days 
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The compressive strength of the copper-doped gelatin coated scaffold decreased upon 
immersion in SBF for 14 days, as shown in Table 33. This result is similar to the previous results and 
to data in the literature which confirmed that combination of gelatin coating degradation, ion release 
and HA precipitation has a detrimental effect on the mechanical competence of the scaffold. (352) (418)  
The compressive strength values are higher than the corresponding value (0.43±0.05MPa) of the BBG 
scaffold, indicating that copper release and degradation of the gelatin coating which have occurred after 
14 days in SBF still have a positive effect on the compressive strength of the scaffold. 
Table 33:- Compressive strength of gelatin coated copper doped BBG scaffolds after immersion in SBF for 14 
days. * Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Polymer type Compressive strength  
and wt%  (MPa) 
Gelatin type A 5wt% 1 ± 0.1  * 
Gelatin type A 6wt% 1 ± 0.1  * 
Gelatin type B 5wt% 1 ± 0.1  * 
Gelatin type B 6wt% 1 ± 0.1  * 
 
 The white light interferometry results for RMS, Ra and PV after the copper-doped gelatin 
coated samples were immersed in SBF for 14 days are shown in Table 34. These values are lower than 
those observed for the BBG samples after the same immersion period in SBF, shown in Table 11. This 
result is likely due to the presence of the polymer coating which has started to degrade and is also 
affected by the precipitation of HA on the samples surface. How this compares to the other modified 
scaffolds in terms of how it would be perform in cell culture tests because of the change in surface 
roughness has been discussed later in this chapter. 
Table 34:- White light interferometry results for the surface roughness of gelatin coated copper doped BBG pellets 
after immersion in SBF for 14 days. * Indicates a significant change between the sample types (p≤0.05) using 
ANOVA analysis. 
Polymer type RMS Ra PV 
and wt% (µm)  (µm)  (µm)  
Gelatin type A 5wt% 5.1±0.1  * 4.1±0.2  * 16±6  * 
Gelatin type A 6wt% 5.1±0.2  * 4.1±0.1  * 16±6  * 
Gelatin type B 5wt% 5.0±0.1  * 4.0±0.1  * 16±4  * 
Gelatin type B 6wt% 5.0±0.1  * 4.1±0.2  * 16±5  * 
 
The wettability results are shown in Figure 102 indicating that the measured contact angles 
were all substantially higher than those recorded for the BBG samples of 28±4o and 23±2o, before and 
after SBF immersion, respectively. In fact these wettability values were higher than those of the separate 
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copper-doped samples and the gelatin coated BBG scaffolds, indicating that the combination of the 
MSIE with polymer coating increases the contact angle measured. The contact angles for the copper-
doped gelatin coated scaffolds were all high enough to fall within the limit of the ideal range of contact 
angles indicated to be suitable for cell attachment of between 48o and 65o. (419) There is little difference 
between the contact angles measured for the two types of gelatin coating or the two concentrations of 
gelatin used. A measure of how this change in contact angle between the different sample types and 
compared the BBG scaffold had not been determined in this work but it has been touched upon in the 
summary of this chapter. 
 
 
Figure 102:- Wettability data for the gelatin coated copper doped BBG scaffolds before and after immersion in 
SBF for 14 days (Data shown are mean values and standard deviation of at least 3 measurements). * Indicates a 
significant change between the sample types (p≤0.05) using ANOVA analysis. 
 
5.7.2 Structural characterisation of polymer coated combination molten salt ion exchange 
scaffolds 
 
 This study investigated silver/copper-doped scaffolds, as described in section 4.2.2.III and 
depicted in Figure 19, which were then coated in gelatin. The shortest immersion period of 15 minutes 
in the molten salt bath containing both silver and copper was used. The MSIE scaffolds were then coated 
in one of the four variation of gelatin coating from 5wt% type A, 6wt% type A, 5wt% type B and 6wt% 
type B. 
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 The porosity of the gelatin coated silver/copper-doped scaffolds was 71±7%, 70±7%, 68±7% 
and 68±7% for 5wt% type A, 6wt% type A, 5wt% type B and 6wt% type B, respectively. These values 
are lower than porosities observed for the silver/copper-doped scaffolds (72±7%) and the gelatin coated 
scaffolds (93±3% and 90±2% for 5wt% and 6wt% type A gelatin coated samples, respectively, and 90 
±2% and 89±1% for 5wt% and 6wt% type B gelatin coated samples, respectively). This reduction of 
the porosity compared to the BBG scaffolds porosity (93±2%) is mainly due to the MSIE process rather 
than for the polymer coating itself. These recorded porosities are still above the ideal porosity threshold 
of 70% as discussed in the literature review. (210) 
 SEM images of the four samples types, as shown in Figure 103, reveal that the surface of the 
scaffold has the peaks and troughs typical of these type of scaffolds shown in Figure 29 and Figure 67, 
respectively. However the scaffolds exhibit also the overall smoothness and homogenous structure of 
the gelatin coated scaffolds shown also in Figure 80 and Figure 81. The scaffolds also maintain the pore 
size, dimensions and pore interconnectivity that is desirable for scaffolds for BTE, as judged by 
observation of the SEM micrographs. 
 
 
Figure 103:- BBG scaffolds doped with copper and silver and then coated with gelatin with A) a 5wt% coating of 
type A gelatin (magnification of x750), B) a 6wt% coating of type A gelatin (magnification of x900), C) a 5wt% 
coating of type B gelatin (magnification of x700) and D) a 6wt% coating of type B gelatin (magnification of x250) 
(arrows indicating the gelatin coating) 
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The XRD analysis of the silver/copper-doped gelatin coated scaffolds is shown in Figure 104. 
The characteristic peaks of the BBG scaffolds (shown in Figure 32) are present. (4) (5) (389) (416) The 
spectra show also the characteristic peaks that were observed for copper and silver in the silver/copper-
doped scaffolds shown previously (Figure 68) (441) (442) (443) and the halo between 2ϐ 5 and 17 
degrees indicating the presence of the amorphous gelatin coating, shown previously in Figure 83. (110) 
(352) As stated in section 5.4 the presence of copper can not be univocally attributed to a single 
crystalline phase due to the fact that in some samples not all the phases were present or overlapping of 
peaks occurred. 
   
 
Figure 104:- XRD analysis of gelatin coated silver/copper-doped BBG scaffolds 
 
The FTIR analysis of the silver/copper-doped gelatin coated samples is shown in Figure 105 
showing the indicative peaks for silver/copper-doped BBG scaffolds, as seen in Figure 69 between 
1400cm-1 and 455cm-1. The following bonds are identified:- NO-3 bond at 1387cm-1 indicates the 
presence of a nitrate, a single shifted Si-O bond at 950-1000cm-1, (444) (445) a pair of P-O bending 
bonds at 720 – 650cm-1 and 625 – 580cm-1, the second shifted Si-O peak was detected at 670-680cm-1 
(428) (429) (430) (444) (445) (446) and the pair of Si-O-Si bending bonds at 528 – 536cm-1 and 455 – 
457cm-1. Figure 105 also shows the peaks indicative of the presence of gelatin, as seen in Figure 85, 
with an amide A group between 3625cm-1 and 2750cm-1, water at between 2500cm-1 and 2250cm-1 and 
an amide I, II, III between 1700cm-1 and 1100cm-1. (456) (457) An expanded view of the peaks 
attributed to the gelatin, from 3750cm-1 to 1200cm-1, in the spectra shown in Figure 105 can be found 
in appendix C as some of the peaks are difficult to see when observing the full spectrum to include the 
peaks attributed to the BBG. 
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Figure 105:- FTIR analysis of gelatin coated silver/copper doped BBG scaffolds showing A) the full spectrum and 
B) the part of the spectrum which shows the typical peaks indicative of the doped scaffold 
 
Figure 106 shows the EDX analysis for the silver/copper-doped gelatin coated samples 
indicating the presence of silver at approximately 3keV and copper at 0.5keV and 8keV which is 
consistent with Figure 70 and the literature. (447) (113) The results also show the other peaks that are 
indicative of the elements that make up the BBG scaffold as expected and as seen in Figure 33. 
 
Figure 106:- EDX analysis of polymer coated silver/copper-doped BBG scaffolds including A) Type A 5wt% 
gelatin coated scaffold, B) Type A 6wt% gelatin coated scaffold, C) Type B 5wt% gelatin coated scaffold and D) 
Type B 6wt% gelatin coated scaffold 
 
The compressive strength of the silver/copper-doped gelatin coated scaffolds is shown in Table 
35. An increase in the compressive strength of the samples compared to the value (0.53±0.08MPa) of 
the BBG scaffolds was measured. (113) (4) These values are higher than those of the silver/copper-
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doped scaffolds, shown in Table 20, and the values measured for the gelatin coated scaffolds shown in 
Table 27. The result indicates that the increased compressive strength observed from the silver/copper-
doped gelatin coated scaffolds compared to the BBG scaffolds is likely due to the introduction of the 
polymer coating but a fraction of it is contributed by the MSIE process as was seen with the copper-
doped gelatin coated scaffolds shown in Table 31. 
Table 35: Compressive strength of silver/copper-doped polymer coated BBG scaffolds. * Indicates a significant 
change between the sample types (p≤0.05) using ANOVA analysis. 
Polymer type Compressive strength  
and wt%  (MPa) 
Gelatin type A 5wt% 1.54 ± 0.08  * 
Gelatin type A 6wt% 1.57 ± 0.04  * 
Gelatin type B 5wt% 1.55 ± 0.06  * 
Gelatin type B 6wt% 1.54 ± 0.06  * 
 
The white light interferometry analysis is shown in Table 36 for the silver/copper-doped gelatin 
coated scaffolds. RMS, Ra and PV values are all significantly lower than those recorded for the BBG 
samples at 3±1µm, 2.6±0.9µm and 19±9µm respectively and slightly lower than those of the 
silver/copper-doped samples at 0.9±0.2µm, 0.7±0.1µm and 8±4µm respectively. However these values 
are in line with those observed for the gelatin coated scaffolds shown in Table 28, indicating that the 
topography of the scaffold was altered by the addition of the polymer coating. How this compares to 
the other modified scaffolds in terms of its performance when seeded with cells has not been 
investigated in this work, however it has been discussed later in this chapter. 
Table 36:- White light interferometry results for the surface roughness of gelatin coated, silver/copper-doped 
BBG pellets. * Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Polymer type RMS Ra PV 
and wt%  (µm) (µm)  (µm)  
Gelatin type A 5wt% 0.5±0.1  * 0.4±0.2 * 4±1  * 
Gelatin type A 6wt% 0.4±0.2  * 0.3±0.1  * 5±1  * 
Gelatin type B 5wt% 0.4±0.3  * 0.3±0.3  * 3±2  * 
Gelatin type B 6wt% 0.5±0.1  * 0.3±0.1  * 4±1  * 
 
The bioactivity of the silver/copper-doped gelatin coated scaffolds was assessed through re-
characterisation of the samples after immersion in SBF for 14 days. The porosities of the silver/copper-
doped gelatin coated scaffolds were measured as 65±7%, 66±7%, 65±7% and 64±7% for type A 5wt%, 
type A 6wt%, type B 5wt% and type B 6wt% gelatin coated silver/copper-doped scaffolds. The porosity 
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of the samples was observed to fall in line with the decrease in porosity measured for the BBG scaffolds 
(approximately 10%). 
 SEM images of  silver/copper-doped gelatin coated scaffolds are shown in Figure 107 
confirming the presence of the gelatin coating (observed in Figure 103) and also showing the presence 
of the characteristic HA knobbles consistent with the SEM images in Figure 34 and the literature, (4) 
(5) indicating that the presence of the silver, copper or gelatin does not have a significant detrimental 
effect on the samples bioactivity (as seen in section 5.5 and 5.6 for silver/copper-doped scaffolds and 
gelatin coated scaffolds, respectively). The SEM images indicate an increase in the roughness of the 
surface topography which can be attributed to the presence of the HA precipitated onto the samples 
surface. SEM images also show that the gelatin is present but has partially degraded exposing the 
surface of the silver/copper-doped scaffold. 
 
 
Figure 107:- BBG scaffolds doped with copper and silver and then coated with gelatin with A) a 5wt% coating of 
type A gelatin (magnification of x150), B) a 6wt% coating of type A gelatin (magnification of x2000), C) a 5wt% 
coating of type B gelatin (magnification of x160) and D) a 6wt% coating of type B gelatin (magnification of x600) 
after immersion in SBF for 14days 
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The XRD analysis, shown in Figure 108, indicates the characteristic peaks of a 45S5 Bioglass® 
-derived scaffold that has undergone SBF immersion, as seen in Figure 37, with the presence of key 
HA peaks consistent with results in the literature. (5) (4) (426) The indicative peaks of both silver and 
copper, shown in Figure 104, are also present indicating that silver and copper remain in the sample. 
(113) (441) (442) (443) The presence of a halo between 2ϐ 5 and 17 degrees which indicates that there 
is an amorphous phase in the sample caused in this case by the presence of the gelatin, as shown in 
Figure 90. (110) (352) As stated in section 5.4 the presence of copper can not be confidently attributed 
to a unique phase due to the fact that in some samples not all the phases where present or overlapping 
of peaks occurred. Therefore it can be stated the presence of silver, copper and the gelatin coating has 
not had a significant detrimental effect on the bioactivity of the sample under the conditions 
investigated. 
 
 
Figure 108:- XRD analysis of gelatin coated silver/copper-doped BBG scaffolds after immersion in SBF for 14 
days 
 
Figure 109 shows the FTIR analysis of silver/copper-doped gelatin coated scaffolds after 
immersion SBF for 14 days. The spectra show the indicative gelatin peaks, as shown in Figure 85, with 
an amide A group between 3625cm-1 and 2750cm-1, water between 2500cm-1 and 2250cm-1 and an 
amide I, II, III between 1700cm-1 and 1100cm-1. (456) (457) An expanded view of the peaks attributed 
to the gelatin, from 3750cm-1 to 1200cm-1, in the spectra shown in Figure 109 can be found in appendix 
C as some of the peaks are difficult to see when observing the full spectrum to include the peaks 
attributed to the BBG. 
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Figure 109:- FTIR analysis of gelatin coated silver/copper doped BBG scaffolds after 14 days immersed in SBF 
with A) showing the full spectrum and B) showing the part of the spectrum which shows the peaks indicative of 
the doped scaffold  
 
The indicative peaks of a silver/copper-doped scaffold are also present between 1400cm-1 and 
455cm-1, as seen Figure 69, the spectra also exhibits the typical changes that indicate that the sample 
has been immersed in SBF, as seen in Figure 74. The peaks indicative of bioactivity in BBG scaffolds 
are present in the form of the C-O bond between 880cm-1 and 900cm-1, (425) the P-O bond at 875cm-1 
to 825cm-1 increasing in size (423) (424) (222)  and the dual P-O bond at 760cm-1 to 650cm-1 merging. 
(424) The peaks associated with a silver/copper-doped sample after SBF immersion include a reduced 
NO-3 bond at 1387cm-1, a shifted reduced Si-O bond between 950-1000cm-1 (428) (429) (430) (444) 
(445) (446) and the second shifted Si-O peak detected at 670-680cm-1 which has been reduced to such 
an extent that it is almost undetectable. This suggests that this bond breaks first when silver and/or 
copper diffuse out of the silicate structure when immersed in SBF. 
The EDX analysis for the silver/copper-doped gelatin coated samples is shown in Figure 110. 
The elemental change in the composition is observed which is indicative of HA precipitation with the 
ratio between phosphorous and calcium changing to approximately 1.67, as seen in Figure 35. The 
presence of copper is also detected at 0.5keV and 8keV and the presence of silver at ~3keV which is 
consistent with the results shown in section 5.4, section 5.3 and the literature (447) This result supports 
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the premise that the addition of silver and copper and the coating of the scaffold with gelatin do not 
have a detrimental effect on the bioactivity of the sample. 
 
 
Figure 110:- EDX analysis of polymer coated silver/copper-doped BBG scaffolds including A) Type A 5wt% 
gelatin coated scaffold, B) Type A 6wt% gelatin coated scaffold, C) Type B 5wt% gelatin coated scaffold and D) 
Type B 6wt% gelatin coated scaffold after immersion in SBF for 14 days 
 
The compressive strength of the silver/copper-doped gelatin coated scaffold has decreased upon 
immersion in SBF for 14 days, as shown in Table 37. This result is in agreement with the previous 
results and the literature as the combination of the degradation of the gelatin coating, the ion release 
and HA precipitation has a detrimental effect on the mechanical competence of the scaffold. (352) (418)  
The compressive strength values are still higher than the corresponding value (0.43±0.05MPa) for the 
BBG scaffold after immersion in SBF for 14 days, indicating that although some of the copper and 
silver has diffused out of the structure and the (partial) degradation of the gelatin coating has occurred 
they are still having a positive effect on the mechanical competence of the scaffold. These 
compressional values are similar to those observed for the SBF immersed copper-doped gelatin coated 
scaffolds in Table 33. 
Table 37:- Compressive strength of silver/copper-doped polymer coated BBG scaffolds after immersion in SBF 
for 14 days. * Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
Polymer type Compressive strength  
and wt%  (MPa) 
Gelatin type A 5wt% 1.01 ± 0.04  * 
Gelatin type A 6wt% 1.00 ± 0.05  * 
Gelatin type B 5wt% 1.02 ± 0.03  * 
Gelatin type B 6wt% 1.00 ± 0.07  * 
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The white light interferometry results for RMS, Ra and PV after the silver/copper-doped gelatin 
coated scaffolds were immersed in SBF for 14 days are shown in Table 38. These values are lower than 
those observed for the BBG samples after the sample immersion period in SBF, shown in Table 11. 
This result is likely due to the presence of the polymer coating, which has started to degrade, and due 
to the precipitation of HA on the samples surface. Whether the change in topography has an effect on 
the scaffolds ability to positively interact with cells has not been explored in this work for this scaffold 
type but the change in relation to the other scaffolds produced in this work has been discussed at the 
end of the chapter. 
Table 38:- White light interferometry results for the surface roughness of gelatin coated, silver/copper-doped 
BBG pellets after immersion in SBF for 14 days. * Indicates a significant change between the sample types 
(p≤0.05) using ANOVA analysis. 
Polymer type RMS Ra PV 
and wt% (µm) (µm) (µm) 
Gelatin type A 5wt% 5.2±0.1  * 4.1±0.2  * 16±2  * 
Gelatin type A 6wt% 5.0±0.2  * 4.4±0.1  * 17±1  * 
Gelatin type B 5wt% 5.2±0.3  * 4.2±0.3  * 15±2  * 
Gelatin type B 6wt% 5.1±0.1  * 4.2±0.1  * 16±1  * 
 
Wettability results are summarised in Figure 111, showing that the contact angles obtained were 
all substantially higher than those recorded for the BBG samples of 28±4o and 23±2o, before and after 
SBF immersion, respectively. In fact these wettability values were higher than those for the separate 
silver/copper-doped samples and the gelatin coated base scaffolds, indicating that the combination of 
MSIE with polymer coating increases the contact angle measured. The contact angles for the 
silver/copper-doped gelatin coated scaffolds were higher than the upper limit of the ideal range of 
contact angles suitable for cell attachment of between 48 and 65o. (419) There is little difference 
between the contact angles measured for the two gelatin types but the 6wt% samples were observed to 
increase the contact angle more that the 5wt% samples. As with the white light interferometry work for 
this type of scaffold, it can not be ascertained how the change in topography will affect the cells ability 
to interact with this type of scaffold, as discussed below. 
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Figure 111:- Wettability data for the gelatin coated silver/copper-doped BBG scaffolds showing spectra from 
before and after immersion in SBF for 14 days (Data shown are mean values and standard deviation of at least 3 
measurements). * Indicates a significant change between the sample types (p≤0.05) using ANOVA analysis. 
 
5.8 Summary of results from the structural characterisation 
 
 Overall this chapter investigated the structural properties of the BBG scaffolds along with 
scaffolds modified by MSIE and polymer coating. The BBG scaffolds were first characterised to ensure 
that the scaffolds fabricated in this work were consistent with the literature and to provide a control 
sample for the modified samples. The results obtained for the base scaffolds were consistent with the 
results obtained in the literature including the porosity of 93±2%, (4) (410) (241) compressive strength 
of 0.53±0.08MPa (4) (352) (418) and the EDX, (5) (394) (417) (420) (421) (422) XRD (4)(5) (389) 
(416) (426) (427) and FTIR spectra, (413) (414) (415) (423) (424) (222) (425) as well as contact angle 
results, (222) (223) (419) white light interferometry data (222) (223) (225) (224)  and SEM 
observations, (4) (5) (222) (223) (410) (411) all matching previous results. The presence of the 
bioactivity indicator, HA formed on the scaffold surfaces upon immersion in SBF for 14 days, was also 
confirmed. 
 The MSIE process used to introduce silver and copper into the structure of the BBG scaffold 
was found to be successful based on the results presented in this chapter. This was demonstrated by the 
EDX, XRD and FTIR results all showing changes in the structure that are a direct result of the 
introduction of silver or copper or both ions. (6) (113) (428) (429) (444) (445) (447) It should be noted, 
however, that it can not be 100% proved with the techniques used in this work that all of the detected 
silver and/or copper was incorporated in the structure of the scaffold. It is possible that some salt residue 
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remaining from the MSIE process not removed by the washing protocol could contribute to the 
measured ions. Another possibility is that salt residue could have infiltrated the micro-cracks present 
on the scaffold surface. Further work is required to prove the exact concentration of the desired ions 
which has entered the silicate network. These characterisation techniques also showed that after the 
MSIE samples were immersed in SBF the addition of copper and/or silver ions did not have a 
detrimental effect on the bioactivity of the sample as the presence of HA was detected throughout. (6) 
(113) (428) (429) (444) (445) (447) 
The porosity of the MSIE samples was lower, by as much as 20%, than the base scaffolds but 
still higher than the ideal threshold porosity described in the literature. Both SEM and white light 
interferometry results have shown that the MSIE process changes the surface topography of the 
scaffold, increasing the surface roughness of the scaffold struts. This result is supported by the increase 
in the contact angles measured for the copper-doped and silver/copper-doped samples however these 
were all still lower than the ideal contact angle value suggested for improved cell attachment. (419) 
(225) (224) 
The MSIE process increased the compressive strength of the scaffold which is likely due to the 
stuffing effect (335) (436) (437)(397) and due to the addition of the silver and/or copper ion in the 
silicate matrix by shortening the non-bridging oxygen bond and forming bond like links to other 
oxygen’s in the matrix. (110) (418) 
The depth EDX and ICP-MS results showed that the release rate of silver ions was a gradual 
process compared to a burst like release of the copper ions out of the scaffold. The silver ions penetrated 
deeper into the silicate matrix but at a lower concentration than the copper ions. For the silver/copper-
doped samples copper was favoured in the MSIE process, in that a greater concentration of copper ion 
was detected compared to that of silver. However the concentration of copper detected was lower, 
because of the presence of the silver ions, compared to the copper only doped scaffolds. This is 
significant as it indicates that the presence of silver in the silver/copper doped samples slows the release 
rate of copper. 
There was an observed change in the surface roughness of the scaffolds which can be attributed 
to the surface modification due to the MSIE process. For example, the silver-doped scaffolds showed a 
small reduction in their surface roughness and both the copper and silver/copper-doped scaffolds 
exhibited a marked increase in their surface roughness values. As stated in the literature review (section 
2.9.3) the surface topography has an effect on the scaffolds ability to interact positively with the host 
tissue as the surface of the biomaterial plays a critical role in the interface interaction between the cells 
and the scaffold. (220) In the literature, a RMS value of between 0.8µm and 1.9µm is reported to provide 
a balance between intermediatary cellular responses such as proliferation, protein content and ALP 
activity and final cellular activity such as bone formation without effecting cell attachment. (461) The 
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silver-doped scaffolds had a measured roughness which was close to this ideal surface roughness, 
however both the copper and silver/copper-doped samples had a surface roughness significantly higher 
than this value. Whether this increase will lead to a significant difference in the cell biology results 
shown in chapter six will be discussed in the relevant section. Certainly, considering that the literature 
shows that the initial cell response can be influenced by the surface roughness this aspect that needs to 
be investigates in terms of how the combination of sintering and the MSIE process changes the surface 
roughness and its effects on cell behaviour. (462) 
Taking all results into account the MSIE scaffolds that were taken forward to further 
optimisation and considered for cell biology work were the lowest concentration 15 minute immersion 
period silver-doped scaffold, the lowest concentration 15 minute immersion period copper-doped 
scaffold and the 15 minute immersion period silver/copper-doped scaffold. These scaffolds exhibited 
the balance between having properties close to those of the base scaffolds, and incorporating therapeutic 
metal ions into the structure without having a detrimental effect the basic characteristics required for 
BTE 
 Coating the BBG scaffolds in gelatin was done to further improve some of the properties of the 
BBG scaffolds. During the main study the two types of gelatin were used at two concentrations and 
PDLLA coated BBG were also investigated for comparison. It was observed that the coating procedure 
had no effect on the chemical composition or crystal structure of the scaffold as observed with EDX 
and XRD. The FTIR analysis showed characteristic peaks corresponding to both the base scaffold 
chemical structure, and of the gelatin and PDLLA coating. 
 The porosity was marginally reduced by the presence of the polymer coating; moreover there 
was little difference between the polymer types or the different types of gelatin. The addition of a 
polymer coating did have an effect on the topography of the scaffold, as observed in the SEM images, 
in that the surface of the struts was smoother and the polymer formed a continuous homogenous layer 
on the struts surface. This observation was supported by the results from the white light interferometry 
and wettability analysis. These results indicated reduced RMS, Ra and PV values and an increase in the 
contact angle which confirmed that the surface of the coated scaffold was smoother than that of the 
BBG scaffolds potentially making the coated scaffolds more suitable for cell attachment. (419) (225) 
(224) There was little difference between the two polymer types or the different types or concentration 
of gelatin in terms of surface roughness.  
 The other area in which the polymer coating had an integral effect on the base scaffolds was 
related to mechanical properties, in particular the increase in the compressive strength. The addition of 
a polymer coating led to a 2x time’s increase of compressional strength compared to the BBG scaffolds. 
The gelatin coatings improved the compressive strength of the BBG scaffolds marginally higher than 
the PDLLA coating.  
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 In addition, it was observed throughout the study that the inclusion of a polymer coating, 
whether it be gelatin or PDLLA, did not have a detrimental effect on the BBG scaffolds ability to form 
a HA layer on the surface after immersion in SBF.  
 Taking all results into account it can be stated that there is no real advantage between using one 
type of gelatin over the other and further assessment of the gelatin coated scaffolds of both types is 
required including cell biology testing. The results also indicate that gelatin improved the BBG 
scaffolds to a higher extent than PDLLA without impairing the fundamental properties that make the 
BBG scaffolds particularly attractive for BTE. 
 Combining ion-exchanged scaffolds with gelatin coating was successful and was found to 
improve the BBG scaffold. Observations made using EDX, FTIR and XRD showed that MSIE and 
polymer coating have not led to changes in the bioactive behaviour of the BBG scaffold. After 
immersion in SBF for 14 days the samples showed precipitation of HA.  
 The topography of the gelatin coated MSIE scaffolds assessed through SEM observations, 
white light interferometry and wettability contact angles indicated that the modified scaffolds were 
smoother than the BBG scaffolds, which confirmed that the polymer coating had reduced the roughness 
caused by the MSIE process. The wettability improved substantially and the contact angle values were 
in the range considered suitable for improved cell attachment, indicating that the combination of MSIE 
and polymer coating changed the strut surface topography in a positive manner. In addition, the 
compressional strength of the gelatin coated MSIE samples improved compared to the BBG scaffolds.  
 Summarising, it can be stated that the combination of MSIE and polymer coating has introduced 
improvements on the BBG scaffolds without compromising the typical characteristics that make these 
scaffolds attractive for BTE specially the highly interconnective pore structure and bioactivity.  
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Chapter Six 
6. Biological Results and Discussion 
 
 This chapter covers the cell biology and bacterial studies carried out on the MSIE scaffolds and 
using the BBG scaffold as a control and to confirm previous biological tests carried out using this 
material. (373) (463) (464) Unless otherwise stated the concentrations of the molten salt baths for MSIE 
used in this chapter were the lowest and the immersion period in the molten salt was 15 minutes. (6) 
The decision to use these parameters was based on previous related work carried out in the literature 
and the results shown in the previous chapter. (6)  
 
6.1 General remarks 
  
This part of the work was carried out in collaboration with the Leeds Dental Institute, UK, for 
the in vitro studies using  HPLSC’s, the Department of Plastic and Hand surgery at the University of 
Erlangen Medical Centre, Germany, for the in vitro studies using rMSC’s and hMSC’s. The Institute of 
Bioprocess engineering at the Friedrich-Alexander University of Erlangen-Nuremberg, Germany 
collaborated with the bacterial work carried out using E.coli and the Institute of Hygiene and 
Biotechnology at Hohenstein Institute in Bönnigheim, Germany collaborated with the bacterial work 
carried out using S. aureus and K. pneumoniae.  All the studies used the BBG scaffold as the control 
sample to give a comparison. 
 
6.2 In vitro cell biology using human periodontal ligamental stromal cells 
 
 This set of studies used HPLSC’s and was carried out in collaboration with Dr R. El-Gendy 
and Prof X.B Yang at the Leeds Dental institute at the University of Leeds, UK. The main purpose of 
this set of studies was to focus on the silver MSIE scaffolds to investigate the possible toxicity and 
biocompatibility of the samples and to assess the concentration of molten salt that can give rise to a 
scaffold that is capable of being implanted without causing cytotoxicity. The cells used in this section 
were prepared as described in section 4.4.1 and were seeded onto the BBG and silver-doped scaffolds 
as shown in section 4.4.2. The scaffolds were then stained using a live/dead marker, as described in 
section 4.4.3, to show the biocompatibility of the samples with the cells. This study used BBG scaffolds 
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as the control samples and three different concentrations of silver MSIE scaffold with an immersion 
period of 15 minutes in line with previous work. (6) 
 
6.2.1 Cell viability assessment using live/dead markers 
 
As described in section 4.4.3 the scaffolds were stained to show the ratio between live and dead 
cells on the scaffolds after three days of dynamic seeding and seven days of static cultivation. Figure 
112 shows two different BBG scaffolds after being subjected to the two cell stains. Both Figure 112A 
and Figure 112B show no presence of cells stained red (the stain to show dead cells), but show a vast 
number of green stained cells attached to the scaffold (the stain to show living cells). This indicates 
qualitatively that the BBG scaffold did not have detrimental effects on cell attachment and it caused no 
toxic effect, which is in agreement with previous work undertaken by other researchers on similar 
scaffolds. (113) (465) (368) The fact that no attached dead cells were detected does not conclusively 
indicate that the BBG scaffolds did not cause cell death during the dynamic seeding process as the dead 
cells could have been washed away before they attached. However based on the high number of green 
dyed living cells, the results give a strong indication that the BBG scaffolds were not toxic to the cells. 
 
 
 Figure 112:- HPLSC’s attachment and viability on the surface of 3D BBG scaffolds with A) and b) two different 
BBG scaffolds. Viable cells are stained green and dead cells are stained red after a total of 10 days of cell culture 
 
 Figure 113 shows low concentration (as described in section 4.2.2) scaffolds that have been 
immersed in the molten salt bath of NaNO3 and AgNO3 for 15, 30, 45 and 60 minutes after being 
subjected to the cell stains and viewed under a CLSM. All scaffolds shown in Figure 113 exhibit 
attached stained living cells (stained green); however the number of living cells has decreased as the 
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immersion period in the molten salt bath increased. Figure 113 also shows the presence of no red dyed 
cells, as observed for the samples shown in Figure 112. Figure 113A shows a quantity of living (green) 
cells comparable with those shown in Figure 112 indicating that at this MSIE concentration and 
immersion period there was no observed detrimental effect of the silver ions on cell attachment. The 
reduction in the number of attached living cells in the samples with increased immersion periods 
(observed in Figure 113B, C and D) could be due to dead cells being washed away before they had a 
chance to attach. 
 
 
Figure 113:- HPLSC's attachment and viability on the surface of low concentration silver MSIE 3D BBG scaffolds 
with a ranged of immersion periods in molten salt: A) immersion period of 15 minutes, B) immersion period of 30 
minutes, C) immersion period of 45 minutes and D) immersion period of 60 minute. Viable cells are stained green 
and dead cells are stained red after a total of 10 days of cell culture 
 
Figure 114 and Figure 115 show the stained cells viewed under a CLSM for the medium and 
high concentrations of silver-doped scaffolds respectively. Both figures show the presence of green 
living cells and no red dead cells, just as in Figure 112 and Figure 113. However there is a marked 
reduction in the number of living cells observed. The number of living cells is decreasing as the 
immersion period in the molten salt bath increases and this was also observed for the low concentration 
scaffolds shown in Figure 113. The number of observed living cells was also seen to decrease as the 
concentration of the silver in the salt bath increased. 
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Figure 114:- HPLSC's attachment and viability on the surface of medium concentration silver MSIE 3D BBG 
scaffolds with a ranged of immersion periods in molten salt: A) immersion period of 15 minutes, B) immersion 
period of 30 minutes, C) immersion period of 45 minutes and D) immersion period of 60 minutes. Viable cells are 
stained green and dead cells are stained red after a total of 10 days of cell culture 
 
 
Figure 115:- HPLSC's attachment and viability on the surface of high concentration silver MSIE 3D BBG 
scaffolds with a ranged of immersion periods in molten salt: A) immersion period of 15 minutes, B) immersion 
period of 30 minutes, C) immersion period of 45 minutes and D) immersion period of 60 minutes. Viable cells are 
stained green and dead cells are stained red after a total of 10 days of cell culture 
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These live/dead markers showed that there is no observed cytotoxic effect caused by the 
samples once the cells have attached, especially in the lowest concentration of silver-doped scaffolds 
as the attached cell density was the highest. However it cannot be stated that samples were not causing 
some toxic effect as most of the cell death would have occurred during the dynamic seeding stage and 
the dead cells would have been removed by the flow of the media and not observed. This set of results 
showed that as the concentration of the silver-doped scaffold increased the observed number of living 
cells decreased. This is useful information for the design of future cell biology and bacterial studies. 
Only the scaffolds with the lowest concentration of silver will be considered as higher concentrations 
of silver will have a negative effect on cell attachment. This result supports work that has been carried 
out previously. (113) 
The results do not show whether the surface roughness, ascertained in chapter five, is having 
an effect on the cells behaviour. The only difference between the cells shown in Figure 112 for the BBG 
scaffolds and those shown in Figure 113, Figure 114 and Figure 115 for the silver-doped scaffold is a 
slight decrease in the overall number of cells, which however needs to be supported by other tests to 
prove conclusive. As this method has a dynamic seeding stage, any cells that might have died will have 
been taken away meaning that healthy robust cells are left to attach and proliferate. A more detailed 
discussion on the surface topography in relation to these results is presented at the end of the chapter. 
It should be noted that the sterilisation method used for this section of cell biology work will 
likely have an effect on the chemical and physical properties of the surface of the samples. This is 
unfortunately unavoidable as any contamination needs to be removed from the scaffolds, which may be 
due to the fabrication process, MSIE process and general handling of the samples. Little work has been 
carried out on understanding how the sterilisation process influences the outcome of cell biology studies 
in this type of scaffolds as it is an important and unavoidable part of the process. This practical aspect 
needs to be looked at in the future as it could potentially change the interpretation of some studies and 
this will be discussed in chapter 8. 
 
6.3 In vitro cell biology using rat bone-marrow stromal cells and human bone-
marrow stromal cells 
 
The set of studies used rMSC’s and hMSC’s and was carried out in collaboration with Dr L. 
Strobel from Dr U. Kneser’s research group at the Department of Plastic and Hand Surgery at the 
University of Erlangen Medical Centre, Germany. The main purpose of this set of studies was to 
establish the toxicity and biocompatibility of the MSIE scaffolds of all sample types (scaffolds doped 
with silver, copper and with both silver and copper), as described in section 4.2.2. From the previous 
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qualitative observations in section 6.2 it has been established that the lowest silver concentration sample 
type at the shortest immersion period would likely yield the most positive reaction from the cells. The 
cells used in this section were prepared as described in section 4.4.4 and were seeded onto the plain and 
ion-doped scaffolds as shown in sections 4.4.5 and 4.4.6. The cells were then tested for their viability 
using an Alamar blue (AB) assay as described in section 4.4.7. 
 
6.3.1 Preliminary toxicity and biocompatibility study of low concentration molten salt ion 
exchange scaffolds using rat bone-marrow stromal cells 
 
 The scaffolds were prepared and seeded for the 2D culture, as described in section 4.4.5. The 
scaffolds were checked every 24 hours to have the CCM replaced and to have the scaffolds and cells 
washed gently in PBS for light microscope observations, as described in 4.4.5. This was repeated for 
three days before confirming that the number of viable cells observed, shown in Figure 116 and Figure 
117, were decreasing and the cells were not of a regular shape compared to the cells in the control wells. 
Figure 116 shows the light microscopy results after one day of the rMSC’s being exposed to 
the samples and there is a marked reduction in the number of healthy attached cells shown in the control 
sample (Figure 116A) compared with not only the cells exposed to the MSIE samples but also with the 
cells in the BBG scaffolds (Figure 116 B-E). There were also a number of dead cells found, these are 
the circular orange cells shown in Figure 116, and this behaviour was observed in all the scaffold 
samples. This result suggests an intrinsic effect of the scaffold which is not due to the influence of the 
additional ions added. The results shown in Figure 116 do not show whether the cell death is due to a 
change in the surface roughness affected by the MSIE processing because a number of cells seeded onto 
the BBG scaffold also suffered from programmed cell death. This hypothesis was further strengthened 
by the results shown in Figure 117, which indicate that after three days the number of cells in the control 
sample (Figure 117A) has remained constant and the cells look healthy having started to spread and 
multiply. However the few remaining cells found on the other samples look irregular and a number of 
dead cells was also observed.  
It is clear that just by observation it can not be concluded that the dead and irregularly shaped 
cells that are shown in Figure 116 and Figure 117 are part of the normal process of programmed cell 
death (apoptosis). In order to reach such conclusion a suitable assay would have to be conducted, for 
example a TUNEL assay which detects DNA fragmentation due to apoptosis. (404) This will be 
discussed further in the summary of this chapter. 
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Figure 116:- 2D seeded rMSC’s on: A) control well with no sample, B) BBG scaffold, C) low concentration silver-
doped BBG scaffold, D) low concentration copper-doped BBG scaffold and E) low concentration combination 
ion BBG scaffold after one day of contact with the cells 
 
 
Figure 117:- 2D seeded rMSC’s on: A) control well with no sample, B) BBG scaffold, C) low concentration silver-
doped BBG scaffold, D) low concentration copper-doped BBG scaffold and E) low concentration combination 
ion BBG scaffold after three day of contact with the cells 
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It was observed, despite the pre-seeding washing, that when the scaffolds were immersed in the 
CCM a colour change from its characteristic orange to a bright pink occurred, because of the presence 
of phenol red which indicates that there is a pH change towards higher alkali pH’s, as shown in Figure 
118. 
 
 
Figure 118:-Image illustrating an increase in the pH which leads to a change in the colouration of the CCM from 
A) the typical orange colouration to B) the bright pink colouration which indicates the activation of the phenol 
red indicator in the media 
 
 Indeed, this pH change of the medium is a known problem with cell biology experiments 
carried out directly on 45S5 Bioglass® samples however there is only limited information in the 
literature. (408) (182) It is worthwhile noting in this regard, that each laboratory develops its own 
protocol for the pre-treatment of BBG scaffolds and there is no general protocol established to reduce 
the pH variation when BBG scaffolds are exposed to the cells. This pH issue was identified in this study 
and it was addressed before any further in vitro work was carried out so that results that are obtained 
are relevant and reflect only the effect caused by the additional metal ions added and are not masked by 
the effects of the chemistry of the base material.  
It should be noted that the autoclaving method of sterilisation used for this section of cell 
biology work has the potential to affect the physical and chemical properties of the surface of the 
samples. This is unavoidable as any contamination needs to be removed from that scaffolds due to the 
fabrication process, MSIE process and general handling of the scaffolds. As stated before, this aspect 
of the cell biology work has not been extensively investigated and it needs to be looked at as it could 
have an effect on the outcome of cell biology experiments. The need for future studies addressing the 
effect of sterilisation on the outcome of cell biology studies is discussed in chapter 8. 
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6.3.2 The effect of pH change  
 
 The results from the preliminary in vitro work, shown in the previous section, indicated the pH 
changes of the CCM after the scaffolds have been added (shown in Figure 116 and Figure 117). The 
pH changes during the washing and sterilization process were observed and then necessary changes to 
the protocol were introduced. Table 39 shows the pH changes during the washing protocol that was 
originally in place to prepare the scaffold samples for in vitro experiments. This table shows that the 
pH of the solutions increased when the BBG scaffold was washed, with an increase of 3.97 from the 
initial pH of the first washing stage before the sample was added to the end of the washing protocol and 
an increase of 0.305 from after the first washing stage to the end of the washing protocol. The final pH 
of 11.71 is far too high for cell culture work. The first three stages of the washing protocol cannot be 
eliminated as these steps are required to remove any residue salt on the surface of the scaffold after the 
MSIE process; however the latter stages can be changed for a different washing process as these latter 
steps contribute to the pH increase. 
Table 39:- pH changes throughout the washing procedure 
 pH 
Washing solution Before After Difference 
De-ionised Water 7.74 11.405 3.665 
70% Ethanol 11.33 12.15 0.82 
De-ionised Water 7.74 11.01 3.27 
2.5% SDS 8.18 10.725 2.545 
De-ionised Water 7.74 10.62 2.88 
5% Extran 12.44 12.465 0.025 
De-ionised Water 7.74 11.71 3.97 
Overall difference 0.305 
 
 After the washing process the scaffolds were then autoclaved in the same conditions as 
previously stated in sections 4.4.5 and 4.4.6 depending on the experiment being carried out. This process 
is required to sterilise the scaffolds in preparation for the in vitro work.  The final stage of the washing 
and sterilisation protocol implemented was a final hour of washing in the selected CCM, samples were 
then patted dry and this was carried out in the sterilised fume hood. The samples were turning the media 
pink after one hour of immersion but the pH of the solution was reduced from pH 11.71 after the last 
stage of washing before the autoclaving to pH 11.34.  
This result indicated a suitable conditioning of the scaffolds by increasing the post autoclaving 
immersion period from one hour up to four days. On the first day the samples would be on a shaker to 
get the CCM infiltrating all of the pores, approaching a dynamic seeding flow through the scaffold, and 
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the final three days would be in an incubator at 37oC at 5% CO2. This stage needed to be long enough 
to reduce the pH but obviously not so long that would lead to the metal ions added through MSIE being 
completely lost. Also the immersion media was changed to determine if this would have an effect in 
lowering the pH. Two solutions were investigated: DMEM/F-12 (without FBS, L-glutamine or 
antibiotics) and a 0.9% NaCl solution. After this stage, it was noted that the DMEM/F-12 media had 
once again turned bright pink but a pH of 8.95 was measured and the 0.9%NaCl had reduced the pH to 
pH 10.38. Finally, to wash the scaffolds for a final time the medium was replaced with fresh medium 
and placed on the shaker, this gave way to a further pH reduction to pH 8.23 and pH 9.95 for the 
DMEM/F-12 and the 0.9% NaCl solution, respectively.  
The samples were then used in 2D culture experiments, as described in section 4.4.5, changing 
the CCM, this was changed back to the standard medium that was used for all cell cultures experiments, 
every 24 hours and observing the cells under the light microscope. Table 40 and Figure 119 describe 
observations over the two days that the 2D culture experiment was running. The results show that the 
pre-conditioning of the scaffolds in DMEM/F-12 had less of a negative effect on the cells compared to 
the scaffolds that were pre-conditioned in 0.9% NaCl. It also unveiled that the presence of the well 
insert had a negative effect on the cells (Figure 119A and Figure 119D) compared to the cells that were 
not restricted by the well insert (Figure 116A). This effect of using the well insert was not investigated 
further in this work and remains a topic for future studies.  
Table 40:- Observations made after introducing a longer pre-conditioning phase based on section 4.4.5 
  Condition of cells after seeding the cells 
Sample type Day 1 Day 2 
Control well with insert some living cells some living cells 
Control well with no insert numerous living cells numerous living cells 
Control well with no insert numerous living cells numerous living cells 
Pre-conditioned in DMEM/F-12 a few living cells some living cells 
Pre-conditioned in DMEM/F-12 no living cells no living cells 
Pre-conditioned in DMEM/F-12 no living cells no living cells 
Pre-conditioned in DMEM/F-12 a few living cells a few living cells 
Pre-conditioned in 0.9% NaCl a few living cells no living cells 
Pre-conditioned in 0.9% NaCl no living cells no living cells 
Pre-conditioned in 0.9% NaCl no living cells no living cells 
Pre-conditioned in 0.9% NaCl no living cells no living cells 
Control well with insert and 1% buffer all numerous living cells numerous living cells 
Control well with insert and 2% buffer all numerous living cells numerous living cells 
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Figure 119:- rMSC’s seeded onto pre-conditioned scaffolds: A) control well with insert one day after seeding, B) 
DMEM/F-12 pre-conditioned scaffold one day after seeding, C) 0.9% NaCl pre-conditioned scaffold one day 
after seeding, D) control well with insert two days after seeding, E) DMEM/F-12 pre-conditioned scaffold two 
days after seeding and F) 0.9% NaCl pre-conditioned scaffold two days after seeding 
 
An interesting observation was that the two DMEM/F-12 pre-conditioned scaffolds that 
produced the least negative impact on the cells were at the lower end of the size range of the scaffolds 
used for the study and this could have affected the number of living cells found. In the preliminary set 
of in vitro work using rMSC’s the size of the samples ranged from 5x5x5mm3 down to 3x3x3mm3. It 
is thus likely that the larger size will have contributed to the pH increase issue. This set of experiments 
also investigated the use of a buffer solution to help to reduce the pH and control the pH after the cells 
have been seeded. For this process two solutions of Bufferall were used at 1% and 2% solutions. Table 
40 shows that the introduction of the solution did not have a detrimental effect on the seeded cells and 
kept the media at a suitable pH to prevent cell death. 
It should be noted that in the studies using HPLSC’s (section 6.2) no pH issues were recorded. 
This was because of the dynamic seeding system used which kept a constant flow of the CCM flowing 
over the seeded scaffolds preventing the local pH increasing significantly as it moved the released ions 
away from the cells. This effect should be considered for future work, certainly dynamic systems should 
be preferred over static culture tests as they represent a condition which is closer to the in vivo situation. 
As with the results shown in Figure 116 and Figure 117, it is important to note that from simple 
observation it can not be said that any observed cell death is caused by the change in the scaffold type 
as natural cell death due to apoptosis can occur. (404) In order to prove that the cell death observed is 
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due to experimental conditions and not apoptosis a suitable assay must be used, such as a TUNEL assay. 
(404) This will be discussed further in the summary of this chapter. 
 
6.3.3 Biocompatibility and toxicity study using low concentration molten salt ion exchange 
scaffolds 
 
 After implementing the new pre-conditioning results explained in section 6.3.2 the samples 
were subjected to the protocols shown in sections 4.4.5 and 4.4.6, in particular Figure 26 and Figure 27. 
These samples were then processed using the AB assay, described in section 4.4.7, to give an assessment 
of the samples biocompatibility. Figure 120 shows the AB assay results for the 2D culture experiments. 
The results show that the BBG scaffolds had an AB reduction comparable with the control group and 
for the first week this was the case for the silver-doped samples. The copper-doped and the combination 
ion-doped samples had no living cells observed after a week and the silver-doped samples had no living 
cells present after the two week mark. 
  
 
Figure 120:- 2D rMSC cultures with inserts containing A) control well with no insert and samples, B) wells 
containing BBG scaffolds, C) wells containing low concentration silver-doped BBG scaffolds, D) wells containing 
low concentration copper-doped BBG scaffolds and E) wells containing low concentration combination ion-
doped BBG scaffolds and then subjected to an AB assay. For copper-doped BBG scaffolds there was no detected 
metabolic activity after 14 days and for silver/copper-doped BBG scaffolds no metabolic activity could be detected 
after 7 days. * Indicates a significant change between the scaffold types (p≤0.05) using ANOVA analysis. 
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The results shown in Figure 120 suggest that the metal ions are being released in a fast burst 
during the first week and this burst release, including sodium and calcium from the BBG scaffold as 
well as the additional therapeutic ions, could be potentially the reason behind the decrease in the number 
of observed living cells found in the wells after one week.  
This burst release action is well documented for copper ions and this was one of the factors for 
a low concentration being used in the in vitro work as it was hypothesized that this would reduce the 
effect of this phenomenon. However from Figure 120 it can be seen that the concentration of copper 
ions in both the copper-doped and combination ion-doped samples is still high enough to have a 
significant detrimental effect on the cells. 
The results of the AB assay on 3D culture samples are shown in Figure 121, these results are 
similar to those found in Figure 120. The cells that were seeded onto the BBG scaffold survived through 
to the end of the two weeks with a slight dip in the number of observed living cells at the end of week 
one. Regarding the cells seeded onto the MSIE samples, it was observed that only a small number of 
cells survived the initial seeding process and each sample type showed a low number of living cells 
after one day. After that there were no living cells detected by the AB assay after one week and two 
weeks. This result also indicates the effect of the metal ions on the cells which is leading to cell death. 
 
 
Figure 121:- 3D rMSC cultures containing A) control well with no samples, B) wells containing BBG scaffolds, 
C) wells containing low concentration silver-doped BBG scaffolds, D) wells containing low concentration copper-
doped BBG scaffolds and E) wells containing low concentration combination ion-doped BBG scaffolds and then 
subjected to an AB assay. * Indicates a significant change between the scaffold types (p≤0.05) using ANOVA 
analysis. 
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 The change in surface roughness could also have an effect on the cell death observed for the 
modified scaffolds but no independent results are available to prove that in this case. This effect will be 
discussed in further detail at the end of the chapter. Apoptosis could also be an explanation to the cause 
of the observed cell death shown both by the images and the AB assays. (404) This can be established 
by using the appropriate assay to show that any cell death observed is caused by the change in the 
sample types and not by natural occurrence. (404) 
 The results  for the silver doped scaffolds, shown in Figure 121, are not in agreement with the 
result shown in section 6.2 using the HPLSC’s, in that the rMSC’s did not survive past the initial seeding 
process. This result leads to a number of possibilities as to why the same sample parameters led to 
different results. The main reason for this behaviour is thought to be related to the difference in the 
seeding processes, with one being dynamic and the second being static. Also the type of cell used could 
have had an effect on the results with the rMSC’s being more susceptible to the burst release of metal 
ions than the HPLSC’s. Future work should investigate in detail this behaviour. 
These results indicate that two options during the next stage of in vitro work can be explored:- 
I). The concentration of the additional metal ions needs to be reduced  
II). Biodegradable coatings need to be added to the samples to slow down the release of the metal 
ions into the CCM. 
 
6.3.4 Biocompatibility and toxicity study using extremely low concentration molten salt ion 
exchange scaffolds 
 
 Based on the preliminary results, presented in section 6.3.3, the concentration of the metal ions 
in the copper and combination ion-doped scaffolds was reduced to a tenth of the low concentration 
samples. hMSC’s were used for this part of the study to investigate cells behaviour when exposed to 
the MSIE samples compared with the previous work with HPLSC’s and rMSC’s. The silver-doped 
samples were not investigated with a reduced concentration as there was sufficient data from the 
previous studies (sections 6.2 and 6.3.3) to prove that the original low concentration with an immersion 
period of 15 minutes produced samples that were sufficiently biocompatible to be used in an in vivo set 
up.  
The other change to the experimental method was an increase in the pre-conditioning time that 
was introduced in section 6.3.2, namely from four days in DMEM/F-12 with no additives to five days 
in DMEM/F-12 with 1% penicillin/streptomycin and the media being changed every other day.  
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 The cells were prepared as described in section 4.4.4 and the samples were prepared as 
described in sections 4.2.2 and preconditioned as described above and in section 6.3.2. This study used 
a 2D culture set up as described in section 4.4.5 over a ten day period. 
 Figure 122A-C shows that after the first day all samples exhibited living cells left in the well. 
It was also observed that qualitatively the BBG scaffolds (Figure 122A) out-performed the two doped 
samples (Figure 122B-C). This result could indicate that the pre-conditioning has effectively reduced 
the pH change caused by the samples as intended. This effect can be confirmed if the BBG samples 
continue to show no observed cell death after five and ten days. The copper and combination ion-doped 
samples showed significantly fewer living cells and also showed dead cells present confirmed by the 
circular pale white cells, Figure 122B-C. It was also observed that there is little difference between the 
two MSIE samples investigated.  
 
 
Figure 122:- 2D culture seeded with hMSC’s onto: A) BBG scaffold after one day, B) extremely low concentration 
copper-doped sample after one day, C) extremely low concentration combination ion-doped sample after one day, 
D) BBG scaffold after five days,  E) extremely low concentration copper-doped sample after five days, F) 
extremely low concentration combination ion-doped sample after five days, G) BBG scaffold after ten days,  H) 
extremely low concentration copper-doped sample after ten days and I) extremely low concentration combination 
ion-doped sample after ten days 
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Figure 122D-F shows qualitatively that after five days all three sample types exhibited the 
presence of living cells and the BBG scaffolds (Figure 122D) had a higher number of living cells, 
assessed by the visual inspection of the samples,  compared to the other two sample types (Figure 122E-
F). One observation made from these results is that the number of living cells found in Figure 122D has 
increased from Figure 122A, indicating that the cells are in suitable conditions to induce cell 
proliferation. The results show that the pH increase issue which is commonly found in cell cultures on 
Bioglass® (408) (182) and was discussed in previous sections, has been partially solved. A second 
observation is that the combination ion-doped samples whilst still showing significantly reduced 
number of living cells compared to the BBG scaffolds, exhibit a slight increase in the number of living 
cells ( at least qualitatively assessed) compared to the results after the first day and also this sample 
shows more living cells compared to the copper-doped samples. 
 Figure 122G-I shows the samples after ten days of exposure and confirms that the pH increase 
issue discussed above has been partially resolved for the BBG scaffolds as Figure 122G indicates an 
increase in the number of living cells present compared to the results shown in Figure 122D and Figure 
122A. This result shows that the pre-conditioning and treatment of the BBG scaffolds is suitable to 
produce samples that will encourage desirable cell attachment and proliferation. Figure 122H and 
Figure 122I show very few living cells present and it was not possible to determine which of the ion-
doped samples performed better in this format. The difference between the two ion-doped samples can 
be seen when the samples are subjected to an AB assay, which is shown in Figure 123. 
 
 
Figure 123:- 2D hMSC cultures with inserts containing A) BBG scaffolds, B) extremely low concentration copper-
doped samples and C) extremely low concentration combination ion-doped samples and then subjected to an AB 
assay after one, five and ten days of being seeded with hMSC’s. For copper-doped and silver/copper-doped BBG 
scaffolds no metabolic activity could be detected after ten days. * Indicates a significant change between the 
scaffold types (p≤0.05) using ANOVA analysis.  
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The AB assay results, conducted in accordance with section 4.4.7, shown in Figure 123 supports 
the observations from Figure 122, with all sample types showing some living cells at the first two time 
points and with the BBG samples outperforming the two ion-doped samples, especially after five days 
of the cells being exposed to the samples. This results supports the previous statement that the pre-
conditioning protocol implemented on the samples has tackled the pH increase issue, discussed 
previously (caused by the release of the ions as the scaffold starts to degrade) thus allowing the cells to 
attach and proliferate. This result also shows that there is no statistically significant difference in living 
cell numbers between the two ion-doped samples over the ten days. Although the combination ion-
doped scaffold performed slightly worse than the copper-doped sample, this sample had a higher copper 
content than the copper only doped sample. It was also confirmed that throughout these in vitro 
experiments using the hMSC’s the copper containing samples caused more cell death than the BBG 
samples and the silver-doped samples. It can be therefore concluded that copper ions are showing a 
cytotoxic effect under the investigated experimental conditions. As the CCM used in this in vitro work 
contains a small amount of copper in it, the additional copper released by the doped scaffolds seems to 
cause cell death through over exposure. This result needs to be investigated further. The tests should be 
repeated using an alternative CCM containing less copper to give an indication of what threshold 
concentration of copper released by the scaffolds will cause cell death. 
Again the change in the surface roughness recorded in chapter five could have attributed to the 
increase in the cell death and the lack of cell attachment observed in this cell biology work. The fact is 
that the cell death can not be attributed to any one factor from these results. This will be discussed in 
detail at the end of the chapter. 
 
6.4 Antibacterial assessment of molten salt ion exchange scaffolds 
 
This set of studies used E.coli and was carried out in collaboration with Mrs A. Amtmann at 
the Institute of Bioprocess Engineering at the Freidrich-Alexander University of Erlangen-Nuremberg, 
Germany. The main purpose of this set of studies was to establish the bacteriostatic and bactericidal 
capabilities of the MSIE scaffolds of all sample types (silver, copper and silver/copper) using the tests 
described in sections 4.4.8 to 4.4.12.I. To give a direct comparison to the in vitro work shown in sections 
6.2 and 6.3 the lowest concentration samples from each of the MSIE obtained at the shortest immersion 
period were tested. The work conducted using the S.aureus and K.pneumoniae was carried out in 
collaboration with Dr T Hammer from the Institute of Hygiene and Biotechnology at the Hohenstein 
Institute in Boennigheim, Germany. The purpose of this set of tests was to give not only a direct 
comparison with the in vitro work shown in previous sections but also to compare how the MSIE 
samples behave in contact with different types of bacteria. This work is described in sections 4.4.12.II 
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and 4.4.13. Again samples involving the lowest concentration of silver, copper and silver/copper 
immersed for the shortest time in the molten salt bath were used. All studies used the BBG scaffolds as 
the control sample. 
 
6.4.1 Growth curves of Escherichia coli 
 
For comparison purposes with the in vitro work, the studies were carried out using the same 
medium that was used previously (section 6.3). In addition, for comparison purposes an industry 
standard medium used in bacterial studies was considered. This was done to have a direct comparison 
between the cell culture studies and the bacterial work carried out in this section, considering that the 
tests will evaluate the antibacterial effectiveness of the MSIE samples with respect to their possible 
cytotoxic effect. The two media are i) DMEM/F-12 with 1% L-glutamine, 10% Foetal bovine serum 
(FBS) and 1% Buffer all (DMEM/F-12), as used in section 6.3 and ii) Muller-Hinton broth (MHB). The 
first task was to establish how the E.coli behaves in DMEM/F-12 compared to how it grows in MHB, 
as described in section 4.4.8. 
 Figure 124 shows the absorbance due to the presence of E.coli in a variety of different media 
over a wavelength range of 350nm to 800nm. To produce growth curves the absorbance is measured at 
a wavelength that shows an absorbance value of approximately 0.1 and that it will not change due to 
indicators within the media. The significance of the absorbance being 0.1 is that it directly corresponds 
to the McFarland standard as this is used to adjust the turbidity of a bacterial suspension and gives an 
industry standard for comparison. (466) (467) 
For MHB the absorbance is normally measured between 550nm and 700nm as the value is 
constant in this range, as shown in Figure 124. However Figure 124 shows that the DMEM/F-12 
medium has a large absorbance peak between 475nm and 625nm and this is due to the presence of the 
indicator phenol red in the medium. The absorbance curve then flattens out which means that an 
absorbance of approximately of 0.1 can be measured for 630nm and 700nm without interference (as 
shown by the inserted graph with the highlighted wavelength band in Figure 124). Because of this, the 
experiments (reported in the next sections) used an absorbance value measured at 650nm for both 
media. 
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Figure 124:- Absorbance measure over a full visible light spectrum for E.coli grown in a variety of different 
media, with the yellow band showing the ideal wavelength range at which the absorbance should be measured 
 
 After establishing the wavelength at which all absorbance values for the E.coli studies would 
be considered, the behaviour of E.coli in DMEM/F-12 compared to the MHB was investigated. The 
results are shown in Figure 125 and Figure 126. Figure 125 shows the change in absorbance, measured 
at 650nm, over a period of 24 hours for both media types. This result indicates that when the E.coli are 
grown in DMEM/F-12 the bacteria take approximately twice as long to reach an absorbance value of 
1.5 compared to the E.coli grown in the MHB, but once this value is reached the growth curves for both 
media are significantly similar. Figure 125B in particular shows that E.coli requires more time to 
acclimatise to the DMEM/F-12 compared to the MHB. This result means that in the rest of the studies 
on E.coli in DMEM/F-12 should be given double the time in the pre-culture stage in order to have 
comparable results with the bacteria in MHB. 
Figure 126 shows the number of E.coli bacteria after 30, 180 and 300 minutes for both types of 
media after being plated onto standard I agar plates and incubated for 24 hours, as described in section 
4.4.8. These results were obtained using the multiple dilutions technique described in section 4.4.8. It 
was found that the E.coli that were grown in DMEM/F-12 exhibited a higher number of bacteria plated 
than those grown in MHB after the first time point. The rate of growth shown by the E.coli in MHB 
exhibits continuous growth and this result supports the growth curve shown in Figure 124. The rate of 
growth over the five hour period for the E.coli in DMEM/F-12 is seen to increase continuously and this 
result also supports the data shown in Figure 124. 
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Figure 125:- Growth of E.coli in both MHB and DMEM/F-12 with A) showing the full incubation period and B) 
showing the growth curves for the first five hours; the absorbance was measured at 650nm.(The lines connecting 
the dots are only to help the eye). * Indicates a significant change between the scaffold types (p≤0.05) using 
ANOVA analysis. 
 
 
 
Figure 126:- E.coli bacteria per ml measured using the CFU plating method taking samples at three time points, 
plating onto standard I agar plates and incubated for 24 hours at 37oC and 5%CO2. (The lines connecting the 
dots are only to help the eye) * Indicates a significant change between the scaffold types (p≤0.05) using ANOVA 
analysis. 
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 In summary, the results have shown that the wavelength at which the absorbance should be 
measured is 650nm for both types of media. It is also concluded that E.coli in DMEM/F-12 needed 
almost twice as long to start growing as this bacteria needed longer to acclimatise to the media, meaning 
that a longer pre-culture stage is required for future work. 
 
6.4.2 Copper nitrate vs copper chloride salts in a growth inhibition study using Escherichia coli 
 
 As described in section 4.4.9 the growth inhibition of copper nitrate needs to be compared to 
that of copper chloride to determine if this metal salt can be used in the main metal salt inhibition study, 
considering that the study is based on the investigation described in Heidenau et al (409) in which copper 
chloride was used. The method used is described in section 4.4.9 with 10µl of E.coli suspension plated 
onto standard I agar plates after four and 24 hours of incubation and then incubated for a further 24 
hours on the plates ready to have the colony forming units (CFU’s) counted and processed.  
Figure 127 shows suspensions of E.coli in DMEM/F-12 (with the two different concentrations 
of E.coli) with both copper salts. It can be seen that, due to the phenol red in the DMEM/F-12, there is 
change in colour due to the presence of E.coli going from the normal orange colour (Figure 127Ai-Di) 
to a cloudy yellow of the control E.coli suspensions (Figure 127Aii-Dii). The image shows that as the 
concentration of copper salts increases, the turbidity of the suspension decreased and the colour changed 
towards the orange end of the scale, suggesting that the bacteria were affected by the presence of the 
copper salts. This is the case for both concentrations of E.coli and for both copper salts, meaning that 
on a qualitative level there is little difference between how the E.coli behaves in the presence of the two 
copper salts.  
Samples from the suspensions, shown in Figure 127, were taken after four and 24 hours, plated 
and incubated for a further 24 hours at 37oC and 5% CO2 and the number of colony forming units was 
counted. The results are shown in Table 41. This study was performed for both media types to enable a 
comparison and to ensure that the next set of experiments would be possible using copper nitrate salt 
and DMEM/F-12. 
Table 41 shows that there is very little difference between the E.coli suspensions containing 
copper chloride and those containing copper nitrate for the bacteria suspended in DMEM/F-12. The 
data shown in Table 41 has been collated from the figures shown in appendix C2 and shows that there 
is a difference in the bacteria’s behaviour in the two media. However since both copper salts behaved 
the same in the two media the result suggests that copper nitrate can be used to replace copper chloride 
and that DMEM/F-12 can be used to replace MHB in the metal salt growth inhibition study. 
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Figure 127:- E.coli suspended in DMEM/F-12 with a range of different concentration solutions of copper nitrate 
or copper chloride after being incubated for 24 hours at 37oC at 5% CO2: A) copper chloride series with an Δ 
absorption of 0.001, B) copper chloride series with an Δ absorption of 0.01 C) copper nitrate series with an Δ 
absorption of 0.001, and D) copper nitrate series with an Δ absorption of 0.01 with concentrations of i) control 
with no E.coli, ii) control with E.coli,  iii) 0.05mM of copper salt, iv) 0.1mM of copper salt, v) 0.5mM of copper 
salt and vi) 1mM of copper salt 
 
6.4.3 Minimum inhibitory concentration testing using metal salts against Escherichia coli 
 
 As described in section 4.4.10, in order to prove whether the metal salts cause a bactericidal or 
bacteriostatic effect, the E.coli/metal salt suspensions need to be subjected to sodium thiosulfate as this 
will neutralise the metal salts, as shown by Heidenau et al. (409) This process was carried out using 
suspensions of silver nitrate and copper nitrate to check that these will be neutralised by the sodium 
thiosulfate, as indicated by Heidenau et al. (409) This means that in the main metal salt study, it is 
possible to determine whether a metal salt concentration causes a bacteriostatic effect (the bacteria are 
“switched off” by the metal ion) or a bactericidal effect (the bacteria are killed by the metal ion).  
This study was thus a qualitative test using E.coli/metal salt suspensions which are then plated 
onto standard I agar plates and compared, as shown in Figure 128.  If the concentration causes a 
bactericidal effect there will be no bacteria present on the plate with and without the additional sodium 
thiosulfate added to the bacteria/metal salt suspension. On the other hand, if the concentration causes a 
bacteriostatic effect, then there will no bacteria present on the plate without the additional sodium 
thiosulfate but there will be bacteria present on the plate with sodium thiosulfate added to the 
bacteria/metal ion suspension. If the metal salt has no effect on the bacteria then both plates, with and 
without the sodium thiosulfate added to the bacteria/metal salt suspension, will show the presence of 
the bacteria 
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Table 41:- CFU counts from copper salt suspensions taken after four and 24 hours using both media types 
    Time point 
  Concentration  Change in    4 hours 4 hours 24 hours 24 hours 
Sample of copper  absorbance of Medium  Colony forming units 
  salt (mM)  the bacteria   (CFU's) 
Control 0 0.01 DMEM  471  720  TMTC TMTC  
Control 0 0.001 DMEM  23 35  TMTC TMTC 
Control 0 0.01 MHB TMTC   TMTC   TMTC TMTC 
Control 0 0.001 MHB  TMTC  TMTC   TMTC  TMTC 
CuCl2 0.05 0.01 DMEM 551 518  TMTC  TMTC 
CuCl2 0.05 0.001 DMEM  12  71  TMTC TMTC 
CuCl2 0.1 0.01 DMEM 698  378  TMTC TMTC 
CuCl2 0.1 0.001 DMEM  8  40 TMTC  TMTC 
CuCl2 0.5 0.01 DMEM TMTC   TMTC   TMTC  TMTC 
CuCl2 0.5 0.001 DMEM  630 753 TMTC  TMTC 
CuCl2 1 0.01 DMEM TMTC  TMTC  TMTC TMTC 
CuCl2 1 0.001 DMEM TMTC   TMTC  TMTC TMTC 
CuCl2 0.05 0.01 MHB TMTC    TMTC  TMTC TMTC 
CuCl2 0.05 0.001 MHB TMTC  TMTC  TMTC TMTC 
CuCl2 0.1 0.01 MHB TMTC  TMTC  TMTC TMTC 
CuCl2 0.1 0.001 MHB TMTC   TMTC  TMTC  TMTC 
CuCl2 0.5 0.01 MHB TMTC   TMTC  TMTC TMTC 
CuCl2 0.5 0.001 MHB TMTC   TMTC   TMTC  TMTC 
CuCl2 1 0.01 MHB TMTC   TMTC   TMTC  TMTC 
CuCl2 1 0.001 MHB TMTC   TMTC   TMTC  TMTC 
Cu(NO3)2 0.05 0.01 DMEM  200  916  TMTC TMTC 
Cu(NO3)2 0.05 0.001 DMEM 9  29  TMTC  TMTC 
Cu(NO3)2 0.1 0.01 DMEM  257 872   TMTC TMTC 
Cu(NO3)2 0.1 0.001 DMEM 13  91   TMTC TMTC 
Cu(NO3)2 0.5 0.01 DMEM TMTC    TMTC   TMTC TMTC 
Cu(NO3)2 0.5 0.001 DMEM  496  477  TMTC TMTC 
Cu(NO3)2 1 0.01 DMEM TMTC  TMTC   TMTC TMTC 
Cu(NO3)2 1 0.001 DMEM  TMTC  TMTC   TMTC TMTC 
Cu(NO3)2 0.05 0.01 MHB  TMTC   TMTC   TMTC TMTC 
Cu(NO3)2 0.05 0.001 MHB  TMTC   TMTC   TMTC  TMTC 
Cu(NO3)2 0.1 0.01 MHB  TMTC   TMTC   TMTC TMTC 
Cu(NO3)2 0.1 0.001 MHB  TMTC   TMTC   TMTC TMTC 
Cu(NO3)2 0.5 0.01 MHB  TMTC   TMTC   TMTC TMTC 
Cu(NO3)2 0.5 0.001 MHB  TMTC  TMTC   TMTC TMTC 
Cu(NO3)2 1 0.01 MHB  TMTC   TMTC   TMTC  TMTC 
Cu(NO3)2 1 0.001 MHB  TMTC  TMTC   TMTC  TMTC 
* TMTC - too many to count on the agar plate 
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Figure 128A shows a substantial growth of bacteria across the plate compared to Figure 128B 
that shows that silver nitrate causes an antibacterial effect as no bacteria are observed, indicating that 
this concentration of silver nitrate caused a bacteriostatic effect. However, it cannot be determined if 
this effect is bactericidal or bacteriostatic from just the results shown in Figure 128B. Figure 128A 
shows bacteria growth in the presence of sodium thiosulfate which indicates that the concentration of 
silver nitrate present in both Figure 128A and Figure 128B had a bacteriostatic effect. 
 
 
Figure 128:- Standard I agar plates showing; A) E.coli suspension with silver nitrate at a concentration 0.05mM 
and additional sodium thiosulfate, B) E.coli suspension with silver nitrate at a concentration 0.05mM, C) E.coli 
suspension with copper nitrate at a concentration 0.05mM and additional sodium thiosulfate and D) E.coli 
suspension with copper nitrate at a concentration 0.05mM after being incubated in suspension for 24 hours, 
plated and further incubated for 24 hours at 5% CO2 and at 37oc using an initial E.coli change in absorption of 
0.01 
 
Figure 128C and Figure 128D show that the copper nitrate concentration does not have an 
antibacterial effect on the E.coli as the plate is observed to be covered in bacteria, which indicates that 
this concentration of copper nitrate is not high enough to have any antibacterial effect on the E.coli. 
These results give an indication for the design of the next set of studies (as shown in section 
4.4.11 onwards), but doesn’t prove that the sodium thiosulfate will neutralise the copper nitrate as 
indicated by Heidenau et al. (409)  
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6.4.4 Metal salts growth inhibition study using Escherichia coli 
 
 This initial study used a range of concentrations of metal salts to give an indication of the 
concentration required to cause not only a bacteriostatic effect but also a bactericidal effect on E.coli 
for comparison with the study on MSIE scaffolds, which is described in the next section. The 
experimental process for this study is described in section 4.4.9. The investigation involved adding 
varying concentrations of silver nitrate or copper nitrate to the DMEM/F-12 with E.coli. This initial 
study gave a starting point for the final range of concentrations used later on, in particular for the study 
carried out with the combination of metal salts. This first study only used the change in absorption as 
the indicator about how bacteria were growing in the metal salt suspension. As shown in section 6.4.1, 
when bacteria are in ideal growing conditions the change in absorbance will increase as the incubation 
period increases, meaning that as the absorption change decreases over time the number of living E.coli 
causing a change in the turbidity of the suspension has decreased. 
 Figure 129 shows the change in absorption for suspensions of E.coli in DMEM/F-12 with a 
range of concentrations of silver nitrate. The lower concentrations of silver nitrate (0mM, 0.005mM, 
0.01mM and 0.02mM) had little effect on the overall growth of E.coli. These concentrations showed 
lower changes in absorption than the suspension that contained no silver nitrate which indicates that the 
presence of silver nitrate, even at these low concentrations, has an effect on the growth of E.coli. 
 
 
Figure 129:- The change in absorption of the bacterial suspension due the presence of a range of concentrations 
of silver nitrate over time which gives an indication of the growth rate of the suspended bacteria. * Indicates a 
significant change between the scaffold types (p≤0.05) using ANOVA analysis. 
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 Figure 129 also showed that for the suspensions containing silver nitrate at a concentration of 
0.05mM or higher, the change in absorption over time, decreased, indicating that E.coli bacteria cells 
were not growing. However, whether the antibacterial effect was bacteriostatic or bactericidal cannot 
be determined from these results. This can only be ascertained by plating the suspensions with sodium 
thiosulfate, as discussed previously. However these values, in Figure 129, do give an indication of which 
concentrations should be considered for the next study where the full inhibition concentration of the 
metal salts will be investigated.  
 Figure 130 shows the change of absorption due to the presence of varying concentrations of 
copper nitrate in E.coli suspended in DMEM/F-12.  It can be seen that there is no negative effect on the 
E.coli suspension caused by the presence of the copper nitrate; in fact Figure 130 shows that E.coli grew 
better in the presence of the copper nitrate compared to the control suspension. Overall this result 
indicates that the concentration of copper nitrate will have to be significantly higher to have any 
negative effect on E.coli bacteria.  
 
 
Figure 130:- The change in absorption of the bacterial suspension due to the presence of a range of concentrations 
of copper nitrate over time which gives an indication of the growth rate of the suspended bacteria. * Indicates a 
significant change between the scaffold types (p≤0.05) using ANOVA analysis. 
 
 From Figure 129 and Figure 130 it can be determined that the concentrations of silver nitrate 
and copper nitrate should be at least 0.01mM and 0.1mM, respectively, for the next study to determine 
the minimum inhibitory concentration of these metal salts. This concentration range will provide a 
suitable cross section of bacteriostatic, bactericidal and no effect results for each metal salt. Also in the 
study, reported in the next section, the silver/copper doped scaffolds need to be represented in a metal 
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salt suspension for comparison with the studies in section 6.4.5. Taking the results from Figure 129, the 
next study investigates concentrations of 0.01mM, 0.05mM, 0.1mM, 0.5mM and 1mM in a ratio of 1:1 
of copper nitrate to silver nitrate in the bacteria suspension, as described in section 4.4.9 and 4.4.10. 
 It was noted that the bacteria were not growing within expected limits in the current conditions 
and in combination with the metal salts the pH of the bacterial suspension increased as described 
previously in section 6.3.2 for the cell culture work. This can be partially resolved by increasing the 
CO2 levels in the incubator during the bacterial immersion as this will reduce the initial pH in the 
DMEM/F-12 and keep the pH down to an acceptable level that corresponds to a suitable pH for cell 
growth, as shown in Figure 131. Using this graph the CO2 levels were increased to 9.5% CO2 in the 
incubator for 24 hours before the samples were plated. This process reduced the pH down to 
approximately 7.1 when the level of NaHCO3 was at 2.4mg/ml which is a suitable pH for both cells and 
bacteria to grow in. 
 
 
Figure 131:- Graph showing CO2 levels required to change the pH for given levels of NaHCO3 found in DMEM/F-
12 to give a suitable pH value for cells and bacteria to grow 
 
 The second study using the metal nitrate salts considered the CFU’s formed after the 
suspensions had been incubated for 24 hours, plated and the results collected after further 24 hours, as 
described in sections 4.4.9 and 4.4.10. The concentrations ascertained from the previous study were 
considered using the change of absorption as the indicator of change in the growth of E.coli. 
 Figure 132 shows the suspensions of the metal salts in DMEM/F-12 with E.coli and gives an 
early indication of which concentrations of the metal salts are affecting the E.coli. Figure 132A shows 
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the suspensions with different concentrations of silver nitrate and compare the media control and the 
E.coli suspension control (Figure 132Ai and Figure 132Aii respectively). The suspensions containing 
silver nitrate (Figure 132Aiii-vi) all show colouring and a clarity which is similar to the media control 
rather than the E.coli suspension control. This result indicates that the silver nitrate has a negative effect 
on the bacteria, as was shown in Figure 127, with the colour and the turbidity of the suspension changing 
from orange to yellow and from clear to cloudy, respectively. 
  
 
Figure 132:- DMEM/F-12 and E.coli suspensions with A) silver nitrate with concentrations of iii) 0.01mM iv) 
0.05mM v) 0.1mM and vi) 0.5mM, B) copper nitrate with concentrations of iii) 5mM iv) 2mM v) 1mM vi) 0.5mM 
and vii) 0.1mM, C) combination of silver and copper nitrate in a ratio of 1:1 with concentrations of iii)1 mM 
iv)0.5mM v)0.1mM vi) 0.05mM and vii) 0.01mM, with i) and ii) in each picture showing a plain media control 
and an E.coli suspension control, respectively 
 
242 
 
Figure 132B shows the copper nitrate suspensions along with a control medium and an E.coli 
suspension control (Figure 132Bi and Figure 132Bii respectively). The suspensions with concentrations 
of copper nitrate of 5mM and 2mM (Figure 132Biii and Figure 132Biv) show the turbidity to be similar 
to the control medium but with some discolouration compared to the control. This result suggests that 
these concentrations of copper nitrate have a negative effect on the E.coli and that the discolouration of 
the media is due to the presence of the dark blue copper nitrate. It is also observed that the suspension 
with a copper nitrate concentration of 1mM (Figure 132Bv) shows an increase in its turbidity compared 
to the control. It maintains a similar colour to the control and this would indicate that this concentration 
has a bacteriostatic effect on the E.coli but it does not exhibit a full bactericidal effect. The lowest two 
copper nitrate concentrations, 0.5mM and 0.1mM, both showed a similar colour and turbidity to that 
seen in the E.coli suspension control (Figure 132Bvi, Figure 132Bvii and Figure 132Bii, respectively). 
This result shows that at these concentrations of copper nitrate E.coli bacteria is not being negatively 
affected. 
 Figure 132C shows the combination silver and copper nitrate suspensions along with a control 
medium and an E.coli suspension control (Figure 132Ci and Figure 132Cii respectively). The lowest 
concentration suspension showed little difference from the E.coli suspension in terms of its turbidity 
and colouring (Figure 132Cvii) which indicates that at this concentration the combined metal salts 
solution has no negative effect on E.coli as the concentration of the metal salts is not sufficiently high. 
The rest of the concentrations of the combined metal salt suspensions (Figure 132Ciii to Figure 132Cvii) 
showed colouring and turbidity similar to that seen in the control (Figure 132Ci) indicating that the 
concentration of metal salts in these suspensions was sufficient to cause a negative effect on  E.coli. 
 Figure 132 gives thus a qualitative representation of the suspensions behaviour after the 
suspensions have been plated onto agar plates indicating which concentrations of the metal salts have 
had an effect on the bacteria. However this representation does not show whether the effect on the 
bacteria will be bacteriostatic or bactericidal. 
 Table 42, Table 43 and Table 44 present the CFU counts from the plated samples shown in 
Figure 132 indicating which concentrations of the metal salts have induced a negative effect on the 
E.coli whether that is bacteriostatic or bactericidal. Each table shows the CFU count for bacteria/metal 
salt suspensions with and without sodium thiosulfate, therefore observed effects can be categorised as 
either bacteriostatic, bactericidal or no effect, as described in section 6.4.3. 
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Table 42:- Colony forming units counted after being exposed to varying concentrations of silver nitrate in the 
E.coli suspension after 24 hours of incubation (TMTC meaning too many to count) 
Concentration Colony forming units 
of silver  With Sodium  Dilution 
nitrate Thiosulfate 3 4 5 6 
0.01 TMTC TMTC 1289 154 11 3 
0.05 526 632 0 0 0 0 
0.1 0 0 0 0 0 0 
0.5 0 1 0 0 0 0 
 
Table 43:- Colony forming units counted after being exposed to varying concentrations of copper nitrate in the 
E.coli suspension after 24 hours of incubation (TMTC meaning too many to count) 
Concentration Colony forming units 
of copper With Sodium  Dilution 
nitrate Thiosulfate 3 4 5 6 
0.1 TMTC TMTC TMTC TMTC 432 58 
0.5 TMTC TMTC TMTC 341 35 5 
1 TMTC TMTC 832 172 18 2 
2 801 821 6 2 0 0 
5 500 621 0 0 0 0 
 
Table 44:- Colony forming units counted after being exposed to varying concentrations of combination of copper 
nitrate and silver nitrate, in a 1:1 ratio, in the E.coli suspension after 24 hours of incubation (TMTC meaning too 
many to count) 
Concentration Colony forming units 
of silver and  With Sodium  Dilution 
copper nitrate Thiosulfate 3 4 5 6 
0.01 TMTC TMTC TMTC 822 114 19 
0.05 TMTC TMTC 50 36 1 0 
0.1 1022 1011 0 0 0 0 
0.5 782 809 0 0 0 0 
 
Table 42 shows the CFU counts for the silver nitrate concentrations indicating that 
concentrations above 0.01mM cause a bacteriostatic effect and for concentrations above 0.05mM a 
bactericidal effect on the E.coli. This result indicates that for the silver nitrate to be an effective anti-
bacterial agent the concentration needs to be higher than 0.01mM. This result also supports previous 
relevant work that has been reported in the literature. (468) (469) 
Table 43 shows the CFU counts for different copper nitrate concentrations and this data shows 
that in order for copper nitrate to produce a bacteriostatic effect the concentration needs to be above 
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2mM and for a bactericidal effect the concentration needs to be above 5mM. These required 
concentrations are significantly higher than the concentrations required for silver nitrate which indicates 
for this set of tests that silver nitrate out performs copper nitrate in terms of anti-bacterial potency.  
Finally Table 44 shows the CFU count for the combination metal salt data indicating that in 
order to have a bacteriostatic effect the combined concentration of the two metal salts must be higher 
than 0.05mM and to produce a bactericidal effect the combined metal salt concentration must be above 
0.5mM. This combination of metal salts outperformed copper nitrate but gave similar results to silver 
nitrate in terms of the bacteriostatic effect. Notably, the bactericidal effect caused by the combination 
of the two metal salts required a higher concentration compared to that used in silver nitrate only. This 
result could indicate that the presence of copper nitrate was hampering silver nitrate in causing a 
bactericidal effect, but the reasons for this behaviour were not further investigated here. These results 
offer no insight into the mechanisms of how the metal ions cause the bactericidal or bacteriostatic effects 
on the E.coli, as seen in work carried out by other researchers. (296) (409) 
   
6.4.5 Growth inhibition capabilities of molten salt ion exchange scaffolds using Escherichia coli 
 
 The results presented in sections 6.4.1 to 6.4.4 are preliminary optimisation studies based on a 
similar investigation presented by Heidenau et al (409) and tailored the experimental conditions for the 
study, which was designed to determine if the MSIE scaffolds will have an antibacterial effect on the 
E.coli. This study uses the supernatants from immersed doped scaffolds, as described in section 4.4.11 
and the results can be compared to those obtained in the previous section. 
 Figure 133 shows the E.coli suspensions with the supernatants after 24 hours of incubation at 
37oC at 9.5% CO2 on a shaking plate. The supernatants covered samples of all types of MSIE scaffolds 
(silver, copper and silver/copper MSIE samples) and the BBG scaffold as a control. Immersion times 
of 1, 3, 7 and 28 days were investigated. Figure 133 shows a medium control in each picture as well as 
an E.coli suspension control for comparison. It can be seen that all of the supernatant samples show 
turbidity and colouring similar to the E.coli suspension control. This result indicates that the 
concentration of ions released by the scaffolds into the media added to the E.coli suspensions was not 
high enough to cause any negative effect on the E.coli. 
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Figure 133:-Suspensions of E.coli in DMEM/F-12 with supernatants added from scaffolds immersed in DMEM/F-
12 for A) 1 day B) 3 days C) 7 days and D) 28 days after 24 hours of incubation at 37oc and 9.5% CO2 
 
The suspensions were then plated onto standard I agar plates with two sets of plates; the first 
set had additional sodium thiosulfate added to the suspensions and it was not diluted while the second 
set only used the suspensions and they were diluted, as described in section 4.4.8. Photographs of the 
plates are shown in appendix C2 and all the collated data shown in the following tables and graphs are 
taken directly from those figures. 
Table 45 to Table 48 show the CFU data for the supernatants taken from the plain, silver, copper 
and silver/copper samples, respectively, immersed in DMEM/F-12 for 1, 3, 7 and 28 days. These figures 
show that none of the samples had an effect on the bacteria as CFU’s were present on all the plates and 
there was no marked reduction during the immersion period, i.e. no statistically meaningful difference 
between the samples taken after one day of immersion compared to those samples taken after 28 days 
of immersion.  
Table 45:- Colony forming units counted after being exposed to supernatants from immersed plain scaffolds after 
24 hours incubating at 37oC at 9.5% CO2 
Immersion  Colony forming units 
period of  with sodium Dilution 
the scaffold thiosulfate 3 4 5 6 
Control n/a n/a TMTC 783 102 18 
1 day  TMTC  TMTC   TMTC 568  108   20 
3 days  TMTC  TMTC   TMTC 691 126   18 
7 days  TMTC  TMTC   TMTC 412 78  8 
28 days  TMTC  TMTC   TMTC 1034  330   37 
 * TMTC - too many to count 
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Table 46:- Colony forming units counted after being exposed to supernatants from immersed low concentration 
silver MSIE scaffolds after 24 hours incubating at 37oC at 9.5% CO2 
Immersion  Colony forming units 
period of  with sodium Dilution 
the scaffold thiosulfate 3 4 5 6 
Control n/a n/a TMTC 783 102 18 
1 day   TMTC   TMTC TMTC TMTC 500 120 
3 days   TMTC   TMTC TMTC 606 54 7 
7 days   TMTC   TMTC TMTC 734 135 20 
28 days   TMTC  TMTC TMTC 931 122 24 
 * TMTC - too many to count 
 
Table 47:- Colony forming units counted after being exposed to supernatants from immersed low concentration 
copper MSIE scaffolds after 24 hours incubating at 37oC at 9.5% CO2 
Immersion  Colony forming units 
period of  with sodium Dilution 
the scaffold thiosulfate 3 4 5 6 
Control n/a n/a TMTC 783 102 18 
1 day   TMTC  TMTC TMTC 682 113 11 
3 days  TMTC  TMTC TMTC 668 142 10 
7 days  TMTC  TMTC TMTC 633 64 11 
28 days   TMTC  TMTC TMTC 171 26 0 
 * TMTC - too many to count 
 
Table 48:- Colony forming units counted after being exposed to supernatants from immersed low concentration 
silver/copper MSIE scaffolds after 24 hours incubating at 37oC at 9.5% CO2 
Immersion  Colony forming units 
period of  with sodium Dilution 
the scaffold thiosulfate 3 4 5 6 
Control n/a n/a TMTC 783 102 18 
1 day   TMTC   TMTC TMTC 631 150 16 
3 days  TMTC   TMTC TMTC 564 121 18 
7 days   TMTC   TMTC TMTC 352 45 3 
28 days  TMTC   TMTC 718 129 11 1 
 * TMTC - too many to count 
 
Several interesting aspects arise from analysing these results. Firstly, the BBG scaffold seems 
to have no anti-bacterial effect on E.coli. Secondly, the concentrations of metal ions introduced through 
MSIE were not high enough to cause any anti-bacterial effect on the E.coli as no difference was seen 
between the plates that had had the supernatant from the MSIE scaffolds and the E.coli plates used as a 
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control. The results also show that there was little difference between the types of metal ions used 
although the longer immersion period did yield slightly better results for the copper and the 
silver/copper samples, in terms of perceived antibacterial effect on the E.coli.  
 
6.4.6 Agar diffusion studies using Escherichia coli 
 
 Agar diffusion tests were carried out, as described in section 4.4.12.I, first using metal salts 
suspended in DMEM/F-12 and then using the supernatants from low concentration MSIE scaffolds in 
DMEM/F-12 from a range of immersion periods. This study was done to give a direct comparison 
between known concentration samples (metal salt solutions) and the unknown concentration samples 
(scaffolds). 
Figure 134 shows agar diffusion using suspensions of silver nitrate in DMEM/F-12 for a range 
of concentrations to determine which concentrations of silver nitrate would cause an antibacterial effect, 
but it should be noted that this type of test will not show if the effect on the E.coli is bacteriostatic or 
bactericidal. The test shows just whether or not the sample is having an effect on the bacteria. It can be 
seen that the lower concentrations of silver nitrate, shown in Figure 134A, exhibits no visible halo 
around the sample discs with silver nitrate concentrations of 0.02mM and 0.05mM, indicating that these 
concentrations had no effect on the E.coli present, however there was a slight halo surrounding the 
sample with a concentration of 0.1mM of silver nitrate. The concentrations of silver nitrate shown in 
Figure 134B all exhibit varying sized halos around the sample disc indicating the occurrence of an 
antibacterial effect. This result confirms the data from section 6.4.4, in that the concentration of silver 
nitrate needs to be above 0.05mM in order to cause an antibacterial effect on the E.coli. 
 The same agar diffusion study was carried out using suspensions of copper nitrate in DMEM/F-
12 at a range of concentrations, as described in section 4.4.12. Figure 135 shows the agar diffusion plate 
of the higher concentration sample discs with concentrations of 0.5mM, 1mM and 2mM of copper 
nitrate (and a medium control disc). It is observed that none of them show any discernible halo 
surrounding the disc indicating that the concentration of copper nitrate was not high enough to have any 
antibacterial effect on the E.coli. This result agrees with the data shown in section 6.4.4 and indicates 
that for copper to be an effective antibacterial agent the concentration of copper needs to be over 2mM. 
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Figure 134:- Results of the agar diffusion study to show the growth inhibition of silver nitrate solutions with A) 
showing a plain media disk, 0.1mM, 0.05mM and 0.02mM concentrations of silver nitrate on filter paper disks 
and B) showing a plain media disk, 1mM, 0.5mM and 0.2mM concentrations of silver nitrate on filter paper disks 
 
 
Figure 135:- Result of the agar diffusion study to show the growth inhibition of dilutions of copper nitrate 
inoculated onto filter paper disks. Concentrations of 2mM, 1mM and 0.5mM were used along with a control disks 
inoculated with media 
 
 The second part of the agar diffusion study involved using supernatant from all the sample types 
to conclude if the concentrations used in the scaffolds are high enough to cause an anti-bacterial effect, 
as described in section 4.4.12.I. Typical resulting plates are shown in Figure 136. The supernatants 
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taken from the immersed plain scaffolds from the varying immersion periods showed no visible halo 
around the discs indicating that these had no anti-bacterial effect on the E.coli, as shown Figure 136A. 
These results thus correspond with the results presented in section 6.4.5. 
Figure 136B and Figure 136D show the results for the silver only scaffolds and the combination 
silver and copper scaffolds along with a metal salt control with a concentration of 1mM. None of the 
supernatant samples presented in these two figures showed any indication of anti-bacterial activity due 
to the lack of a halo around the disc; however each of the control samples showed a halo indicating that 
this concentration was sufficient to cause an anti-bacterial effect on the E.coli. These results are in 
agreement with the data shown in the previous section. 
 
 
Figure 136:- Results of the agar diffusion study to show the growth inhibition of: A) BBG scaffold, B) Low 
concentration silver-doped BBG scaffold, C) Low concentration copper-doped BBG scaffold and D) Low 
concentration combination ion-doped BBG scaffold in the presence of E.coli bacteria 
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 Finally Figure 136C shows the supernatant results for the copper scaffolds with a metal salt 
control with a concentration of 1mM. None of the sample discs, including the control, showed any anti-
bacterial effect leading to the conclusion that the copper concentration was not high enough in these 
samples. This data was also in agreement with the results found in the previous work (reported in section 
6.4.5).  
In conclusion the lack of any visible halo surrounding the supernatant discs confirms the results 
found in section 6.4.5 indicating that the concentration of metal ions introduced using the MSIE 
technique is not high enough to cause any antibacterial effect on the E.coli. These agar diffusion tests 
also support the results shown in section 6.4.4 with respect to the concentration of metal salts required 
to cause an antibacterial effect on the E.coli.   
 
6.4.7 Agar diffusion studies using Staphylococcus aureus 
 
 The effect of the different MSIE scaffolds, at their lowest concentration, and of a control BBG 
scaffold on S.aureus was tested using agar diffusion, as described in section 4.4.11, to give an indication 
of the growth inhibition caused by these samples. If the scaffolds had a bacteriostatic or bactericidal 
effect on S.aureus, a halo effect would be seen on the agar plate surrounding the sample. As mentioned 
above, the clearer and larger this halo is, the more effective is the sample against bacteria in qualitative 
terms. The results of the diffusion test carried out using S.aureus are shown in Figure 137. 
It can be seen from Figure 137A that BBG scaffolds have no bacteriostatic or bactericidal effect 
as there is no perceptible halo around the scaffold. Figure 137B-D all show at least a limited amount of 
bactericidal or bacteriostatic effect as they all exhibited varying degrees of the antibacterial halo. This 
result is encouraging as it means that the concentration of therapeutic metal ions in the samples is high 
enough to cause a reaction to S.aureus. The copper-doped sample showed the highest effect against 
S.aureus as it had the largest antibacterial halo surrounding it compared to the silver-doped sample and 
the combination ion-doped sample. The combined Cu/Ag-doped sample showed the smallest 
antibacterial halo but the halo was still present, after the incubation period of 24 hours, indicating that 
if the sample was left for longer the ions might produce a longer lasting antibacterial effect.  
This result must be considered in future work involving MSIE scaffolds as it gives an indication 
of whether the samples are bacteriostatic or bactericidal against S.aureus. If the halo stayed visible or 
increased further in size, this would indicate that the bacteria cells were being killed by the scaffold and 
therefore the sample would be considered bactericidal. However if the halo decreased in size this would 
indicate that the sample was bacteriostatic. 
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Figure 137:- Results of agar diffusion to show the growth inhibition properties of: A) BBG scaffold, B) Low 
concentration silver-doped BBG scaffold, C) Low concentration copper-doped BBG scaffold and D) Low 
concentration combination ion-doped BBG scaffold in the presence of S.aureus bacteria after an incubation 
period of 24 hours 
 
 Comparing this result with the results found using E.coli, it is shown that S.aureus was more 
susceptible to the MSIE samples than the E.coli. This also showed that whilst the concentration of the 
MSIE metal ions was high enough to have an antibacterial effect on the S.aureus bacteria it was not 
high enough to have effect on the E.coli bacteria. The main reason is related to the fact that E.coli is a 
gram-negative bacteria and S.aureus is a gram-positive bacteria, which means that the bacteria behave 
differently in terms of how they react to the metal ions present in the incubation medium, as described 
in the literature review. 
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6.4.8 Growth inhibition studies using Klebsiella pneumoniae 
 
 The quantitative bacterial experiment using K.pneumoniae following the method described in 
section 4.4.13 showed that 18 hours after being seeded with K.pneumoniae there was a complete 
reduction in the number of CFU’s present, as shown in Table 49, compared with the control sample, 
which was an industry standard textile (PES). (470) (471) (472) 
Table 49:- Results of bacterial experiments carried out on 3D scaffolds loaded with K.pneumoniae and incubated 
for 18 hours at 36oC 
 Initial Load Final load Change cfu Increase  
Sample type Number of cfu’s per sample Percentage (%) or decrease 
Control textile PES 4.91 x 104  1.24x107  25154.58 Increase 
45S5 Bioglass scaffold 4.91 x 104  <20 -99.96 Decrease 
Silver-doped scaffold (*) 4.91 x 104 <20 -99.96 Decrease 
Copper-doped scaffold (*) 4.91 x 104 <20 -99.96 Decrease 
Combination ion-doped scaffold (*) 4.91 x 104 <20 -99.96 Decrease 
(*) All at the lowest concentration of MSIE samples 
 
 All four sample types showed an almost complete reduction in the number of CFU’s, which 
indicated that all samples had antibacterial effect on the K.pneumoniae bacteria, including the BBG 
scaffold. Although this study showed that all four sample types affected K.pneumoniae bacteria the 
results gave no indication as to which of the MSIE samples was more effective, thus it cannot be 
ascertained which of the released metal ions (whether from the BBG scaffold or from the additional 
ions for example for silver and copper) gave the most effective antibacterial activity. 
 However this study also indicated, as was the case with the results presented in section 6.4.5 
for the S.aureus bacteria, that the concentration of the added metal ions in the MSIE samples was high 
enough to cause an effect on the K.pneumoniae bacteria, although this effect cannot be attributed to the 
release of the additional metal ions introduced through MSIE over the ions released from the BBG 
scaffold. This study did not provide any insight or support to the current theories as to how the bacteria 
are disrupted by the metal ions, as described in the literature review. Comparing this study to the agar 
diffusion results shown in section 6.4.6 for the E.coli, it can be stated that the samples were toxic enough 
to have an effect on the K.pneumoniae but not on the E.coli despite the fact they are both gram-negative 
bacteria. 
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6.5 Summary of results from the cell biology and bacterial studies 
6.5.1 Summary of cell biology work 
 
 Overall the cell biology work in collaboration with the Leeds Dental Institute produced relevant 
results and paved the way forward for the work that was carried out in collaboration with the University 
of Erlangen-Nuremberg.  This work showed that whilst all silver-doped scaffolds obtained by different 
concentrations and immersion periods produced no observable cytotoxic effect according to the 
live/dead staining study, the best results were seen on scaffolds obtained by the lowest concentration of 
silver, and immersed for the shortest time in the salt bath. These results support data published by other 
researchers on similar scaffold types and parameters. (6) (113)  
 The studies using rMSC’s showed that the samples needed to go through a more rigorous pre-
conditioning before being exposed to the cells in-order to reduce the potential cytotoxic effect caused 
by the rise in pH. This work showed that once scaffolds were conditioned both the plain and silver 
doped samples had reduced cytotoxicity compared to that found in preliminary studies. However it was 
seen that the copper doped samples and silver/copper doped samples created an environment that was 
cytotoxic, this could suggest that the concentration of the metal ions was too high or that the release 
rate was excessive and caused an overdose when exposing cells to the samples.  
 The studies using hMSC’s showed that despite the reduction in concentration in the copper and 
silver/copper MSIE samples, they still produced a cytotoxic effect on the cells. This result suggests that 
further optimization of these MSIE scaffolds is required before further in vitro and in vivo work can be 
carried out with them. 
 The significant difference between the work carried out at the Leeds Dental Institute and that 
carried out with the University of Erlangen-Nuremberg is likely related to the seeding system in each 
case. The HPLSC work used a dynamic seeding system that was constantly moving the cell culture 
media through and around the scaffolds and therefore washing away dead cells and ions away from the 
scaffolds. On the other hand the rMSC and hMSC cell culture work was carried out using a static 
seeding technique which did not allow any movement of the medium around the cells. In terms of this 
work it can be seen that the dynamic seeding system gave more consistent results and in terms of 
accuracy it is closer to the actual in vivo environment than the static seeding model. This result also 
confirms that future studies will benefit from introducing the application of bioreactors into the 
development of similar scaffolds to optimise scaffold composition in conditions closer to the in vivo 
environment. (473) (474) (475) It is worth noting that most in vitro work carried out previously on BBG 
scaffolds was conducted in static conditions. (476) (352) (477) (478) Our results have confirmed, 
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especially in the case of ion-doped scaffolds, the relevance of understanding the in vitro behaviour in 
dynamic conditions. 
 As stated in chapter five, the surface of a biomaterial plays a crucial role in the establishment 
of the interface between the seeded cells and the scaffold and the literature has shown that the quality 
of the initial cell attachment to a scaffold’s surface determines subsequent cell behaviour including 
adhesion, spreading, morphology, migration, proliferation and differentiation. (462) However recent 
findings have shown that not only the roughness is an important parameter but also the surface 
morphology, in terms of a surfaces texture and overall diversity of observed features, especially for 
long term cell adhesion compared to the surface chemistry and roughness. (462) 
Cells cultures on very rough surfaces, such as those observed for the copper and silver/copper 
doped scaffolds, tend to exhibit an increase in osteoblasts differentiation, ALP activity and protein 
production and a decrease in cell proliferation. (461)  Cells have been observed to be smaller on rougher 
surfaces, which was observed in some of the images in this work, with the quality of the cell contact on 
a rough surface being related to the minimum width of the peaks and troughs on the surface. (462) 
These observations are a good indicator as to whether the surface roughness affects cell behaviour in 
the context of the present investigation.  
It should be noted that another aspect that makes the assessment of the effect of surface 
roughness difficult is the MSIE doping process itself. (461) Indeed, the effect of surface roughness on 
cells maybe be attributed to the actual roughness itself or to the pre-conditioning, sterilisation treatment 
or to the presence of additional metal ions or a combination of these factors. (461) Clearly, these 
complex effects need to be investigated further to produce a complete protocol that will take into 
account some of these parameters to eliminate their additional error, and to be able to ascertain the 
independence of the different variable involved. 
Just as with the changes in surface roughness, the available data do not allow to conclude that 
the cell death observed was caused by the change in sample type solely as cell death detected could 
have also been by normal apoptosis. (404) In the future an additional assay needs to be carried out to 
rule out cells that died due to apoptosis. (404) 
 
6.5.2 Summary of bacterial studies 
 
Overall the bacterial work carried out in this project produced results which confirmed the 
viability of the use of metal ions in the development of multifunctional Bioglass® -based scaffolds. The 
growth curves that were first produced showed that whilst the bacteria grew in the CCM that was used 
255 
 
in the cell biology studies, the bacteria suspension required more acclimatisation time compared to the 
more conventional bacteria media (Mueller Hinton broth in this case), but once this period was over the 
growth exceeded that of the conventional medium.  
It was discovered that the optimum growing conditions for the bacteria included a two hour 
acclimatisation period and that the bacteria suspensions were incubated in 9.5%CO2 and 37oC compared 
to standard conditions of 5%CO2 and 37oC. This increase in CO2 levels decreased the pH in the bacteria 
suspension making the growing conditions in the suspension suitable for the experiments in the content 
of this work. 
The use of sodium thiosulfate was considered to deactivate the silver and copper salts to show 
whether the addition of these salts had a bactericidal or bacteriostatic effect. The experiment showed 
that in the DMEM/F-12 medium the presence of sodium thiosulfate deactivated the metal salts which 
made it possible to determine which concentrations of the metal salts were bactericidal or bacteriostatic. 
After 24 hours incubation and 24 hours on agar plates the minimum bactericidal and 
bacteriostatic concentration for the silver nitrate suspension was found to be 0.05mM. The minimum 
bacteriostatic concentration for the copper nitrate suspension was found to be 5mM and after using 
sodium thiosulfate to deactivate the metal nitrate salts the minimum bactericidal concentration was 
found to be above 5mM. The minimum bacteriostatic concentration for the combined copper and silver 
nitrate suspension was found to be 0.1mM and after using sodium thiosulfate to deactivate the metal 
nitrate salts the minimum bactericidal concentration was found to be above 1mM.  
A higher concentration of copper nitrate is required to produce the desired antibacterial effect 
and the presence of the copper nitrate salt appears to have a detrimental effect on the effectiveness of 
the silver nitrate as suggested by the increased concentration required when the combination of metal 
nitrate salts was tested. This experiment thus gave insight into the concentration of silver and copper 
nitrate, separately and in combination, required in the samples in order to be effective as an antibacterial 
scaffold. It should be noted that although the bactericidal concentrations for the copper and combination 
nitrate were not determined, the bacteriostatic concentrations were obtained, and this result is important 
because if a bacteria is held in a bacteriostatic environment for a sufficient period of time, bacteria cells 
will start to die due to being held in an environment that is toxic. 
The experiments then required the use of supernatant that was taken from DMEM/F-12 that 
had been in contact with MSIE scaffolds for 1,3,7 and 28 days, combined with a bacteria suspension to 
investigate whether the concentrations of metal ions in the scaffold are sufficient to produce the desired 
antibacterial effect. The suspensions that were plated with the addition of sodium thiosulfate showed 
almost complete growth for all sample types over all immersion time points. The suspensions plated 
without the presence of sodium thiosulfate all showed no effect on the bacterial growth across all sample 
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types and immersion periods in DMEM/F-12. This result indicates that the concentration of the metal 
salts present in the scaffolds was not high enough to have a bacteriostatic effect or bactericidal effect.  
Determining the antibacterial effect of copper and silver doped samples (and nitrate salts) 
through diffusion gave similar results to the previous set of experiments. Indeed, none of the samples 
that had been subjected to the various scaffold supernatants showed any inhibition zones in a laboratory 
setting. This behaviour suggests that the concentration of the metal ions present in the scaffolds was not 
high enough to cause either a bacteriostatic or bactericidal effect under the experimental conditions 
investigated. However this diffusion experiment did correlate with the results found in the minimum 
inhibition experiments in the presence of varying concentrations of metal nitrates, thus enforcing the 
minimum inhibition values found there. 
The minimum inhibition zone experiments carried out using S.aureus (carried out by Dr Timo 
Hammer from Hohenstein Institut für Textilinnovation e.V, Germany) showed that the presence of the 
metal ions had an effect on the bacterial growth with the copper scaffold having the largest antibacterial 
effect on the bacteria out of the four sample types. This result indicates that the concentrations, whilst 
not being high enough to have an antibacterial effect on the E.coli, are high enough to have at least a 
bacteriostatic effect. A quantitative test using K.pneumoniae was also carried out to show how the 
scaffolds performed against this type of bacteria. These preliminary tests showed that all four types of 
scaffold, including the BBG scaffold, had at least a bacteriostatic effect on this type of bacteria, 
compared to the control. This finding is useful as it gives an indication that for some types of bacteria 
the concentration of metal ions present in the scaffolds was high enough to have the desired effect on 
the bacteria cells and clearly confirmed that the incorporation of metallic ions into bioactive glasses as 
antibacterial agent needs to be tailored based on the target bacteria.  
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Chapter Seven 
7. Concluding remarks 
 
 In the scope of this project, the fabrication and characterisation of novel multifunctional three 
dimensional bioactive composite scaffolds based on 45S5 Bioglass® -derived glass-ceramics intended 
for BTE applications have been investigated. The overall aim of this work, as described in chapter three, 
was to improve the existing conventional BBG scaffolds whilst maintaining their desirable intrinsic 
bioactive properties. The BBG scaffolds were modified using a combination of MSIE processing and 
polymer coating to produce novel scaffolds with enhanced properties for use in BTE.   
 The experiments, described in chapter four, were designed and carried out to achieve the 
objectives set out in chapter three and the results of this work are presented in chapters five and six. In 
general, the results of this work have demonstrated that the introduction of silver and/or copper through 
MSIE and the addition of a gelatin coating have improved the mechanical properties, whilst 
simultaneously introducing additional functionality (antibacterial for example) and maintaining the 
desirable bioactivity of the BBG scaffolds. The forthcoming sections summaries the key results 
achieved, presented in chapters five and six. In addition, this section presents a final outlook on how 
this work contributes to the general field of BTE. This chapter does not explore the scope of future work 
as this is covered in the next chapter. 
 
7.1 General observations on 45S5 Bioglass®- derived glass-ceramic scaffolds 
 
 This work has established that the foam replication technique reliably produces bone tissue 
scaffolds suitable for further modification. The initial characterisation of the BBG scaffolds was carried 
out to establish a robust control for comparison with the modified scaffolds and to check that these BBG 
scaffolds exhibited the established properties discussed in previous research for this class of scaffolds, 
described in chapter two. It was established that the BBG scaffolds produced using the foam replication 
technique were similar to those reported previous work as follows:- 
 Scaffolds exhibited an average porosity of 93±2% which fell by an average of 10% to 84±2% 
after immersion in SBF for 14 days 
 SEM analysis showed that the scaffolds had a pore size in the range of 200-600µm, a strut 
cross-section of between 25 and 75µm and maintained a pore shape and interconnectivity 
suitable for BTE, after immersion in SBF for 14 days 
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 Chemical composition and crystalline structure of the BBG scaffolds were investigated using 
XRD, EDX and FTIR, pre and post SBF immersion 
 After immersion in SBF, SEM analysis showed the presence of HA which is the marker for 
bioactivity in the context of bone contacting materials and it has  been identified in the literature 
as the precursor to enable bone attachment 
 Scaffolds showed a surface topography suitable for cell attachment displaying a contact angle 
of 28±4o and 23±2o pre and post SBF immersion and white light interferometry RMS, Ra and 
PV values of 3±1µm, 2.6±0.9µm and 19±9µm pre-SBF immersion and 6±1µm, 6±1µm and 
26±9µm post-SBF immersion, respectively 
 Scaffolds exhibited a compressional strength in the range of 0.4-0.5MPa, which did not 
significantly after immersion in SBF for 14 days 
 The BBG scaffolds increased the pH of the SBF and CCM through the rapid release of ions 
once the scaffolds are immersed, which can cause a cytotoxic effect on any cells or bacteria 
present 
 When HPLSC’s were exposed to the BBG scaffolds in CCM in a dynamic cell seeding 
environment there was no cytotoxic effect on the cells detected and the scaffolds did not have 
a detrimental effect on the cells ability to attach to the surface of the scaffold 
 The pH increase caused by the BBG scaffolds caused significant cell death (in the rMSC study) 
when using a static cell seeding environment  
 Once the pre-conditioning treatment was introduced, cell death significantly reduced and gave 
AB results similar to those observed in the control well, confirming that the conditioned BBG 
scaffolds were suitable to seed rMSC’s and hMSC’s 
 BBG scaffolds had no anti-bacterial effect on E.coli after the bacteria was added to supernatant 
CCM or during agar diffusion studies 
 The BBG scaffolds had no anti-bacterial effect on S.aureus after an agar diffusion study as no 
perceptible halo around the scaffold was observed 
 The BBG scaffolds caused a significant reaction when K.pneumoniae was exposed to the 
scaffolds indicating that there was an anti-bacterial reaction caused by the scaffold 
Overall the results of the structural and biological characterisation agree with published 
literature results and they contribute to the overall knowledge and understanding about these 
increasingly used BBG scaffolds for BTE. 
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7.2 Molten salt ion exchange scaffolds 
 
 This work has established for the first time that the MSIE technique can be used to introduce 
therapeutic metal ions into prefabricated BBG scaffolds. The introduction of silver and/or copper 
through MSIE produced the following results:- 
 Silver and copper were successfully introduced into BBG scaffolds as confirmed by XRD, 
FTIR, ICP-MS and EDX and were still present after immersion in SBF for 14 days. Ion doping 
by MSIE did not alter the scaffold structure significantly so that after immersion in SBF HA 
was detected on the surface of the scaffold indicating that the introduction of the silver and/or 
copper did not have a detrimental effect on the desirable bioactivity of the BBG scaffolds 
 The porosity of the MSIE scaffolds was, on average, 20% lower than that observed for the BBG 
scaffolds but it was still above the ideal threshold of 75%. The porosity of the ion-doped 
scaffolds after immersion in SBF, was seen to reduce by approximately 10% which was similar 
to the reduction of the porosity of the BBG scaffolds after immersion in SBF 
 The pore size, shape and interconnectivity were observed to be similar to those observed in the 
base scaffolds indicating that the MSIE processing does not detrimentally effect the overall 
pore structure of the base scaffold 
 The surface topography was significantly altered due to the MSIE processing, namely the MSIE 
process changed the surface roughness of struts. The silver-doped scaffolds exhibited a slightly 
smoother surface topography with a reduction in the contact angle whilst the copper-doped and 
silver/copper-doped scaffolds exhibited an increase in their surface roughness along with an 
increase in the contact angles compared to those observed for BBG scaffolds. This result 
indicated the possibility of coupling chemical modification and surface roughness control by 
designing the parameters of the MSIE technique. It can not be conclusively proved that the 
change in the surface roughness will lead to a change in cell behaviour. 
 The ion-doped scaffolds had a marginally higher, on average 15% higher, compressional 
strength than the BBG scaffold. After SBF immersion, the ion-doped samples showed a slight 
reduction in their compressional strength as the BBG scaffolds 
 Depth EDX analysis showed that silver penetrated deeper into the scaffolds silicate structure 
compared to copper but a higher concentration of copper was detected infiltrating the ion-doped 
scaffolds compared to silver 
 ICP-MS along with EDX analysis showed that copper was released in a fast intense burst 
compared to the slow, controlled and low release of the silver within the ion-doped scaffolds 
 It can not be conclusively proved that the MSIE process has led to a complete incorporation of  
the ions into the glass-ceramic structure as the silver and copper detected could be also from 
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residue salt that have infiltrated the micro-cracks on the surface of the scaffold. Additional 
characterisation work is required in this instance 
 When the silver-doped samples were dynamically seeded with HPLSC’s the silver-doped 
scaffolds did not have a detrimental effect on the attachment of  HPLSC’s and did not cause a 
cytotoxic effect 
 Initial cell biology studies with rMSC’s showed that all three ion-doped scaffold types, along 
with the BBG scaffolds, caused a significant cytotoxic effect, which was mainly attributed to 
the pH increase caused by the release of ions from the BBG scaffolds. It can not be proved that 
the change in surface roughness caused by the MSIE process did not have effect on the cell 
behaviour  
 After additional pre-conditioning was introduced, the copper-doped and silver/copper-doped 
scaffolds still had a detrimental cytotoxic effect on the rMSC’s while the silver-doped scaffolds 
were found to only cause a slight cytotoxic effect. This result indicated that the concentrations 
used in the copper-doped and silver/copper-doped scaffolds are too high as they are cytotoxic 
on the rMSC’s. The lowest concentration of silver in the molten salt bath coupled with an 
immersion period of 15 minutes produces a scaffold that allows cell attachment and does not 
cause a detrimental cytotoxic effect. The change in topography could be attributed to the change 
in cell behaviour as well as the introduction of the therapeutic ions 
 Minimum inhibitory concentrations of silver nitrate and/or copper nitrate to give either a 
bacteriostatic or bactericidal effect on the E.coli were established as 0.05mM, 5mM and 1mM 
for silver nitrate in CCM, copper nitrate in CCM and a 1:1 CCM suspension of silver nitrate to 
copper nitrate, respectively 
 The concentrations of the therapeutic ions in the silver-doped, copper-doped and silver/copper-
doped scaffolds were not sufficient to cause either a bacteriostatic or bactericidal effect on the 
E.coli 
 Agar diffusion studies carried out using S.aureus showed that the concentrations of the 
therapeutic ions in the silver-doped, copper-doped and silver/copper-doped scaffolds was high 
enough to cause an anti-bacterial effect on the S.aureus 
 Test carried out using K.pneumoniae also indicated that the concentrations of the therapeutic 
ions in the silver-doped, copper-doped and silver/copper-doped scaffolds were high enough to 
cause a decrease in the bacteria population 
In conclusion, when balancing the structural results with the biological and bacterial studies, 
the lowest concentration silver-doped scaffold with a 15 minute immersion period in the molten salt 
bath gives a scaffold which has the desirable properties of the BBG scaffold, such as bioactivity, whilst 
improving others, such as slightly the mechanical competence, allowing cell attachment and causing an 
antibacterial effect on some bacteria types. The copper-doped and silver/copper-doped scaffolds 
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exhibited encouraging results compared to the BBG scaffold by improving the compressional strength, 
whilst not compromising the bioactivity and having suitable antibacterial properties. However an 
unacceptable cytotoxic reaction was detected when the scaffolds were exposed to rMSC’s and hMSC’s. 
The copper-doped and silver/copper-doped scaffolds both require further refinement in the MIB 
concentration before they are further considered for in vivo studies. 
 
7.3 Polymer coated scaffolds 
 
 This work has established that gelatin (of both type A and B) can be used to coat the BBG 
scaffolds to improve the stability and mechanical competence. The use of gelatin as a novel natural 
polymer coating agent compared with the established synthetic polymer (e.g. PDLLA) coated scaffolds 
gave the following outcomes:- 
 Through a preliminary porosity study it was established that gelatin coating concentrations of 
5wt% and 6wt% for both gelatin types gave the best trade-off between porosity and a suitable 
continuous homogeneous coating 
 It is possible to create a multi-layered coating on the BBG scaffolds that did not compromise 
the porosity significantly 
 Fraying of the polymers was observed at the edges of cracks during fracture which indicates 
that the polymer is capable of bridging cracks thus keeping the structure together, which is a 
desirable property to increase the structural integrity of scaffolds 
 After immersion in SBF, the presence of HA on the scaffolds struts was also detected, which 
indicated that the presence of the polymer coating did not hinder the precipitation of HA and 
therefore did not have a detrimental effect on the BBG scaffolds bioactivity 
 The polymer coating significantly changed the surface topography of the BBG scaffolds by 
creating a smooth, relatively continuous, and homogeneous layer on the scaffold. The contact 
angles for the polymer coated scaffolds were higher than those observed for the BBG scaffolds, 
with the 6wt% gelatin (of both types) and PDLLA coated scaffolds falling within the ideal 
contact angle range for promoting cell attachment. It could not be proved whether these values 
would cause a positive reaction when seeded with cells due to the change in surface roughness 
 The compressional strength was significantly improved by the presence of the gelatin coating 
compared to both the BBG scaffolds and the PDLLA coated scaffolds. The PDLLA coated 
scaffolds improved the compressional strength of the BBG scaffolds by 14% and 1% for pre 
and post SBF immersion, respectively, and the gelatin coated scaffolds improved the 
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compressional strength of the BBG scaffolds by 87% and 57% for pre and post SBF immersion, 
respectively 
Overall the polymer coated scaffolds exhibited superior mechanical competence in comparison 
to BBG scaffolds without compromising bioactivity. There was little difference between the PDLLA 
coated scaffolds and those coated in gelatin except that gelatin coated scaffold had a far higher, and 
therefore more desirable, improvement in the compressional strength. There was little difference 
between the two types of gelatin or the two concentrations used. Further work is required to determine 
the most suitable gelatin coating which will provide the best balance between improvements in 
mechanical competence by keeping the highest possible bioactivity. 
 
7.4 Composite scaffolds 
 
 This work has established that composite scaffolds can be produced by incorporating 
therapeutic ions through MSIE and then coating the ion-doped scaffolds in gelatin. The following 
results were obtained:- 
 The porosity was approximately 20% lower than that of the BBG scaffolds, in line with the 
porosities observed for the ion-doped scaffolds, nevertheless the porosity was still in the 
desirable range. After SBF immersion the ion-doped gelatin coated scaffolds’ porosity dropped 
by approximately 10% which is the same observation made for the BBG scaffolds 
 Structurally these ion-doped gelatin coated scaffolds exhibited the same characteristics as their 
ion-doped and gelatin coated counter parts and the BBG scaffolds. Of importance, the presence 
of HA after SBF immersion was confirmed indicating that the bioactivity of the BBG scaffold 
has not been compromised by either the MSIE process or the gelatin coating 
 The surface topography was changed compared to the BBG scaffolds which is because the 
MSIE process increased the surface roughness and the gelatin coating formed a smooth and 
continuous layer over the top. This surface modification increased the contact angles measured 
into the suggested ideal contact angle required for cell attachment. It can not be concluded that 
the change in surface roughness will have an effect on the cells behaviour due to the change in 
surface roughness 
 The compressional strength was significantly improved compared to the BBG scaffolds with 
an increase of 102% and 58% pre and post SBF immersion, respectively. There is also 
improvement over the ion-doped scaffolds and the gelatin coated scaffolds indicating that the 
combination of MSIE processing and polymer coating is very convenient to improve on the 
mechanical competence of the BBG scaffolds 
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 It should be noted that as with the scaffolds that were doped but not coated with a polymer, it 
can not be stated that the ions have entered the silicate matrix without further investigation, 
which is also discussed in chapter eight. The detected ions could be from any remaining 
remnants of the salt that may have infiltrated the micro-cracks present on the scaffolds surface 
due to the sintering process 
Overall combining the MSIE process with gelatin coating improved upon the BBG scaffold by 
increasing the compressive strength without compromising the desirable intrinsic properties of the BBG 
scaffold. The next step would be to investigate the release rate and release mechanism of the added ions 
and the degradation rate of the gelatin before completing cell biology work on the ion-doped gelatin 
coated scaffolds. Indeed the control of ion release by the incorporation of gelatin coatings of different 
thickness is an intriguing possibility for future studies, as discussed in the next chapter. 
 
7.5 Summary 
 
It is hoped that this work will make a significant contribution to the field of BTE using bioactive 
glass scaffolds as suggested in Figure 138. This work has aimed to fill the gaps in existing knowledge 
through the production, optimisation and characterisation of these novel scaffolds and this contributes 
to the emerging field of multifunctional scaffolds for BTE. 
 
264 
 
 
Figure 138:- Author’s assessment of the contribution to the field of BTE based on the results of the present work 
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Chapter Eight 
8. Future work 
 
 This chapter discusses future work that is suggested to be carried out based on the results and 
conclusion drawn from this project. This includes suitable improvements to the scaffolds used and the 
application of complementary characterisation experiments that could be carried out to gain further 
understanding of the samples behaviour under different conditions. This section also shows some of the 
preliminary work that has been already carried out to assess the scaffolds feasibility in vivo in future 
projects based on expanding the use of the BBG scaffolds made by the foam replication technique.  
 
8.1 Expanding the use of the foam replication technique 
 
 Throughout this work the technology on which scaffold development was based has been the 
simple, cost effective and reproducible foam replication technique. This traditional scaffold fabrication 
method is always evolving in order to produce improved scaffolds for BTE.  Significant work has 
already been carried out defining the processing parameters required to use when the starting material 
used is the standard 45S5 Bioglass® powder, as has been shown in previous chapters. The next possible 
improvement step for this technique would be to consider reproducible industrial-scale fabrication for 
commercial uses which should lead to high quality scaffolds that can be tailored to fit individual patients 
specific bone defect. This technique so far has only been utilised on a relatively small scale and in order 
to be considered for use in industry it needs to be scaled up for manufacturing. The key advantage of 
this technique over other scaffold manufacturing methods is that it is very straightforward and 
reproducible without the requirement of complex and expensive processing equipment. It is, in 
principle, easy to produce high quality scaffolds of identical 3D, interconnected pore structure and 
specific dimensions.  
The other avenue for future investigations is to use other bioactive glass compositions and to 
tailor the processing parameters for those compositions. Using this established technique to produce 
novel scaffolds with alternative bioactive glass compositions gives a base for comparison with the BBG 
scaffolds developed in this study. The foam replication technique has been used to produce scaffolds 
using for example borosilicate glass scaffolds (479) (CaO-Na2O-MgO-K2O-SiO2-B2O3-P2O5), calcium 
phosphate- based glass-ceramic scaffolds (480) (CaO-P2O5-Na2O-trace element oxide) and silicate 
phosphate- based glass-ceramic scaffolds (411) (SiO2-P2O5-CaO-MgO-Na2O-K2O). This technique can 
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be expanded into other novel biomaterials, such as titanium phosphate glass-ceramics (481) (P2O5-CaO-
Na2O-TiO2) and magnesium oxide containing glass-ceramics (482) (SiO2-CaO-MgO-P2O5), novel 
mesoporous glasses (483) (484) (485) or exploring “older” materials in a new light such as HA based 
scaffolds. (486) 
However the performance of bioactive scaffolds fabricated by the foam replica method should 
be compared, specifically in vivo, with scaffolds of similar chemical composition but obtained by 
alternative methods, such as sol-gel, (244) (487) (201) freeze drying, (488) (489) (490) evaporation-
induced self-assembly (484) (491) (492) and rapid prototyping. (484) (106) (493) 
Another possible expansion of the foam replica method to produce improved scaffolds is the 
application of alternative sacrificial porous templates to create scaffolds with different pore structure, 
for example using plant-derived sponges such as flax scaffolds, (494) wood-derived scaffolds (495) and 
herbal scaffolds which incorporated the plant Cissus quadrangularis. (496) 
 
8.2 The use of molten salt ion exchange to introduce multifunctional ions into 
scaffolds 
 
 This work has started to explore the use of MSIE (113) (497) (6) as a technique to introduce 
therapeutic metal ions into prefabricated BBG scaffolds and has examined two strong candidates 
namely silver and copper. Future work could take a number of directions including: -  
I). The continuation of this project to find the most suitable processing parameters for the dual 
doping with silver and copper  
II). Choosing other candidate ions, for example zinc (498) and cobalt, (499) to be introduced using 
MSIE  
III). Making the MSIE process suitable for mass producing samples. 
 With respect to the MSIE work carried out in this project further refinement of the parameters 
used needs to be carried out in order to obtain samples that are suitable for use in BTE. The 
concentrations studied for the silver MSIE seem to require only a minor further optimisation effort as 
the biological studies showed that the lowest concentration at the lowest immersion period gave silver 
doped samples that were not toxic to the cells, showed the formation of HA on their surface during SBF 
immersion and exhibited improved mechanical competence. The copper and silver/copper ion doped 
samples still require refinement before they will be suitable for in vivo studies. The concentration of 
copper needs to be reduced from a salt bath ratio of 2000:1 and 20000:1, stated in sections 4.2.2.II and 
6.3.4, respectively, to values ranging between 50,000:1 and 100,000:1 of sodium nitrate to copper 
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nitrate in the salt bath, as the copper was found to be toxic at the current levels. It should be also 
investigated if in combination with other ions a suitable copper level will be obtained. 
 In addition, further research and refinement need to be carried out in order to enhance the MSIE 
technique for this application to produce samples in a more controllable manner. Even though the depth 
EDX studies, as described in section 4.3.11 with the results presented in sections 5.3, 5.4 and 5.5, 
showed an average ion penetration of 8nm, 12nm and 9-10nm for silver, copper and silver/copper doped 
samples, respectively, the lack of homogeneity of the ion penetration depth is a problem that needs to 
be addressed. 
 
8.2.1 Other candidates for molten salt ion exchange processing 
  
 As mentioned in the last section one of the next steps for the further development of MSIE 
scaffolds would be to investigate other therapeutic metal ions that could be introduced into the 
prefabricated BBG scaffolds. In chapter two criteria for candidate ions were set out and this should be 
followed when selecting other ions to use. There are a number of suitable candidates that should be 
considered and these are shown in Table 50, which also includes the most relevant functions of those 
ions. Suitable review articles are available (Hoppe et al, (12) Mourino et al (202) and Boccaccini et al 
(134)), which provide useful information to guide the design of ion doped scaffolds for BTE. 
All ions shown in Table 50, for example, have the potential of being introduced using MSIE 
albeit not necessarily using the metal nitrate salt, as was used during this work, but using metal 
chlorides, for example, instead. These different metal ions would provide functional alternatives to the 
silver and copper ions that were investigated during this work. To our knowledge, this work was the 
first work that successfully used MSIE technique to introduce simultaneously two therapeutic metal 
ions into a prefabricated scaffold.  The next steps would be to further refine the processing parameters 
to optimise the production of silver and copper doped samples. This could lead to expanding the 
technique for wide spread use in industry and to investigate different ions in different combinations. 
Clearly, the potential and limitations of the MSIE technique to incorporate all or some of the ions listed 
in Table 50 remain to be investigated and this opens avenues for future interesting research. 
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Table 50:-Relevant metallic ion candidates for MSIE scaffolds 
Ion  Functions of interest Reference 
Cobalt 
 
 Stimulating red blood cell production 
Increases the expression of pro-angiogenic growth factors 
(500) (501) (502) 
(503) (499) 
Gallium 
 
 
Antibacterial 
Inhibits bone resorption 
Treatment of hypercalcaemia associated with tumours in bone 
(500) (504) (505) 
(506) (507) (508) 
(509) (510) (511) 
Iron 
 
 Promotion of cell attachment and differentiation 
Involved in redox reactions of oxygen carrier proteins 
(500) (512) (513) 
(514) (515) 
Magnesium 
 
 
 Interacts with phosphate ions 
Osteoconductive 
Stimulates the adhesion of osteoblasts 
(498) (480) (500) 
(516) (517) (518) 
(519) (520) (521) 
Manganese 
 
Cofactor for a range of important enzymes 
Detoxification of free radicals 
 (500) (522) (523) 
 
Potassium 
Reduces bone resorption 
Increases cell proliferation 
(524) (525) (526) 
 
Strontium 
 
 
Stimulates bone formation 
Reduction of bone resorption 
Incrementation of osteoblast differentiation 
(498) (480) (500) 
(511) (527) (528) 
(529) (530) (531) 
Titanium 
 
Osteoconductive 
Antibacterial 
(532) (533) 
(534) (481) 
Vanadium 
 
 
 
Promotes mineralization 
Promotes osteoblast proliferation and differentiation 
Increases collagen synthesis 
Inhibits alkaline phosphatise associated osteoblast differentiation 
(500) (535) (536) 
(537) (538) (539) 
(540) (541) (542) 
(543) (544) 
Zinc 
 
 
 
 
 
Antibacterial 
Anti-inflammatory 
Associated with bone growth hormone  
Enhances osteoblast differentiation 
Improves wound healing 
Increases Runt-related transcription factor 2 
(498) (480) (500)  
(501) (503) (545) 
(546) (547) (548) 
(549) (550) (551) 
(552) (553) (554) 
(555) (556) 
  
8.3 The use of polymers in combination with bioactive glass scaffolds 
 
 The main focus of applying polymer coatings on a BBG scaffold is to improve the scaffold’s 
mechanical competence as low compressive strength is one of the main disadvantages that BBG 
scaffolds exhibit, and which must be tackled in order to be realistically considered in in vivo and clinical 
studies. Any additional properties or functionalities that a polymer coating can provide represent extra 
advantages of the approach.  
The literature review, chapter two, reported on using biodegradable, synthetic polymers derived 
from a number of sources, including poly(L-lactide-co-D,L-lactide) (PLDLLA), (109) poly(lactide-co-
glycolide) (PLGA), (557) poly(DL-lactide) (PDLLA) (558) and poly(3-hydroxybutyrate) (P3HB). (486) 
These polymers exhibit a range of desirable properties along with improving the mechanical 
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competence of the scaffold but some of the newer novel polymers are difficult to produce and  expensive 
at the current time. (559) (560) (561).  
 A suitable alternative is to use natural polymers that have not been used extensively to develop 
coatings on BTE bioceramic or bioactive glass scaffolds. These polymers include gelatin, (562) 
chitosan, (563) collagen (564) and alginate. (565) As this project has shown, gelatin is a suitable 
polymer for this application and the increasing literature being published on this topic indicates that 
there is now a sway towards using some of these cost-effective and highly biocompatible polymers. 
Another advantage of using natural polymers is that they have in most cases a proven biological track 
record and the fundamental knowledge on their behaviour in biomedical applications already exists. 
 Chitosan and alginate are two examples of “older” polymers that have been revisited to be 
considered as coatings for three dimensional scaffolds and the research community is starting to 
optimise these polymers for this use. (566) (567) (568) Chitosan in combination with poly(epsilon-
caprolactone) (PCL), for example, has shown enhanced cell differentiation (569) in osteoblasts and 
heparin-functionalized chitosan scaffolds have shown to increase the viability and differentiation of 
preosteoblasts (570) as well as increasing the mechanical competence of the scaffold in question. (563) 
(571) (266) Alginate in combination with HA has shown suitable cell attachment properties (572) and 
a composite of calcium phosphate and alginate has shown osteogenic differentiation (573) whilst once 
again maintaining suitable mechanical properties. (574) (573) Other significant function of polymer 
coatings has been considered, which is their use as a drug delivery vehicle, including  novel copper ion 
releasing composite scaffolds containing alginate, (575) calcium phosphate/chitosan composite 
scaffolds for antibiotic delivery, (576) growth factor delivery by both chitosan and alginate composite 
materials (577) (578) (579) and novel gallium cross-linked with alginate composite scaffolds. (580) 
(581) Indeed the field of natural polymer coated bioceramics and bioactive glass scaffolds is receiving 
an increasing amount of attention, in this context, the present study has contributed knowledge and 
expertise on the production of the gelatin/Bioglass® system 
 
8.4 Gelatin as a drug delivery vehicle  
 
 As discussed in previous sections, the main purpose for the gelatin coating in the present project 
was to improve the mechanical properties of the BBG scaffolds. After this has been achieved, additional 
functions of the gelatin coating can be investigated. For example it is interesting to investigate how 
gelatin coating can be used as a functional drug delivery system. Indeed incorporating drug delivery 
carriers in the form of a gelatin coating will give the BBG scaffolds another function or local drug 
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delivery device. (500) This will involve introducing a range of additives including growth factors (582)  
and/or therapeutic drugs, including antibiotics. (583) 
   
8.4.1 Introducing antibiotics and growth factors into gelatin coatings 
 
 Introducing a range of functional additives to a polymer is not a novel concept in itself and even 
introducing additive load polymers onto three dimensional scaffolds has also been investigated. The 
particular novel concept that it is hoped to expand upon the basis of the present results is the use of an 
additive loaded gelatin coating on ion-doped BBG scaffolds. A range of additives can be added to the 
gelatin coating to make the composite scaffold more functional.  
 Antibiotics are obvious drugs to be introduced into the gelatin composite scaffold to combat 
possible post-operative infections. Antibiotics, however pose certain challenges when introduced into 
a system including dosing (584) (585) and degradation issues. (586) (587) Numerous antibiotics have 
been used in polymer coatings including tetracycline, (588) gentamicin (589) and vancomycin. (583) In 
addition to some previous work that has been carried out with gelatin loaded with vancomycin, (583) 
doxorubicin (590) and colistin. (591) One of the main issues is to keep the antibiotic stable before the 
gelatin degrades and this can only be solved by choosing a suitable antibiotic dose and gelatin 
concentration. (592) (593) The approach based on therapeutic ion releasing scaffolds presented here, 
would be radically innovative, as it would combine ion releasing capability with antibiotic release from 
the degrading gelatin coating. 
 Growth factors can be incorporated into polymer coatings to promote bone formation (594) 
(595) and angiogenesis. (596) (597) (598) For example, PDLLA with insulin-like growth factor-1 and 
transforming growth factor-beta 1, (356) alginate with angiogenic growth factors (177) and P3HB with 
insulin like growth factors, myostatin and vascular endothelial factors (VEGF) (599) and in gelatin 
loaded with growth factor-beta 1, (600) fibroblast growth factor 2 (582) and myoglobin (601) have been 
investigated. The importance of introducing these additives into a biological system during implantation 
is that they provide extra signalling molecules to the surrounding cells in order to induce a certain 
function. For example, introducing additional VEGF into a bone scaffold will encourage faster 
angiogenesis of the surrounding tissue which in turn accelerates the bone healing process. 
 There are numerous challenges remaining to create composite systems incorporating additive 
loaded gelatin coatings on three dimensional scaffolds. However this is a rapidly changing field, being 
investigated extensively and further developments of gelatin coated scaffolds incorporating antibiotics 
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and growth factors is expected and these developments will benefit from the results presented in this 
thesis. 
 
8.4.2 Therapeutic metal nano-particles – Copper oxide and Iron oxide 
 
 The incorporation of metallic nano-particles can be an interesting further aspect for 
investigation aiming at enhancing the performance of bioceramic and bioactive glass scaffolds 
including imparting specific electromagnetic properties. (602) (603) (604) (605) Preliminary work was 
undertaken in the course of this thesis to introduce therapeutic metal nano-particles into both gelatin 
types on model systems for in vitro studies. Following the processing technique described in section 
4.4, but after the gelatin is thoroughly mixed, the metal nano-particles are added to the beaker and the 
mixture is sonicated to evenly disperse the metal nano-particles throughout the gelatin. The BBG 
scaffolds are then coated by the gelatin/metal nano-particle composite, the coated samples are left to 
dry and characterisation studies can then be carried out. The preliminary study carried out included the 
scaffolds characterisation by SEM, porosity measurement, mechanical properties determination and 
FTIR studies. The porosity of these scaffolds were comparable with the gelatin only coated scaffolds 
with a porosity ranging between 77% and 86% and the mechanical competence of these scaffolds was 
also in the same range as the gelatin only composite scaffolds (approximately 1.30 ±0.05MPa). Figure 
139 shows the slight change in colour of the scaffolds after the addition of the metal nano-particles to 
the gelatin coatings. SEM images, shown in appendix D.3, indicate little visible difference between 
these scaffolds and those shown in chapter five. Moreover the FTIR results, shown in appendix D.3, 
mirror the FTIR spectra shown in chapter five with the two amide peaks which are attributed to gelatin, 
(457) (191) the peaks due to water (457) (191) and the previously identified peaks of the BBG scaffold. It 
shows no unidentifiable peaks, suggesting that the metal nano-particles were not detected by the FTIR. 
Additional characterisation studies, including in vitro studies, should be the next step for these 
composite scaffolds to determine their suitability for use in BTE. In particular the degradation of the 
polymer and the release of the metal nano-particles should be extensively studied given the possible 
cytotoxic effect of released nano-particles. (606) (607) (608) 
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Figure 139:- Metal nano-particle loaded gelatin coated BBG scaffolds: A) gelatin type A coated scaffold, B) 
gelatin type A coated scaffold loaded with copper oxide nano-particles, C) gelatin type A coated scaffold loaded 
with iron oxide nano-particles, D) gelatin type B coated scaffold, E) gelatin type B coated scaffold loaded with 
copper oxide nano-particles, and F) gelatin type B coated scaffold loaded with iron oxide nano-particles. 
 
8.5 Combining molten salt ion exchange scaffolds with polymer coatings 
 
 In this work the preliminary studies of combining MSIE scaffolds with polymer coatings have 
been carried out, proposing these composite scaffolds as promising multifunctional structures for BTE. 
However these scaffolds are still in the concept stage and any future work will need to characterise, 
refine and improve these samples before they can be investigated in vivo. Only structural 
characterisation of these scaffolds has been carried out in this work, the next stage is to carry out initial 
viability in vitro studies to understand the response of specific relevant cells, such as the HPLSC’s and 
rMSC’s used in chapter six, to these rather promising but complex scaffolds. Since this work contained 
the preliminary work on combining ion-doped scaffolds with polymer coatings the suggested route 
would be for further studies to build upon the results achieved here. One specific experiment that needs 
to be carried out first is to ascertain the degradation and release mechanisms of the polymer and ions, 
respectively, as this knowledge will give initial information about the behaviour of the composite 
scaffold in vitro and eventually in vivo. 
 This recommendation for future research is also relevant when additives (e.g. bio-molecules or 
drugs (609) (610) (611)) are added to the gelatin coatings, where it is important to consider the biological 
and structural performance of the scaffolds containing and releasing these additional factors. There is a 
great deal of scope for the use of gelatin on ion-doped bioactive glass scaffolds as this is a novel concept 
for developing advanced scaffolds for BTE and the system represents an interesting field for future 
research. 
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8.6 Issues brought forward by this work 
 
 In the course of this work a number of issues have risen which need to be looked into in greater 
detail in future investigations. In particular the issue of the pH change due to the presence of the BBG 
scaffold and the possible changes to the samples due to the sterilisation techniques used as two relevant 
aspects requiring special attention in future research involving BBG scaffolds. 
 
8.6.1 pH issue with the base scaffolds 
 
 As discussed in chapter 6, there is no set protocol that can be adopted to reduce the effect of 
the change pH occurring due to the presence of the base scaffold. This effect needs to be addressed and 
more research needs to be carried out to find a suitable protocol for 45S5 Bioglass® -derived glass-
ceramic scaffolds. Currently each laboratory has its own method of reducing the pH issue caused by 
45S5 Bioglass® -derived glass-ceramic scaffolds. The difference in these methods could account for the 
different conclusions observed in the literature highlighting the need for a standardised protocol for cell 
culture studies on 45S5 Bioglass® -derived glass-ceramic scaffolds. A review of the available protocols 
in the literature needs to be undertaken and a consensus protocol needs to be developed. The work 
shown in chapter 6 on the pre-conditioning of the scaffolds in order to reduce the cell toxicity due to 
pH change represents a convenient start point 
 
8.6.2 Sterilisation  
 
 As discussed in chapter 6, the sterilisation process of the scaffolds will have an effect on the 
physical and chemical properties of the sample surface which will possibly impact the results. The 
surface changes induced by different sterilization techniques need to be discussed and reviewed as this 
could relate to a difference between different cell biology studies on 45S5 Bioglass® -derived glass-
ceramics scaffolds in the literature. It should be noted that surface changes due to the sterilization 
process on glass-ceramic scaffolds will be relatively small due to their robust inorganic nature but on 
materials such as polymers the sterilisation technique could change the very nature of the polymer which 
would have an impact on the results. This effect will be relevant for example in polymer coated BBG 
scaffolds such as the gelatin coated samples developed in this project. A review of the current processes 
and results needs to be undertaken to produce a protocol for which future work can be based on in order 
to achieve reproducible and comparable results between different laboratories.  
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8.7 Further structural characterisation of the scaffolds 
 
 In general further structural characterisation will need to be carried out on the modified 
scaffolds to gain knowledge on their overall behaviour targeting in vivo applications. One suggestion 
for future research is to confirm the statement made in chapter five in that the improved mechanical 
competence of MSIE scaffolds was due to the change in atomic structure of the silicate network. (438) 
(113) Further investigation to confirm this statement could be explored through extended x-ray 
absorption fine structure (EXAFS) data in combination with Reverse Monte Carlo (RMC) modelling as 
this study will give an answer as to why the mechanical properties have been improved through molten 
salt ion exchange and this is discussed further in section 8.7.1.   
Other techniques should be used to further explore the scaffolds developed in this work such as 
Raman spectroscopy and optical emissions work to further characterise the microstructure of the 
samples in particular the dynamics of the introduced metal ions in the silicate structure of crystallised 
Bioglass®. (612) In addition NMR spectroscopy (613) (614) will be useful to further investigate the 
atomic structure of the developed scaffolds.  
 
8.7.1 Molecular modelling using the Reverse Monte Carlo method 
 
 As suggested in chapter five, the addition of the larger network modifiers ionically bonded to 
non-bridging oxygen in the silica network will also interact with the nearby bridging oxygen to form an 
additional two-coordinate structure. (438) (113) These additional structures could be the reason behind 
the increase in mechanical strength, as discussed in chapter five. In order to ascertain if this effect is 
actually occurring in the MSIE material, additional experiments need to be carried out and then used as 
a basis for a modelling platform to give a pictorial view of the atomic structure of the MSIE material. 
 Reverse Monte Carlo (RMC) modelling is specifically used to model amorphous and 
disorganised crystalline structures. (615) Using x-ray absorption spectroscopy (XAS) specifically 
EXAFS in combination with a RMC modelling platform a three dimensional model can be produced, 
whilst being subject to certain constraints consistent with available experimental data. (615)  A more 
detailed explanation of how RMC modelling achieves the required three-dimensional model can be 
found in appendix D.1. Once this has been done, suitable structural models will be available that can be 
used to determine if the addition of the new network modifiers after MSIE is having structural effects 
that would lead to the increase in the scaffolds mechanical competence. An example of a basic RMC 
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model of silicon oxide is shown in Figure 140. This RMC model realistically represents the structure 
of the material and indicates how the bonds and atoms interact. 
 
 
Figure 140:- RMC model of silicon oxide showing the atomic structure as extrapolated from EXAFS data and 
other constraints (616) 
 
8.8 Further in vitro characterisation 
 
 A main objective of this work has been to produce novel scaffolds which are intended for 
clinical applications in BTE approaches. These scaffolds thus need to go through a series of rigorous in 
vitro studies in order to comprehensively understand their behaviour in contact with relevant cells. This 
work investigated preliminary the interaction of the scaffolds with cells and bacteria and following 
sections will expand on recommendations for further research in this particular topic. 
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8.8.1 Cell culture characterisation 
 
 The main focus of future work concerning the in vitro response of the scaffolds should 
concentrate on determining a concentration of the therapeutic metal ion that is high enough for it to 
deliver its desirable function, i.e. be antibacterial in the case of the silver ions, whilst still being 
biocompatible with the cells. Achieving such optimal ion concentrations has not been completely 
successful as yet, however the scaffold technology developed in this project is suitable to deliver 
scaffolds for future studies. The next step should be to fine tune the doped MSIE scaffolds to obtain 
biocompatible samples which cause no toxic effect to the cells. The design of the study should involve 
changing the ion concentration and then testing it in vitro, the analysis of cytotoxicity will establish the 
window of concentrations at which the samples are biocompatible. This process needs to be repeated 
until the sample has demonstrated full biocompatibility with the target cells. 
 Once the samples have been deemed biocompatible other in vitro tests can be carried out, as 
was briefly discussed in chapters 4 and 6, including identifying specific osteogenic markers (617) (618) 
(619) which are indicative of the formation of new bone tissue and, in the case of the copper doped 
samples, the presence of angiogenic markers. (620) (621) (622)This would involve RNA extraction, 
(623) (624) PCR testing (625) (626) and carrying out a range of standard histological / 
immunohistochemical assays. (627) (628) (629) (630) 
In the context of the present project, relevant preliminary work was carried out using BBG 
scaffolds in collaboration with Dr R El-Gendy from Prof X.B Yang’s research group at the Leeds Dental 
Institute at the University of Leeds (UK). Using human dental pulp stromal cells (HDPSC’s) in 
combination with BBG scaffolds a promising combination that promotes bone repair and angiogenesis 
in vitro has been achieved. (631) (225) These studies used the dynamic seeding technique described in 
section 4.4.2 which is a model that is closer to in vivo implantation than static seeding techniques 
(including the ones used in this work), as described in sections 4.4.5 and 4.4.6. These studies then 
assessed the expression of certain osteogenic (COLIA1, ALP, RUNX-2, OC) and angiogenic (CD34, 
PECAM1 & VEGFR2) genes and found that in general there was a positive effect on the expression of 
these genes due to the presence of the BBG scaffolds. (631) (225) Clearly, future work is required 
following the same experiment protocol, but incorporating ion-doped scaffolds, to increase our current 
understanding of the scaffolds bone regeneration ability and how the release of copper and silver might 
affect the expression of relevant genes of HDPSC;s. 
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8.8.2 Bacterial characterisation 
 
 The present work used three bacterial strains to test the antibacterial potential of the variety of 
samples produced.  As a suggestion for future research, the bacterial work needs to be carried out in 
conjunction with the in vitro cell culture, which will lead to identify the effectiveness of a particular or 
anti-bacterial agent, without causing a toxic effect to the surrounding tissue.  Fine tuning of the current 
crop of ion-doped samples needs to be carried out first to achieve this balance. For the silver doped 
samples, the optimal concentration window has been approached in this study (as described in chapter 
six). 
 Continued work using a range of bacteria that are known to cause post-operative infections 
should be carried out on the evolving ion-doped samples to further evaluate the samples suitability as 
an antibacterial agent in more relevant conditions. As stated in section 2.13.1 the most common bacteria 
involved in post-operative infections is S.aureus especially in terms of its resistance to the common 
antibiotics which are given if an infection occurs. The agar diffusion study carried out using S.aureus 
was a convenient starting point and it should be continued to obtain the bacteriostatic and bactericidal 
concentrations of the antibacterial ion as it was done with E.coli in chapter six of this thesis. It can be 
suggested that this bacteriostatic/bactericidal study should be carried out for each sample type and for 
each different bacteria tested. Other relevant bacteria should be investigated, including methicillin-
resistant Staphylococcus aureus (MRSA), (632) Clostridium difficile (633) and Staphylococcus 
epidermidis, (634) to produce scaffolds that are effective against the most common bacteria in post-
operative infections. 
 
8.9 In vivo characterisation 
 
 Preliminary relevant work has been carried out on the BBG scaffolds produced in this study 
using different animal models. Since these studies were preliminary and only on one type of scaffolds, 
the summary of achieved results is presented in this section specifically because they show a clear path 
for future in vivo studies. Indeed, a wide range of relevant in vivo models are available to explore 
different conditions, including large cortical bone defects, (635) canine segmental defects (636) and 
subcutaneous rat implantation model. (637) Specific bone vascularisation in vivo models, such as the 
A-V loop model, are also available (318) and of relevance in the context of developing new scaffolds 
with vascularisation potential. 
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8.9.1 In vivo studies using 45S5 Bioglass® –derived scaffolds using human dental pulp stromal 
cells 
 
 In collaboration with Dr R El-Gendy from Prof X.B Yang’s research group at the Leeds Dental 
Institute at the University of Leeds, UK, the BBG scaffolds produced in this study were combined with 
human dental pulp stromal cells (HDPSC’s) to form a suitable combination intended to promote bone 
repair and angiogenesis in vivo. (631) (225)  
In these studies HDPSC’s were dynamically seeded, as described in section 4.4.2, onto the BBG 
scaffolds for five days and then statically cultured for a further two days, sealed in Millipore diffusion 
chambers and implanted into mice for eight weeks. After removal, the samples were subjected to a 
range of assays to ascertain the osteogenic and angiogenic potential of the scaffolds. It was seen that 
the scaffolds are biocompatible in vivo, showed suitable cell attachment, formation of neo-tissue 
structures within the construct, presence of angiogenic gene expression (225)  and evidence of 
osteogenic differentiation. (631) (225) These results are supported by PCR data and a range of 
histological staining, including evidence of collagen type I which is characteristic of the presence of 
mature osteoblasts (631) and the presence of PECAM1 and VEGFR2 markers indicating the angiogenic 
potential of the construct. (225)  Organised capillary-like structures were observed after eight weeks of 
implantation and this along with the presence of PECAM1 and VEGFR2 markers suggest the 
angiogenic potential of the BBG scaffolds. (225)   
The Millipore diffusion chamber provided a suitable bioreactor for the scaffolds for this 
preliminary work using HDPSC’s as it provides a stable environment for the scaffold whilst enabling a 
medium for the exchange of fluids, blood, cells and diffusible products from the host animal. The 
bioreactor supports studies, in vivo, which provide an environment suitable for angiogenesis and bone 
remodelling like bone defect models. The application of vascularisation models can be considered the 
next step for this cell type. (631) Indeed, expansion of these studies incorporating ion-doped scaffolds, 
particularly the copper-doped scaffolds developed in this work should be carried out. Future studies 
also should investigate BBG scaffolds which incorporate other angiogenic ions such as cobalt. (500) 
(501) (502) 
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8.9.2 In vivo study using 45S5 Bioglass® –derived scaffolds in an arteriovenous loop model 
 
 In collaboration with Dr A Arkudas from the Department of Plastic and Hand Surgery at the 
University of Erlangen Medical Centre, Germany, BBG scaffolds, produced in this study, were used 
for the first time in vivo in an arteriovenous (AV) loop model that was implanted into rats to investigate 
the angiogenic potential of 45S5 Bioglass®. (318) The full explanation of the AV loop model including 
materials, techniques and characterisation that relates to the recent publication of the results (318) are 
shown in appendix D.2 with only a summary of the results and concluding remarks being presented 
here. 
 Figure 141 shows the AV loop containing pieces of BBG scaffold (between 1x1x1mm3 and 
2x2x2mm3 in size) in fibrin gel during the implantation process. Figure 142 shows the construct 
removed from the Teflon cage after being implanted for three weeks, indicating that the 45S5 Bioglass® 
pieces showed no outward signs of significant biodegradation. There was some evidence of 
vascularisation of the matrix and the patency of the AV loop as the colour change to yellow indicating 
that functional vessels are being filled with the injected Microfil. (318) Figure 142 does not give a 
definitive answer to whether the presence of the BBG scaffold pieces has a significant effect on the 
angiogenesis process in the AV loop. This can only be shown through further characterisation, and 
results are shown in Figure 143 and Figure 144, showing histological staining and micro CT results, 
respectively.  
   
 
Figure 141:- The AV loop was directed through a Teflon isolation chamber which was filled with the BBG scaffold 
pieces and fibrin gel with a fibrinogen concentration of 10mg/ml and a thrombin concentration of 2 I.U./ml. (318) 
With A) showing the vascular pedicle in place in the cage before being covered in more BBG pieces and fibrin 
gel and B) showing the Teflon cage before the lid is placed.  
280 
 
 
Figure 142:- Macroscopic appearance of the inside of the Teflon cage, (shown in Figure 141) after three weeks 
upon explanation. (318)  
 
Figure 143 shows that the tissue formed in the implantation period of three weeks was localised 
around the vascular pedicle, indicated by the arrows and shown in Figure 141A). Figure 144 shows the 
micro CT analysis (carried out by Dr T Fey from the Institute of Glass and Ceramics, University of 
Erlangen-Nuremberg, Germany) of the material removed from the Teflon cage indicating that a 
significant level of angiogenesis has occurred during the implantation period. This is particularly 
evident in Figure 144C) where the full vessel network is shown. This result implies at least on a 
qualitative basis that the newly formed tissue infiltrates the BBG pieces in the construct, thus the 
presence of the scaffold has a positive effect on the angiogenesis process occurring in vivo. (318) 
 
 
Figure 143:- The material removed from the Teflon cage after being subjected to hematoxylin and eosin (H&E) 
staining to show newly formed tissue in the sample. The arrows are indicate the vascular pedicle that passed 
through the BBG scaffold and fibrin gel sample with a magnification of x25. (318)  
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Figure 144:- Micro CT analysis giving a 3D representation of the newly formed vessels found within the material 
removed from the Teflon cage showing the final network structure of the vessels including the original vascular 
pedicle (318) (Micro CT images obtained by Dr T Fey from the Institute of Glass and Ceramics, University of 
Erlangen-Nuremberg, Germany) 
 
This in vivo work shows for the first time that axial vascularisation of BBG scaffolds can be 
achieved using the AV loop model in a rat. Through micro CT and histological staining it was confirmed 
that after three weeks a new vascular network was created and has infiltrated the implanted BBG 
scaffold pieces. This infiltration and creation of a new network of vessels will allow transplantation of 
the whole construct using the AV loop model in the future. (318) Based on these first results future work 
can be suggested, exploiting the versatility of the AV loop model. 
 For example, a relevant next step would be to introduce the different types of scaffolds 
examined during the course of this project to ascertain if the presence of ions, in particular copper ions, 
improves the blood vessel network formed compared to the BBG scaffolds. These studies should only 
be carried out in the future investigations after the MSIE samples have been completely optimised in 
vitro to prevent complications in the in vivo work due to possible toxicity caused by the uncontrolled 
ion release. 
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Appendices 
Appendix A – Background theory 
A.1 Multifunctional scaffolds 
 
Table 51:- Collated data for a variety of materials fabricated by one of the four fabrication methods discussed in 
chapter two, showing the change in porosity against compressional strength with FC meaning freeze casting, FR 
meaning foam replication, SFF meaning solid free-form replication and SG meaning sol-gel processing 
Sample  Fabrication Porosity Compressive  Reference 
material method (%) Strength (MPa)   
13-93 FC 50±4 35±11 (638) 
13-93 FC 50±4 47±5 (638) 
13-93 FC 20 180 (639) 
13-93 FC 60 16 (639) 
13-93 FC 57 25±3 (640) 
13-93 FC 57 10±2 (640) 
HA FC 50 12±1 (641) (642) 
HA FC 50 5±1 (641) (642) 
HA FC 57 13 (642) 
HA FC 52 93 (642) 
Alumina ceramic FC 63 2.6 (643) 
Alumina ceramic FC 82 37 (643) 
13-93 FC 55 25 (2) 
13-93 FC 60 16 (2) 
13-93 FC 50 47 (2) 
HA FC 68 20 (247) 
HA FC 48 60 (247) 
HA FC 76±2.75 5.26±0.52 (247) 
HA FC 47 145 (644) 
HA FC 56 65 (644) 
HA FC 75 8 (645) 
HA FC 76 16.7 (646) (647) 
HA FC 55 2.5 (646) (647) 
HA FC 71 1.1±0.2 (647) (648) 
HA FC 72 1.5±0.5 (647) (648) 
HA FC 73 2.3±0.5 (647) (648) 
HA FC 73 1.6±0.5 (647) (648) 
HA FC 79.3 2.7 (649) 
HA FC 41.9 35.1 (649) 
Alumina ceramic FC 75 11 (650) 
Alumina ceramic FC 65 12 (650) 
Alumina ceramic FC 60 13 (650) 
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Alumina ceramic FC 45 15 (650) 
CaP FC 62 93±1.6 (647) (260) 
CaP FC 65 6.2±1.3 (647) (260) 
HA FC 75 0.94 (647) (651) 
HA FC 56 17 (647) (651) 
TCP/HA FC 72.5 2.3 (647) (652) 
TCP/HA FC 31.4 36.4 (647) (652) 
HA FC 75 13.1 (647) (653) 
13-93 FR 80±5 11±1 (241) 
13-93 FR 78±2 7±0.5 (241) 
13-93 FR 82±3 5±0.5 (241) 
boron modified 45S5 FR 72±3 6.4±1 (479) 
13-93 FR 85±2 11±1 (239) 
HA FR 86 0.21 (642) 
HA FR 74 2.5 (642) 
45S5 Bioglass® FR 90 0.35 (642) 
SCNPK FR 84 1.48 (654) 
45S5 Bioglass® FR 89 0.41 (4) 
45S5 Bioglass® FR 89 0.31 (4) 
45S5 Bioglass® FR 90 0.25 (4) 
45S5 Bioglass® FR 91 0.37 (4) 
45S5 Bioglass® FR 91 0.35 (4) 
45S5 Bioglass® FR 92 0.3 (4) 
45S5 Bioglass® FR 92 0.25 (4) 
HA FR 86 0.21 (4) 
HA FR 88 0.1 (4) 
HA FR 90 0.12 (4) 
HA FR 93 0.05 (4) 
45S5 Bioglass® FR 90 0.13 (224) 
45S5 Bioglass® FR 90 0.53 (113) 
45S5 Bioglass® FR 70 3 (655) 
45S5 Bioglass® FR 90 0.4 (2) 
13-93 FR 85 11 (2) 
45S5 Bioglass® FR 90 0.4 (410) 
45S5 Bioglass® FR 45 6 (410) 
BioK FR 75 0.16 (410) 
SCNM FR 40 6 (410) 
SCK FR 61 4 (410) 
FaGC FR 35 40 (410) 
FaGC FR 75 2 (410) 
CEL2 FR 48 7 (410) 
CEL2 FR 65 3.5 (410) 
13-93 FR 85 11 (410) 
13-93 FR 75 7 (410) 
ICEL2 FR 85 0.4 (410) 
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Beta-TCP FR 72 4 (410) 
45S5 Bioglass® FR 65 1.7 (656) 
6P53B SFF 60 136±22 (657) 
HA SFF 35 30 (642) 
HA SFF 41 34 (642) 
CaP SFF 73 6 (259) 
6P53B SFF 60 150 (2) 
13-93 SFF 50 140 (2) 
13-93 SFF 50 20 (2) 
Bioactive glass SFF 60 16 (2) 
CaP SFF 54.45 5.8±0.8 (265) 
Beta-TCP SFF 56 1.33±0.03 (658) 
Beta-TCP SFF 60 1.20±0.02 (658) 
Beta-TCP SFF 61 1.19±0.04 (658) 
CaP SFF 35 4 (659) 
CaP SFF 40 3 (659) 
CaP SFF 77 0.4 (659) 
CaP SFF 79 0.2 (659) 
CaP SFF 30 31 (659) 
CaP SFF 3 45 (659) 
CaP SFF 7 25 (659) 
CaP SFF 27 4 (659) 
CaP SFF 39 0.8 (659) 
CaP SFF 36 4.3 (659) 
CaP SFF 35 34 (659) 
Titanium foam SFF 80 150 (660) 
Titanium foam SFF 17 240 (660) 
13-93 SFF 47 250 (661) 
HA SFF 45 10 (662) 
HA SFF 45 15 (662) 
HA SFF 25 50 (662) 
HA SFF 35 35 (662) 
HA SFF 45 25 (662) 
HA SFF 55 20 (662) 
HA SFF 65 5 (662) 
HA SFF 35 45 (662) 
HA SFF 65 10 (662) 
TCP/HA SFF 55 17 (662) 
TCP/HA SFF 60 10 (662) 
TCP/HA SFF 65 8 (662) 
TCP/HA SFF 70 4 (662) 
TCP/HA SFF 80 2 (662) 
SCNPK SG 82 1.22 (654) 
SCNPK SG 81 1.79 (654) 
SCNPK SG 82 2 (654) 
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SCNPK SG 75 2.31 (654) 
SCNPK SG 74 2.82 (654) 
SCNPK SG 80 1.67 (654) 
SCNPK SG 74 1.75 (654) 
SCNPK SG 79 1.88 (654) 
SCNPK SG 75 2.07 (654) 
70S30C SG 88 0.36 (663) 
70S30C SG 86 0.51 (663) 
70S30C SG 82 2.26 (663) 
70S30C SG 82 2.25 (663) 
45S5 Bioglass® SG 85 2.3 (244) 
45S5 Bioglass® SG 87 1.6 (244) 
45S5 Bioglass® SG 90 1.1 (244) 
45S5 Bioglass® SG 92 1 (244) 
HA SG 87.2±2.1 0.75 (664) 
HA SG 86.8±2.8 0.9 (664) 
HA SG 86.4±2.6 1.1 (664) 
HA SG 87 1.5 (665) 
13-93 SG 82 2.5 (2) 
70S30C SG 85 1.8 (410) 
CaP SG 73 6 (259) 
Bioglass/HA SG 86 2.78 (666) 
Bioglass/HA SG 84±1 1.36±0.09 (666) 
Bioglass/HA SG 85±1 2.78±0.11 (666) 
Bioglass/HA SG 86±1.5 1.95±0.16 (666) 
Bioglass/HA SG 86±2 1.21±0.05 (666) 
Bioglass/HA SG 88±2 0.92±0.09 (666) 
Bioglass/HA SG 881 1.54±0.08 (666) 
Bioglass/HA SG 91±1.7 0.87±0.12 (666) 
Titanium foam SG 81±2 7 (667) 
Titanium foam SG 70 18±0.3 (668) 
58S SG 70 2.4 (669) 
70S30C SG 70 0.25 (669) 
58S SG 55 30 (670) 
58S SG 54 15 (670) 
58S SG 59 14 (670) 
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Table 52:- Collated data for a variety of materials fabricated by one of the four fabrication methods discussed in 
chapter two, with the addition of a polymer coating, showing the change in porosity against compressional 
strength with FC meaning freeze casting, FR meaning foam replication, SFF meaning solid free-form replication 
and SG meaning sol-gel processing 
Sample  Fabrication Additives Porosity Compressive  Reference 
material method   (%) Strength (MPa)   
HA FC Coated with Alginate 88 6.3 (671) 
HA FC Coated with Alginate 88 8.3 (671) 
HA FC Coated with gelatin 56±2 13.8±1.3 (647) (672) 
HA FC Coated with gelatin 48±2 11.5±1.3 (647) (672) 
Beta-TCP FC Coated with gelatin 78.04±1.58 0.15±0.03 (673) 
Beta-TCP FC Coated with gelatin 82.65±4.17 0.11±0.01 (673) 
Beta-TCP FC Coated with gelatin 77.29±0.68 0.78±0.03 (673) 
Beta-TCP FC Coated with gelatin 85.83±1.02 0.53±0.05 (673) 
Alumina 
ceramic FC Coated with chitosan/gelatin 91.8±0.1 0.244±0.044 (674) 
Alumina 
ceramic FC Coated with chitosan/gelatin 90.2±0.1 0.346±0.023 (674) 
45S5 
Bioglass® FR Coated in P(3HB) microspheres 70 0.27 (224) 
Sr-doped  
Bioglass® FR Coated in gelatin 79±1.9 1.4±0.09 (675) 
45S5 
Bioglass® FR Coated in gelatin 87 1 (363) 
45S5 
Bioglass® FR Coated in PDLLA 90 0.3 (2) 
45S5 
Bioglass® FR Coated in PHB 90 0.3 (2) 
HA FR P(3HB) 90 1.46 (486) 
45S5 
Bioglass® FR coated with chitosan  75 4±2 (676) 
45S5 
Bioglass® FR coated with chitosan 75 15±5 (676) 
45S5 
Bioglass® FR Coated with Alginate 75 12±4 (676) 
45S5 
Bioglass® FR coated with chitosan 75 1.2±0.9 (676) 
Beta-TCP SFF coated in collagen 60 12 (677) 
CaP SFF composite with PLA/PEG 75±0.86 92.32±2.18 (678) 
CaP SFF composite with PLA/PEG 75±0.86 28.38±3.99 (678) 
CaP SFF composite with PLA/PEG/G5 70±1.2 99.81±3.55 (678) 
CaP SFF composite with PLA/PEG/G5 70±1.2 44.19±2.67 (678) 
Beta-TCP SFF coated with PLA 49 60±10 (679) 
Beta-TCP SFF coated with PCL 49 130±20 (679) 
Beta-TCP SFF PCL/TCP composite 65 14 (680) 
Beta-TCP SFF PCL/TCP composite with CHA 65 17 (680) 
Beta-TCP SFF 
PCL/TCP composite with 
CHA/gelatin 65 16 (680) 
CaP SG composite with CPP fibre 72.1 9.28 (681) 
CaP SG composite with CPP/bone 58.2 6.21 (681) 
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70S30C SG composite with gelatin 75 0.32±0.03 (682) 
70S30C SG composite with gelatin 75 0.24±0.04 (682) 
Silica glass SG hybrid with gelatin 90 1 (683) 
Silica glass SG hybrid with gelatin 80 4 (683) 
Silica glass SG hybrid with gelatin 85 2 (683) 
Silica glass SG hybrid with gelatin 75 5 (683) 
Silica glass SG hybrid with gelatin 70 6 (683) 
Silica glass SG hybrid with gelatin 65 8 (683) 
 
Table 53:- Collated data for a variety of materials fabricated by one of the four fabrication methods discussed in 
chapter two, subjected to MSIE coating, showing the change in porosity against compressional strength with FR 
meaning foam replication 
Sample  Fabrication Additives Porosity Compressive  Reference 
material method   (%) Strength (MPa)   
45S5 Bioglass® FR Silver MSIE 75 0.63 (113) 
45S5 Bioglass® FR Silver MSIE 75 0.67 (113) 
45S5 Bioglass® FR Silver MSIE 75 0.7 (113) 
Fa-GC FR Silver MSIE 75 2 (684) 
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Appendix B – Experimental methods 
B.1 Pellet production  
 
This method will make pellets that have a thickness of approximately 1mm and they will have 
a diameter that depends on which pellet dye is used. Before starting the pellet making press needs to be 
thoroughly cleaned with acetone and dried. When this is carried out the following things are needed:- 
 Tissue paper 
 2 weighing boats (one for the weighing and one to hold the pellets) 
 Gloves 
 Bioglass powder 
 Spatula 
 
Method 
1) Take the dye out of its box and clean everything with acetone and dry everything thoroughly. 
2) Take the large cylinder and place the bottom cap in its correct position, as shown below. 
3) Slot into the hole on of the small metal disc’s making sure that the shiny side is facing towards 
the top of the hole as this is the side that will be in contact with the Bioglass® powder. 
4) Weigh out 0.03-0.05g of the Bioglass powder and pour it into the top of the large cylinder. Give 
the cylinder a sharp tap and make sure that the bottom disc is completely covered. 
5) Slot the second metal disc into the tube making sure that the shiny side is facing down when 
you place it into the dye. 
6) Place the whole ensemble into the press machine and tighten the top screw until it feels tight. 
7) Close the side screw and gradually increase the pressure, by using the lever at the side of the 
machine, until it is very hard to move the lever. 
8) Leave for five minutes or until the dial on the front of the machine stabilises and release the 
pressure by turn the screw at the side. 
9) Take the whole ensemble out of the press machine and turn it upside down. 
10) Take the bottom cap off and replace it with the large collar. 
11) Place the whole ensemble back into the press machine making sure that the rod is pointing 
down. 
12) Tighten the top screw and put a little pressure on the powder press. When a small hissing sound 
is heard, or you can feel the pellet has come loose, remove the whole ensemble from the press 
machine. 
13) Remove the newly made pellet and place in the second weighing boat. 
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14) Clean the powder press with acetone and repeat until all the pellets that are required have been 
made. 
15) Sinter in the same manner as a Bioglass scaffold, described in chapter four. 
 
B.2 Preparation of samples for EDX depth studies  
 
This method describes how the samples were prepared ready for depth EDX analysis. This 
technique requires prefabricated pellets that are to be characterised and these are prepared in accordance 
with the methods described in chapter four. When this is carried out the following things are needed:- 
 Prefabricated sample pellets 
 Bakelite 
 Mounting press 
 Polishing machines with 500, 400, 300, 200 and 100 grit values 
 70% Ethanol 
 
Method 
1) The sample has to be embedded in Bakelite to make this characterisation possible. The 
prefabricated tablet is placed into the mounting press with its edge pointing up. 
2) Add 20 to 30 ml of Bakelite powder into the press insuring that the pellet stays upright and is 
completely covered. 
3) Place the upper ram back into the mounting press and seal it up. The press will then heat and 
press the Bakelite to mount the pellet. 
4) Once cooled, remove the mounted pellet from the press. Wash the mounted pellet with 70% 
Ethanol and then water. Leave to dry thoroughly before the grinding and polishing process. 
5) The mounted pellet now needs to be ground down to expose the pellet ready for EDX 
characterisation across the pellets cross-section. Gently apply pressure to the mounted pellet as 
you start polishing using the 500 grit values. Continue until a suitable pellet area has been 
exposed. 
6) Now polish the mounted pellet using progressively finer grit values on the polishing machines. 
7) Wash again in 70% Ethanol and then water and leave to dry. 
8) Coat the whole top surface, the surface with the exposed pellet cross-section, with a layer of 
gold, as you would if you were going to carry out normal EDX or SEM, before characterising 
the mounted pellet. 
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B.3 Extraction of tooth pulp to obtain human periodontal ligamental stromal cells  
 
This method describes the extraction of human periodontal ligamental stromal cells from teeth 
which were used to assess the suitability of the silver ion exchanged scaffolds for implantation. All the 
work is done in a tissue culture hood with all the utensils being sterilised using heat or watered down 
ethanol before being placed under the hood. The teeth used are donated adult wisdom teeth or premolars. 
This process removes the pulp from the centre of the tooth. When this process is carried out the 
following equipment is required:- 
 Collagenese P 
 Lab standard gloves 
 Phosphate buffer solution 
 Samples tubes 
 Syringe and 0.45µm cellulose acetate filter 
 Petri dishes 
 70% Ethanol 
 Scalpel 
 Wire cutters or vice 
 Suction air pump 
 Incubator  
 α-MEM with 20% FBS, 2nm of L-glutamine and 100 units/ml of penicillin/streptomycin  
 
Method 
The first process is to prepare the enzyme which is used to digest the collagen matrix to delink 
the cells from the tooth pulp. 
1) Collagenese P needs to be suspended in phosphate buffer solution (PBS). Suspend the enzyme 
in a ratio of 5mg of the powdered enzyme to 1ml of PBS. 40mg of enzyme to 8ml of PBS is 
enough enzyme to digest the pulp of two teeth 
2) Place the enzyme and PBS in a 45ml sample tube and mix thoroughly. The suspension will 
change from a clear solution to pale yellow when the enzyme is fully suspended. 
3) The suspension is now filtered to remove contamination and bacteria using a 0.45µm cellulose 
acetate filter and syringe. 
The next stage is to prepare the teeth by removing the pulp 
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1) Each tooth comes with a corresponding serial number which should be noted as these will 
correspond to the patient that they were removed from as this will have some bearing on the 
results. As younger teeth generally give better results. 
2) Wash the tooth in ethanol to start the sterilisation process and removed any excess ethanol using 
an air suction pump. Wash the tooth in PBS and then removed any excess using an air suction 
pump. 
3) Scrape any excess tissue from the outside of the tooth with a scalpel and wash again in PBS 
and remove any excess PBS using the air suction pump. The tooth is now ready to have the 
pulp removed. 
4) Place the tooth into the thumb of a sterilised glove and is cracked open using a pair of wire 
cutters. If the wire cutters do not work, place the glove wrapped tooth in a vice until it cracks 
open. 
5) Scrape out the pulp from the centre of the tooth and place into a petri dish with PBS to keep it 
moist. Discard the rest of the tooth and chop the pulp up into very small pieces to aid the enzyme 
digestion process 
6) Transfer the tooth pulp into sample tubes that contain the enzyme only half closing the lids, to 
allow the cells to breathe, and place into an incubator at 37oC at 5%CO2 for a minimum of 10 
minutes but no longer 30 minutes. This allows the enzyme to digest the collagen matrix which 
holds the cells together in the pulp. If the enzyme has not had enough time to work there will 
be wisps of collagen visible in the sample tube. If the enzyme is left too long the enzyme will 
start to digest the cell membranes which will kill the cells that are required in the work.  
7) The cells can now be suspended in the CCM and are ready for use in the cell culture work 
described in chapter four 
 
B.4 Extraction of rat bone-marrow stromal cells  
 
This method describes the extraction of rat bone marrow cells from rat femurs used for this 
work. All the work is done in a tissue culture hood with all the utensils being sterilised using heat or 
watered down ethanol before being placed under the hood. In the cells are extracted from 12 week old 
rats and the extraction protocols have been approved by the CPCSEA. This process is carried out the 
following equipment is required:- 
 Phosphate buffer solution 
 Samples tubes 
 1 ml Syringe and needle 
 0.45µm cellulose acetate filter 
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 70% Ethanol 
 DMEM/F-12 with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin 
 
Method 
1) The rats have to be humanely sacrificed and are sterilised by placing them in 70% ethanol for 
10 minutes. 
2) The femurs are removed and stripped of adherent muscle and other connective tissue. 
3) Insert a needle into the bone and aspirate the cells out of the bone using a 1ml syringe containing 
the CCM until all the bone marrow has been removed. 
4) The cell suspension is then passed through the 0.45µm filter to remove any contamination and 
bacteria. This will also form a single cell suspension which is then ready for use in the 
experiments described in chapter four. 
 
B.5 Extraction of human bone-marrow stromal cells  
 
This method describes the extraction of human bone marrow cells from femoral heads used for 
this work. All the work is done in a tissue culture hood with all the utensils being sterilised using heat 
or watered down ethanol before being placed under the hood. This process is carried out the following 
equipment is required:- 
 Phosphate buffer solution 
 Samples tubes 
 0.45µm cellulose acetate filter 
 DMEM/F-12 with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin 
 
Method 
1) The human bone marrow stem cells where extracted from the femoral heads that were removed 
during total hip arthoplasty procedures. The femoral heads where segmented into two 
hemispheres to expose the trabecular bone whilst still in the sterile conditions of the operating 
theatre. 
2) When the femoral heads are received in the laboratory they are placed into the tissue hood and 
the cells are they aspirated from the heads using PBS. 
3) The cells suspension is then filtered using a 0.45µm filter to remove contamination and bacteria. 
4) The cells are then suspended in the CCM and are then ready to be used once they are filtered 
to form a single cell suspension 
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B.6 Standard I Agar plate production 
 
Standard I agar, also known as Standard methods agar, Plate count agar and Tryptone Glucose 
yeast agar is a growth media used for the enumeration of bacteria from a variety of sources. It is a 
translucent pale yellow colour when agar plates are formed using this media, this makes the bacteria 
growing on the surface easy to spot and count. The peptone, yeast extract, and glucose in the media 
provides the nutritional requirements needed for growth of the E.Coli bacteria 
 This media can be brought pre-mixed although in this work won’t be using pre-mixed media. In order 
to make one litre of the media you need the following quantities:- 
 3g of Yeast extract (CARL ROTH, Germany) 
 1.1g of α-D(+)-Glucose monohydrate (CARL ROTH, Germany) 
 15g of Peptone from casein (pancreatically digested)(Merck, Germany) 
 5.85g of Sodium chloride (CARL ROTH, Germany) 
 20g of Agar – Kobe I (CARL ROTH, Germany) 
 800ml of Deionised water 
Using these quantities approximately 60 to 65 agar plates can be produced, assuming that 15ml of 
the solution is used per plate. These chemicals are used in the following method to produce the Standard 
I agar ready for use in agar plates:- 
1) Weigh out the chemicals stated above, in that order, into a glass bottle with a plastic seal using 
a glass funnel. 
2) When adding the first of the deionised water wash the funnel to ensure all of the weighed out 
chemicals make it into the solution, also make sure that none of the powder clings to the side 
of the bottle by swirling it gently whilst adding the deionised water. 
3) Once all of the deionised water has been added place a magnetic stirrer bar into the bottle and 
place on a magnetic stirrer to dissolve the chemicals. 
4) The pH of the solution needs to be approximately pH 7.4; the pH of the solution is adjusted by 
adding Sodium Hydroxide to the solution. 
5) Once the pH has been adjusted, the bottle and its contents need to be autoclaved for sterilisation 
purposes. Indicator tape must be placed on the bottle to prove that the autoclaving process has 
worked. The bottle needs to be autoclaved for 15minutes at 121oC at a pressure of 2bar. 
6) Remove the bottle once it is cool enough to handle and use as indicated in appendix B.11 to 
produce agar plates. 
If too much of the Standard I agar solution has been produced it can be stored for up to 6 months at 
4-8oC, but it is important to test the pH before its use as it might be better to make a fresh batch.  
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This protocol can be followed for most types of media but for this work it is for producing Endo 
Agar plates and Standard I Agar plates. All this work is to be carried out under a sterilised fume cabinet 
hood in order not to contaminate or spread the bacteria to other sources. At the bacteria lab in Erlangen, 
where this work was carried out, no gloves where to be worn whilst using the hood, instead from elbow 
to fingers were washed in a sticky disinfection solution to prevent the bacteria from being spread. Before 
starting  the agar solutions need to be liquid, which isn’t an issue if they have been freshly made, but if 
they have been stored then they need to be heated up for a short period to return them to their liquid 
form. It should also be noted when handling anything or opening anything within the hood it should 
always been done coming from the side to prevent contamination. 
To start the autoclaved solutions and sterile Petri dishes should be brought to the hood. Using 
a gas lamp run the mouth of the agar flasks in the flame to prevent any contamination getting into the 
flasks. Then it is just a case of pouring approximately 15ml of the agar solution into each Petri dish and 
then replacing the lid. These need to be left for about 10 minutes to start solidifying with their lids on 
and then a further 15 minutes without their lids to prevent condensation that might have built up from 
the slightly warm agar. Check if the plates have completely solidified, if not leave them a little longer, 
and then replace the lids. These are then ready to use straight away. These plates can also be stored at 
4-8oC for up to six months but if they show signs of cracking then it is advisable to make some new 
plates. 
 
B.7 Bacteria counting  
 
During the course of the cell culture work and the bacteria studies the number of cells and 
bacteria need to be counted in order to progress with the experiment. In general the way cells and 
bacteria are counted is very similar with only a few minor differences. Each counting plate will have at 
least one counting chamber, as shown in Figure 145. 
The counting chamber is divided into a number of counting squares or cells and it is in these 
that the bacteria and cells are counted underneath a light microscope. The bacteria don’t need a stain in 
order to be seen but the cells need to be stained with Trypin blue in order to be counted. A small amount 
of the bacteria or cell suspension is pipette into the counting chamber and a glass plate is placed on top 
of the counting chamber as shown Figure 146. 
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Figure 145:- Schematic of a counting plate showing the areas that cells and bacteria are counted in 
 
 
Figure 146:- Counting chamber used in bacteria and cell counting 
 
This ensemble is placed under the microscope and the bacteria or cells are then counted 
manually. The number of bacteria or cells is counted per little square, ideally at least four of the smallest 
counting chambers need to be counted in order for a more accurate count to be measured. It should be 
noted that the bacteria can swim in and out of focus of the light microscope and therefore a larger 
number of counting chambers should be looked at to take into account this movement.  When counting 
pick two adjacent sides of the counting area and any bacteria or cells straddling them should be count 
and any that are straddling the other two sides should be disregarded for that particular counting area, 
as shown in Figure 147. 
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Figure 147:- Schematic of which cells/bacteria can be included in the counting process 
 
Once an average number of bacteria or cells per counting area has been taken this can be scaled 
up in order to calculate the number of bacteria or cells per millilitre and then this number can be used 
in further calculates used in the experiment. To do this the volume of the counting chambers needs to 
be calculated using the values given on the plate, as shown in Figure 146, and then using this, the 
number of bacteria can be scaled up accordingly. 
For example, a chamber has a height of 0.1mm and a small square area of 0.0025mm2, meaning each 
small square has a volume of 2.5x10-4mm3. If an average of 24 bacteria per small counting square were 
counted then it could be said that there are 24 bacteria per 2.5x10-4mm3 or per 2.5x10-4µl. This is 
scaled up to work out how many bacteria per µl and then per ml, eventually it is calculated that there 
are 9.6x107 bacteria per ml. 
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Appendix C – Results 
C.1 Silver molten salt ion exchange scaffolds 
 
 
Figure 148:- 45S5 Bioglass® –derived glass-ceramic scaffolds immersed in a medium concentration molten salt 
bath for A) 15 minutes, B) 30 minutes, C) 45 minutes and D) 60 minutes Images have a magnification of x150. 
 
Figure 149:- 45S5 Bioglass® –derived glass-ceramic scaffolds immersed in a high concentration molten salt bath 
for A) 15 minutes, B) 30 minutes, C) 45 minutes and D) 60 minutes Images have a magnification of x150. 
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Figure 150:- Low concentration of silver MSIE scaffolds with immersion periods of 15, 30, 45 and 60 minutes  
 
 
Figure 151:- High concentration of silver MSIE scaffolds with immersion periods of 15, 30, 45 and 60 minutes  
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Figure 152:- 45S5 Bioglass® –derived glass-ceramic scaffolds immersed in a low concentration molten salt bath 
for A) 15 minutes, B) 30 minutes, C) 45 minutes and D) 60 minutes and then immersed in SBF for 14 days. Images 
have a magnification of x1500 
 
 
Figure 153:- 45S5 Bioglass® –derived glass-ceramic scaffolds immersed in a high concentration molten salt bath 
for A) 15 minutes, B) 30 minutes, C) 45 minutes and D) 60 minutes and then immersed in SBF for 14 days. Images 
have a magnification of x1500. 
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Figure 154:- High concentration of silver MSIE scaffolds with immersion periods of 15, 30, 45 and 60 minutes 
after immersion in SBF for 14 days 
 
 
Figure 155:- Medium concentration of silver MSIE scaffolds with immersion periods of 15, 30, 45 and 60 minutes 
after immersion in SBF for 14 days 
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C.2 Bacterial assessment of molten salt ion exchange scaffolds 
 
 
Figure 156:- Control samples taken after four and 24 hours of exposure E.coli and being plated onto standard I 
agar plates and incubated for 24 hours at 37oc at 5% CO2: A) initial bacterial absorbance of 0.01 and 0.001 after 
four hours of exposure, B) initial bacterial absorbance of 0.001 after 24 hours of exposure and C) initial bacterial 
absorbance of 0.01 after 24 hours of exposure using DMEM/F-12 as the suspension media 
 
Figure 157:- Control samples taken after four and 24 hours of exposure E.coli and being plated onto standard I 
agar plates and incubated for 24 hours at 37oc at 5% CO2: A) initial bacterial absorbance of 0.01 and 0.001 after 
four hours of exposure, B) initial bacterial absorbance of 0.001 after 24 hours of exposure and C) initial bacterial 
absorbance of 0.01 after 24 hours of exposure using MHB as the suspension media 
 
Figure 158:- Samples taken after four hours of exposure to varying concentrations of copper chloride salt and 
being plated onto standard I agar plates and incubated for 24 hours at 37oc at 5% CO2: A) concentrations of 
copper chloride of 1mM and 0.5mM with an initial bacterial absorbance of 0.01, B) concentrations of copper 
chloride of 0.1mM and 0.05mM with an initial bacterial absorbance of 0.01, C) concentration of copper chloride 
of 1mM with an initial bacterial absorbance of 0.001, D) concentration of copper chloride of 0.5mM with an 
initial bacterial absorbance of 0.001, E) concentration of copper chloride of 0.1mM with an initial bacterial 
absorbance of 0.001 and F) concentration of copper chloride of 0.05mM with an initial bacterial absorbance of 
0.001 using DMEM/F-12 as the suspension media 
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Figure 159:- Samples taken after four hours of exposure to varying concentrations of copper chloride salt and 
being plated onto standard I agar plates and incubated for 24 hours at 37oc at 5% CO2: A) concentrations of 
copper chloride of 1mM with an initial bacterial absorbance of 0.01, B) concentrations of copper chloride of 
0.5mM with an initial bacterial absorbance of 0.01,C) concentrations of copper chloride of 0.1mM with an initial 
bacterial absorbance of 0.01, D) concentrations of copper chloride of 0.05mM with an initial bacterial 
absorbance of 0.01E) concentration of copper chloride of 1mM with an initial bacterial absorbance of 0.001, F) 
concentration of copper chloride of 0.5mM with an initial bacterial absorbance of 0.001, G) concentration of 
copper chloride of 0.1mM with an initial bacterial absorbance of 0.001 and H) concentration of copper chloride 
of 0.05mM with an initial bacterial absorbance of 0.001 using MHB as the suspension media 
 
Figure 160:- Samples taken after four hours of exposure to varying concentrations of copper nitrate salt, an E.coli 
suspension in DMEM/F-12 and being plated onto standard I agar plates and incubated for 24 hours at 37oc at 
5% CO2: A) concentration of copper nitrate of 1mM with an initial bacterial absorbance of 0.001, B) 
concentration of copper nitrate of 0.5mM with an initial bacterial absorbance of 0.001,  C) concentration of 
copper nitrate of 0.1mM with an initial bacterial absorbance of 0.001,  D) concentration of copper nitrate of 
0.05mM with an initial bacterial absorbance of 0.001,  E) concentration of copper nitrate of 1mM with an initial 
bacterial absorbance of 0.01,  F) concentration of copper nitrate of 0.5mM with an initial bacterial absorbance 
of 0.01, G) concentration of copper nitrate of 0.1mM with an initial bacterial absorbance of 0.01, and H) 
concentration of copper nitrate of 0.05mM with an initial bacterial absorbance of 0.01 using DMEM/F-12 as the 
suspension media 
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Figure 161:- Samples taken after four hours of exposure to varying concentrations of copper nitrate salt, an E.coli 
suspension in MHB and being plated onto standard I agar plates and incubated for 24 hours at 37oc at 5% CO2: 
A) concentration of copper nitrate of 1mM with an initial bacterial absorbance of 0.001, B) concentration of 
copper nitrate of 0.5mM with an initial bacterial absorbance of 0.001,  C) concentration of copper nitrate of 
0.1mM with an initial bacterial absorbance of 0.001,  D) concentration of copper nitrate of 0.05mM with an initial 
bacterial absorbance of 0.001,  E) concentration of copper nitrate of 1mM with an initial bacterial absorbance 
of 0.01,  F) concentration of copper nitrate of 0.5mM with an initial bacterial absorbance of 0.01, G) 
concentration of copper nitrate of 0.1mM with an initial bacterial absorbance of 0.01, and H) concentration of 
copper nitrate of 0.05mM with an initial bacterial absorbance of 0.01  
 
Figure 162:- Samples taken after 24 hours of exposure to varying concentrations of copper chloride salt, an E.coli 
suspension in DMEM/F-12 and being plated onto standard I agar plates and incubated for 24 hours at 37oc at 
5% CO2: A) concentration of copper chloride of 1mM with an initial bacterial absorbance of 0.01, B) 
concentration of copper chloride of 0.5mM with an initial bacterial absorbance of 0.01,  C) concentration of 
copper chloride of 0.1mM with an initial bacterial absorbance of 0.01,  D) concentration of copper chloride of 
0.05mM with an initial bacterial absorbance of 0.01,  E) concentration of copper chloride of 1mM with an initial 
bacterial absorbance of 0.001,  F) concentration of copper chloride of 0.5mM with an initial bacterial absorbance 
of 0.001, G) concentration of copper chloride of 0.1mM with an initial bacterial absorbance of 0.001, and H) 
concentration of copper chloride of 0.05mM with an initial bacterial absorbance of 0.001  
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Figure 163:- Samples taken after 24 hours of exposure to varying concentrations of copper chloride salt, an E.coli 
suspension in MBH and being plated onto standard I agar plates and incubated for 24 hours at 37oc at 5% CO2: 
A) concentration of copper chloride of 1mM with an initial bacterial absorbance of 0.01, B) concentration of 
copper chloride of 0.5mM with an initial bacterial absorbance of 0.01,  C) concentration of copper chloride of 
0.1mM with an initial bacterial absorbance of 0.01,  D) concentration of copper chloride of 0.05mM with an 
initial bacterial absorbance of 0.01,  E) concentration of copper chloride of 1mM with an initial bacterial 
absorbance of 0.001,  F) concentration of copper chloride of 0.5mM with an initial bacterial absorbance of 0.001, 
G) concentration of copper chloride of 0.1mM with an initial bacterial absorbance of 0.001, and H) concentration 
of copper chloride of 0.05mM with an initial bacterial absorbance of 0.001 
 
Figure 164:- Samples taken after 24 hours of exposure to varying concentrations of copper nitrate salt, an E.coli 
suspension in DMEM/F-12 and being plated onto standard I agar plates and incubated for 24 hours at 37oc at 
5% CO2: A) concentration of copper nitrate of 1mM with an initial bacterial absorbance of 0.01, B) concentration 
of copper nitrate of 0.5mM with an initial bacterial absorbance of 0.01,  C) concentration of copper nitrate of 
0.1mM with an initial bacterial absorbance of 0.01,  D) concentration of copper nitrate of 0.05mM with an initial 
bacterial absorbance of 0.01,  E) concentration of copper nitrate of 1mM with an initial bacterial absorbance of 
0.001,  F) concentration of copper nitrate of 0.5mM with an initial bacterial absorbance of 0.001, G) 
concentration of copper nitrate of 0.1mM with an initial bacterial absorbance of 0.001, and H) concentration of 
copper nitrate of 0.05mM with an initial bacterial absorbance of 0.001  
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Figure 165:- Samples taken after 24 hours of exposure to varying concentrations of copper nitrate salt, an E.coli 
suspension in MHB and being plated onto standard I agar plates and incubated for 24 hours at 37oc at 5% CO2: 
A) concentration of copper nitrate of 1mM with an initial bacterial absorbance of 0.01, B) concentration of copper 
nitrate of 0.5mM with an initial bacterial absorbance of 0.01,  C) concentration of copper nitrate of 0.1mM with 
an initial bacterial absorbance of 0.01,  D) concentration of copper nitrate of 0.05mM with an initial bacterial 
absorbance of 0.01,  E) concentration of copper nitrate of 1mM with an initial bacterial absorbance of 0.001,  F) 
concentration of copper nitrate of 0.5mM with an initial bacterial absorbance of 0.001, G) concentration of 
copper nitrate of 0.1mM with an initial bacterial absorbance of 0.001, and H) concentration of copper nitrate of 
0.05mM with an initial bacterial absorbance of 0.001 
  
 
Figure 166:- Supernatents plated after an immersion period of 28 days in DMEM/F-12, added to an E.coli 
suspension for 24 hours and then plated onto standard I agar plates with sodium thiosulfate; A) plates showing 
the supernatents taken from sample 1 with samples including a plain 45S5 Bioglass® -glass-ceramic scaffold, the 
lowest concentration MSIE samples of each type and B) plates showing the supernatents taken from sample 2 with 
samples including a plain 45S5 Bioglass® -glass-ceramic scaffold, the lowest concentration MSIE samples of 
each type 
 
350 
 
 
Figure 167:- Supernatents plated after an immersion period of 7 days in DMEM/F-12, added to an E.coli 
suspension for 24 hours and then plated onto standard I agar plates with sodium thiosulfate; A) plates showing 
the supernatents taken from sample 1 with samples including a plain 45S5 Bioglass® -glass-ceramic scaffold, the 
lowest concentration MSIE samples of each type and B) plates showing the supernatents taken from sample 2 with 
samples including a plain 45S5 Bioglass® -glass-ceramic scaffold, the lowest concentration MSIE samples of each 
type 
 
 
Figure 168:- Supernatents plated after an immersion period of 3 days in DMEM/F-12, added to an E.coli 
suspension for 24 hours and then plated onto standard I agar plates with sodium thiosulfate; A) plates showing 
the supernatents taken from sample 1 with samples including a plain 45S5 Bioglass® -glass-ceramic scaffold, the 
lowest concentration MSIE samples of each type and B) plates showing the supernatents taken from sample 2 with 
samples including a plain 45S5 Bioglass® -glass-ceramic scaffold, the lowest concentration MSIE samples of each 
type 
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Figure 169:- Supernatents plated after an immersion period of 1 day in DMEM/F-12, added to an E.coli 
suspension for 24 hours and then plated onto standard I agar plates with sodium thiosulfate; A) plates showing 
the supernatents taken from sample 1 with samples including a plain 45S5 Bioglass® -glass-ceramic scaffold, the 
lowest concentration MSIE samples of each type and B) plates showing the supernatents taken from sample 2 with 
samples including a plain 45S5 Bioglass® -glass-ceramic scaffold, the lowest concentration MSIE samples of each 
type 
 
C.3 Polymer coated 45S5 Bioglass® -derived glass-ceramic scaffolds 
 
 
Figure 170:- FTIR spectra for PDLLA coated BBG scaffolds before and after immersion in SBF for 14 days from 
Figure 84 showing just the section of the spectra relating to the PDLLA peaks 
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Figure 171:- FTIR spectra for gelatin coated BBG scaffolds from Figure 85 just showing the peaks relating to the 
gelatin coating 
 
 
Figure 172:- FTIR spectra for gelatin coated BBG scaffolds after immersion in SBF for 14 days from Figure 91 
just showing the peaks relating to the gelatin coating 
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C.4 Polymer coated molten salt ion exchanged 45S5 Bioglass® -derived glass-ceramic scaffolds 
 
 
Figure 173:- FTIR spectra for gelatin coated copper-doped BBG scaffolds from Figure 96 just showing the peaks 
relating to the gelatin coating 
 
 
Figure 174:- FTIR spectra for gelatin coated copper-doped BBG scaffolds after immersion in SBF for 14 days 
from Figure 100 just showing the peaks relating to the gelatin coating 
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Figure 175:- FTIR spectra for gelatin coated silver/copper-doped BBG scaffolds from Figure 105 just showing 
the peaks relating to the gelatin coating 
 
 
Figure 176:- FTIR spectra for gelatin coated silver/copper-doped BBG scaffolds after immersion in SBF for 14 
days from Figure 109 just showing the peaks relating to the gelatin coating 
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Appendix D – Future Work 
 
D.1 Reverse Monte Carlo modelling 
 
Reverse Monte Carlo (RMC) modelling is a technique for generating a 3D computer model 
based on experimental data for amorphous and disordered crystalline structures. (616) The experimental 
data is now not considered in isolation, but can be treated as complementary to the process of producing 
a 3D model of the materials’ structure. (616) 
A “box” is set up and a set of atoms are placed in the box where a calculation takes place 
based on the current atom configuration and chemical formula. Then one atom is randomly selected and 
is moved a random amount and the calculation is re-done based on the new configuration. (616) This 
movement will either be accepted or rejected based on whether the atom overlaps another atom or 
whether the value is similar to the starting experimental value. (616) If the move is rejected the atom is 
moved back to its original starting position and the process is repeated. If the move is accepted then 
another atom is selected at random and the process of moving the atoms can start again. (616) As the 
number of successfully moved atoms increases the calculated values will start to get closer towards the 
given experimental value until they reach a certain point (the point where the calculated value equals 
the experimental value) and at this point the calculated values will oscillate slightly. (616) This will then 
lead to an atomic configuration that will give rise to a model that is plausible and consistent with the 
experimental data. (616) 
The atomic structure produced by RMC modelling isn’t unique; it’s just the model that is 
consistent with the given experimental data and any other given constraints. (616) Other modelling 
techniques produce 3D models which are valid with the given data but there is no way, at present, of 
determining which the correct model is without referring to additional information. (616)  
RMC is independent of potential, so it is not affected by potential parameters. Most models 
are compared to the experimental data at the radial distribution function stage (G(r)), which describes 
how on average the atoms in a system are packed around each other, because the configurations are just 
too small for the models to be compared to experimental data at the structure factor stage (F(Q)). (616) 
For a model that fits to the experimental data the comparison needs to be made whilst the data is at the 
F(Q) stage. (616)  
As RMC models a 3D atomic structure, the real radial distribution and the real structure factor 
(Gc(r) and Fc(Q) respectively) must correspond to a possible valid physical structure. However the 
experimental radial distribution function (Ge(r)), may contain errors which could potentially mean that 
the atomic model would not correspond to a possible valid physical structure, meaning the model is 
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inconsistent with the given experimental data. (616) In RMC, the partial radial distribution functions 
(PRDF’s) have to be consistent with each other and they have to be valid in order to produce an atomic 
model that is consistent with the given experimental data. This constraint in RMC helps to improve the 
partials (partials meaning only looking at one particular pair of atoms) separation and means that 
information can be obtained from undetermined cases, where no PRDF’s have been determined by 
conventional methods. (616) 
In principle a configuration of atoms with a Boltzmann distribution of energies needs to be 
produced. To produce configurations like this the Markov chain (weighted sampling procedure) is used 
to generate and samples configurations. (616) The Markov chain satisfies a number of requirements that 
are needed for producing a model: -  
 The first being that variables x(n) are found by using a rule that requires the (n + 1)nt 
to have a probability distribution of x(n+1) that is dependent on the distribution, of the 
nth element, of x(n).  
 The second requirement is that if P(x => y) is the probability of getting to the y state 
from the x state, then P(x =>y) must allow the movement to every state within the 
configuration.  
 The last requirement states that microreversibilty must be satisfied, such that                       
xP(x => y) = yP(y => x) when the system of atoms is in equilibrium. 
This can be achieved by the following process, but can only be done for a system of atoms 
where the number of atoms, volume and temperature are kept constant.  Firstly the a number of atoms 
(let’s call this number N) are placed inside a “box” which is surrounded by other identical boxes, in 
most cases cubes are used as the box shape, these cubes have a side length of L. The atom number 
density can be described as   ρ = N/L3 and this atom number density must be equal to the required density 
of the system. The probability of this configuration is described in Equation 16.  This shows the original 
probability of the configuration before anything was done to the system. (616) 
Equation 16 :- MC modelling – the probability of the original configuration 
 kTUP oo  exp  
 The total potential energy (Uo) can be calculated on the basis of the specified form of inter-
atomic potential. (616) 
 Next one atom is moved at random and meaning the probability changes from that calculated in 
Equation 16. Equation 17 shows the new probability after one atom is moved at random. Where Un is 
the new total potential energy at that point. (616) 
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Equation 17 :- MC modelling – the probability of the new configuration after one atom move 
 kTUP nn  exp  
 If Equation 16 and Equation 17 are combined, the constraint for whether the atom stays in that 
new position or whether it is moved back to its original position can be derived. Equation 18 shows the 
probability of the new configuration divided by the probability of the old configuration. (616) 
Equation 18 :- MC modelling – Constraint of whether an atom stays in the new position or moved back to its 
original position 
    kTUkTUUPP onon  expexp  
 If ΔU is less than zero the new configuration of atoms is accepted and the atom that was moved 
stays put in that new position and this becomes the new starting point. (616) If ΔU is greater than zero 
then the move is rejected and the atom is moved back to its original position. This process of moving 
atoms and checking there probabilities is repeated until ΔU decreases such that it reaches an equilibrium 
value and then it oscillates about this value. That was a brief description of the theory behind the Monte 
Carlo modelling (MC) which is needed as a starting point for RMC modelling. (616) 
 In experiments it is expected for the data collected to have some errors within it, we can assume 
that the experimental structure factor (FE(Qi)) only has statistical errors that have normal distributions 
on them. The difference between the real structure factor (FC(Qi)) and the structure factor that is found 
experimentally (Ei) is expressed by Equation 19. (616) 
Equation 19 :- RMC modelling –Experimental Structure factor relationship 
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 The probability of this difference can be expressed in terms of the standard deviation of the 
normal distribution (σ(Qi)), shown in Equation 20. Where σ is the error and Qi is the scattering vector. 
(616) 
Equation 20 :- RMC modelling – Probability of the difference in experimental structure factors in terms of the 
standard deviation of the normal distribution 
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 Knowing this probability (the probability of the difference between the real structure factor and 
the experimental structure factor) the probability for the real structure factor can be calculated, shown 
in Equation 21. (616) 
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Equation 21 :- RMC modelling – Probability of the real structure factor 
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 Where m is the number of Qj points in FE and  is shown in Equation 22. (616) 
Equation 22 :- RMC modelling –Standard deviation in terms of the scattering vector 
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 In order to model a system using the real structure factor (FE(Q)) a statistical configuration of 
atoms whose F(Q)’s need to satisfy the probability distribution shown in Equation 19. Then the exponent 
can be written in terms of א2 and this is shown in Equation 23. (616) 
Equation 23:- RMC modelling - Constraint of whether an atom stays in the new position or moved back to its 
original position 
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 Then it can be seen that the probability is proportional to exp(-א2/2) and from this it can be seen 
that א2/2 in RMC is the equivalent of U/kT in the MC method, shown in Equation 17. (616) 
Like the MC method, a starting configuration is needed, the positions of the N atoms may be 
chosen at random, and they may be obtained from either another model or from a known crystal 
structure. The next step is to calculate the radial distribution function for the initial configuration of 
atoms, shown in Equation 24. (616) 
Equation 24 :- RMC modelling – Radial distribution function for the initial configuration of atoms 
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 Where noC(r) is the number of atoms at a distance r and r+Δr from a random central atom, this 
is averaged over when all the atoms that were used as the central point and ρ is the number density. 
(616) The length of the box is once again L and this should be large enough so that g(r > L2) = 1. The 
radial distribution function, g(r) is only ever calculated for r < L/2 and the nearest image convention is 
used to determine the atomic separations. The next thing that should be calculated is the transformation 
of the radial distribution into the total structure factor; this is shown in Equation 25, where Q is the 
momentum transfer in this case. (616) 
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Equation 25 :- RMC modelling – Transformation of the radial distribution into the total structure factor 
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 Now the difference between the experimental measured structure factor [FE(Q)] and the 
structure factor that is obtained from the starting configuration can be found [FC(Q)]. This gives אo2 and 
this is shown in Equation 26. (616) 
Equation 26 :- RMC modelling – Difference between the experimental structure factor and the starting structure 
factor 
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 Where the sum is over the m experimental points and σ(Qi) is the experimental error on those 
points. In practical situation a uniform σ is normally used because the distribution of the systematic 
errors is unknown. (616) Next is the part were one atom is moved and a new radial distribution needs to 
be calculated as well as a new total structure factor and this is done by combining Equation 21and 
Equation 22. The new א2 is given in Equation 27. (616) 
Equation 27 :- RMC modelling - Constraint of whether an atom stays in the new position or moved back to its 
original position 
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 If אn2 less than אo2 then the atom’s move is accepted and the new configuration becomes the new 
starting configuration and the atom is left in its new position. If however אn2 is great than אo2, then the 
move can be accepted as long as the probability is exp(-(אn2-אo2)/2), otherwise the move is rejected. (616) 
 As with the MC method, the value of א2 will decrease until it reaches an equilibrium point and 
the function will oscillate around that point. The resulting configuration file that is produced will then 
(once run through the proper plotting program) produced a 3D structure model that is consistent with 
the given experimental structure factor within an experimental error. (616)  
 There is one thing that should be considered and this is the idea of the constraints. There are 
two very important constraints within the RMC method:-  
 The constraint on the closest distance of approach of two atoms  
 The constraint on the coordination of the atoms.  
The first constraint that shall be discussed is the constraint on the distance of closest approach 
of two atoms. Due to errors on the experimental data and the limited range of the data, the data would 
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not forbid some atoms getting close to each other. (616) Realistic values for closest approach distances 
can be obtained by the use of the direct Fourier transformation of the experimental total structure factor. 
(616) One dominant effect of determining the structure of a material is the packing of the atoms. To 
include the information of the different atom sizes in the model would limit the number of structures 
that would be consistent with the given data. (616) 
 The second constraint is the one that is concerned with the coordination of the atoms.  A 
coordination number nαβ, this is defined as the number of atoms of type β between two fixed distances 
of one atom of type α. (616) The lower fixed distance is the same as the closest distance of approach of 
the two atom types (or zero). (616) If the proportion of α type atom’s in the configuration with 
coordination of fRMC and the required proportion of α atoms as freq then an additional term can be added 
to Equation 23, shown in Equation 28. (616)  
Equation 28 :- RMC modelling - Constraint of whether an atom stays in the new position or moved back to its 
original position plus the new coordination factor 
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 Multiple coordination constraints can be added to the model by adding additional term to 
Equation 26. (616) σc acts as a weighting function of the coordination constant relative to the given data. 
If σc is approximately equal to zero then it is impossible for atoms with the constrained coordination to 
change it, this is used to mimic covalent bonding. (616) In a lot of cases hard sphere Monte Carlo 
simulation with such constraints, this is RMC with no data and is used to produce a structure with 
suitable topology (it’s an extension of geometry) before experimental data is fitted to it. (616) 
 
D.2 The Arteriovenous loop 
 
 The arteriovenous loop model (AVL) is based on a loop created in vivo in the medial thigh of 
a rat with a vein graft from the contralateral leg. This model has shown to enhance neovascularisation. 
The cage prevents vascularisation occurring from surrounding tissue and therefore the observed 
vascularisation is exclusively from the construct matrix. 
 The in vivo model consists of a heat resistant medical grade Teflon® cage with an inner 
diameter of 10mm, height of 10mm and a lid. Four green plastic tubes where evenly spaced out in the 
cage to keep the loop in shape and from touching. 
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 The construct matrix consisted of pieces of BBG ranging in size between 1mm to 2mm and a 
fibrin gel. The fibrin gel had a thrombin concentration of 2 I.U./ml, a fibrinogen concentration of 
10mg/ml and an aprotinin concentration of 1500 K.I.E/ml. 
 The model is then surgically implanted into the rat and left for three weeks before being 
removed ready for characterisation to determine the vascular network. Using histology and micro 
computed topography the vascular network established in the cage can be established. 
 
D.3 Therapeutic metal nano-particles – Copper oxide and Iron oxide 
 
 
Figure 177:- FTIR analysis of BBG scaffolds coated with a) 6wt% type A gelatin with copper nano-particles, b) 
6wt% type A gelatin doped with iron oxide nano-particles, c) 6wt% type B gelatin doped with copper nano-
particles and d) 6wt% type B gelatin doped with iron oxide nano-particles 
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Figure 178:- BBG scaffolds coated with gelatin with A) a type A 5wt% coating with iron oxide nano-particles 
(magnification of x500), B) a type B 5wt% coating with iron oxide nano-particles (magnification of x250), C) a 
type A 5wt% coating with copper oxide nanoparticles (magnification of x 300) and D) a type B 5wt% coating with 
copper oxide nanoparticles (magnification of x160) 
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Appendix E – Statistical Analysis 
 
 The mean of a data set is the sum of the data (xn) devided by the number of samples in the data 
set (n), as shown by Equation 29. 
Equation 29:- Mean of a data set 
 
Data values are described as the mean ± standard error (SE) where the SE is shown in Equation 
30.  
Equation 30:- Standard error on the mean 
 
 To ascertain the ANOVA value (F) a number of steps must be taken, first being working out 
the total mean of all of the data collect, as shown in Equation 31. With n being the number of samples 
in total and a being the number of data sets. 
Equation 31:- Group mean of multiple data sets 
 
In its simplest form, ANOVA analysis is the variance (the standard deviation squared) between 
the data sets divided by the variance within a data set, as shown by Equation 32. 
Equation 32:- ANOVA analysis of multiple data sets 
 
 This is calculated by working out the mean square value between the data sets divided by the 
mean square value within a data set, as shown in Equation 33. 
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Equation 33:- ANOVA analysis of multiple data sets 
 
 The mean square between the data sets is calculated by dividing the sum of the squares between 
the data sets by the number of data sets minus one and the mean square within a group is calculated by 
dividing the sum of the squares within a data set by the number of samples from that data set minus 1. 
This is represented in Equation 34 and Equation 35. 
Equation 34:- ANOVA analysis of multiple data sets 
 
Equation 35:- ANOVA analysis of multiple data sets 
 
 The value of observed F is then compared to a critical value of F from the literature derived 
according to the significance wanted, which in this case is p ≤0.0. If the observed value for F is greater 
than or equal to the critical value of F, then the difference between the data sets is due to the change in 
parameters and not chance or a random error. 
This can be compared to the student T Test looking at the difference between two data sets to 
assure that the ANOVA analysis is correct as shown in Equation 36. 
Equation 36:- Student T Test of two data sets 
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Appendix F – Copyright permissions 
 
 Table 54 showing the status of copyright permissions obtained for this work.  
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265 Figure 141 Dr A Arkudas Dr A Arkudas 2013 Permission granted 
266 Figure 142 Dr A Arkudas Dr A Arkudas 2013 Permission granted 
266 Figure 143 Dr A Arkudas Dr A Arkudas 2013 Permission granted 
267 Figure 144 Dr A Arkudas Dr A Arkudas 2013 Permission granted 
62 Figure 12 John Wiley and Sons John Wiley and Sons 2010 Permission granted 
56 Figure 11 Elsevier Elsevier 2006 Permission granted 
44 Figure 4 Springer Springer 2001 Permission granted 
35 Figure 7 Springer Springer 2006 Permission granted 
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Permission granted for use of the images and data shown in Figure 137 and Table 49 from Dr 
Timo Hammer is shown in Figure 179. 
 
Figure 179:- Permission granted for the use of the images and data shown in Figure 137 and Table 49 from Dr 
Timo Hammer 
 
Permission granted for use of the images and data shown in Figure 116, Figure 117, Figure 119, 
Figure 120, Figure 121, Figure 122 and Figure 123 from Dr Leonie Strobel is shown in Figure 180. 
 
Figure 180:- Permission granted for the use of the images shown in Figure 116, Figure 117, Figure 119, Figure 
120, Figure 121, Figure 122 and Figure 123 from Dr Leonie Strobel 
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Permission granted for use of the images and data shown in Figure 112, Figure 113, Figure 114 
and Figure 115 from Dr Reem El-Gendy is shown in Figure 181. 
 
Figure 181:- Permission granted for the use of the images shown in Figure 112, Figure 113, Figure 114 and 
Figure 115 from Dr Reem El-Gendy 
 
Permission granted for use of the images and data shown in Figure 141, Figure 142, Figure 143 
and Figure 144 from Dr Andreas Arkudas is shown in Figure 182. 
 
Figure 182:- Permission granted for the use of the images shown in Figure 141, Figure 142, Figure 143 and 
Figure 144 from Dr Andreas Arkudas 
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 Permission granted for the use of the image shown in Figure 12 from the publisher John Wiley 
and Sons is shown in Figure 183. 
 
Figure 183:- Permission granted for the use of the image shown in Figure 12 from the publisher John Wiley and 
Sons 
 
 Permission granted for the use of the image shown in Figure 11 from the publisher Elsevier is 
shown in Figure 184. 
 
Figure 184:- Permission granted for the use of the image shown in Figure 11 from the publisher Elsevier 
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 Permission granted for the use of the image shown in Figure 4 from the publisher Springer is 
shown in Figure 185. 
 
Figure 185:- Permission granted for the use of the image shown in Figure 4 from the publisher Springer 
 
Permission granted for the use of the image shown in Figure 7 from the publisher Springer is 
shown in Figure 186. 
 
Figure 186:- Permission granted for the use of the image shown in Figure 7 from the publisher Springer 
